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Kayleigh Bassiri 
Title: Identifying common therapeutic targets in Merlin-deficient brain tumours  
Abstract  
Neurofibromatosis type 2 (NF2) is an autosomal dominant inherited condition that 
predisposes individuals to develop multiple nervous system tumours, primarily 
schwannoma, meningioma and ependymoma. NF2 is characterised by loss of the 
tumour suppressor protein Merlin, caused by bi-allelic mutations of the encoding gene 
NF2 or by loss of heterozygosity. These tumours can occur either sporadically or as 
part of the NF2 condition. The majority are slow growing and display benign features, 
but this benignancy renders them largely unresponsive to classic chemotherapeutic 
agents leaving surgery and radiosurgery as the only remaining treatment options. 
Depending on their location, NF2-related tumours can cause a number of side effects, 
including nausea, balance problems, and in some cases hearing and/or vision loss.  
   Phosphorylation is a key regulatory mechanism leading to changes in cell signalling. 
By identifying phosphoproteins that are significantly activated in tumour cells, novel 
therapies can be developed aiming to specifically target the phosphorylated status of 
these proteins thus ‘switching off’ the signalling cascade. The objective of this study is 
to identify and validate common targets in both Merlin-deficient meningioma and 
schwannoma to eventually exploit in novel therapeutic approaches. 
   Using phosphoprotein purification followed by mass spectrometry analysis, we 
identified Signal Transducer and Activator of Transcription 1 (STAT1), phosphorylated 
at Serine (S) 727 and Tyrosine (Y) 701, PDZ and LIM domain protein 2 (PDLIM2), Heat 
Shock 70kDa Protein 1A (HSPA1A) and Filamin B (FLNB) as potential common, novel 
therapeutic targets. We validated these candidates in human primary meningioma and 
schwannoma tumour cells using a variety of techniques. We also showed that specific 
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knockdown of STAT1 and PDLIM2 was related to a significant decrease in cellular 
proliferation. 
   Additionally, we performed co-immunoprecipitation using PDLIM2 as the bait protein 
and identified STAT1, HSPA1A and FLNB as binding partners, suggesting a novel 
interaction network involving all of the potential targets identified in this study. We also 
identified activation of several pathways and/ or biological processes in both tumour 
types that warrant further investigation i.e. endocytosis in schwannoma and the 
proteasome in meningioma. 
   In conclusion, with our approach we substantially increased the overall body of 
knowledge regarding the proteome and phosphoproteome of meningioma and 
schwannoma. We generated a comprehensive set of data that highlighted several 
potential therapeutic targets and dysregulated pathways which will be further 
investigated.  
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Chapter 1- Introduction 
 
1.1    Background to this study  
 
Meningiomas are usually low-grade tumours affecting the brain and spinal cord, while 
schwannomas are found in the peripheral nervous system (Ammoun and Hanemann 
2011). There are currently no drugs clinically approved for the treatment of either 
meningioma or schwannoma. Individuals with the genetic condition neurofibromatosis 
type 2 (NF2) suffer with frequent recurrences of both tumour types, and must endure 
multiple surgeries and occasionally radiosurgery throughout life as their primary 
treatment option, which can have profound effects on patient’s quality of life. The 
identification of novel therapeutic targets will help to inform the search for more efficient 
and less invasive ways of treating patients with NF2, and potentially many spontaneous 
meningiomas, schwannomas and other Merlin-deficient tumours (Ammoun and 
Hanemann 2011).  
   The importance of this thesis lies in the fact that most studies focus solely on one or 
the other tumour type and are frequently hypothesis driven, thus biased. In this project, 
both meningioma and schwannoma were extensively studied to identify common 
features that could be exploited in both tumours, so that they could be treated 
simultaneously with the same drug leading to the same therapeutic benefit, especially 
important in NF2 patients. The following introduction will discuss the current literature in 
more detail and summarize some of the technologies utilized in drug target discovery, 
including how they have been used specifically for identifying therapeutic targets. 
1.2    Schwannoma and meningioma aetiology  
1.2.1    The neurofibromatoses   
There are three genetic conditions that fall under the general term of 
neurofibromatoses, these are; Neurofibromatosis type 1 (NF1), Neurofibromatosis type 
2 (NF2), and schwannomatosis. Each of these conditions predisposes individuals to 
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various tumours. NF1 is the most common of the three and is characterised by the 
presence of neurofibromas and malignant peripheral nerve sheath tumours (MPNST). 
It has a prevalence of 1:2500-3000 (Jones, Tep et al. 2008, Rodriguez, Stratakis et al. 
2012) and is caused by mutations in the gene encoding for the tumour suppressor 
protein neurofibromin. Neurofibromas can undergo malignant transformation, are 
difficult to resect without residual nerve damage and are usually histopathologically 
distinct from schwannomas. Schwannomas are only rarely associated with NF1 and 
meningiomas are not associated with loss or mutation of NF1 (Hilton and Hanemann 
2014).  
1.2.2    Schwannomatosis  
Schwannomatosis was first alluded to in 1984 (Shishiba, Niimura et al. 1984) and is 
pathologically distinct from NF2 due to the absence of bilateral vestibular 
schwannomas (VS) associated with the condition and absence of ependymomas 
(Jacoby, Jones et al. 1997). There are few patients with schwannomatosis who have a 
demonstrated family history of the condition, therefore most cases are deemed 
sporadic (Hilton and Hanemann 2014). MacCollin et al. studied 14 patients presenting 
with multiple schwannomas and found that one patient had a positive family history 
(MacCollin, Woodfin et al. 1996). Schwannomatosis therefore, although bearing 
similarity to NF2, is a largely distinct condition.  
   In 2007, a study reporting a link between SMARCB1 gene mutation and 
schwannomatosis was published, identifying it as an underlying genetic cause of the 
condition (Hulsebos, Plomp et al. 2007). More recently in 2014, Piotrowski and 
colleagues showed that loss of function mutations in the LZTR1 gene also predispose 
individuals to the formation of multiple schwannomas and in some of those cases, 
SMARCB1 mutations were not observed (Piotrowski, Xie et al. 2014).  
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1.2.3    Neurofibromatosis type 2 
Neurofibromatosis type 2 (NF2) is an autosomal dominant inherited condition that 
predisposes individuals to develop multiple nervous system tumours; primarily 
schwannomas, meningiomas and ependymomas. Prevalence is considered to be 
1:33000-40000 (Rodriguez, Stratakis et al. 2012). NF2 is characterised by loss of the 
tumour suppressor protein Merlin, first identified as the product of the NF2 gene in 
1993 (Rouleau, Merel et al. 1993). A number of mutations have been described 
including nonsense mutations, frame-shift deletions and splice site mutations 
(Ruttledge, Andermann et al. 1996). Disease severity was shown to correlate with type 
of mutation, and those with only single amino acid mutations tended to have milder 
disease than those with mutations leading to protein truncation. 
   Individuals with NF2 are born with a germline mutation in one NF2 allele leading to a 
genetic predisposition to develop multiple tumours early in life, frequently and often 
simultaneously (Bijlsma, Brouwer-Mladin et al. 1992, Rouleau, Merel et al. 1993). Most 
people with NF2 accumulate a somatic mutation in the wild-type allele and it is at this 
point that tumours start to develop; in accordance with the knudson 2-hit hypothesis 
where the second mutation is necessary for loss of tumour suppressor function 
(Knudson 2001).   
1.2.4    Non-NF2 related schwannoma and meningioma 
Sporadic schwannomas not associated with the aforementioned genetic conditions all 
harbour NF2 mutations resulting in Merlin loss (Hanemann 2008). It has been 
estimated that overall one in 1000 people will be diagnosed with a vestibular 
schwannoma in their lifetime (Evans, Moran et al. 2005).  
   Meningiomas are one of the most common brain tumours representing 30% of all 
cases, second only to glioma (Laurendeau, Ferrer et al. 2010). Hereditary 
meningiomas arise as part of genetic predisposition syndromes, most commonly loss 
of the NF2 gene resulting in neurofibromatosis type 2, or to a much lesser extent 
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familial multiple meningiomas; the latter less well defined in its aetiology. Mutations in 
the SMARCB1 gene have been associated with some familial meningiomas. For 
instance, a study conducted on a family of patients with multiple meningiomas 
concluded that along with NF2 gene mutation, mutation in exon 2 of SMARCB1 was a 
relevant factor in these particular tumours (Christiaans, Kenter et al. 2011).  A year 
later, another study on a Finnish family identified loss of function in the SUFU gene in 
seven meningiomas from the same family and not in healthy controls (Aavikko, Li et al. 
2012). SUFU is linked to the Hedgehog signalling pathway, important in oncogenesis 
and previously implicated in NF2 deficient malignant pleural mesothelioma (Felley-
Bosco and Stahel 2014), meningioma (Mawrin and Perry 2010) and some 
schwannomas (Yoshizaki, Nakayama et al. 2006). Mutations in SMARCE1, EPB41L3 
and SHH have also been reported (Smith 2015).  
   Genomic screens are pivotal in identifying mutated genes that allow tumours/ 
patients to be placed in particular sub-groups that only contain those most likely to 
respond to a particular drug. Heterogeneity among tumours in different patient 
populations is perhaps the largest barrier in the way of successful drug therapy (Marte 
2013). Most recently, there have been a number of mutations identified in large-scale 
studies of meningioma that have been hailed as the most significant in non-NF2 
tumours and may pave the way for the development of personalized treatment 
regimens. These are AKT1, SMO, TRAF7 and KLF4 (Brastianos, Horowitz et al. 2013, 
Clark, Erson-Omay et al. 2013)  
   Brastianos and colleagues identified a subset of meningiomas with oncogenic 
mutations in SMO and AKT1. The authors defined significance of each mutation 
identified in the analysis relative to genome wide background rates. In doing this, they 
identified six genes with significant mutation rates in meningioma. These included SMO 
and AKT1, as well as NF2, KDM5C, RGPD3 and CD300C (Brastianos, Horowitz et al. 
2013). The AKT1 mutation identified, E17K, has already been implicated as an 
oncogenic determinant in breast cancer and is able to activate downstream mTOR 
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signalling, known to be relevant in Merlin deficient tumours. Similarly, mutations in 
SMO contribute to activated hedgehog signalling in meningiomas and may act as a 
therapeutic target (Laurendeau, Ferrer et al. 2010). 
   Clark et al also identified SMO and AKT1 mutations although they found TRAF7 to be  
the most frequently mutated gene, in almost 35% of 300 meningiomas analysed (Clark, 
Erson-Omay et al. 2013). A conclusion drawn by the authors was that that these 
distinct subsets of meningiomas generally convey chromosomal stability, whereas 
meningiomas harbouring NF2 mutations tended to be more atypical in nature, with 
chromosomal instability, indicating that NF2 mutation is a potent stimulus for further 
mutations in downstream signalling pathways.  
   Studies like these represent a mainstay of translational cancer research and are 
becoming indispensable in the search for novel targets and more effective therapies.  
1.3    Diagnosis and pathogenesis of NF2 
NF2 is diagnosed clinically according to the Manchester criteria listed in meningiomas 
1.1 (Evans 2009). The majority of NF2-related schwannomas occur around the 
vestibular branches of the eighth cranial nerve, responsible for transmitting sound and 
balance information from the inner ear to the brain. The presence of these 
schwannomas often leads to hearing loss, tinnitus and loss of balance (Evans, Huson 
et al. 1992, Sabha, Au et al. 2012).  
   Meningiomas originate from the arachnoidal cap cells of the meninges and can occur 
either in the brain or the spinal cord (James, Lelke et al. 2008). Their presence can 
impact on surrounding tissue and compress adjacent nerves and blood vessels 
resulting in focal deficits and seizures. Meningiomas also cause increased intracranial 
pressure that can lead to sickness and headaches. 
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Diagnostic ‘Manchester criteria’ for neurofibromatosis type 2 (NF2) (Hilton and 
Hanemann, 2014) 
1 Bilateral vestibular schwannoma (VS) or family history of NF2 plus unilateral 
VS or two of; meningioma, glioma, neurofibroma, schwannoma, posterior 
subcapsular lenticular opacities.  
2 Unilateral VS plus two of meningioma, glioma, neurofibroma, schwannoma, 
posterior subcapsular lenticular opacities.  
3 Two or more meningioma plus unilateral VS or two of; glioma, neurofibroma, 
schwannoma, cataracts. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.1: The Manchester criteria for NF2 diagnosis.   
27 
 
   Schwannomas associated with NF2 are exclusively benign, as are around 80% of 
meningiomas. Around 15% are classified as ‘atypical,’ defined by higher recurrence 
rates and decreased survival compared to benign meningiomas. The remaining few are 
anaplastic meningiomas, and these are characterised by malignant brain invasion and 
poor prognosis (Commins, Atkinson et al. 2007). This benignancy renders them largely 
unresponsive to classic chemotherapeutic agents, leaving surgery and radiosurgery as 
the only remaining treatment options. Furthermore, NF2 patients not only have multiple 
tumours but often experience tumour regrowth following resection (Maillo, Orfao et al. 
2007). As no drugs are currently approved for the treatment of NF2, an effective 
therapeutic is urgently required.  
   NF2 also predisposes to the development of ependymomas which belong to the 
glioma family and effect ependymal tissue within the central nervous system. Around 6% 
of NF2 patients will develop ependymomas (Hanemann 2008), making them the least 
common of the three tumours associated with the condition.  Whilst they have not been 
studied in this project, the aetiology they share with meningiomas and schwannomas 
suggests that the findings presented here may also be relevant for their treatment.  
1.4    Other Merlin-deficient tumours 
In addition to tumours associated with NF2, Merlin loss is also implicated in a number 
of other cancers including Malignant Pleural Mesothelioma (MPM). This is an 
aggressive form of lung cancer caused by asbestos exposure (Bianchi, Mitsunaga et al. 
1995). The association was first reported in 1995 and 40-50% of cases are thought to 
be linked to Merlin loss. More recently, a 2014 study showed that Merlin-deficient 
mesothelioma cells were sensitive to VS-4718 (Shapiro, Kolev et al. 2014) a drug 
targeting the Focal Adhesion Kinase (FAK) pathway, also commonly abrogated in 
schwannomas (Ammoun, Schmid et al. 2012). This suggests that any therapeutic 
targets identified in schwannomas may also be beneficial for a subset of MPM patients.  
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   Merlin deficiency has also been linked to melanoma where Merlin knockdown in a 
melanoma cell line led to increased growth and proliferation. The mammalian ste20 
kinases 1 and 2 (MST1/2) of the Hippo pathway were rendered inactive in this 
experiment and therefore were unable to phosphorylate Yes activated protein (YAP), 
leading to an increase in transcription and thus cell growth (Murray, Lau et al. 2012).  
   Merlin loss has further been linked to malignant breast cancer, where upon Akt-
induced phosphorylation, it is degraded. Re-establishment of Merlin expression in 
breast cancer cell lines led to decreased invasion, migration and cell motility (Morrow, 
Das et al. 2011). Most recently, Merlin expression was assessed in colorectal cancer 
where a distinct pattern of Merlin phosphorylation was detected in tumour compared to 
normal tissue (Cacev, Aralica et al. 2014).  
   NF2 aberrations have also been reported in thyroid, endometrial and liver cancers, as 
well as glioblastoma (GBM) (Houshmandi, Emnett et al. 2009, Schroeder, Angelo et al. 
2014, Garcia-Rendueles, Ricarte-Filho et al. 2015). Recently in 2015, a link between 
Merlin deficiency and pancreatic cancer was identified. The study showed that restored 
Merlin expression led to decreased growth and metastasis in pancreatic cancer cells 
(Quan, Cui et al. 2015).  
   Taken together, these studies indicate a wider role for Merlin loss in tumorigenesis 
outside of NF2 related nervous system tumours and thus make any findings from this 
project potentially valuable for a broad range of cancers.  
1.5    Merlin 
Merlin is an acronym derived from ‘Moesin, Ezrin and Radixin like protein,’ named so 
because of its structural similarity to the ERM superfamily which includes the 
aforementioned proteins. Their function is to transmit signals from the cell membrane/ 
extracellular matrix (ECM) to downstream components inside the cell (Bretscher, 
Chambers et al. 2000, Li, Nance et al. 2007). ERM proteins are able to interact directly 
with actin and can play crucial roles in cell remodelling and the localization of receptor 
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tyrosine kinases (RTKs) to the cell membrane. A FERM domain is shared by all 
members of this family and its amino acid sequence is highly conserved.  Found at the 
N-terminus, the FERM domain facilitates the interaction between ERM proteins and the 
cell membrane, and is the key functional feature of these ‘membrane-cytoskeletal linker 
proteins’ (Chishti, Kim et al. 1998).  
   Merlin is expressed as two isoforms; predominantly isoform 1, the structure of which 
can be viewed in Figure 1.1A. Isoform 1 is 595 amino acids (AA) in length, whereas 
isoform 2 is 590 AA. The two share identical sequence homology for 579 residues, but 
after this point isoform 2 lacks the necessary C-terminal motif required for 
intramolecular binding (Cooper and Giancotti 2014). Nonetheless, isoform 2 has been 
shown to possess tumour suppressive capabilities much in line with those reported for 
isoform 1 (Lallemand, Saint-Amaux et al. 2009, Sher, Hanemann et al. 2012).  
1.5.1    Regulation of Merlin  
Post-translational control of Merlin is crucial to its proper functioning. Like other ERM 
proteins, Merlins FERM domain is able to interact directly with its C-terminus tail (CTT) 
forming a closed loop structure (Gary and Bretscher 1995) (Figure 1.1B). In most ERM 
proteins, this association is regulated by phosphorylation of a conserved threonine (Thr) 
residue contained within the CTT. When this Thr is phosphorylated, the interaction is 
disrupted, leading to an open and activated state. Merlin on the other hand is 
phosphorylated at a unique Serine (Ser/ S) residue, S518. Rong et al observed that 
S518 phosphorylation, induced by PAK2, reduced the association between the two 
domains, leading to an open conformation of the protein. Interestingly, in contrast to 
other ERM proteins this renders Merlin inactive by negatively modulating its ligand 
binding capability (Rong, Surace et al. 2004).  
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Figure 1.1: A) A schematic representation of the structure of Merlin (Adapted from Giancotti and 
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from Li et al (Li, Zhou et al. 2015)). CTT: C-Terminal Tail. 
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   Most recently, an idea has been proposed that Merlin is neither fully open nor fully 
closed and that this is dependent on its environment at any given time (Sher, 
Hanemann et al. 2012). This study concluded that S518 phosphorylation points Merlin 
towards a more, but not fully, closed conformation whereby its growth suppressive 
function is compromised, and that unphosphorylated Merlin is in a more, but not fully, 
open state. As such, there is a high degree of flexibility whilst Merlin remains in this 
conformation allowing subtle changes dependent on post-translational modifications. 
1.6    Merlin as a tumour suppressor protein 
The most significant characteristic that sets Merlin apart from other ERM proteins is its 
putative role as a tumour suppressor protein (TSP). There are a variety of mechanisms 
by which Merlin is able to perform its tumour suppressive duties, and these are 
summarised in Figure 1.2.  
   In contrast to other TSPs Merlin generally localizes to the interface between the cell 
membrane and the Extracellular Matrix (ECM). In 2003 it was reported that the major 
consequence of Merlin deficiency in primary cells is the inability to undergo contact-
dependent growth arrest (Lallemand, Curto et al. 2003). In the normal confluent cell, 
Merlin translocates to adherens junctions (AJ) where it is able to orchestrate contact-
inhibition signals and encourage growth arrest (Flaiz, Utermark et al. 2008). Adherens 
junctions are important for the stabilization of cell-cell adhesion and are central to 
contact inhibition of cell growth, and as such are important for tumour suppression 
(Hartsock and Nelson 2008). Merlin interacts specifically with β-catenin at adherens 
junctions, as identified by Lallemand et al. who were able to show that the two proteins 
co-immunoprecipitate.  
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Figure 1.2: A flowchart highlighting the tumour suppressive activities of Merlin. Merlin 
loss leads to the activation of several Receptor Tyrosine Kinases (RTKs) in turn permitting 
tumour growth, survival and proliferation.  
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Later, Zhou et al. showed that Merlins interaction with β-catenin at the site of adherens 
junctions is inhibitory to cell growth and proliferation. In Merlin-deficient schwannoma 
cells an increase of β-catenin phosphorylation was observed at tyrosine (Tyr/ Y) Y654, 
mediated by Src/ PDGFR (Platelet Derived Growth Factor Receptor) which contributed 
to enhanced nuclear translocation of β-catenin and subsequent AJ destabilization 
(Zhou, Ercolano et al. 2011). 
1.7    Receptor tyrosine kinase expression in meningioma and schwannoma 
Merlin controls membrane receptor availability by regulating endocytic trafficking 
(Fraenzer, Pan et al. 2003, Maitra, Kulikauskas et al. 2006, Muranen, Gronholm et al. 
2007). Muranen et al. proposed that Merlin deficiency leads to a decrease in 
microtubule polymerization and that resultant microtubule dysregulation then leads to 
slower receptor recycling. As a result, receptors are not internalized as efficiently or 
quickly ultimately leading to prolonged activation of downstream signalling pathways. 
This was supported by Hennigan et al. in 2013 who showed that Merlin loss led to 
decreased intracellular vesicular trafficking, in a Rac dependent manner (Hennigan, 
Moon et al. 2013). Maitra et al. suggested that Merlin plays a role in sorting of cargo 
between endosomes and lysosomes for degradation (Maitra, Kulikauskas et al. 2006). 
As such, the authors showed that in Merlin-deficient cells, there was an increased 
presence of receptors on the cell membrane. Further, Scoles et al. showed that Merlin 
co-localized to early endosomes with a Hepatocyte Growth Factor (HGF) receptor 
substrate (Scoles, Huynh et al. 2000). As early endosomes are important for 
determining membrane receptor fate, this study supports the notion that Merlin in part 
exhibits its tumour suppressive effects via early endosome regulation.  
   The PDGFR-BB is a cell surface tyrosine kinase receptor highly expressed in 
meningioma and schwannoma cells, as such it has been extensively studied in both 
cell types (Yang and Xu 2001, Fraenzer, Pan et al. 2003, Ammoun, Flaiz et al. 2008). 
In 2014, Agnihotri and colleagues performed gene expression profiling of 47 vestibular 
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schwannomas and identified PDGFRβ as upregulated with an overall fold change of 
37.2 compared to seven normal control nerves (Agnihotri, Gugel et al. 2014). PDGFRβ 
activation was most recently confirmed in meningioma in 2015, with 83% of tumours 
staining positive for the receptor upon immunohistochemical analysis (Hilton, Shivane 
et al. 2015). A study by Fraenzer et al. found that overexpression of Merlin increased 
the rate of PDGFR degradation and decreased the proliferation rate of a human 
schwannoma cell line (Fraenzer, Pan et al. 2003). Mukherjee et al. also showed that 
Imatinib (Gleevec) treated schwannoma cells exhibited deceased viability and 
proliferation, as mediated by deactivation of PDGFRα and PDGFRβ (Mukherjee, 
Kamnasaran et al. 2009). Ammoun et al. also showed that Imatinib was able to 
decrease PDGFRβ mediated ERK1/2 and Akt phosphorylation in primary schwannoma 
cells (Ammoun, Schmid et al. 2011). Payre and colleagues demonstrated a correlation 
between Merlin loss and PDGFR expression in human meningioma samples, and 
showed that NF2-deficient mice overexpressing PDGF developed malignant 
meningiomas (Peyre, Salaud et al. 2015).  
   Merlin is also able to regulate ErbB family receptors and several studies have 
highlighted the Epidermal Growth Factor Receptor (EGFR) family as potential 
therapeutic targets for both meningioma and schwannoma. Merlin knockdown in 
primary human Schwann cells led to the upregulation of ErbB2/3 and consequent 
increased proliferation (Ahmad, Brown et al. 2010). Curto and colleagues showed that 
Merlin is able to regulate EGFR at the site of adherens junctions, by sequestering it in a 
membrane compartment where it is not able to signal (Curto, Cole et al. 2007). In 
Merlin-null mouse embryonic fibroblasts, osteoblasts and liver-derived epithelial cells, 
the EGFR was able to constitutively drive proliferation that could be abrogated by 
EGFR inhibitors. Similarly Ammoun and Cunliffe identified consistent overexpression 
and activation of ErbB receptors, and showed that their inhibition led to significant 
decreases in primary schwannoma cell proliferation (Ammoun, Cunliffe et al. 2010). 
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   Baxter et al. found that over 80% of meningiomas stained positive for EGFR 
suggesting it as a possible therapeutic target (Baxter, Orrego et al. 2014). This was 
supported by Wernicke et al. who found that almost all of 85 meningioma samples 
analysed were EGFR positive. Furthermore, they found staining to be highest in benign 
tumours, suggesting it might be more relevant for these than those of higher grade 
(Wernicke, Dicker et al. 2010). In contrast to these findings, Hilton and colleagues 
performed immunohistochemical analysis in 30 meningioma samples of varying grade 
and sub-type, and were only able to identify EGFR activation in NF2 wild type tumours, 
concluding that it may not be a good target for Merlin-deficient meningiomas (Hilton, 
Shivane et al. 2015). Whilst there are several studies of EGFR expression in 
meningioma, there are no reported functional studies of the receptor in these tumours. 
There have however been a number of clinical trials assessing the effectiveness of 
various EGFR inhibitors, and these will be discussed in more detail later.   
   Another receptor known to be important in schwannomas is the Insulin-like growth 
factor receptor (IGFR). Ammoun et al. showed that the IGF-IR is strongly expressed 
and activated in primary human schwannoma cells (Ammoun, Schmid et al. 2012). This 
overexpression was linked to enhanced growth and survival via ERK1/2 and AKT, and 
inhibition of the receptor led to reductions in both. Lallemand and colleagues also found 
that the levels of IGF1R on the membrane of Merlin-null Schwann cells were elevated 
compared to control cells expressing Merlin (Lallemand, Manent et al. 2009). 
Dysregulation of IGFs has also been proposed as a marker of anaplasia in 
meningiomas, and a high ratio of IGF-II vs. IGFBP-2 stimulates proliferation (Nordqvist, 
Peyrard et al. 1997). Later studies were also able to identify various members of the 
IGF signalling family as upregulated in meningioma, with Wrobel et al. also suggesting 
this phenomenon as an indicator of meningioma progression (Watson, Gutmann et al. 
2002, Wrobel, Roerig et al. 2005, Hilton, Shivane et al. 2015).  
   Another RTK that has been studied in both tumour types is the Vascular Endothelial 
Growth Factor Receptor (VEGFR) that is integral to angiogenesis in a wide variety of 
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tumours. The receptor has been reported as highly expressed in both meningioma and 
schwannoma (Uesaka, Shono et al. 2007, Baumgarten, Brokinkel et al. 2013, Hilton, 
Shivane et al. 2015), and as a direct contributor to vestibular schwannoma growth 
(Caye-Thomasen, Werther et al. 2005). Pfister et al. also observed that VEGF is able 
to signal through the PDGFR-β causing tyrosine activation and a proliferative response 
in meningiomas, comparable to that after stimulation with its own ligand (Pfister, 
Pfrommer et al. 2012). In 2010 Wong and colleagues implanted mice with Merlin-
deficient cells that would mimic growth of central and peripheral schwannomas. They 
found that treatment with Bevacizumab and Vandetanib led to reductions in growth and 
increased apoptosis (Wong, Lahdenranta et al. 2010). Collectively these data support 
the VEGFR as a suitable therapeutic target; however the validity of VEGFR inhibitors in 
a clinical setting will be re-visited later on in the chapter.  
   Merlin-deficient cells exhibit increased mitogenic signalling in part due to integrin 
overexpression on the cell membrane. Utermark et al. identified integrins alpha6, beta1 
and beta4 clustered on the schwannoma cell surface and showed that they were 
largely responsible for the enhanced ECM adhesion observed in schwannoma cells, 
compared to normal Schwann cells (Utermark, Kaempchen et al. 2003). Integrin 
overexpression was previously shown to activate mitogenic signalling inside the cell 
and an earlier study demonstrated that the coupling of integrin alpha6 and beta4 was 
able to stimulate both RAS and ERK activation (Mainiero, Murgia et al. 1997). This 
helps to explain the hyper-activation of these signalling cascades that contribute to  
schwannoma pathology, and highlight disruption of integrin mediated signalling as a 
promising avenue for therapeutic intervention.  
   Merlin also plays a role in FAK/Src signalling via a variety of mechanisms. FAK is 
important for transducing signals from integrins and RTKs at the membrane inside the 
cell and is overexpressed in schwannoma (Ammoun, Flaiz et al. 2008). Ammoun et al. 
demonstrated that FAK signalling can be regulated by Axl, an RTK that is upregulated 
in schwannoma and meningioma (Ammoun, Provenzano et al. 2014, Hilton, Shivane et 
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al. 2015) and is negatively regulated by Merlin. Increased Axl signalling increases FAK 
expression leading to pathological cell-matrix adhesion and enhanced survival.  
1.8    Regulation of downstream signalling pathways by Merlin  
Merlin can directly bind to tubulin increasing stability and reducing turnover (Smole, 
Thoma et al. 2014). The resulting disequilibrium between polymerization and 
depolymerisation that occurs when Merlin is lost contributes to enhanced cytoskeletal 
reorganization and tumorigenesis, and forms the basis of pathologies associated with 
Merlin deficiency.  
   Merlin is also a potent inhibitor of p21-Activated kinase 1 (PAK1). PAK1 and other 
members of this protein family are regulators of cell morphology, motility and apoptosis 
(Jaffer and Chernoff 2002). It has been shown that Merlin interacts with PAK1 thereby 
modulating its function (Kaempchen, Mielke et al. 2003, Kissil, Wilker et al. 2003, 
Hirokawa, Tikoo et al. 2004, Xiao, Gallagher et al. 2005). In normal cells, PAK1 is 
inhibited by Merlin leading to suppression of Rac signalling and ultimately growth arrest. 
Shaw et al. found that inhibition of Rac by Merlin in the mouse embryonic fibroblast cell 
line NIH3T3 led to decreased colony formation and reduced levels of downstream 
phosphorylated c-Jun N-terminal kinase (JNK). Merlin is also able to inhibit PAK1 
induced cyclin D1 expression, causing a decrease in proliferation rate through G1 cell 
cycle arrest in mesothelioma cell lines (Xiao, Gallagher et al. 2005).  
   Merlin has also been linked to the Hippo pathway, which is important for organ size 
control and contributes to tumorigenesis when deregulated. In confluent cells, the 
Hippo pathway is activated resulting in phosphorylation of Yes Activated Protein (YAP) 
that leads to its retention in the cytoplasm; whereby it cannot translocate to the nucleus 
and act as a transcriptional activator (Zhao, Li et al. 2010). A 2010 study found that 
inactivation of Merlin led to liver cell hyperplasia and a decrease in YAP 
phosphorylation, supporting Merlins cytoplasmic role as a facilitator of growth 
suppressive Hippo signalling (Zhang, Bai et al. 2010). In addition, Merlin is also able to 
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act in the nucleus directly, by binding to and inhibiting the promitogenic E3 ubiquitin 
ligase and general transcription regulator, CRL4DCAF1 (Li, Cooper et al. 2014). The 
authors found that Merlin re-expression induced similar effects to DCAF1 silencing in 
primary human schwannoma cells, indicating that CRL4DCAF1 activation caused by loss 
of Merlin is significant in tumorigenesis. 
   Another pathway in which Merlin is centrally involved is the Mitogen Activated Protein 
Kinase (MAPK) pathway that is notably deregulated in schwannoma (Kaempchen, 
Mielke et al. 2003, Morrison, Sperka et al. 2007, Ammoun, Flaiz et al. 2008). Merlin 
deficient schwannoma cells displayed prolonged ERK1/2 activation in comparison to 
healthy Schwann cells in response to elevated PDGFB signalling. Yi et al. found that 
Merlins action on the MAPK pathway is related to another protein, angiomotin (Yi, 
Troutman et al. 2011). The two were found to co-localize in Schwann cells functioning 
antagonistically to regulate signalling. When Merlin is bound to angiomotin, an effector 
protein, rich1, is released and able to inactivate Rac1 leading to decreased proliferation.  
   Merlin is also implicated in PI3K/Akt/mTOR signalling. A 2004 study showed that 
Merlin disrupts the binding of PIKE-L to PI3K, inhibiting its kinase activity and 
attenuating the signalling cascade (Rong, Tang et al. 2004). PI3K signalling is linked to 
enhanced proliferation in a variety of tumours and is associated with both meningioma 
and schwannoma tumorigenesis.  
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Figure 1.3: Drug targets and inhibitors reported to have beneficial effects on NF2 
tumours. There are several proteins that have been identified as drug targets for NF2 tumours 
including growth factor receptors that are overexpressed in both schwannoma and meningioma 
(adapted from (Agarwal, Liebe et al. 2014) 
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   Studies have shown via both immunohistochemistry and microarray that PI3/Akt 
components are upregulated and activated in schwannomas compared to normal nerve, 
thus representing potential therapeutic targets (Hanemann, Bartelt-Kirbach et al. 2006, 
Jacob, Lee et al. 2008, Hilton, Ristic et al. 2009). Similarly in meningiomas, 100% of 
tumours of all grades stained positively for pAkt (Hilton, Shivane et al. 2015). In 2014, 
Petrilli et al. identified an effective PI3K inhibitor (AS605420) via high-throughput 
compound screening and showed that it had potent pro-apoptotic effects on 
functionally Merlin-null Schwann cells inducing autophagy in those cells (Petrilli, Fuse 
et al. 2014). Altogether, the PI3K/ mTOR pathway represents a promising avenue for 
therapeutic intervention and inhibitors targeting this signalling cascade have been 
trialled in both meningioma and schwannoma. These results will be discussed in more 
detail later in the chapter.  
1.9    Molecular targets and NF2 drug candidates  
The mainstays of treatment for NF2, surgery and radiosurgery, have been associated 
with complications including vestibular dysfunction and the development of secondary 
malignancies (Evans, Birch et al. 2006). As no drugs have been approved for patients 
with NF2, translational research remains ongoing in efforts to identify new targets 
and/or therapies already approved for other tumour types that might be effective also 
for NF2 brain tumours. Figure 1.3 highlights the most relevant signalling pathways in 
NF2 and also shows some of the inhibitors known to have beneficial effects in NF2- 
related tumours models.  
   The most straightforward way to target cancer cells is to inhibit receptors at the cell 
membrane. Since the VEGFR is highly expressed in meningioma and schwannoma, 
targeting its ligand VEGF represents a promising treatment strategy for NF2. A phase II 
trial of PCT299, a VEGF inhibitor, began recruiting in 2009 but is yet to report any 
findings. Another VEGF inhibitor that has received considerable attention is 
Bevacizumab, that has been previously studied in glioblastoma (Uesaka, Shono et al. 
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2007, Chamberlain 2011). A 2012 retrospective review of 31 patients found that 
bevacizumab treatment led to tumour shrinkage in over 50% of NF2 patients with 
vestibular schwannomas, accompanied by hearing improvement (Plotkin, Merker et al. 
2012). Another review of 12 NF2 patients showed that bevacizumab was effective in 50% 
of the cases. One patient however died from cerebral haemorrhage possibly in 
response to the therapy, highlighting the chance of fatal complications (Alanin, Klausen 
et al. 2014). Bevacizumab has also been linked to long-term toxicity relating to blood 
pressure and proteinuria in NF2 patients, emphasizing the need for rigorous dose 
control and monitoring by clinicians (Slusarz, Merker et al. 2014). This is because any 
therapy approved for NF2 treatment must confer long-term tolerability, given the benign 
nature of these tumours and the requirement for lifelong drug treatment. In meningioma, 
a response to bevacizumab was observed in only 14 out of 48 tumours indicating that it 
is not ideal as a general treatment for NF2 (Nunes, Merker et al. 2013). 
   A clinical trial for another VEGFR inhibitor, Axitinib, began recruiting in 2014 and 
aims to assess whether the drug is able to reduce schwannoma and possibly 
meningioma volume in NF2 patients. It has already been shown to have a favourable 
tolerability profile in renal cell carcinoma (Escudier and Gore 2011), and may therefore 
represent a good alternative to Bevacizumab.  
   As studies have identified the RTKs EGFR and ErbB2 as overexpressed/ activated in 
schwannoma (Curto, Cole et al. 2007, Ammoun, Cunliffe et al. 2010), the efficacy of 
the dual inhibitor Lapatinib was assessed in a phase II clinical trial for vestibular 
schwannoma (Karajannis, Legault et al. 2012). 17 out of 21 patients experienced a 
reduction in tumour volume of at least 15%, although usually a 20% reduction is 
considered to be a significant response. Several of those also experienced 
improvements in hearing. The authors concluded that, whilst objectively efficacious in 
some patients, Lapatinib might be more suitable as a combinatorial therapy alongside 
Bevacizumab. A phase II trial testing this combination found it effective in several 
patients with metastatic breast cancer (Rugo, Chien et al. 2012) . An inhibitor of ErbB2, 
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Trastuzumab, has also been assessed in a preliminary study looking at VS xenografts 
in mice. The inhibitor was able to induce a significant decrease in tumour growth, 
warranting further investigation (Clark, Provenzano et al. 2008).  
   Nilotinib, a small molecular inhibitor targeting both the PDGF receptor and the BCR-
ABL oncoprotein has also been assessed in vitro for the treatment of schwannoma 
(Ammoun, Schmid et al. 2011, Sabha, Au et al. 2012). Both studies showed significant 
anti-tumour effects demonstrated by downregulation of PDGF mediated cell growth and 
proliferation. As Nilotinib has already been shown through trials to have generally high 
safety and tolerability, it therefore represents a good candidate for clinical trials in 
schwannoma. A phase II trial began in 2010 (NCT01201538) however no results have 
yet been reported.  
   Sorafenib, another small molecular inhibitor targeting the PDGFR and VEGFR is 
currently being assessed in a phase 0 trial for the treatment of schwannomas. This is 
based on in vitro results obtained by Ammoun et al. that showed Sorafenib treatment 
decreased ERK1/2 activity and decreased proliferation in human primary schwannoma 
cells (Ammoun, Flaiz et al. 2008).  
   The mTOR pathway is also an important mediator of growth and proliferation in 
Merlin null tumour cells (James, Han et al. 2009) thus warranting investigation as a 
potential target in NF2 treatment. The mTOR inhibitor Everolimus has been tested in 
clinical trials as a general therapy for NF2. The results of a phase II study assessing 
the effectiveness of Everolimus in NF2 patients were published early in 2015. The 
primary endpoint was a reduction of > 20% in tumour volume from baseline, which 0/10 
patients were able to achieve (Goutagny, Raymond et al. 2015). Goutagny et al. found 
that although Everolimus was unable to induce VS shrinkage, it was able to increase 
stabilization and cause growth delay (Goutagny, Raymond et al. 2015). Everolimus 
was also able to decrease cell survival and growth in both malignant and benign 
meningioma cell lines (Pachow, Andrae et al. 2013). Whilst Everolimus was unable to 
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reduce tumour size in schwannoma, its ability to cause growth delay means that it 
might still represent a potential drug therapy for NF2.  
    The MEK inhibitor Selumetinib (AZD6244) has also been tested pre-clinically in 
primary schwannoma cells and was shown to completely abolish PDGF mediated cell 
proliferation (Ammoun, Ristic et al. 2010). As this pathway is the most prominent in 
schwannoma pathogenesis, these results highlight MEK as a promising therapeutic 
target that may also be useful for meningioma treatment. 
   Another inhibitor that has proven efficacy in both meningioma and schwannoma is 
AR-42, targeting Histone deacetylases (HDAC). Burns and colleagues showed that 
AR-42 induced the pro-apoptotic protein Bim and decreased the potential for tumour 
re-growth after treatment in meningioma cells (Burns, Akhmametyeva et al. 2013). 
Further, Jacob et al. also showed that AR-42 was able to suppress growth and induce 
apoptosis in murine schwannoma xenografts (Jacob, Oblinger et al. 2012). Both 
studies also concluded that AR-42 is well tolerated. Subsequently, a phase 0 trial 
began recruiting in 2014 (NCT02282917) assessing AR-42 in both schwannomas and 
meningiomas and is still actively recruiting.  
1.10    Omics approaches to identify novel targets in NF2  
“Omics” is a term used to describe holistic approaches to the study of expression 
and/or regulation in any given organism. As such, omics techniques may be used to 
study genomes, proteomes, transcriptomes and metabolomes, among others 
(Chambliss and Chan 2016).  Commonly used methods include Next Generation 
Genome Sequencing (NGS) which is a collection of techniques useful for identifying 
DNA mutations or epigenetic regulatory mechanisms that can be exploited in disease 
therapy, particularly in cancer (Chambliss and Chan 2016). Mass spectrometry is used 
to study protein expression, and also post-translational modifications (PTMs) such as 
phosphorylation and acetylation. The main advantage of omics technologies is their 
provision of large, complex, unbiased data sets otherwise difficult to obtain. Most omics 
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techniques are intended to identify biomarkers for more efficient diagnostics, and new 
targets for disease treatment. There have been a wealth of studies conducted utilizing 
genomics technologies in the search for NF2 biomarkers, drug targets and markers of 
progression (Buckley, Mantripragada et al. 2005, Lusis, Chicoine et al. 2005, Wrobel, 
Roerig et al. 2005, Hanemann, Bartelt-Kirbach et al. 2006, Aarhus, Bruland et al. 2010, 
Caye-Thomasen, Borup et al. 2010, Chang, Shi et al. 2013, Agnihotri, Gugel et al. 
2014) and also for predicting disease recurrence (Bie, Zhao et al. 2011).  
   Hanemann et al. identified 41 genes by cDNA microarray and validated 36 of those 
by Real-Time Polymerase Chain Reaction (RT-PCR), finding seven to be significantly 
upregulated in schwannoma compared to Schwann cell cultures including VEGF and 
IGFBP-1 (Hanemann, Bartelt-Kirbach et al. 2006). A 2014 study of 49 schwannomas 
vs. 7 vestibular nerve tissues, the largest to date, identified over 4000 differentially 
expressed genes by Affymetrix gene expression profiling. They concluded that the 
PI3K/Akt/mTOR pathway is the most relevant therapeutic target for schwannoma 
patients (Agnihotri, Gugel et al. 2014). Caye-Thomasen et al. performed microarray 
analysis of 16 schwannomas compared to vestibular nerves and found proteins linked 
to the extracellular matrix and cell adhesion to be the most relevant (Caye-Thomasen, 
Borup et al. 2010). Finally Torres-Martin and colleagues performed a genomic analysis 
of 31 vestibular schwannomas and identified dysregulation among 1,516 genes 
compared to normal control nerves, concluding that there is considerable upregulation 
of several miRNAs that may represent therapeutic targets (Torres-Martin, Lassaletta et 
al. 2013). 
   Several studies looking at gene expression in meningioma have focussed on 
obtaining specific genomic signatures relating to WHO grade I, II or III (Wrobel, Roerig 
et al. 2005, Carvalho, Smirnov et al. 2007, Fevre-Montange, Champier et al. 2009). 
Carvalho et al. failed to find any significant difference in expression between benign, 
atypical and anaplastic meningioma (Carvalho, Smirnov et al. 2007), but found that 
tumours across all three grades can be defined collectively as either ‘low proliferative,’ 
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or ‘high proliferative.’ The latter were generally classified based on the reduced 
expression of genes corresponding to Transforming Growth Factor-beta (TGF-β) 
signalling. These data indicate that perhaps targets should be identified that are 
overexpressed in all tumour grades compared to control, allowing us to treat all grades 
with the same therapeutic agents. In contrast, a 2012 study looking at differences 
between benign meningioma and brain arachnoid tissue by cDNA microarray found 
that ECM interaction and focal adhesion pathways were more highly activated in grade 
II meningioma compared to grade I. EGFL6, a member of the EGF family of proteins, 
was upregulated in benign tumours compared to healthy arachnoidal tissue and, similar 
to Agnihotris study in schwannomas, several components of the PI3K/Akt pathway 
were upregulated in meningioma tumour tissue (Wang, Gong et al. 2012). This reflects 
what was already known in the field and highlights it as a promising area for further 
study.  
   A recent genomic analysis between meningioma and schwannoma identified Platelet- 
Derived Growth Factor Alpha (PDGFA), Slit Guidance Ligand 2 (SLIT2), Cadherin-1 
(CDH1) and tyrosine-kinase protein met (MET) as mutually upregulated compared to 
their respective controls. Functional annotation identified both the inflammatory 
response and cell migration as biological processes concomitantly upregulated in both 
tumour types (Torres-Martin, Lassaletta et al. 2014). The authors concluded that 
pathways relating to PDGF, c-MET and SLIT2 were the most promising targets for 
therapeutic intervention.  
1.11    The proteomic approach 
Proteomic methods are generally more time consuming and require more biological 
material than genomic techniques. For this reason, more studies have been published 
that look at gene expression, which does not always correspond to what is happening 
at the protein level. And since it is proteins that are more commonly exploited as drug 
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targets, analysing the proteome is a more relevant method to identify potential novel 
therapeutic candidates and/ or biomarkers.   
   Most proteomics studies utilize mass spectrometry (MS), which allows the 
identification of thousands of proteins in individual experiments. As it is quite a 
specialised and expensive technique, the number of studies published in this field is 
relatively few. The first example of a proteomic comparison between meningioma 
grades was published in 2006 (Okamoto, Li et al. 2006). Using 2D gel electrophoresis 
coupled with MS, the investigators identified nine proteins significantly overexpressed 
in atypical compared to benign meningiomas, and six that were downregulated. A later 
study compared grade I meningioma with arachnoid tissue and found 281 proteins to 
be differentially expressed, including several proteins of the minichromosome 
maintenance (MCM) family, many of which were exclusively expressed in tumours and 
might therefore represent reliable meningioma biomarkers (Saydam, Senol et al. 2010). 
In 2015, Sharma et al. identified 290 upregulated proteins across 14 grade I 
meningiomas compared to healthy brain tissue. These represented several biological 
pathways including integrin signalling and, as in the genomic studies discussed 
previously, mTOR signalling (Sharma, Ray et al. 2015).  
   There is one study published that utilized MS to analyse VS, which only compared 
two schwannomas against two healthy nerve specimens. The authors identified 29 
differentially expressed proteins, and concluded that seven are involved in apoptosis.  
(Seo, Park et al. 2015). An earlier study was able to identify the most frequently 
activated RTKs in 68 schwannomas, using RTK arrays to confirm the activation of 
PDGFR and ErbB2. The study also used reverse-phase protein array (RPPA) to 
measure the activity of known components of mitogenic signalling pathways, and 
identified a YAP-driven network linked to proliferation (Boin, Couvelard et al. 2014). 
This is in keeping with Merlins known regulatory role within the Hippo pathway (Zhao, 
Li et al. 2010).  
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1.12    Studying the phosphoproteome 
Phosphorylation is a post-translational modification and a key mechanism of protein 
regulation. Abnormalities in protein phosphorylation give rise to various disease states, 
including cancer (Blume-Jensen and Hunter 2001, Zhou, Di Palma et al. 2013). 
Approximately 30% of the whole eukaryotic proteome is transiently phosphorylated at 
any one time (Cohen 2000, Ruprecht, Koch et al. 2015). As phosphorylated proteins 
represent a relatively small fraction of the total proteome, enrichment is necessary to 
minimize background noise from more abundant non-phosphorylated proteins. The 
study of phosphorylation has seen the most advances over the course of the last 20 
years, and there are now several methods that have been developed to enable the 
most comprehensive coverage of the phosphoproteome than ever before.   
   Phosphoprotein isolation (Figure 1.4, left) separates phosphorylated proteins from 
their unphosphorylated counterparts prior to in-gel digestion. Phosphoproteins bind by 
affinity chromatography to a column and non-phosphorylated proteins flow through. 
Phosphoproteins are then eluted, separated on an acrylamide gel, digested and 
measured by MS.  
   Phosphopeptide enrichment begins when whole cell lysates are first subjected to in-
gel tryptic digestion, and resulting peptides are subsequently enriched. At this point, the 
majority of unphosphorylated peptides are washed away leaving only phosphorylated 
peptides for MS analysis (Figure 1.4, right).  
1.12.1    Phosphopeptide enrichment  
The primary enrichment techniques are Immobilized Metal Affinity Chromatography 
(IMAC) and the more recently developed Titanium dioxide (TiO2). The latter has been 
used for phosphopeptide enrichment since 2004/5 when the first studies were 
published (Kuroda, Shintani et al. 2004, Pinkse, Uitto et al. 2004, Larsen, Thingholm et 
al. 2005) providing proof of concept that TiO2 was a suitable material for this purpose. 
Larsen’s study included 2, 5-dihydroxy- benzoic acid (DHB) in the loading buffer in an 
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attempt to decrease non-specific binding and found that this increased the selectivity to 
above that of previous reports for IMAC (Larsen, Thingholm et al. 2005). The authors 
tested both methods with a variety of different detergents/ buffers and found TiO2 to 
retain some binding efficacy, even in the presence of strong detergents such as 
Sodium Dodecyl Sulphate (SDS). Whilst IMAC is still widely used and somewhat 
effective, TiO2 may be considered superior simply because it is compatible with a wider 
spectrum of reagents. For this reason, TiO2 was selected for use in this project. 
1.12.2    Phosphoprotein purification  
Phosphoprotein purification can be used to separate phosphorylated proteins from their 
non-phosphorylated counterparts prior to digestion. Whilst this method is effective, 
unlike phosphopeptide enrichment it is more difficult to derive phospho site-specific 
information. This is because there is generally a higher ratio of non-phosphorylated 
peptides in the final sample, which can affect the overall identification of 
phosphopeptides. However, advantageously the technique requires less material and 
is technically less challenging than the phosphopeptide enrichment procedure.  
   There are several examples in the literature detailing the successful application of 
this method, including studies in mammalian cells, yeast and plants (Metodiev, 
Timanova et al. 2004, Makrantoni, Antrobus et al. 2005, Meimoun, Ambard-Bretteville 
et al. 2007, Santamaria, Sanchez-Quiles et al. 2012). All of them concluded that the 
Qiagen™ affinity column is efficient and effective for the selective purification of 
phosphorylated proteins that can then be analysed by MS. 
   Metodiev and colleagues were able to demonstrate the striking capability of these 
columns to retain phosphorylated proteins whilst their non-phosphorylated counterparts 
flow through. Using a phospho-tyrosine specific antibody, the authors showed that the 
flow-through fraction did not contain any tyrosine-phosphorylated proteins whilst many 
were seen in the retained fraction. Similarly, Meimoun et al. used 32p-phosphate 
labelled proteins to analyse the phosphoproteome of Sorghum plants, concluding that 
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the affinity column is able to capture at least 80% of phosphorylated proteins (Meimoun, 
Ambard-Bretteville et al. 2007). 
   Based on the positive results reported in these studies, this method was utilized 
extensively for the global phosphoproteomic analysis of meningioma and schwannoma 
cells compared to their respective controls.  
1.13    Aim 
The aim of this study is to identify and validate novel therapeutic targets to enable 
treatment of Merlin-deficient meningiomas and schwannomas especially when they 
arise as part of the genetic condition NF2. This study presents a novel, comparative 
exploration of commonly aberrantly phosphorylated proteins in both cell types, as a 
step towards an effective treatment for NF2 patients. Using a combination of 
phosphoprotein purification, MS and complex data analysis, we aim to identify 
phosphoproteins that have the potential to be further analysed and eventually 
harnessed in a clinical setting. 
 
   The datasets obtained for both tumour types will first be analysed independently to 
identify changes specific to either schwannoma or meningioma. Following that, the 
data will be analysed comparatively to identify common potential therapeutic targets 
that will be validated and functionally assessed in both cell types. 
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.  
Figure 1.4: A schematic representation of the phosphoproteomic workflow. Phosphoprotein 
isolation separates phosphorylated whole proteins from non-phosphorylated whole proteins. 
Phosphopeptide enrichment is performed on digested peptides. In both cases, proteins/ peptides 
that are not phosphorylated do not bind to the column and are washed away. 
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Chapter 2- Materials and methods 
Antibodies 
Table 2.1: Antibodies used in this study 
Antibody Type Clone Company Dilution 
Merlin/ NF2 Rabbit 
polyclonal 
D1D8 Cell signalling 1:1000 
GAPDH Mouse 
monoclonal 
6C5 Millipore 1:50000 
STAT1_Y701(Western blot) Rabbit 
polyclonal 
 R and D 
systems 
1:1000 
STAT1_Y701 
(Immunoprecipitation) 
Rabbit 
monoclonal 
D4A7 Cell signalling  1:40 
STAT1_S727 Rabbit 
polyclonal 
 Cell signalling 1:1000 
STAT1 Rabbit 
polyclonal 
 Santa Cruz 
biotechnology 
1:1000 
pERK Rabbit 
polyclonal 
 BD biosciences  1:1000 
Total ERK Rabbit 
monoclonal 
137F5 Cell signalling 1:2000 
PDLIM2 (western blot) Rabbit 
polyclonal 
 Cell signalling 1:500 
PDLIM2 
(Immunocytochemistry and 
immunoprecipitation) 
Rabbit 
polyclonal 
H-71 Santa Cruz 
biotechnology 
1:200 
HSPA1A Mouse 
monoclonal  
C92F3A-5 Novus 
biologicals 
1:1000 
HSPA1A_Y525 
(Immunohistochemistry) 
Rabbit 
polyclonal 
 Biorbyt 1:200 
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HSPA1A_Y41 Rabbit 
polyclonal 
 
 
Pierce  1:200 
FLNB Mouse 
monoclonal 
 Santa Cruz 
biotechnology 
1:1000 
KI-67 Rabbit 
polyclonal 
 Abcam  1:1000 
pFLNA/FLNB Rabbit 
polyclonal  
 Abcam  1:1000 
IgG control  Rabbit 
polyclonal 
D145 Santa Cruz 
Biotechnology 
1µg/mg 
EGFR_T693 Rabbit 
polyclonal  
EP2256Y Cell signalling  1:1000 
SMAD2_T8 Rabbit 
polyclonal  
 Abcam  1:500 
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2.1    Cell culture 
2.1.1    Sample collection and culture conditions 
All primary tumour and normal tissue specimens used throughout this project were 
obtained either as part of the ‘Investigation into the expression of signalling molecules 
in human brain tumour samples (REC number 6/Q2103/123)’ or the ‘Identifying and 
validating molecular targets in low grade brain tumours (REC number 14/SW/0119) 
study’. Fresh tumours were made in to cell cultures by tumour digestion with 
collagenase upon arrival at the laboratory.   
   Human Schwann cells were obtained from post mortem tissue of consented 
individuals with no medical history of peripheral neuropathy. Donated tissue was 
transported from the hospital to the laboratory in DMEM (Gibco, Life technologies) 
supplemented with 10% FBS, 500 U/ml Penicillin/ Streptomycin (Gibco) and 2.5 μg/ml 
Amphotericin B (Simga- Aldrich). Tumours were obtained after surgery and upon arrival 
were incubated for 24 hours in petri dishes containing DMEM supplemented with 10% 
FBS, 500 U/ml Penicillin/ Streptomycin (penstrep), 2 μM forskolin (Sigma-Aldrich) and 
2.5 μg/ml Amphotericin B at 37oC and 10% CO2. Primary meningiomas were 
transported in media containing 10% FBS/500 U/ml penstrep and incubated for 24 
hours at 37oC/ 5% CO2.  
   Tumour/ nerve samples were mechanically digested with glass pipettes of decreasing 
diameter and thereon cultured in respective media; for Schwann/ schwannoma cells: 
DMEM, 10% FBS, 100 U/ml Penicillin/ Streptomycin, 0.5 μM forskolin, 2.5 μg/ml 
amphotericin, 2.5 μg/ml insulin and 10nM β-heregulin, at 37oC and 10% CO2. Schwann 
and schwannoma cells were cultured on plates coated with poly-L-lysine (PLL) (30 
minutes at room temperature) followed by laminin (overnight at 4oC). Meningioma cells 
were cultured in HAMS F-12 media (Gibco) containing 10% FBS, 1% Penicillin/ 
streptomycin and 12.5 ng/ ml insulin. 
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2.1.2    Cell lines 
A meningioma cell line, Ben-Men-1, was used throughout this project. This is an 
immortalized cell line derived from a benign meningioma originally developed by 
Puttmann et al. (Puttmann, Senner et al. 2005). Cells were grown in DMEM, 10% FBS 
and 100 U/ml Penicillin/Streptomycin and kept at 5% CO2/ 37oC. Human meningeal 
cells (HMC) were obtained from Sciencell™ and maintained in the manufacturers 
recommended media and grown under the same conditions.  
 2.1.3    Passaging of cells 
Primary cells were cultured until confluent or required cell density. For passaging, cells 
were washed once with phosphate buffered saline (PBS, Gibco®) and incubated with 
trypsin/EDTA (Gibco®) at 37oC for approximately 2 minutes until all cells were 
detached. Trypsin was neutralised with normal medium and solutions were 
resuspended in an appropriate volume of culture medium before seeding in fresh flasks 
(Greiner®).  
2.2    Western blotting 
2.2.1    SDS-PAGE 
Cells were lysed in RIPA buffer consisting of  150mM NaCl, 5mM of 0.5 M EDTA, pH 
8.0, 1M Tris, pH 8.0, 1% NP-40, 0.5% of 10% sodium deoxycholate, 10% SDS, 84% 
H2O. Protein concentration was determined using a colorimetric BCA protein assay 
(Pierce®) by measuring absorbance at 562 nm. A reference curve was generated 
based on protein standards of decreasing concentration from a stock solution of 2 
mg/ml Bovine Serum Albumin (BSA). Comparison of sample absorbencies to the 
standard curve provided a relative analysis of protein concentration. Equal sample 
amounts were mixed with 4x reducing buffer (250 mM Tris-HCL [pH6.8], 8% SDS, 40% 
glycerol, 200 mM DTT and 0.4% bromophenol blue) and boiled for 5 minutes at 90oC.  
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Table 2.2: Gel recipes 
 
Component 
Percentage acrylamide (resolving gel) Stacking gel 
6% 8% 10% 4% 
40% acrylamide  1.2ml 1.6ml  2ml 0.75ml 
1.5M Tris HCl, pH 8.8 2ml 2ml 2ml  X 
1M Tris HCl, pH 6.8 X X X 1.25ml 
10% SDS 80μl 80μl 80μl  50μl 
10% ammonium 
persulfate 
80μl 80μl 80μl  50μl 
TEMED 8μl  8μl 8μl 5μl 
Distilled H2O 4.6ml 4.2ml 3.8ml 2.9ml 
 
Proteins were then separated via SDS-PAGE electrophoresis. 6-10% resolving gel/ 
stacking gel recipes are shown in table 2.2. Gels were run at constant amperage of 30 
mA for 60 minutes at Room Temperature (RT). Samples intended for MS measurement 
were separated using 4-15% gradient pre-cast gels (Biorad).  
2.2.2   Transfer and immunoblotting 
Proteins were transferred to PVDF membranes (Biorad) at 400 mA constant for 70 
minutes at RT, via wet blotting in transfer buffer (25 mM Tris, 19.2 mM glycine and 15% 
methanol). Membranes were blocked for 1 hour at RT in blocking milk (5% dried 
skimmed milk and 0.1% Tween in PBS) before being probed with primary antibody, 
shaking overnight at 4oC. Membranes were then washed in PBS-tween and incubated 
with appropriate HRP-conjugated secondary antibodies (Biorad) diluted 1:5000 in 
blocking milk for 1 hour at room temperature. After three washes in PBS-tween, ECL 
was used for detection (Pierce®) and light sensitive films (hyperfilm ECL, Amersham) 
were used for exposure. GAPDH was used as a loading control in all cases. 
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2.2.3    Protein quantification and statistical analysis 
Films were scanned in greyscale at a resolution of 600 dpi. Image J was used for 
relative quantification of Western blots, where amounts of protein are recorded as 
ratios - protein band: loading control band in the same lane. Prior to density 
measurement, all blots were inverted so bands appeared white on a black background. 
The rectangle tool was selected and used to draw a box around the largest band and 
was subsequently used to measure the density of all other bands. The same box was 
used to take a background measurement containing no protein bands which would 
later be subtracted from each individual band measurement. The same was done for 
loading control bands corresponding to each protein band. Finally, protein band 
densities were normalized to corresponding loading control values.  
   Average values were calculated across control samples and across tumour samples. 
The average for tumour samples was then divided by the average for the control. The 
control value was divided by itself, giving a reference value of 1, against which the 
average tumour value would be plotted graphically. T-tests were then performed on 
normalized density values to determine whether the difference between control and 
tumour values were significant.  
2.3    Proteomics 
2.3.1    In-Gel Digestion 
In-gel digestion was performed based on a previously published protocol (Shevchenko, 
Wilm et al. 1996). Protein gels were stained with colloidal coomassie blue stain (life 
technologies) for 3 hours at RT. De-staining was achieved by incubation with mass 
spectrometry grade water (Fisher) overnight at  RT. Gels were fractionated by cutting in 
to small 1 mm x 1 mm pieces before the in-gel digestion protocol proceeded as follows. 
Per slice, equilibration in 200 µl of 50 mM Ammonium Bicarbonate (ABC) for 5 minutes 
at 37oC, de-staining in 200 µl of 50% acetonitrile (ACN)/ 50% H2O for 5 minutes at 
37oC  then 200 µl of 100% ACN for 5 minutes at 37oC. These steps are repeated 3 
57 
 
times. 200 µl of reduction buffer (10 mM dithiothreitol in ABC) was added to the gel 
slices and incubated for 20 minutes at 56°C. Slices were then shrunk using 100% ACN 
for 5 minutes at RT and alkylated using 200 μl of alkylation buffer (23.35 mg 2-
choloroacetamide, 5ml of 50 mM ABC) for 20 minutes at RT in the dark. The gel pieces 
were incubated with digestion buffer (12.5 ng/μl trypsin in ABC) overnight at 37 °C. 
Digested peptides were extracted by the addition of 2% Trifluoroacetic Acid (TFA) to 
the digestion buffer incubated for 20 minutes on a shaker at 37oC. Peptide solutions 
were then transferred to fresh tubes, and 100 μl of buffer B (80% ACN, 0.5% acetic 
acid, 1% TFA) was added to the gel pieces and incubated for a further 20 minutes on a 
shaker at 37oC. The buffer B solution was then combined with the respective solution 
from the first peptide extraction, and samples were concentrated in a DNA centrifuge 
(Labconco centrivap®) until less than 40 μl of sample was left.  
2.3.2    Stage Tips 
Stage-tipping was performed as previously described (Rappsilber, Ishihama et al. 
2003). Stage tips were assembled by placing high performance extraction disk (C18) 
into a pipette tip using a picking tool. 50 µl of methanol was added to the prepared 
stage tips and centrifuged until the whole volume has passed through in order to 
hydrate the matrix. This is repeated with buffer B (80% acetonitrile, 0.5% acetic acid) 
and then twice with buffer A (0.5% acetic acid) for equilibration. Samples are 
centrifuged (1 minute; 10,000 g; room temperature) and added to stage tips and 
centrifuged again till the sample has passed through. 50 µl of buffer A was added and 
centrifuged until all the volume has passed through. Peptides are then eluted by 
addition of 20 µl of buffer B and centrifugation. The samples are then concentrated 
using a concentrator and buffer A is added to give a final volume of 25 µl.  
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2.3.3    Titanium dioxide (TiO2) phosphopeptide enrichment 
Titanium dioxide (TiO2) was performed based on a report published in 2013 (Fukuda, 
Hirabayashi-Ishioka et al. 2013). Peptide concentration per sample was determined 
before being mixed with TiO2 beads in a 2:1, peptide: bead ratio. First, the beads were 
equilibrated with 200 μl of buffer A (5% TFA, 5% glycerol, 60% ACN, 30% H2O), 
shaking for 5 minutes at RT. 200 μl of buffer B (5% TFA, 5% glycerol, 60% ACN, 30% 
H2O) was then added to the beads and mixed for 5 minutes on a shaker. During this 
time, samples were sonicated to sheer DNA and dissolve peptides. Samples were then 
mixed with beads and incubated for 1 hour at RT on a shaker. During incubation, 
individual columns were constructed by inserting small silica frits in to pipette tips. After 
incubation, samples were added to the pipette tips and centrifuged (7000 g, 3 minutes) 
to pack the beads and allow unbound phosphopeptides to flow through. The beads 
were then washed three times with buffer A, and then three times with buffer A for 1 
min at 300 g each time. Bound phosphopeptides were then eluted with two subsequent 
100 μl volumes of NaOH, before neutralization with an equal volume of 10% TFA ready 
for stage tipping.   
2.3.4    Phosphoprotein purification  
Phosphoprotein purification kits were purchased from Qiagen® and incorporate affinity 
chromatography for the selective isolation of phosphorylated proteins. The procedure 
was performed on cultured cells using lysis buffer containing 0.25% CHAPS, 
benzonase and protease inhibitors supplied by the company. For each sample, a T75 
flask (Greiner) of cells was lysed and incubated for 30 minutes at on ice with vortexing 
every 10 minutes before centrifugation at 10000 g for 30 minutes at 4oC. During 
centrifugation columns were equilibrated with 4ml lysis buffer that was allowed to flow 
through. Supernatant was harvested from centrifuged samples and protein 
concentration was adjusted to 0.1 mg/ml to ensure accessibility and maximal binding of 
phosphoproteins. Half of the lysate was added to the column and allowed to flow 
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through, followed by the second half. When all the lysate passed through, 6 ml of lysis 
buffer was applied to wash the column. After, 3 ml of elution buffer (supplied with the kit) 
was added to the column to elute the phosphoproteins. SDS-PAGE and in-gel 
digestion were subsequently performed prior to MS.  
2.4    Mass spectrometry  
2.4.1    Liquid Chromatography Tandem Mass Spectrometry 
MS was carried out using an ultimate 3000 UPLC system (Thermo Fisher, Germany) 
connected to an Orbitrap Velos Pro mass spectrometer (Thermo Fisher, Bremen, 
Germany). The prepared peptides were loaded on to a 2 cm Acclaim™ PepMap™100 
Nano-Trap Column (Thermo Fisher, Germany) and separated by a 25cm Acclaim™ 
PepMap™100 Nano LC column (Thermo Fisher, Germany) that is packed with C18 
beads of 3 μm and running a 120 min gradient of 95 % buffer A /5% buffer B (buffer A 
contains 0.5% acetic acid and buffer B contains 0.5% acetic acid in 100% acetonitrile) 
to 65% buffer A /35 % buffer B and a flow rate of 300 nl/min. Eluted peptides were 
electrosprayed into the mass spectrometer at a spray voltage of 2.5 kV. The Orbitrap 
instrument performs data acquisition in a data dependent mode to switch between MS 
and MS2. The Orbitrap cell with a resolution of 60,000 acquires a full-scan MS spectra 
of intact peptides (m/z 350–1500) with an automated gain control accumulation target 
value of 10,000,000 ions. In the linear ion trap the ten most abundant ions are isolated 
and fragmented by applying collision induced dissociation using an accumulation target 
value of 10,000, a capillary temperature of 275°C, and normalized collision energy of 
30%.  A dynamic exclusion of ions previously sequenced within 45 s was applied. Any 
singly charged ions and unassigned charged states were excluded form sequencing 
and also a minimum of 10000 counts was required for MS2 selection. 
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2.4.2    Peptide identification and Quantification   
The Andromeda search engine (Cox, Neuhauser et al. 2011) integrated in Maxquant 
version 1.5.3.8 (Cox and Mann 2008) was used to identify the proteins. Protein 
sequences were downloaded from UNIPROT. A mass tolerance of six ppm for the 
parental peptide, 0.8 Da for fragmentation spectra and a trypsin specificity allowing up 
to 2 mis-cleaved sites were set as Andromeda search parameters. Fixed modification 
of carboxyamidomethylation of cysteines and variable modification of deamidation of 
glutamine, and a minimal peptide length of six amino acids were set. Maxquant 
performed an internal mass calibration of measured ions and peptide validation by the 
target decoy approach as described  (Elias and Gygi 2010).  Proteins and peptides with 
better than 1% false discovery rate (FDR) were accepted. Proteins were quantified by 
normalised summed peptide intensities computed as label free quantification (LFQ) 
values in Maxquant (Cox, Hein et al. 2014).  
2.4.3    Raw data processing 
Data generated by Maxquant were processed using Microsoft Excel and specially 
developed proteomics software, Perseus®. LFQ values were Log2 transformed and 
fold change was calculated based on the equation: Average Log2 LFQ tumour – 
Average Log2 LFQ control. A 2 sample t-test with equal variance was performed 
generating p-values for each identified protein/ phosphoprotein. The proteins with a p-
value < 0.05 were considered for further analysis. Benjamani-Hochberg False 
Discovery Rate (FDR) was explored using Perseus but was not used for the final 
selection of candidates. Significantly changed phosphoproteins were then compared 
against respective total protein changes to identify those with ‘true’ activation i.e. a 
significant change in phosphorylation and little/no change or a decrease in total protein 
abundance.  
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2.5    Immunostaining  
2.5.1    Immunocytochemistry 
Cells were cultured to desired confluency in labtek™ 8-well chambers. Fixation was 
carried out using ice-cold methanol for five minutes. Cells were blocked in 10% BSA/1% 
PBS for one hour at RT and washed three times for five minutes in PBS. Primary 
antibodies were diluted in 1% BSA and applied overnight at 4oC. Slides were then 
washed twice for five minutes in PBS before the addition of appropriate fluorescent 
secondary antibodies (Alexa, Life technologies) for one hour in the dark at RT. After 
one five minute wash with PBS, DAPI nuclear stain (1:500 from a stock solution of 1 
mg/ml) was added for 10 minutes at RT in the dark. Slides were washed three times in 
PBS for five minutes each before the addition of vectashield® mounting medium and 
cover slips. Slides were then stored at 4oC in the dark until imaging.  
   To determine the localization of proteins, imaging was performed using a Leica TCS 
SP8 confocal microscope and images were taken using the associated LAS X software. 
All images were captured at 40x magnification.   
2.5.2    Immunohistochemistry 
Formalin fixed Paraffin Embedded Tissue (FFPE) tissue sections were cut at 20 μm. 
Paraffin was removed from the sections by incubation at 60oC for 20 minutes. This was 
performed at the histopathology lab at Derriford hospital, Plymouth. Preliminary 
experiments were performed by Leanne Kirk to determine the optimal pre-treatment 
and antibody dilution conditions.   
   For phospho-Heat Shock 70kDa Protein 1A (pHSPA1A) staining: Sections were 
washed twice in xylene for five minutes followed by a five minute wash in 100% ethanol. 
Sections were then washed for five minutes in running water before blocking with 3% 
H2O2 in methanol for 60 minutes. Sections were then washed in running water for ten 
minutes, and boiled for 30 minutes in citrate buffer as a pre-treatment (2.1 g of citric 
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acid in 2L of deionised water, pH 6.0) for the purpose of antigen retrieval to allow the 
antibody to bind. Slides were subsequently washed for ten minutes in running water 
before immersion for five minutes in TBST for equilibration. After, sections were 
blocked for 30 minutes in 5% normal horse serum in TBST. Primary antibody was then 
applied at 1:200 overnight at 4oC.  
   Slides were washed twice in TBST for five minutes each before secondary antibody 
was applied for 30 minutes at RT. After, slides were washed twice in TBST for five 
minutes each and tertiary antibody was applied for 30 minutes at RT which is designed 
to bind to the secondary antibody. The tertiary antibody is conjugated to horse radish 
peroxidase that yields a coloured product upon reaction with the substrate, that is 
detectable using a light microscope. Slides were washed again in TBST for five 
minutes before DAB (3,3'-diaminobenzidine) solution was applied for five minutes to 
produce brown staining. After a ten minute wash in running water, slides were 
immersed in copper sulphate DAB enhancer for five minutes. Slides were washed 
again in running water for five minutes, before haematoxylin counterstain was applied 
for a further two minutes. Slides were finally washed twice for five minutes in 100% 
ethanol for complete dehydration, followed by two washes in xylene. DPX mounting 
media was applied to coverslips, and slides were applied face down.  
   Images were acquired using a Leica DMRB and the intensity of staining was 
assessed semi-quantitatively with the help of consultant neuropathologist, Dr David 
Hilton (Derriford hospital, Plymouth). 
2.6    shRNA mediated gene silencing 
Cultured cells were seeded at 80% confluency before transfection with lentiviral 
particles directed towards either STAT1 (Santa Cruz) or PDLIM2 (Sigma) in the 
presence of 5 μg/ml polybrene (Santa Cruz biotechnology), using a multiplicity of 
infection (MOI) of 5 in each case. Lentivirus was applied for 24 hours, at which point 
media was removed and replaced with normal media for a further 24 hours. Puromycin 
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was then applied to cells at a concentration of 5 μg/ml to facilitate selection of those 
expressing the Puromycin resistance gene. Selection took place over 4-5 days, at 
which point cells were lysed for Western blot analysis, fixed and stained for Ki-67 
expression.  
2.7    Antibody crosslinking  
Prior to MS analysis, antibodies were cross-linked to agarose beads to inhibit co-
elution of IgG fragments with the bait protein and to stabilize the transient interactions 
between binding partners, replacing weak interactions with covalent bonds. These 
large proteins make it difficult for the instrument to identify signals from less abundant 
proteins that have also co-eluted. Antibody crosslinking was performed using a 
commercial kit from Pierce ® and all centrifugation steps were performed at 1000g for 
one minute unless stated otherwise.  
   For each antibody, 20 μl of protein A/G plus agarose slurry was pipetted into a Pierce 
spin column and centrifuged. The resin was then washed twice with 1x coupling buffer 
(0.01 M sodium phosphate, 0.15 M NaCl; pH 7.2) and centrifuged each time. 10 μg of 
antibody, 20x coupling buffer and water were mixed together to a final volume of 100 μl. 
This mixture was then applied to the column and incubated on a mixer at RT for 60 
minutes. After this time, the column was centrifuged and the resin was washed three 
times with 1x coupling buffer.  
   Cross-linking of the bound antibody was achieved using disuccinimidyl suberate 
(DSS). 2.5 μl of coupling buffer, 9 μl of 2.5 M DSS and 38.5 μl of ultrapure water were 
added to the column containing the antibody resin. The column was the incubated on a 
mixer for one hour at RT. The column was then centrifuged and the flow-through 
discarded. 50 μl of elution buffer (containing primary amine, pH 2.8) was added to the 
column and centrifuged. The column was then washed twice with elution buffer to 
quench the reaction and remove any non-crosslinked antibody. After two wash steps 
with 200 μl cold IP/ lysis buffer (0.025 M Tris, 0.15M NaCl, 0.001M EDTA, 1% NP-40, 5% 
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glycerol; pH 7.4),the column was either stored in PBS containing 0.02% sodium azide 
or utilized for the co-immunoprecipitation (co-ip) protocol. 
2.8    Co-immunoprecipitation  
Cultured Ben-Men-1 cells were washed once in PBS before IP/ lysis buffer was added 
to the flask and incubated on ice for five minutes. The lysate was then transferred to a 
micro centrifuge tube and centrifuged at 13000g for 10 minutes. The supernatant was 
transferred to a new tube, before determination of the protein concentration using the 
BCA protein assay (as described previously).  
   Lysates were pre-cleared to reduce non-specific binding prior to each co-ip 
experiment. For 1 mg of lysate, 80 μl of control agarose slurry was added to a spin 
column and centrifuged to remove storage buffer. 100 μl of coupling buffer was added 
and centrifuged. 1 mg of lysate was added to the column and incubated for one hour 
with gentle end-over-end mixing at 4oC and then centrifuged. The pre-cleared lysate 
was added to the column containing the antibody cross-linked resin and incubated 
overnight with end-over-end mixing at 4oC.  
   After overnight incubation, the column was centrifuged and washed twice with 200 μl 
of IP/ lysis buffer. A final wash with 100 μl of 1x conditioning buffer (neutral pH) 
preceded elution. First, 10 μl of elution buffer was added to the column and centrifuged. 
A further 30 μl of elution buffer was then added to the column and incubated at RT for 
five minutes. The column was then centrifuged and the eluate retained for subsequent 
analysis. 5x reducing buffer was added to each eluted sample before and boiled at 
90oC for five minutes prior to SDS-PAGE followed by either Western blotting or MS 
analysis.  
2.9    Ki-67 immunofluorescent proliferation assay 
The KI-67 proliferation assay was employed after shRNA protein knockdown in order to 
assess the subsequent effects on cellular proliferation. Cells were first washed in PBS 
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before fixation in ice-cold methanol for 5 minutes. The cells were then blocked in 0.1% 
PBS-tween containing 10% normal goat serum and 0.3 M glycine for one hour at RT. 
The cells were then incubated with anti-ki67 antibody at 1:1000 overnight at 4oC. Alexa 
fluor 488 anti-rabbit secondary antibody was then applied for 1 hour at RT, followed by 
DAPI nuclear stain for 10 minutes at 4 μg/ml. Cover slips were applied to slides using 
vectashield and stored at 4oC until imaging.  
   Stained slides were visualised under a Nikon Eclipse 80i Fluorescence microscope 
(Nikon, Kingston upon Thames, Surrey). Photos were taken using an intensilight C-
HGF1E lightbox (Nikon) and the NIS Elements software package. Photos were taken 
under the 40x objective lens. 
2.10    Cytoplasmic and nuclear extraction  
In order to ascertain the cellular location of PDLIM2, a cytoplasmic and nuclear 
extraction assay (Thermo scientific) was performed. Primary adherent meningioma 
cells were harvested with trypsin and centrifuged at 500 g for 5 minutes. The cell pellet 
was then washed once in PBS, transferred to a micro centrifuge tube and centrifuged 
for 3 minutes at 500 g. Ice cold CER I reagent (Cytoplasmic Extraction Reagent, 
provided with the kit) was added to the pellet, vortexed vigorously for 15 seconds and 
incubated on ice for 10 minutes. Ice cold CER II was then added to the tube and 
vortexed for 5 seconds on the highest setting before incubation on ice for 1 minute. The 
tube was then centrifuged for 5 minutes at 16000 g and the supernatant immediately 
transferred to a pre-chilled tube (the cytoplasmic fraction). Ice cold NER (Nuclear 
Extraction Reagent, provided with kit) was added to the remaining pellet and vortexed 
for 15 seconds. After incubation on ice for 40 minutes with rigorous vortexing every 10 
minutes, the tube was centrifuged at maximum speed for 10 minutes. The supernatant 
(nuclear fraction) was transferred to a clean tube and both extracts were stored at -
80oC until analysis by Western blot.  
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2.11    Lambda phosphatase assay  
In the absence of phospho-specific antibodies to PDLIM2, it was necessary to perform 
a lambda phosphatase assay that would theoretically lead to a change in protein 
mobility, detected via a band shift upon Western blot analysis. After lysis in RIPA buffer 
containing protease inhibitors, 20ug of protein was mixed with 4 μl of lambda 
phosphatase, 2.5 μl MnCl, 2.5 μl 10x buffer (New England Biolabs) and H2O to a final 
reaction volume of 25 μl. The reaction was allowed to proceed for 2 hours on a mixer at 
30oC. This lysate was then analysed in parallel with non-phosphatase treated lysate. 
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Chapter 3- Total and phosphoproteomic analysis of primary human 
schwannoma vs. Schwann cells. 
3.1    Introduction  
Individuals with the genetic condition NF2 experience multiple tumour growths 
throughout life, including both schwannoma and meningioma. No drugs are currently 
approved for the treatment of NF2 reflecting the urgent need for an effective 
therapeutic (Evans 2009). Proteomic techniques afford the possibility of high-
throughput, unbiased screens between normal and tumour tissue to identify the most 
promising candidates that might represent attractive novel therapeutic targets. 
   This chapter presents the data obtained from global analyses of both total and 
phosphoprotein expression in human Schwann and schwannoma cells. Previous 
studies of the proteome in meningioma and schwannoma have provided some data 
from which potential therapeutic targets have been identified (Boin, Couvelard et al. 
2014, Sharma, Ray et al. 2015). These studies looked at the genome or at the 
proteome, and Boin’s study in particular was a biased approach centred on targets 
already known in schwannoma. The research presented here aims to take target 
identification a step further - by analysing the phosphoproteome to identify aberrantly 
activated proteins and dysregulated signalling networks. Targeting the 
phosphoproteome has the potential to inhibit entire signalling cascades, in turn 
providing a powerful tool to interrupt tumorigensis, cellular growth and proliferation. We 
analysed both total and phosphoprotein expression in order to identify overexpressed 
protein aberrantly phosphorylated compared to normal Schwann cells.  
   Presented here will be a list of potential therapeutic targets, both phosphorylated and 
not, that warrant further investigation.  
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3.2    Phosphoprotein purification and data processing 
At the outset of this project, three primary Merlin-deficient schwannoma-derived cell 
populations were analysed vs. one sample of human primary Schwann cells (three 
technical repeats). Their Merlin status was confirmed by Western blot prior to MS 
(Figure 3.1). As expected, the analysis confirmed the Merlin-deficient status of all 
schwannomas. We wanted to ensure that the schwannomas were Merlin-deficient so 
that any targets identified would potentially be translated across all Merlin-deficient 
tumours associated with NF2.  
   Over 2000 phosphoproteins were identified in primary schwannoma and Schwann 
cells, as represented in the scatter plot (Figure 3.2, the full list of significantly changed 
phosphoproteins is provided in supplementary table S1). All the dots above the blue 
line represent phosphoproteins that are significantly changed between the two cell 
types (P < 0.05, -log2 P > 4.32). A total of 101 phosphoproteins were significantly 
downregulated with a log2 fold change of at least -1, and 122 were significantly 
upregulated with a log2 fold change of at least 1. This corresponds to fold changes of 
at > 2 and < 0.5, and only these were considered for further analysis.    
   To maximise the number of proteins for the eventual comparative analysis with 
meningioma cells, Multiple Correction Testing (MCT) was avoided and unadjusted p-
values were used for defining statistical significance. The reason for this is because 
MCT can substantially reduce the number of proteins identified as statistically 
significant (Gyorffy et al. 2005). Our approach was to maximise the number of proteins 
that could be taken forward for common target selection, and the candidate proteins 
that were selected would be validated by Western blot later on in chapter 5.  
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Figure 3.1: The Merlin status of all Schwann and schwannoma samples. Western 
blot analysis of all schwannoma and Schwann cells further analysed by MS. MOS= 
normal human Schwann cells, NF= human schwannoma cells.  
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Figure 3.2: Scatter graph representation of Schwannoma phosphoprotein dataset. 
2628 phosphoproteins identified in a comparison between Schwann and schwannoma cells 
are represented by each point in the scatter graph. Dots below the blue line represent those 
that failed to reach the significance threshold of P < 0.05 (-log2 P > 4.32).  
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3.3    Schwannoma phosphoprotein data 
3.3.1    Functional enrichment analysis of schwannoma phosphoprotein data 
In order to identify individual proteins that may be of interest, it is useful to first analyse 
the dataset with respect to whole pathways and/ or biological processes that are 
significantly represented. Using DAVID (Database for Annotation, Visualization and 
Integrated Discovery (Huang da, Sherman et al. 2009), the upregulated 
phosphoproteins were mapped to several pathways (Figure 3.3A). DAVID compares 
uploaded datasets against a defined background proteome. In this case, the dataset 
submitted was compared to the background ‘Homo sapiens’ to identify pathways and/ 
or processes that are ‘functionally enriched’ within the submitted dataset. Functional 
enrichment is calculated based on the proportion of a particular class of proteins in the 
users dataset (i.e. kinase) compared to the proportion in the background overall. For 
instance, if 10% of submitted proteins are kinases vs. 1% of the background, kinases 
would be statistically over-represented in the data set by 10-fold, and would therefore 
be assumed to play an important role within the experimental cell type.  
   Among the statistically enriched pathways (Benjamini-Hochberg Adjusted P < 0.05) 
are focal adhesion, regulation of the actin cytoskeleton and the MAPK pathway. These 
are well characterised in relation to schwannoma pathology, and Merlin is known to 
play a key role in each. As such, we would expect to identify them in a global 
phosphoproteomic analysis. As we have done so, it can be inferred that the experiment 
worked well and that the dataset as a whole is reliable. Among the proteins are MEK1 
and NFκB, both already identified as upregulated in schwannoma and integral to 
mitogenic signalling.   
   Glycolysis and gluconeogenesis were also identified as significant (Figure 3.3A), 
suggesting increased metabolism and/or glucose production to aid the growth and 
survival of schwannoma cells. Among those proteins involved in glycolysis is enolase 1 
alpha (ENO1, Log2 FC 2.9) which has been reported to promote proliferation and 
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migration in cancer cells, and has been shown to interact with tubulin (Diaz-Ramos, 
Roig-Borrellas et al. 2012).  
   Phosphofructokinase (PFKL), a component of the pentose phosphate pathway (PPP) 
and a key glycolysis enzyme, was also found to be upregulated with a log2 FC of 24.9. 
Targeting PPP components has shown promise in leukaemia (Chen, Xu et al. 2015) 
and may also represent a potential therapeutic approach for schwannomas.   
   Functional enrichment analysis was also performed to identify the most significantly 
enriched Gene Ontology (GO) terms within this same dataset. Gene ontology is a 
system of classification that allows genes/ proteins identified by omics experiments to 
be grouped together within distinct ‘annotation terms,’ depending on their function and 
or/ location within the cell. These include; Biological Processes (BP), Cellular 
Components (CC) and Molecular Functions (MF).  
   Unsurprisingly, given its known contribution to schwannoma pathology, RAS protein 
signal transduction is the most enriched biological process with a fold enrichment value 
of 8.75 (Figure 3.3B), further demonstrating the reliability of the dataset. The most 
enriched GO term overall is ‘AP-2 adaptor complex,’ linked to a process known as 
clathrin-mediated endocytosis. The second and third most enriched GO terms are also 
related to this process i.e. ‘clathrin coated endocytic vesicle membrane,’ and ‘clathrin 
coat of endocytic vesicle.’ 
   Clathrin mediated endocytosis is important for intracellular transport, and can 
mediate several processes including membrane protein turnover and nutrient uptake 
(Robinson 2015). The implications of increased endocytosis in schwannoma cells are 
or in some cases e.g. that of the EGF receptor can actually facilitate constitutive 
signalling by constant receptor recycling.  
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Figure 3.3: Functional enrichment analysis and associations between upregulated 
phosphoproteins in schwannoma cells.  A. The pathways represented by the largest number 
of proteins are focal adhesion and the MAPK pathway. B. The most enriched processes, cellular 
components and molecular functions represented by upregulated phosphoproteins in 
schwannoma. GO= Gene Ontology (Benjamani-Hochberg adjusted P < 0.05). C. The 
upregulated phosphoproteins that interact with either the MAPK or focal adhesion pathways, and 
their associations with each other as identified by string.db. 
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   Further, these findings are in concordance with the reported consequences of Merlin 
deficiency i.e. deregulation of endocytic vesicle sorting (Hennigan, Moon et al. 2013) 
and may help us to understand more about the regulation of the proteins involved in 
these processes. The data may indicate increased endocytosis in an attempt to remove 
signalling molecules from the cell membrane to downregulate mitogenesis, however in 
the absence of Merlin the number of those targeted for degradation may be fewer. 
Determining site-specific phosphorylation information would be useful in determining 
the consequences of AP-2 component overexpression in schwannoma compared to 
normal cells.  
   Figure 3.3C shows a STRING (Search Tool for the Retrieval of Interacting Genes 
(Franceschini, Szklarczyk et al. 2013) generated predicted protein-protein interaction 
map highlighting the proteins from the data set involved specifically in the MAPK and 
focal adhesion pathways that have been linked to each other previously. String 
identifies associations between proteins based on direct experimental evidence, 
computational prediction methods and also co-occurrence in published literature. 
Identifying specific interactions using string can help to identify proteins that, if targeted 
therapeutically, could affect multiple other proteins within the cell.  
   These pathways were investigated in more detail because of their relation to 
schwannoma pathology. Filamin A (FLNA), Filamin B (FLNB) and Filamin C (FLNC) 
appear as central nodes in Figure 3.3C suggesting that they may be important effectors 
of MAPK/ focal adhesion signalling in schwannoma. The filamins are important for 
anchoring transmembrane proteins to cytoskeleton and have been shown to interact 
directly with integrins, which are known to play a role in schwannoma growth and 
proliferation (van der Flier and Sonnenberg 2001). They have not been previously 
linked to schwannoma however their roles in the above pathways highlight them as 
potential therapeutic targets.  
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3.3.2    Gene functional classification of schwannoma phosphoprotein data 
DAVID also provides another feature termed ‘Gene functional classification.’ This is 
designed to identify functionally related clusters of genes based on their co-occurrence 
within different annotation terms e.g. cytoskeletal binding. The difference between this 
and functional enrichment analysis is that functional classification does not compare 
proteins to any background, but rather simply categorizes them into groups based on 
their structure/ function. This allows large numbers of proteins to be condensed into 
biologically related and therefore meaningful clusters, from which useful information 
can be extracted. 
   Using this tool we were able to identify a cluster of proteins with several unifying 
features, the identities of which can be viewed in Table 3.1. The overriding feature of 
these proteins is their cytoskeletal binding capability. Given Merlin’s role as a master 
regulator of the cytoskeleton, the activation of these proteins might be a consequence 
of Merlin deficiency in schwannoma cells. Secondly, all six proteins contain a LIM 
domain, and several contain a PDZ domain. 
   LIM domains orchestrate protein-protein interactions and play roles in a number of 
signalling pathways. PDZ domains are also important for the organization of 
macromolecular signalling complexes, particularly for linking membrane proteins to the 
cytoskeleton (Krcmery et al. 2010). We also performed Maxquant analysis setting 
‘phosphorylation,’ as a variable modification allowing us to identify specific 
phosphorylation sites. In doing so, we identified phosphorylation sites for two of these 
PDZ/ LIM domain proteins; LASP1_S146 and MICAL1_S613. These may be important 
when assessing their suitability as therapeutic targets. 
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Table 3.1 
Gene symbol Protein name Function  
PDLIM2 PDZ and LIM domain 
containing protein 2 
Cytoskeletal binding protein that promotes 
migration and adhesion. 
PDLIM5 PDZ and LIM domain 
containing protein 5 
Cytoskeletal binding. Functions as a 
scaffold protein in cardiac cells.  
PDLIM7 PDZ and LIM domain 
containing protein 7 
Cytoskeletal binding. Involved in actin-
filament complex formation. 
ZYX Zyxin  Actin binding, important for the formation of 
focal adhesions.  
LASP1 LIM and SH3 domain 
protein 1 
Regulation of actin based cytoskeletal 
activity. 
MICAL1 Protein-methionine 
sulfoxide oxidase MICAL1 
Promotes depolymerisation of F-actin. 
 Table 3.1: Functional cluster of phosphoproteins that are upregulated in schwannoma 
compared to Schwann cells. 
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3.3.3    Downregulated phosphoprotein analysis  
Among the downregulated phosphoproteins, there is significant enrichment of 
lysosomal proteins (Figure 3.4). These are ARSA, AGA, CTSD, GUSB, PSAP and 
SMPD1. CTSD, or Cathepsin D, in particular is associated with caspase-3 induction of 
cell death and its downregulation may be related to schwannoma cell survival. 
Downregulation of lysosomal proteins coupled with the upregulation of AP-2 complex 
proteins discussed earlier may indicate increased receptor internalization counteracted 
by decreased degradation.  
   DAVID analysis also highlighted a functional cluster of proteins that are linked to the 
spliceosome, with an enrichment p-value of 2.4E-7, suggesting significant 
downregulation of phosphoproteins relating to mRNA processing. The proteins within 
the cluster are RALY, U2AF2, HNRNPC and SNRPD2. Spliceosome activity gives rise 
to alternative splicing and thus different protein isoforms. Deregulation may lead to the 
expression of inactivated tumour suppressors, or certain protein isoforms that can 
influence tumour progression (Ghigna, Valacca et al. 2008). As such, spliceosome 
deregulation may represent a therapeutic target for schwannoma.  
 
 
 
 
 
 
 
 
79 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0 5 10 15 20 25 30 35 40 45
Regulation of microtubule
depolymerization
Negative regulation of microtubule
polymerization
Regulation of transcription from RNA
polymerase II
Melanosome
Lysosome
Cell cortex
Cytoskeletal protein binding
Enzyme binding
Fold enrichment
GO enrichment
Molecular function  
P=0.007  
P=0.010 
Cellular component  
P=0.001 
P=0.03 
P=0.001 
P=0.023 
P=0.026 
P=0.027 
Biological process  
Figure 3.4: GO enrichment analysis of downregulated phosphoproteins identified in 
schwannoma vs. Schwann cells.  
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3.4    Primary schwannoma total protein data analysis 
Total protein was measured in parallel with phosphoprotein to allow an indirect 
comparison between total and phosphoprotein abundance, and also to identify 
potential non-phosphorylated protein targets. The comparison was indirect because 
although the total protein sample was taken from the lysate just before it was subject to 
phosphoprotein purification, the samples were measured independently of one another 
resulting in two distinct data sets that were then compared with each other. A scatter 
plot representing the total protein data is shown in Figure 3.5. 16 proteins were found 
to be upregulated with a log2 fold change of > 1, and 93 proteins were significantly 
downregulated with a log2 fold change of < -1 (the full list of significantly changed 
proteins can be seen in supplementary Table S2). 
   All upregulated proteins were grouped based on protein class and are represented by 
a pie chart (Figure 3.6A). The largest proportion of upregulated proteins are 
cytoskeletal. Interestingly, 11 of the 16 upregulated proteins interact with one another, 
as identified by string.db (Figure 3.6B). ALDOC and ALDOA are both enzymes 
involved in gluconeogenesis, echoing the results obtained in the phosphoproteomic 
analysis and further suggesting that this pathway may be a potential therapeutic target 
for schwannoma. ALDOA in particular has been identified as an important enzyme 
promoting the survival of glioblastoma xenografts and may represent a way of targeting 
this potentially key metabolic pathway in schwannoma (Sanzey, Abdul Rahim et al. 
2015).  
   We also identified two proteasomal subunits as upregulated, PSMB5 and PSMA1. 
Since the proteasome is important for the degradation of proteins which promote 
proliferation and cell survival, targeting it represents a useful therapeutic strategy. 
Bortezomib, an inhibitor targeting PSMB5, has already been shown to have efficacy in 
multiple myeloma (Hideshima, Chauhan et al. 2005) and may also warrant 
investigation in schwannomas.  
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Figure 3.5: Scatter graph representation of schwannoma total protein dataset. 1659 
proteins identified in a comparison between Schwann and schwannoma cells are represented 
by each point in the scatter graph. Points below the blue line represent those that failed to 
reach the significance threshold of P < 0.05 (-log2 P > 4.32).   
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Figure 3.6: Schwannoma total protein data analysis. A. Classification based on protein class 
shows that half of the upregulated proteins are related to the cytoskeleton. B. 11 are known to be 
associated with each other, as identified by string.db. Several of those are cytoskeletal binding 
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   DAVID analysis of the downregulated total protein dataset identified significant 
enrichment of ribosomal proteins. Whilst ribosomal proteins are generally regarded as 
housekeeping genes, their significant representation among the downregulated protein 
data set for schwannoma cells may cause decreased global protein synthesis. 
Additionally, downregulation of ribosomal proteins might also affect apoptosis and DNA 
damage responses, and many of them may act as tumour suppressors including L13, 
L36 and S15 (Amsterdam, Sadler et al. 2004), all identified as significantly 
downregulated in the present study.  
3.5    Phosphoproteins vs. total proteins   
The primary aim of this study was to identify phosphorylated protein targets, as they 
present the opportunity to ‘switch off’ tumorigenic signalling. Therefore, it was 
necessary to identify proteins that displayed a small change in total abundance relative 
to phosphoprotein changes or a decrease in overall total protein. This would be the 
most appropriate method to identify proteins that are ‘truly’ activated.  
   In the absence of a quantifiable labelling technique e.g. Stable Isotopic Labelling with 
Amino acids in Cell culture (SILAC), that allows phosphorylated peptides to be 
measured simultaneously and normalized to their non-phosphorylated counterparts 
during the same MS run, it is not possible to directly compare separate, label-free 
experiments. Therefore, a method of comparing two distinct datasets was necessary. 
The simplest way of doing this was to plot both datasets against each other, in a graph 
(Figure 3.7), allowing for fast visual identification of the best targets. Significantly 
changed phosphoproteins with a p-value of < 0.05 are plotted on the x axis, against 
their respective total protein amounts (irrespective of p-value).  
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Figure 3.7: A graphical aid to represent the relationships between significantly changed phosphoproteins and total protein abundance in 
schwannoma cells. Phosphoproteins significantly up or downregulated (P < 0.05) in primary schwannoma cells compared to Schwann cells plotted 
against their respective total protein amounts. 
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LASP1 for instance represents a good therapeutic target when considering 
phosphoprotein data alone. It is significantly increased in schwannoma cells compared 
to Schwann cells and is also a member of the functionally enriched cluster of proteins 
discussed earlier in the chapter. However, as it also increases to a similar degree in 
total protein abundance, it becomes a less attractive candidate in this particular study.   
3.6    Potential therapeutic targets  
Only upregulated candidates were selected for further analysis. A selection of ideal 
schwannoma phosphoprotein candidates based on the criteria outlined above is 
displayed in Table 3.2. The final selection will come in chapter 5, after acquisition of 
meningioma data, in order to identify common targets.  
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Table 3.2 
Gene 
symbol  
Protein name  Gene 
symbol 
Protein name  
PFKL Phosphofructokinase, liver RPS3A Ribosomal protein S3A 
RSU1 Ras suppressor protein 1 ACTR3 Actin related protein 3 homolog 
VARS Valyl-TRNA synthetase CHMP2B 
Charged multivascular body 
protein 2B 
ROCK1 Rho-associated protein kinase 1 VPS29 
Vacuolar protein sorting-
associated protein 29 
PDLIM7 PDZ and LIM domain 7 PDLIM2 PDZ and LIM domain protein 2 
AIMP2 
ARS-Interacting Multi-Functional 
Protein 2 
LMOD1 Leiomodin-1 
OAT Omithine aminotransferase PDLIM5 PDZ and LIM domain protein 5 
NAPA 
N-Ethylmaleimide-Sensitive 
Factor Attachment Protein Alpha 
STAT1 
Signal transducer and activator of 
transcription-1 
VCL Vinculin DSP Desmoplakin 
FLNB Filamin-B PACSIN3 
Protein Kinase C and casein 
kinase substrate in neurons 
protein 3 
Table 3.2: 21 phosphoproteins that represent ideal schwannoma therapeutic targets, 
displaying little or no change in total protein abundance. 
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3.7    Discussion  
 
 
This chapter has explored (phospho) proteomics as a tool to identify potential 
therapeutic targets for the treatment of schwannoma. We were able to implement 
phosphoprotein purification followed by MS analysis, successfully leading to the 
identification of over 2000 proteins. We also analysed total protein abundance in 
parallel, culminating in an indirect comparison between total and phosphoprotein 
abundancies in order to select the most promising, activated potential targets.              
 
   As identified earlier in the chapter, there are three significantly changed 
phosphoproteins belonging to the PDZ and LIM domain family of proteins; PDLIM2, 
PDLIM5 and PDLIM7. These each show a decrease in total protein or a relatively small 
increase when compared to their phosphorylated equivalents. There are no reports in 
the literature referring to the role of these particular proteins in schwannoma. There are 
a large and diverse range of functions reported for this family of proteins and it would 
be interesting to learn more about their roles in schwannoma pathology. 
 
   Vinculin (VCL) may also be an interesting target for further investigation, given its role 
in cell-cell/ cell-matrix adhesion in similar fashion to Merlin. It has been shown to 
stabilize focal adhesions and promote tumour progression in breast cancer and could 
represent a useful way to target pathological focal adhesion in schwannomas 
(Rubashkin, Cassereau et al. 2014). Desmoplakin (DSP) also signifies an interesting 
target for further validation. The human protein atlas (www.proteinatlas.org) shows that 
it is largely absent in most cancers, therefore it has been proposed as a tumour 
suppressor whose downregulation is a tumour promoting factor.  
 
   The total protein analysis also identified proteins that warrant further investigation, 
not least Transgelin (TAGLN), a protein involved in actin cross-linking. It was recently 
identified as an important driver of progression in Malignant Peripheral Nerve Sheath 
Tumours (MPNST) associated with the genetic condition neurofibromatosis type 1 
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(NF1) (Park, Lee et al. 2014). As NF1 and NF2 share commonality in their activated 
signalling networks, TAGLN may be a candidate target for both conditions. In this 
experiment, it showed a Log2 FC of 22 in total protein abundance, and a Log2 FC of 28 
in phosphoprotein amount. As such, TAGLN is most likely a relevant therapeutic target 
for schwannoma treatment.  
 
   In summary, this global total and phosphoproteomic analysis of schwannoma has 
highlighted several areas, not previously reported, that warrant further investigation 
including; the AP-2 adaptor complex and lysosomal degradation, the specific roles of 
endocytosis in schwannoma pathogenesis and the PDZ and LIM domain containing 
family of proteins as potential therapeutic targets.  
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Chapter 4 - Total and phosphoproteome analysis of meningioma cells 
compared to normal meningeal cells.  
4.1     Introduction  
Meningiomas represent the second most common intracranial brain tumours, 
accounting for almost 35% of all cases (Wiemels, Wrensch et al. 2010). Around half of 
those are attributable to loss of the Merlin protein, commonly as part of the genetic 
condition neurofibromatosis type 2 (NF2). There are currently no drugs approved for 
NF2 and the need to identify novel therapeutic targets remains urgent. This chapter 
explores phosphopeptide enrichment and phosphoprotein purification to identify 
potential therapeutic targets for meningiomas, and the results of each of these 
analyses will be presented throughout this chapter.  
   Three primary human meningioma-derived cell populations and a meningioma cell 
line (Ben-Men-1) were analysed against a common normal control cell line, Human 
Meningeal Cells (HMC). All samples were analysed for Merlin expression by Western 
blot prior MS (Figure 4.1).   
 
 
 
 
 
 
 
 
 
A 
Merlin  
GAPDH 
75- 
37- 
Figure 4.1: The Merlin status of all meningioma samples submitted for MS 
analysis.   A. As expected three HMC cell populations that were separately cultured 
and processed from one another were confirmed as Merlin-positive by Western blot, 
and three independently cultured populations of Ben-Men-1 cells were confirmed as 
Merlin-negative. B. Three primary meningioma cell populations (MN) were confirmed 
as Merlin-negative. 
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   As with schwannoma, samples were passed through a commercial affinity column to 
achieve phosphoprotein purification. A total protein aliquot was removed prior to this for 
parallel measurement of total protein abundance. After mass spectrometry, data were 
processed as described in the previous chapter. Fold changes and p-values were 
calculated for each quantified protein.  
4.2    Analysis of primary meningioma 
4.2.1    Phosphoprotein analysis of primary meningiomas 
In a comparative analysis between HMC and three primary meningioma-derived cell 
populations, we identified a total of 3464 proteins and quantified 2647. Of those, 500 
were significantly changed between the two cell types. 35 proteins were significantly 
upregulated and 443 were significantly downregulated (Log2 FC > 1, < -1). Table 4.1 
shows all the upregulated proteins (the complete list of significantly downregulated 
proteins is presented in supplementary Table S3). 
   There was a lot of missing data across the primary meningioma phosphoprotein 
dataset that meant LFQ values were not assigned for each protein across each of the 
three repeats. As such, statistical analyses revealed considerably more significantly 
downregulated proteins than upregulated proteins compared to HMC. Enrichment 
analysis of the upregulated phosphoproteins identified one significantly enriched 
pathway, the proteasome. There were four proteasome subunits included in the list; 
PSMC2, PSME1, PSMB3 and PSMB2. This indicates that proteasome inhibition may 
be a therapeutic strategy in meningioma.  
   The phosphoprotein with the largest fold change was TGM2, or transglutaminase 2. 
The expression of this protein has been previously studied in meningioma and was 
found to be highly upregulated and a proposed therapeutic target (Huang, Wei et al. 
2014) . The authors also showed that loss of the NF2 gene was associated with high 
expression of TGM2. 
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Table 4.1 
Gene 
symbol 
Protein name  Log2 FC 
TGM2  Protein-glutamine gamma-glutamyltransferase 2  25.03 
CNPY2  Protein canopy homolog 2  24.75 
CTSD  Cathepsin D  24.61 
CARHSP1  Calcium-regulated heat stable protein 1  24.47 
TXNL1  Thioredoxin-like protein 1  24.34 
PDCD5  Programmed cell death protein 5  24.25 
TUBA4A  Tubulin alpha-4A chain  24.22 
SMAD2 Isoform Short of Mothers against decapentaplegic homolog 2  23.72 
KPNA3  Importin subunit alpha-4  23.48 
CCDC6  Coiled-coil domain-containing protein 6  22.64 
NUCB2  Nefastin-1  22.64 
KPNA1  Importin subunit alpha-5  22.60 
NUCB1  Nucleobindin-1  22.19 
TXNDC5 Isoform 2 of Thioredoxin domain-containing protein 5  22.06 
IFIT2  Interferon-induced protein with tetratricopeptide repeats 2  21.30 
DNAJA1  DnaJ homolog subfamily A member 1  21.15 
TSSC1  Protein TSSC1  20.64 
C1QBP  Complement component 1 Q subcomponent-binding protein 3.74 
TUFM  Elongation factor Tu, mitochondrial  2.39 
FASN  Fatty acid synthase  2.28 
PSMB2  Proteasome subunit beta type-2  2.06 
COPB2  Coatomer protein complex, subunit beta 2 (Beta prime) 1.82 
CALU  Calumenin  1.74 
MAGOHB  Protein mago nashi homolog 2  1.71 
PSMB3  Proteasome subunit beta type-3  1.69 
PSME1  Proteasome activator complex subunit 1  1.63 
PPME1  Protein phosphatase methylesterase 1  1.61 
NT5C2  Cytosolic purine 5-nucleotidase  1.54 
PDIA6  Protein disulfide-isomerase A6  1.52 
TUBB4B  Tubulin beta-4B chain  1.40 
HSPH1 Isoform Beta of Heat shock protein 105 kDa  1.39 
MYO1C  Unconventional myosin-Ic  1.23 
CHMP3  Charged multivesicular body protein 3  1.10 
PSMC2  26S protease regulatory subunit 7  1.10 
ATP5A1  ATP synthase subunit alpha, mitochondrial  1.06 
Table 4.1: 35 phosphoproteins were significantly upregulated in primary meningioma cells 
compared to HMC (P < 0.05, Log2 FC > 1).  
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   Phosphorylated SMAD2 was also found to be highly upregulated in meningioma cells. 
SMAD2 is a major component of TGF-beta signalling, which itself can have either pro 
or anti-proliferative consequences for cancer cells (Massague 2008). We were able to 
identify a specific phosphorylation site for SMAD2 by setting phosphorylation as a 
variable modification in Maxquant. 
 
 
 
 
 
 
   We found that that SMAD2 is phosphorylated at Thr8 (T8) and confirmed this finding 
in three primary meningioma samples (Figure 4.2). Phospho-SMAD_T8 is expressed in 
meningioma and is not present in HMC cells. Total SMAD2 expression was previously 
identified as upregulated in meningioma by Wang et al. along with several other 
members of the TGF-beta signalling family (Wang, Gong et al. 2012).  
   Fatty Acid Synthase (FAS) was also identified as upregulated, with a log2 FC of 2.28. 
This has already been identified as overexpressed in several cancers and its inhibition 
may represent a plausible therapeutic strategy (Mullen and Yet 2015). Unpublished 
data from our group has already shown FAS to be upregulated in Merlin-deficient cells 
and could represent a good target for Merlin-deficient tumours. The data obtained here 
confirms that, and suggests that FAS phosphorylation may also be important for the 
pathogenic consequences of its overexpression compared to normal cells.  
Phospho-cathepsin D is also upregulated in primary meningioma however as it was 
significantly downregulated in schwannoma cells; it is not an ideal common target.  
pSMAD2_T8 
GAPDH 
70- 
37- 
Figure 4.2: Analysis of SMAD2_T8 expression in primary meningioma 
cells. HMC cells do not express SMAD2_T8, whilst all primary meningioma 
samples do.  
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4.2.2     Downregulated phosphoproteins in primary meningioma  
As there was a large amount of missing data for the primary meningioma samples, 
functional analysis of the downregulated data may have been misleading. For a large 
number of the downregulated proteins, mass spectrometry failed to identify any 
peptides in many proteins across the three meningioma repeats. These particular 
proteins were assigned a 0 value in meningioma, and when fold changes were 
calculated between normal and tumour cells, large fold change values were assigned, 
even though in reality the protein was never actually identified in the sample. This 
makes it difficult to make a proper conclusion regarding the quantitative difference 
between the two cell types, as the question must be raised; is the protein truly absent 
or was it simply not identified or quantified for any number of different reasons. This is 
something that should be considered in all proteomic analyses, but that becomes much 
more pertinent in datasets that contain lots of missing values (Karpievitch, Dabney et al. 
2012).  
   As such, functional enrichment analysis of the downregulated dataset included only 
entries that had at least one quantitative value in meningioma. Significantly enriched 
pathways represented by these phosphoproteins were monosaccharide metabolism 
and ribose phosphate metabolism; two pathways employed by cells in order to 
generate energy.  
4.2.3    Primary meningioma total protein data  
There were more total proteins identified and significantly changed than in the 
phosphoprotein experiment.  A total of 2886 quantified proteins are represented in a 
scatter plot (Figure 4.3). 540 were significantly downregulated and 197 were 
significantly upregulated (the full list can be viewed in supplementary Table S4).  
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Figure 4.3: Scatter graph representation of primary meningioma total protein data set. A total of 
2886 proteins were identified in a comparison between primary meningioma cells and HMC. 197 
proteins were significantly upregulated and 540 were significantly downregulated. 
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Figure 4.4: GO enrichment analysis of proteins significantly upregulated in primary 
meningioma cells compared to Human Meningeal Cells (HMC). A majority of the identified 
terms relate to cellular metabolic processes (Benjamini-Hochberg adjusted P < 0.05). 
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   GO enrichment analysis of the upregulated proteins identified 12 significantly 
enriched (Benjamani-Hochberg adjusted P < 0.05) GO terms overall (Figure 4.4). Many 
of them are related to processes involving cholesterol, lipids and steroids, suggesting 
that these processes are perhaps growth permissive for meningioma and are therefore 
potential targets for therapeutic intervention.  
4.2.4    Phosphoprotein vs. total protein expression in primary meningioma 
A graph plotting significantly changed phosphoproteins against their respective non-
phosphorylated counterparts can be viewed in Figure 4.5. At first glance, there are a 
number of proteins that might represent potential therapeutic targets, owing to their 
large change in phosphorylation compared to total protein abundance. These include 
Nucleobindin 1 (NUCB1), Interferon-Induced Protein With Tetratricopeptide Repeats 2 
(IFIT2), Transglutaminase 2 (TGM2), Thioredoxin-like protein (TXNL), Thioredoxin 
domain-containing protein 5 (TXNDC5), heat shock protein J2 (DNAJA1), Nucleobindin 
2 (NUCB2), cathepsin D (CTSD) and karyopherin α (KPNA).  
   There were several proteins identified that do not change in total protein amount but 
display large decreases in phosphoprotein abundance. These correspond to the cluster 
at the bottom of the Y-axis in Figure 4.5 that were difficult to label on the graph. Of 
those, MAP1S in particular is regarded as a tumour suppressor protein via its ability to 
induce autophagy in tumour cells (Xie, Nguyen et al. 2011). The amount of total protein 
hardly changed between the two cell types however the phosphorylated protein is 
downregulated with a log2 fold change of 24.18. This suggests that phosphorylation of 
MAP1S is important for its activity, and that its downregulation in meningioma cells is 
beneficial. As such it would be interesting to investigate it further. 
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Figure 4.5: A graphical aid to show the relationship between significantly changed phosphoproteins and respective total protein 
abundance in primary meningioma compared to Human Meningeal Cells (HMC). Significantly changed phosphoproteins (P < 0.05) plotted 
against total protein change (irrespective of significance). 
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4.3     Analysis of Ben-Men-1 cells 
4.3.1    Ben-Men-1 phosphoprotein data 
A comparison between normal HMC and the benign meningioma cell line Ben-Men-1 
was the next experiment performed. All phosphoproteins identified are represented in a 
scatter plot (Figure 4.6). A total of 243 phosphoproteins were significantly upregulated, 
whilst 196 were significantly downregulated (P < 0.05, Log2 FC > 1/ < -1, all 
significantly changed phosphoproteins can be viewed in supplementary Table S5). The 
upregulated phosphoproteins were submitted for functional enrichment analysis using 
DAVID. The top enriched pathways are the ribosome and spliceosome (Figure 4.7A). 
The spliceosome has been proposed to represent an attractive therapeutic target in 
tumour cells and may warrant investigation in meningiomas (Bonnal, Vigevani et al. 
2012). 
   There is also significant representation of phosphoproteins involved in non-
homologous end joining and nucleotide excision repair. The data therefore also 
indicates there may be alterations in DNA repair mechanisms. We identified functional 
enrichment of the cell-cycle among the upregulated phosphoproteins including Cyclin-
dependent kinases 1 and 2 (CDK1/ CDK2). Both proteins are known to drive cell-cycle 
progression and proliferation, particularly in cancer. CDK inhibition is a valuable 
strategy in cancer treatment, and targeting CDKs 4 and 6 is emerging as the most 
effective option (Asghar, Witkiewicz et al. 2015). We identified CDK4 with a log2 fold-
change of 2.9 in Ben-Men-1 cells that fell just below the significance threshold with a p-
value of 0.07.  
   Gene Ontology (GO) enrichment analysis identified significant enrichment of 
proteasome activation with almost 80-fold enrichment (Figure 4.7B) echoing what was 
observed in primary meningioma cells. This may indicate an increase in the 
degradation of proteins that would otherwise be detrimental to tumour growth and 
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proliferation and also further adds to the body of evidence highlighting the proteasome 
as a therapeutic target. 
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Figure 4.6: 2827 phosphoproteins identified in a comparison between Human Meningeal 
Cells (HMC) and Ben-Men-1 cells. The points above the blue line represent phosphoproteins 
that are significantly (-log2 P = > 4.32) up (243) or downregulated (196) in Ben-Men-1 cells. 
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Figure 4.7: Functional enrichment analysis of phosphoproteins upregulated in Ben-Men-
1 cells A. Pathways significantly enriched in Ben-Men-1 cells (Benjamani-Hochberg adjusted P 
< 0.05). B. Gene Ontology (GO) enrichment analysis highlighting a number of enriched GO 
terms (Benjamini-Hochberg adjusted P < 0.05). C. Classification of upregulated 
phosphoproteins based in protein class shows that the majority are nucleic acid binding 
proteins.  
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Classification of the upregulated phosphoproteins based on protein class shows that 63 
are nucleic acid binding proteins, including several DEAD-box helicase (DDX) proteins 
and ribosomal proteins (Figure 4.7C). DDX5 in particular, which we identified with a 
log2 FC of 2.05, has been implicated in breast, colon, ovarian and prostate cancer, as 
a key contributor to tumour growth and proliferation (Janknecht 2010). As such, it might 
represent a potential therapeutic target for meningioma. 
   The next largest group is represented by 24 cytoskeletal proteins. Included in that list 
was PDLIM2, already identified as a potential target in primary schwannoma cells.  
4.3.2    Downregulated phosphoproteins 
There were several proteins identified as downregulated that are related to 
organization of the cytoskeleton (Figure 4.8), including Merlin. Unlike in schwannoma 
cells, PDLIM5 was identified as downregulated ruling it out of common target selection. 
Another cytoskeletal protein, Junction Plakoglobin (JUP) was also found to be 
downregulated with a fold change of -20.663. The total protein abundance was almost 
completely unchanged indicating that decreased phosphorylation of JUP in tumour 
cells is perhaps growth permissive. JUP, also known as γ-catenin is structurally and 
functionally related to β-catenin. Phosphorylated β-catenin was also found to be 
downregulated in Ben-Men-1 cells. The specific site of phosphorylation would first need 
to be elucidated before the effects of this downregulation can be fully appreciated.  
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Figure 4.8: Gene Ontology (GO) enrichment of significantly downregulated 
phosphoproteins in Ben-Men-1 cells. The majority of enriched GO terms correspond to 
cytoskeletal regulation (Benjamini-Hochberg adjusted P < 0.05). 
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 A number of downregulated phosphoproteins also mapped to the GO term 
‘lamellipodium’ (Figure 4.8), which are actin projections on the leading edge of the cell 
and are important in cell migration and invasion (Kiosses, Shattil et al. 2001). The 
proteins involved include β-catenin and paxillin. Like β-catenin, the amount of total 
paxillin protein did not significantly change between normal and tumour cells. The 
activity of paxillin can change depending on exactly where it is phosphorylated 
therefore site-specific information would need to be obtained to understand the 
consequences of phospho-paxillin downregulation.  
4.3.3    Ben-Men-1 total protein data 
There were 3176 proteins originally identified and quantified, represented by a scatter 
plot (Figure 4.9). 177 were significantly upregulated, and 233 were significantly 
downregulated (the full list is presented in supplementary Table S6). 
   Among the pathways significantly enriched in Ben-Men-1 cells were focal adhesion 
and ECM-receptor interaction, largely characterised by the upregulation of several 
integrins (Figure 4.10A).  Expression has been studied previously in meningioma and 
all three WHO grades have been shown to express a variety of integrins including beta 
3 and alpha 5, as identified by Bello and colleagues (Bello, Zhang et al. 2000).  
   Significant enrichment of spliceosomal proteins was also observed. Among them was 
HSPA2 which has been identified as overexpressed in a large number of cancers and 
therefore represents a potential novel target in meningioma (Scieglinska, Gogler-
Piglowska et al. 2014).  
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Figure 4.9: Scatter graph representation of meningioma total protein data set. A total of 
3176 proteins identified in a comparison between Ben-Men-1 and HMC cells. The points above 
the blue line represent proteins that are significantly up (177) or downregulated (233) in Ben-
Men-1 cells compare to HMC.  
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Figure 4.10: Functional enrichment analysis of proteins upregulated in Ben-Men-1 cells 
compared to Human Meningeal Cells (HMC) A. ECM-receptor interaction and focal adhesions are 
among the functionally enriched pathways (Benjamini-Hochberg adjusted P < 0.05) B. GO enrichment 
analysis identified collagen binding and ECM organization as significantly enriched (Benjamini-Hochberg 
adjusted P < 0.05). 
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GO enrichment analysis of upregulated proteins identified terms relating largely to ECM 
interaction, collagen and integrin mediated signalling (Figure 4.10B). We also found the 
PDGFRβ receptor as upregulated with a log2 FC of 1.6. Previous work within the group 
has shown that the overexpression of PDGFRβ is closely linked to integrin signalling. 
Collagen can also have major implications on tumour growth and progression, and can 
dictate to which degree a tumour is vascularized or how strongly it associates with its 
matrix (Fang, Yuan et al. 2014). There are in total seven collagens upregulated in Ben-
Men-1 cells (COLL11A1, COL18A1, COL1A1, COL1A2, COL4A1, COL5A1, COL6A2), 
each with varying functions.  
4.3.4    Downregulated total protein data  
The most downregulated protein identified was THY1, or CD90. The significant 
decrease observed in Ben-Men-1 cells would suggest an important role for this protein 
in inhibiting tumorigenesis. Many of the downregulated proteins are involved in cellular 
metabolism including purine metabolism, starch and sucrose metabolism and like in 
schwannoma several are also related to lysosomes. There is downregulation of 
cathepsins C, D and Z indicating defects in lysosomal protein degradation.  
4.3.5   Phosphoprotein vs. total protein in Ben-Men-1  
Significantly changed phosphoproteins were plotted in a graph against their respective 
non-phosphorylated counterparts (Figure 4.11). There are several proteins that warrant 
further investigation as potential phosphorylated targets in meningiomas. They display 
large changes in phosphoprotein abundance and either no change or a decrease in 
total protein. Several of the most promising phosphorylated targets are shown in Table 
4.2, chosen because they have all been previously linked with cancer and are among 
the most highly upregulated in Ben-Men-1 cells. Whilst these proteins and many others 
represent potential therapeutic targets, it would be necessary to confirm their 
expression by Western blot in subsequent analyses.  
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Figure 4.11: A graphical aid to represent the relationships between total and phosphoprotein levels in Ben-Men-1 cells. 
Phosphoproteins significantly up or downregulated (P < 0.05) in Ben-Men-1 cells plotted against their respective total protein amounts. 
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   TAGLN2 is a protein similar in its function to TAGLN, which was identified as a 
possible therapeutic target in schwannoma. The transgelins are a family of proteins 
able to influence a diverse range of cellular processes, including proliferation, migration 
and apoptosis (Dvorakova, Nenutil et al. 2014). Non-phosphorylated TAGLN has been 
identified as a tumour suppressor in several cancers, but there has been limited 
research in to the phosphorylated form of either TAGLN or TAGLN2. Site-specific 
phosphorylation modulation may have different effects on TAGLN2, depending on the 
region of modification. It might be that phosphorylation is in fact an inhibitory 
mechanism interfering with tumour suppressive activity. Overall, the transgelins 
represent potential common NF2 targets, although this would require further 
investigation, particularly elucidation of specific phosphorylation sites. 
   CACYBP (Calcyclin binding protein) is a protein reported to have a number of 
functions in the cell, and can act as either an oncogene or a tumour suppressor, 
depending on the type of cancer (Topolska-Wos, Chazin et al. 2016). It can function as 
a component of E3 ubiquitin ligase complexes, is able to bind to the actin cytoskeleton 
Table 4.2 
Gene symbol  Protein name  Function  
CACYBP Calcyclin binding protein  Drives glioma proliferation  
DTX3L Deltex-3-like E3 ubiquitin ligase DNA damage response modulation  
RAB11FIP1 Rab11 family interacting protein 1 Promotes breast cancer growth, 
activates RAS and ERK 
TAGLN2 Transgelin 2 Stabilizes actin filaments  
Table 4.2: Potential therapeutic targets identified from a comparative analysis between a 
benign meningioma cell line, Ben-Men-1 and the normal meningeal cells HMC. 
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and may play a role in cell cycle regulation. CACYBP therefore represents an 
interesting target for further investigation in meningioma.  
   RAB11FIP1 is able to regulate Integrin alpha 5 trafficking which leads to the 
formation of membrane ruffles and increased cell invasiveness (Paul, Allen et al. 2015). 
Given the role of integrins in meningioma pathology, targeting RAB11FIP1 might be a 
valuable therapeutic strategy.  
   DTX3L is an E3 ubiquitin ligase able to modulate DNA damage responses rendering 
cancer cells resistant to certain chemotherapy drugs, and also promotes invasion in 
melanoma cells (Thang, Yajima et al. 2015). As we were also able to identify the DNA 
damage response as dysregulated in Ben-Men-1 cells, DTX3L could be an important 
protein through which this pathway can be targeted.  
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4.4    Phosphopeptide enrichment  
In addition to phosphoprotein purification, phosphopeptide enrichment was utilized in 
an attempt to identify site-specific information that may have been of use in functional 
analysis. Firstly, Filter Aided Sample Preparation (FASP) was trialled in conjunction 
with SDS lysis buffer. This was to achieve buffer exchange and eliminate any detergent 
incompatible with subsequent phosphopeptide enrichment. The advantage of FASP is 
that it facilitates the use of SDS, which is considered the strongest and most effective 
lysis buffer particularly for permitting comprehensive membrane proteome coverage 
(Wisniewski, Nagaraj et al. 2010). Identifying active, targetable receptors on the cell 
membrane would be of particular importance in the search for possible therapeutic 
targets. However, detergents like SDS are incompatible with downstream enrichment 
techniques, hence the requirement for FASP. Urea buffer was also tested and is 
routinely used in phosphopeptide enrichment experiments. RadioImmunoprecipitation 
(RIPA) buffer was tested in parallel, as a gentler alternative to SDS. Neither of these 
requires FASP. In this comparative experiment, lysis with SDS followed by buffer 
exchange led to the lowest protein concentration overall. RIPA buffer and urea buffer 
yielded concentrations within 1ug/ml of each other (Table 4.3). Based on these results, 
RIPA buffer was chosen for the enrichment experiment.  
 
 
 
Table 4.3 
Lysis buffer Protein concentration (ug/ml) No. cells 
RIPA 331 106 
SDS 258 106 
Urea 330 106 
Table 4.3: Analysis of different lysis buffers prior to phosphopeptide enrichment. 
Three lysis buffers were tested and the resulting total protein yield was measured. RIPA 
buffer was identified as the buffer yielding the highest amount of protein.  
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4.4.1    Phosphopeptide data analysis 
Titanium dioxide (TiO2) enrichment was performed as described in chapter 2. 1 mg of 
Ben-Men-1 cell lysate was first digested with trypsin overnight, before three sequential 
incubations with TiO2 beads and subsequent MS analysis of the pooled eluates. Figure 
4.12 presents the data obtained. Identified peptides were filtered to contain only those 
with a localization probability of > 0.75 and only phosphopeptides with a peptide score 
of > 50 were allowed through the second filter. These are criteria set by Olsen et al in 
2006 based on specially developed algorithms to ensure data quality and maximise 
correct phospho-site assignment. Further, the authors also state that the majority of 
identified peptides should be Serine (S) phosphorylated, followed by Threonine (T) with 
Tyrosine (Y) phosphorylated peptides representing the smallest group (Figure 4.12A) 
(Olsen, Blagoev et al. 2006). There were 216 phosphopeptides identified that fit the 
specified criteria, corresponding to 144 proteins. The full list can be viewed in 
supplementary Table S7. Functional enrichment using DAVID identified five significant 
pathways (Figure 4.12B). The majority of these have been previously linked to Merlin 
deficient tumours.  
   Figure 4.12C shows specific phospho-site information for proteins related to focal 
adhesion, regulation of the actin cytoskeleton and adherens junctions, chosen because 
they are the most pertinent and well characterized in Merlin-deficient tumours.  
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Amino acid Number of peptides 
Serine (S) 155 (71.8%) 
  Threonine (T) 46 (21.3%) 
      Tyrosine (Y)   15 (6.9%) 
Gene symbol Modified sequence Phospho site 
PAK2 _YIS(ph)FTPPEK_ S141 
EGFR PIT(ph)PSGEA T693 
FLNB S(ph)PGSANET S2478 
LAMA5 IAIS(ph)AS(ph)IGR S2715 
PDPK1 ANS(ph)FVGT S241 
PPP1CA MSDS(ph)EKIN S4 
PPP1R12A GS(ph)YGAIAE S445 
CFL1 AS(ph)GVAVSD S3 
CFL2 S(ph)GVTVND S3 
BAIAP2 FNPS(ph)IRN S27 
LMO7 S(ph)PTSPFS/ S(ph)IDNID S991/ S1510 
CTNNA1 DDS(ph)DFETE S641 
MAPK37 S(ph)IQDITVTG S439 
SLIT3 Y(ph)VEIASA Y1168 
EIF4EBP1 TT(ph)PGGTIFS T46 
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Figure 4.12: Ben-Men-1 phosphopeptide data analysis. A. The proportion of Serine (S), Threonine (T) 
and Tyrosine (Y) phosphorylated peptides identified in Ben-Men-1 cells via TiO2 enrichment. B. Functional 
enrichment analysis identified five significantly enriched pathways represented by the dataset (Benjamini-
Hochberg adjusted P < 0.05) C. Specific phospho-sites that correspond to proteins mapping to 
cytoskeletal, focal adhesion and adherens junction pathways. 
A 
114 
 
The acquisition of site specific information can assist greatly in the identification of 
suitable drugs and in the drug design process. It gives us a greater chance of 
identifying specific kinases that can also be exploited as a therapeutic strategy. The 
PAKs in particular are known to be implicated in schwannoma pathogenesis via their 
involvement in RAC signalling (Flaiz, Chernoff et al. 2009). PAK2_S141 has not been 
previously reported in schwannoma or meningioma and may represent a novel target.  
   We were also able to identify two cofilins, CFL1 and CFL2, phosphorylated at S3 by 
LIM-domain kinases, which have been previously linked to schwannoma (Petrilli, Copik 
et al. 2014). A study published in 2014 identified an inhibitor, T56-LIMKi, which was 
able to decrease the level of S3 phosphorylation of cofilin in a schwannoma cell line, 
thus leading to decreased growth. It may therefore represent a valuable therapeutic 
option for Merlin-deficient tumours (Rak, Haklai et al. 2014).  
   We also identified the EGF receptor, phosphorylated at T693. The EGFR has been 
previously identified as constitutively active at this site in lung cancer (Assiddiq, Tan et 
al. 2012) and the receptor is known to be linked to several pathways including the 
MAPK and PI3K/Akt, known to be important in meningioma pathology. As such, we 
validated the expression of pEGFR_T693 by western blot in Ben-Men-1 cells compared 
to HMC, detecting it in Ben-Men-1 cells but not in the control (Figure 4.13A). Figure 
4.13B shows that pEGFR_T693 was also activated in primary meningioma cells, 
further pEGFR_T693 activation was detected in grade I meningioma tumours, but not 
in normal meningeal tissue lysate (Figure 4.13C). The data also highlights the fact that 
EGFR_T693 activation appears to be independent of Merlin status.  
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Figure 4.13: Phosphopeptide data validation for pEGFR_T693 expression in meningioma cells. 
A. Western blot showing that EGFR_T693 is detected in Ben-Men-1 cells but not in HMC B. 
EGFR_T693 is activated in primary meningioma cells. C. Western blot analysis of pEGFR_T693 
detected in grade I meningioma tumours, but not in normal meningeal tissue.  
EGFR_T693 175- 
37- GAPDH 
EGFR_T693 
GAPDH 
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GAPDH 
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Merlin 75- 
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4.5   Discussion  
We have been able to identify several potential therapeutic targets for the treatment of 
meningioma. One of the important points learned from the analysis presented here is 
that MS results need to be interpreted carefully. Raw data must be scrutinized to make 
clear distinctions between proteins that are genuinely differentially expressed, and 
those that appear to be so. It must be stressed that any information identified by MS 
should be properly validated by other means before firm conclusions are drawn.  
   As part of the analysis to identify targets in meningioma, we analysed both a 
meningioma cell line, Ben-Men-1 and three primary meningioma cell populations, both 
against a common control, normal Human Meningeal Cells (HMC). We were able to 
identify many more proteins in the cell lines than we were in primary cells, the possible 
reasons for which will be discussed in more detail throughout the final discussion. In 
the two sets of significantly changed phosphoproteins, there were 80 that were 
common to both Ben-Men-1 and primary meningioma cells (Supplementary Table S8). 
One of these was CTSD (Cathepsin D). This upregulation can lead to a number of 
cellular responses including increased angiogenesis, and enhanced invasion (Pranjol, 
Gutowski et al. 2015). Further characterization would be required to determine the 
suitability of CTSD as a meningioma target. Of note, phospho-CTSD was 
downregulated in schwannoma cells, which rules it out as a common NF2 drug target.  
   The data presented here provides further rationale for targeting the proteasome in 
meningioma treatment, as it was among the most significantly enriched pathways 
represented by upregulated phosphoproteins in Ben-Men-1 cells and primary 
meningioma cells. There is also scope for investigating DNA repair mechanisms and 
the spliceosome as potential therapeutic targets. The phosphorylated proteins fatty 
acid synthase (FAS), transglutaminase 2 (TGM2) and Mothers against decapentaplegic 
2 (SMAD2), identified as upregulated in primary meningioma are also candidates for 
further analysis as potential meningioma targets.  
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   We have also identified a number of phosphorylation sites corresponding to several 
proteins. Although this was not a comparative analysis of phosphopeptides between 
tumour and normal cells, it does provide an indication of which proteins are activated in 
Ben-Men-1 cells that might act as therapeutic targets. We confirmed the expression of 
EGFR_T693 in primary meningioma cells and tumour samples, and it would be 
interesting to further analyse this phosphoprotein in relation to meningioma 
pathogenesis.  
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Chapter 5- Selection, validation and functional assessment of candidate 
therapeutic targets 
5.1    Introduction  
The aim of this thesis has been to identify targets common to both meningioma and 
schwannoma in an innovative step toward the simultaneous treatment of NF2-related 
tumours. We demonstrated in the previous chapters that the use of MS in conjunction 
with phosphoproteomics is a valuable tool for identifying upregulated and aberrantly 
activated proteins in both primary meningioma and schwannoma cells that might 
represent novel therapeutic targets.  
   This chapter will describe the process of candidate target selection for further 
analysis, and present validation data of a number of potential, common targets. Whilst 
until now the datasets obtained from each individual experiment were treated 
independently of one another, this chapter focusses on the data overall. Particular 
proteins that were identified as potential therapeutic targets in the previous chapters 
may not appear on the final list chosen for further analysis, simply because in looking 
for commonality between distinct datasets, the pool was somewhat reduced. It must 
therefore be stressed at this point that a number of potential targets have not been 
taken forward as part of this project, but hold promise for future analyses.  
5.2    Common targets in primary meningioma and schwannoma 
We compared primary meningioma with primary schwannoma to identify potential 
targets for future analyses.  There were 42 phosphoproteins that were commonly and 
significantly changed in both primary meningioma and primary schwannoma cells, 
compared to their respective controls.  Of these, the majority showed opposite 
differential expression in either cell type i.e. if a protein was upregulated in 
schwannoma, it was downregulated in meningioma and vice versa. There were 10 that 
were commonly up or downregulated, and these are listed in Table 5.1.  
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Table 5.1 
Gene symbol  Protein name  Log2 FC 
meningioma 
Log2 FC 
schwannoma 
SPAG9  C-Jun-amino-terminal kinase-interacting 
protein 4 
-2.05 -1.99 
TRIO  Triple functional domain protein  -23.52 -1.16 
TALDO1  Transaldolase -1.13 -1.25 
TUFM   Elongation factor Tu, mitochondrial 2.39 1.56 
NT5C2  Cytosolic purine 5-nucleotidase  1.54 1.25 
CLASP1  CLIP-associating protein 1 -22.00 -1.69 
PPIL4  Peptidyl-prolyl cis-trans isomerase-like 4 -21.31 -1.02 
PSMB7  Proteasome subunit beta type-7 -1.72 -1.32 
YTHDC2  Probable ATP-dependent RNA helicase 
YTHDC2  
-22.33 -2.13 
KIF13B  Kinesin-like protein KIF13B -21.47 -2.51 
 
 
 
 
 
 
 
 
 
 
 
Table 5.1: Phosphoproteins commonly and significantly up or downregulated in primary 
meningioma and primary schwannoma cells (P < 0.05).  
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Of the 10, there were two phosphoproteins that were commonly upregulated in both 
cell types; TUFM and NT5C2. Mitochondrial Tu translation elongation factor (TUFM) is 
involved in mitochondrial protein translation and has been linked to several cancers. 
NT5C2, or 5'-Nucleotidase, Cytosolic II is an enzyme involved in purine metabolism 
and mutations of this protein have been heavily linked with leukaemia. Both therefore 
warrant further investigation as common NF2 targets.  
5.3    Common targets in Ben-Men-1 and primary schwannoma 
When significantly changed phosphoproteins in Ben-Men-1 cells were compared with 
those in primary schwannoma cells, the majority again showed opposite expression in 
both cell types and of those, 15 were commonly up or downregulated (Table 5.2). 
There was however considerably more overlap between these two datasets than 
between primary meningioma and schwannoma, and so the final selection of candidate 
targets was based on this comparison.  
   To select candidates for further analysis we applied the following criteria; firstly, it 
was decided that only upregulated proteins would be considered as it is not feasible to 
target downregulated proteins. This reduced the pool to 11 proteins.  
   Availability of phospho-specific antibodies was also a consideration and of the 11 
remaining proteins, there were commercially available antibodies only for STAT1 and 
HSPA1A. We had previously identified two STAT1 phospho-sites, S727/ Y701, by 
selecting phosphorylation as a variable modification using maxquant and these were 
confirmed by Western blot. We did not obtain site-specific information for HSPA1A 
therefore two sites were analysed using two available antibodies; Y525 and Y41.  
   Finally, because we had previously identified FLNB and PDLIM2 by phosphopeptide 
enrichment in Ben-Men-1 cells, these were also selected for further analysis; however 
no phospho-specific antibodies are currently available. For validation experiments, we 
were able to obtain an antibody dually targeting pFLNA /pFLNB. Table 5.3 summarizes 
the candidate targets selected and briefly describes their known functions.  
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Table 5.2 
Gene symbol  Protein name Log2 FC 
Ben-men-1 
Log2 FC 
schwannoma 
CORO1C Coronin-1C 2.60 1.45 
CTPS CTP synthase 1 1.23 3.70 
CUTA Protein CutA 1.44 1.50 
EPS8L2 Epidermal growth factor receptor 
kinase substrate 8-like protein 2 
3.36 24.27 
FLNB Filamin-B 1.22 24.49 
HSPA1A Heat shock 70 kDa protein 1A/1B 1.21 3.23 
PDE1C Calcium/calmodulin-dependent 3,5-
cyclic nucleotide phosphodiesterase 
1C 
3.16 1.36 
PDLIM2 PDZ and LIM domain protein 2 3.94 24.53 
PSMB8 Proteasome subunit beta type-8 1.40 1.29 
STAT1 Signal transducer and activator of 
transcription 1-alpha/beta 
4.57 26.24 
TCEB2 Transcription elongation factor B 
polypeptide 2 
1.01 1.02 
MAP1A Microtubule-associated protein 
1A;MAP1 light chain LC2 
-19.89 -1.00 
PACSIN2 Protein kinase C and casein kinase 
substrate in neurons protein 2 
-2.11 -1.19 
PSMB7 Proteasome subunit beta type-7 -1.17 -1.32 
UFL1 E3 UFM1-protein ligase 1 -1.14 -1.43 
Table 5.2: Phosphoproteins commonly and significantly up or downregulated in Ben-Men-1 
and primary schwannoma cells (P < 0.05). 
122 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.3 
Protein name Gene 
symbol 
Function 
Filamin B FLNB 
Actin cross-linking, providing a communicative link 
between the cell membrane and the cytoskeleton. 
Heat shock protein family  A 
member 1A 
HSPA1A 
Facilitates correct protein folding, transport and 
degradation. 
PDZ and LIM domain 
containing protein 2 
PDLIM2 
Promotes cell migration and adhesion, and has E3 
ubiquitin ligase activity. 
Signal Transducer and 
Activator of Transcription 1 
STAT1 
Activated in response to Interferons and various RTKs, 
involved in inflammation.  
Table 5.3: The candidate therapeutic targets selected for further analysis based on commonality 
between overexpression in Ben-Men-1 cells compared to control, and primary schwannoma cells 
compared to control.  
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5.4    Candidate target validation  
The next stage of the project involved validation of chosen targets in several primary 
tumour samples, as overexpressed compared to their respective controls. Following 
that, the most promising candidate therapeutic targets were functionally assessed in 
vitro forming the initial stages of valuation of their suitability as novel drug targets for 
the treatment of NF2.   
   These targets represent those that are truly activated, and not just increased 
because of changes in total protein amount, potentially making them important targets 
for the ‘switching off’ of  tumorigenic signalling.  
5.4.1    Total and phospho STAT1 expression in meningioma and schwannoma  
Total STAT1, pSTAT1_S727 and pSTAT1_Y701 expression were analysed in primary 
meningioma cells and tissue. Western blot analysis showed a significant increase of 
total STAT1 in Ben-Men-1 cells and primary meningioma cells, compared to HMC 
(Figure 5.1A and B). Analysis of phospho-STAT1 confirmed expression of both 
phospho-STATs in Ben-Men-1 and primary meningioma cells, and also showed that 
HMC cells do not express either pSTAT1_Y701 or S727.  
   We were also able to confirm the expression of both STAT1 phosphorylation sites by 
immunohistochemistry (IHC) in primary meningioma tissue sections (Figure 5.2A and 
B). Positive staining for both Y701 and S727 was seen in all cases - a total of 30 
sections. STAT1_Y701 stained strongly in the cytoplasm (Figure 5.2A) and conversely 
727 stained exclusively in the nucleus (5.2B). We additionally confirmed localization of 
Y701 and S727 in primary meningioma cells by immunocytochemistry (ICC) (Figure 
5.2C and D). Again, pSTAT1_Y701 was expressed strongly in the cytoplasm but not in 
the nucleus (Figure 5.2C), and  pSTAT1_S727 was seen exclusively within the nucleus, 
and not at all in the cytoplasm (Figure 5.2D).  
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Figure 5.1: Total and phospho STAT1 expression in primary meningioma cells. A. Total and 
phospho-STAT1 expression were analysed by Western blot in Human Meningeal Cells (HMC) and 
Ben-Men-1 cells (BM) in triplicate. Total STAT1 was significantly increased in BM cells, and both 
pSTAT1_Y701 and pSTAT1_S727 were expressed in BM but not in HMC. B. Total STAT1 and 
phospho-STAT1 expression in primary meningioma cells (MN) was analysed by Western blot. Total 
STAT1 expression was significantly increased in primary meningioma cells compared to HMC.  
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200μm 
Figure 5.2: Phospho-STAT1 in primary meningioma cells and tissue. A/ B. pSTAT1_Y701 and 
S727 were analysed by IHC in frozen grade I meningioma tissue. Neither Y701 nor S727 were 
observed in normal meningeal tissue. Phospho-STAT1_Y701 was exclusively cytoplasmic and 
pSTAT1_S727 was almost entirely nuclear. C/ D. pSTAT1_Y701 and pSTAT1_S727 were analysed 
by ICC in primary meningioma cells. Again pSTAT1_Y701 stained exclusively in the cytoplasm and 
S727 was observed in the nucleus. All ICC images were taken at 40x magnification and all IHC 
images at x200. No primary= no primary antibody control. The same antibody was used for control 
and tumour samples.  
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5.4.2    Confirming total and phospho STAT1 expression in primary schwannoma 
cells 
Western blot analysis of seven primary schwannoma vs. three primary Schwann cell 
samples showed an overall non-significant (NS) increase in total STAT1 expression 
(Figure 5.3A) in tumours compared to controls. Expression of pSTAT1_701 and S727 
varies among the seven tumours analysed, with four out of seven expressing both 
phospho-STATs and three of seven not expressing them at all. None of the controls 
were found to express either phospho-STAT1. As was observed in primary 
meningiomas, in the four schwannomas that do express phosphoprotein, both sites 
were simultaneously activated.   
   Immunofluorescent staining showed that pSTAT1_Y701 was cytoplasmic, and that 
STAT1_S727 was nuclear (Figure 5.3B and C).  
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Figure 5.3: Total and phospho-STAT1 expression in primary schwannoma cells. A. Western 
blot analysis of total and phospho- STAT1 in primary Schwann (MOS) and schwannoma (NF) cells. 
Total STAT1 expression was non-significantly increased in primary NF and both pSTAT1_Y701 and 
S727 were co-expressed in four out of seven NF samples, and not at all in MOS. B/ C. pSTAT1 
expression was analysed by ICC in NF cells. Phospo-STAT1_Y701 was localized to the cytoplasm 
(B) while pSTAT1_S727 was completely nuclear (C). All Images were taken at 40x magnification. 
NS= non-significant, no primary= no primary control. 
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5.4.3    PDLIM2 protein expression in primary meningioma and schwannoma 
We next sought to validate PDLIM2 expression in primary meningioma cells. We were 
unable to find any phospho-specific antibodies, including for PDLIM2_S137 that was 
identified by phosphopeptide enrichment (Table S7). Reports in the literature have 
shown this phosphorylated form of PDLIM2 is able to act specifically on STAT1, 
targeting it for degradation via its E3 ubiquitin ligase activity (Guo, Mi et al. 2010). 
Without a specific antibody, unfortunately it would be difficult to test this mechanism in 
our cells.  
   Total PDLIM2 expression was analysed in five primary meningioma samples as well 
as Ben-Men-1 and HMC cells. PDLIM2 was not detected in HMC but was expressed to 
varying degrees in all Ben-Men-1 and primary meningioma samples (Figure 5.4A and 
B). Analysis of grade I primary meningioma tissue samples further confirmed that 
PDLIM2 was not expressed in primary meningeal tissue, and was expressed in all 
meningioma tissue samples (Figure 5.4C).  
   Western blot analysis also showed that PDLIM2 was not detected in two out of three 
Schwann cells tested, but was very weakly expressed in MOS0114. PDLIM2 
expression was observed in five out of seven primary schwannoma samples (Figure 
5.4D).  
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D 
Figure 5.4: PDLIM2 expression in primary meningioma cells and tissue, and in primary 
Schwann and schwannoma cells. A. Western blot analysis of PDLIM2 expression in 
triplicate in Ben-Men-1. B. PDLIM2 immunoreactivity was detected in five primary meningioma 
cell samples vs. HMC. C. PDLIM2 was expressed in four primary meningioma tissue samples 
vs.  normal meningeal tissue. D. Western blot analysis of PDLIM2 expression shown in five of 
seven NF samples and weakly in one out of three MOS samples. 
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5.4.4    PDLIM2 phosphorylation and localization in primary meningioma cells.  
Given that PDLIM2 phosphorylation at S137 was identified by phosphopeptide 
enrichment in Ben-Men-1 cells, an in vitro dephosphorylation assay was performed 
using lambda phosphatase. This experiment would confirm whether the 
phosphorylated form of PDLIM2 is expressed in Ben-Men-1 cells. In the absence of a 
phospho-specific antibody, this is an alternative method of assessing the 
phosphorylation status of proteins. A shift in band mobility is detected via Western blot, 
where phosphorylated proteins migrate slower than their non-phosphorylated 
counterparts, leading to the detection of a higher molecular weight band after probing 
with a total protein antibody.  
   We were able to detect a lower molecular weight band by Western blot analysis after 
phosphatase treatment of Ben-Men-1 cell lysate, indicating that PDLIM2 is indeed 
phosphorylated in these cells (Figure 5.5A). 
   Nuclear and cytoplasmic extraction was also performed to determine the cellular 
localization of PDLIM2 in Ben-Men-1 cells and three primary meningiomas. This is 
because the cellular location of PDLIM2 may be important for its function. PDLIM2 was 
found to be almost entirely nuclear, with no bands present in the cytoplasmic fraction 
upon Western blot analysis apart from a very faint band in MN0065 cells (Figure 5.5B).  
HDAC was used as a nuclear control, and GAPDH was used as a cytoplasmic control 
to ensure successful fractionation.  
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Figure 5.5: PDLIM2 phosphorylation and localization in Ben-Men-1 and primary 
meningioma cells. A. Ben-Men-1 cell lysate was treated with lambda phosphatase and 
analysed for the expression of PDLIM2. After phosphatase treatment, the band for PDLIM2 was 
of lower molecular weight. B. Nuclear and cytoplasmic extraction was performed using Ben-
Men-1 and two MN cell populations to determine the localization of PDLIM2. In all cases, 
PDLIM2 was found to be almost entirely nuclear.  
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5.4.5    FLNB expression in primary meningioma cells and tissue 
 
Due to unavailability of a phospho-FLNB, we tested total FLNB, and also an antibody 
dually targeting phospho-filamin A (FLNA) and phospho-FLNB_S2107.  
   There was overall a non-significant decrease observed in total FLNB expression 
between HMC and Ben-Men-1 cells repeated in triplicate (Figure 5.6A). FLNB 
expression in primary meningioma cells showed a non-significant increase compared 
to HMC (Figure 5.6B).  
   Again, a non-significant increase of pFLNA/pFLNB expression was observed in 
primary meningioma cells compared to HMC (Figure 5.6C). However, we identified 
pFLNA/pFLNB expression in four primary meningioma tumour tissue samples, but not 
in normal meningeal control tissue (Figure 5.6D). 
5.4.6    FLNB expression in primary Schwann and schwannoma cells 
We analysed total and phospho-FLNB expression by Western blot in primary Schwann 
and schwannoma cells. We identified a significant increase in total FLNB expression in 
schwannoma cells (Figure 5.7A), and an overall non-significant decrease in 
pFLNA/pFLNB expression (Figure 5.7B).  
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Figure 5.6: Total and phospho- FLNB expression in primary meningioma cells and tissue. A. 
Total FLNB was non-significantly decreased in Ben-Men-1 cells compared to HMC. B. Total FLNB 
expression was non-significantly increased in primary meningioma cells compared to HMC. C. 
pFLNA/pFLNB expression was non-significantly increased in MN cells compared to HMC. D. 
pFLNA/pFLNB was identified in four primary meningioma tumour samples, but not in normal 
meninges.  
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Figure 5.7: Total and phospho- FLNB expression in primary schwannoma. A. Western blot 
analysis showing FLNB expression in three MOS samples and five NF samples revealing a non-
significant increase in schwannoma cells. B. pFLNA/pFLNB expression was found to be non-
significantly decreased in primary schwannoma compared to Schwann cells. 
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5.4.7    Total and phospho-HSPA1A expression in primary meningioma cells and 
tissue 
Total HSPA1A was significantly decreased in Ben-Men-1 cells compared to HMC 
(Figure 5.8A), as analysed by Western blot. However, a significant increase was 
observed in primary meningioma cells, compared to HMC, mainly due to clear 
increased expression in samples MN0611 and MN0715 (Figure 5.8B).  
   As we did not identify any specific phosphorylation sites on HSPA1A, we tested two 
different antibodies, one targeting pHSPA1A_Y41, and one targeting pHSPA1A_Y525. 
We analysed pHSPA1A_Y41 expression by Western blot and identified a non-
significant increase in primary meningioma cells compared to HMC (Figure 5.8C).  
However, Western blot analysis of pHSPA1A_Y41 expression in primary meningioma 
tissue lysate revealed expression in four tumour samples and very little expression in 
normal meningeal tissue (Figure 5.8D).  
   We used anti-HSPA1A_Y525 to assess expression on frozen grade I meningioma 
tumour sections as anti-pHSPA1A_Y41 was not suitable for IHC. Weak or moderate 
staining was observed in all cases (10 in total). We also looked for HSPA1A_Y525 
expression in five normal meningeal controls, and in all cases staining was either 
negative or weak (Figure 5.8E). 
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200μm 
Figure 5.8: Total and phospho-HSPA1A expression in primary meningioma cells and tissue. A. Western blot 
analysis of total HSPA1A expression in Ben-Men-1 cells vs. HMC performed in triplicate.  B. HSPA1A expression in 
primary meningioma’s (MN) vs. HMC. C. Western blot analysis of pHSPA1A_Y41 in MN compared to HMC. D. 
pHSPA1A_Y41 was highly expressed in primary meningioma tumour tissue compared to normal meninges. E. 
Immunohistochemical analysis of grade I meningioma tissues showing weak to moderate HSPA1A_Y525 
expression compared to no expression in normal meningeal tissue. The same antibody was used for control and 
tumour samples. 
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5.4.8    Total and phospho-HSPA1A expression in primary schwannoma cells and 
tissue 
Western blot analysis showed Total HSPA1A expression was non-significantly 
increased in primary schwannoma compared to primary Schwann cells (Figure 5.9A). 
PHSPA1A_Y41 was also identified as non-significantly increased overall in primary 
schwannoma cells (Figure 5.9B). Immunohistochemical analysis of HSPA1A_Y525 
expression in schwannoma revealed moderate or strong staining across 10 sections 
from different tumours (Figure 5.9C). We also analysed five normal nerve specimens 
that were all negative or weakly positive for HSPA1A_Y525. 
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Figure 5.9: Total and phospho-HSPA1A expression in primary schwannoma cells. A. Western 
blot showing a non-significant increase of total HSPA1A expression in NF compared to MOS cells.    
B. pHSPA1A_Y41 expression was identified by Western blot as non-significantly higher in NF than 
Schwann cells. C. Immunohistochemical analysis of pHSPA1A_Y525 expression in schwannoma 
tissue showing moderate to strong expression compared to normal nerve tissue. All IHC images 
were recorded at x200 magnification. The same antibody was used for control and tumour samples. 
 
A B 
----------------------HSPA1A_Y525----------------------- NERVE 
C 
200μm 
139 
 
5.5    PDLIM2 co-immunoprecipitation  
At this point the most promising candidates among the four validated so far were 
STAT1 and PDLIM2. This is because these two proteins were not expressed in control 
cells or tissue, whereas FLNB and HSPA1A showed inconsistencies in expression 
between normal and tumour cells. Nonetheless, there is evidence to suggest 
overexpression of the latter two proteins in primary tumour tissue. 
   To understand how PDLIM2 might be involved in tumour pathogenesis, we 
performed an experimental co-immunoprecipitation (co-ip) of PDLIM2 in Ben-Men-1 
cells that was then submitted for MS to identify binding partners and the wider 
interaction network. Approximately 1mg of total lysate was incubated with agarose 
beads that had been previously cross-linked to the PDLIM2 antibody. This step was 
performed to limit interference from co-eluted IgG peptides upon MS measurement that 
might otherwise limit the detection of less abundant, more important peptides. Prior to 
MS, we verified the success of the co-ip by Western blot analysis (Figure 5.10A).  After 
MS, we were able to identify 243 proteins overall in both the PDLIM2 pull-down and the 
IgG control experiment (supplementary Table S9). 156 of those were unique to the 
PDLIM2 condition, and are listed in Table 19. Strikingly all of the potential targets 
identified previously co-eluted with PDLIM2 suggesting a novel signalling network 
involving STAT1, HSPA1A, FLNB and PDLIM2 that has not previously been reported in 
meningioma. Figure 5.10B shows a Western blot confirming that STAT1 does indeed 
co-elute with PDLIM2. 
   DAVID analysis reveals significant enrichment of ribosomal proteins compared to the 
human proteome background, with 22 ribosomal proteins eluting with PDLIM2. In 
addition, there were also several translation elongation factors identified. GO 
enrichment analysis of the dataset identified glycolysis, translation and ribosomal 
processes as functionally enriched (Figure 5.10C), indicating varied roles for PDLIM2 in 
Ben-Men-1 cells.  
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IP: PDLIM2                                          WB: STAT1 
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Figure 5.10: PDLIM2 co-immunoprecipitation data. A. Western blot analysis confirming that the 
co-ip experiment was successful. Co-ip with IgG antibody was performed as a control.  B. STAT1 
co-elutes with PDLIM2, as analysed by Western blot. C. Gene Ontology (GO) enrichment analysis 
corresponding to proteins that eluted with PDLIM2. 
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5.6    Phospho-STAT1_Y701 co-immunoprecipitation  
 
As STAT1 was the other most promising candidate and had co-eluted with PDLIM2, we 
also performed a co-ip with pSTAT1_Y701.  
   PSTAT1_Y701 was chosen over 727 because Y701 is the primary phosphorylation 
site activated in response to Interferon-γ (IFNγ) stimulation in the classical signalling 
cascade. The cytoplasmic localization of pSTAT1_Y701 in our cells contrasts with 
several reports in the literature that show STAT1 translocates to the nucleus rapidly 
upon phosphorylation of the Y701 site. The failure of this to occur in this case 
suggested there may be other regulatory signals involved.  
   Using the cross-linking co-ip protocol as before, we identified 48 proteins that co-
elute with pSTAT1_Y701 and not with the IgG control antibody (supplementary Table 
S10). Figure 5.11 shows a Western blot confirming the pull-down. There were several 
cytoskeletal proteins that co-eluted with pSTAT1_Y701 and JUP and DSG1 were also 
on the list. These are found at sites of cell-cell adhesion, suggesting that 
pSTAT1_Y701 may have a role in this process.  
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WB/IP: STAT1 
 
 
 
 
 
 
5.7    Functional assessment of candidate targets 
 
 
 
 
 
 
 
 
 
 
 
 
84/91-  STAT1_701 
Figure 5.11: Phospho-STAT1_Y701 co-immunoprecipitation. PSTAT1_Y701 antibody 
was crosslinked to agarose beads prior to incubation with Ben-Men-1 cell lysate. Western 
blot analysis confirms a successful co-ip (left). Co-ip with IgG control antibody did not pull 
down pSTAT1_Y701 (right).  
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After confirming the overexpression of PDLIM2 and STAT1 highlighting them as 
potential therapeutic targets for both meningioma and schwannoma, it was necessary 
to understand whether the two proteins actually contribute to tumour proliferation. To 
do this, we used lentivirus mediated protein knockdown in primary meningioma and 
primary schwannoma cultured cells. In the absence of specific phosphorylation 
inhibitors, total protein knockdown was the best method to assess the suitability of both 
proteins as therapeutic targets. To analyse the effects of the knockdown on cellular 
proliferation, ki-67 staining was performed. 
5.7    STAT1 protein knockdown 
Using a multi-clone commercial mix of lentiviral particles, STAT1 was knocked down in 
three primary meningiomas and three primary schwannomas. STAT1 was successfully 
and significantly knocked down in three primary schwannoma cell cultures compared to 
cells infected with control shRNA particles (Figure 5.12A).  
   A ki-67 proliferation assay highlighted significantly decreased proliferation in 
response to STAT1 knockdown (Figure 5.12B). Of note, there are also a lot fewer cells 
after STAT1 knockdown, indicating some form of cell death. We performed a western 
blot assessing cleaved-caspase 3 induction but were unable to detect it upon Western 
blot analysis. These results overall indicate that STAT1 is a contributing factor in 
schwannoma proliferation, and therefore warrants further investigation as a novel 
schwannoma drug target.  
   We also attempted STAT1 knockdown in primary meningioma cells, but unfortunately 
were unable to achieve a significant level of knockdown across three cell populations 
(Figure 5.13).  
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Control Knockdown 
Figure 5.12: STAT1 knockdown in primary schwannoma cells. A. Western blot analysis confirmed 
that STAT1 was significantly knocked down in three primary schwannoma cell populations. B. The 
number of ki-67 (green) positive cells is significantly reduced (P < 0.001) in STAT1 knockdown cells 
compared to cells infected with control shRNA. The panels on the left represent three repeat control 
samples and the panels on the right represent their respective repeat knockdowns. DAPI (blue) was 
used as a nuclear stain. All images were taken at 40x magnification.  
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Figure 5.13: STAT1 was not knocked down in these primary meningioma cells. STAT1 was not 
significantly knocked down in three primary meningioma cell populations.   
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5.8    PDLIM2 protein knockdown  
We used lentiviral particles to successfully knockdown PDLIM2 in three primary 
schwannomas (Figure 5.14A) and three primary meningiomas (Figure 5.14A). PDLIM2 
was significantly knocked down in schwannomas, and this led to a significant reduction 
in ki-67 positive cells (P < 0.001), reflecting a substantial reduction in proliferation in 
response to the knockdown (Figure 5.14B).   
   A significant reduction was also observed in meningioma cells, again leading to a 
significant reduction in proliferation as measured by a ki-67 proliferation assay (Figure 
5.15B). These data suggest that PDLIM2 is a novel drug target for schwannoma and 
meningioma treatment. 
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Figure 5.14: PDLIM2 knockdown in primary schwannoma cells (N=3) A. Western blot 
analysis confirmed significant PDLIM2 knockdown in three primary schwannoma cell 
populations. B. PDLIM2 knockdown led to a significant reduction (P < 0.001) in cell proliferation, 
as measured by the number of ki-67 (green) positive cells. The panels on the left represent three 
repeat control samples and the panels on the right represent their respective repeat knockdowns 
DAPI (blue) was used as a nuclear marker. All images were taken at x20 magnification.  
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Figure 5.15: PDLIM2 knockdown in primary meningioma cells. A. Western blot analysis confirmed 
significant lentiviral mediated knockdown of PDLIM2 in three primary meningioma cell populations. STAT1 
was also reduced in response to PDLIM2 knockdown, although this was not significant. B. Ki-67 (green) is 
significantly reduced in PDLIM2 knockdown cells, compared to cells infected with control shRNA. The panels 
on the left represent three repeat control samples and the panels on the right represent their respective 
repeat knockdowns. DAPI (blue) was used as a nuclear stain. All images were recorded at x40 magnification.  
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5.9    Discussion  
We have been able to validate the expression of four candidate novel, therapeutic 
targets in primary meningioma and schwannoma cells. The data so far has suggested 
that the most promising candidates are PDLIM2 and STAT1 as these were not 
expressed at all in normal cells. Furthermore, Merlin has already been shown to inhibit 
the phosphorylation thus activation of STAT3 and STAT5 in schwannoma cells (Scoles, 
Huynh et al. 2000).  
   FLNB and HSPA1A showed inconsistencies in their expression between normal and 
tumour cells, and as such would not be ideal candidates for the treatment of patients. 
We were however able to demonstrate the expression of pHSPA1A_Y525 in both 
primary meningioma and schwannoma via IHC, and it was not strongly expressed in 
normal tissue. Therefore, this phosphorylated form of HSPA1A might still represent a 
therapeutic target.  
   We have uncovered interaction networks for both PDLIM2 and STAT1 via co-
immunoprecipitation in Ben-Men-1 cells that suggest possible roles for both proteins. 
PDLIM2 is most likely related to ribosome biogenesis and/ or protein synthesis, 
whereas pSTAT1_Y701 may be linked to cellular adhesion. Furthermore, all of the 
candidates identified in our proteomic screen co-eluted with PDLIM2, suggesting a 
novel interaction network involving all candidate therapeutic targets. We confirmed the 
co-elution of STAT1 by Western blot, and future studies would focus on confirming the 
interaction between PDLIM2, STAT1 and HSPA1A/ FLNB, before concluding whether 
these interactions are important for meningioma/ schwannoma pathology.  
   STAT1 knockdown in primary schwannoma cells led to a marked decrease in 
proliferation and a dramatic decrease in cell number in schwannoma cell populations. 
This could however also be related to decreased cell density in comparison to control 
cells after the addition of lentiviral particles, which may also have contributed to 
decreased proliferation. While we also saw reduced proliferation in primary 
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meningioma, the knockdown would first need to be improved to ensure significant 
reduction of STAT1. Taken together, these data indicate that STAT1 is a promising 
therapeutic target for the treatment of schwannoma, and possibly also for the treatment 
of meningioma.  
   We later used lentiviral shRNA to significantly knockdown PDLIM2 in primary 
meningioma cells and primary schwannoma cells. In both cases, a significant reduction 
in proliferation was observed highlighting the potential of PDLIM2 as a therapeutic 
target. It would be important in future studies to further confirm the overexpression of 
PDLIM2 in several primary meningiomas and schwannomas, and potentially other 
Merlin-deficient tumours, to properly conclude that it represents an attractive target.  
   As there are currently no drugs available that target PDLIM2, it is difficult to test the 
therapeutic benefit of PDLIM2 in primary cell models, or patients. As such, specific 
inhibitors would need to be developed in order to fully characterise PDLIM2 as a 
common NF2 drug target.  
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Chapter 6 - Discussion  
6.1    Introduction  
The aim of this project was to utilize mass spectrometry to analyse the proteome and 
phosphoproteome of Merlin-deficient tumour cells. In doing so, common targets have 
been identified that have the potential to be exploited by existing and/or novel drugs for 
the treatment of NF2-related tumours. At present, there remain no FDA/EMEA 
approved drugs for meningioma or schwannoma and surgery/ radiosurgery remain the 
only treatment options, highlighting the urgent need for an effective drug therapy. Prior 
to this study, there was only one comparative analysis between meningioma and 
schwannoma reported in the literature, and this was only on the genomic level (Torres-
Martin, Lassaletta et al. 2014). The novelty of the research presented in this thesis, is 
that it represents the first and only comparison between meningioma and schwannoma 
to identify novel phosphoprotein drug targets and potential biomarkers.  
   Past studies have identified biomarkers and therapeutic targets for a range of 
neoplasms, including meningioma and schwannoma (Seo, Park et al. 2015, Sharma, 
Ray et al. 2015). Omics technologies in general have become a mainstay in 
translational research and are indispensable in the era of personalized medicine, 
allowing patients to be placed in to separate groups and have treatments and/ or drugs 
tailored to them. The findings outlined in this thesis provide the foundations and 
rationale for further investigation in to pSTAT1 and PDLIM2 as novel common 
therapeutic targets for both meningioma and schwannoma, and potentially other 
Merlin-deficient tumours. There is also scope for further investigation of FLNB and 
HSPA1A as therapeutic targets, plus a myriad of proteins that may represent potential 
targets in meningioma or schwannoma. The following paragraphs will discuss the 
results obtained in more detail, their congruence with the literature and suggest future 
research directions. 
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6.2    Proteomics   
6.2.1    Sample losses in proteomic sample preparation  
There have been several phosphoproteomic studies reported in recent years that have 
identified thousands of phosphopeptides, using phosphopeptide enrichment 
(Wisniewski, Nagaraj et al. 2010, Zhou, Di Palma et al. 2013, Sharma, D'Souza et al. 
2014). Since it has been proposed that over 500000 phosphorylation sites are likely to 
exist in a cellular proteome (Lemeer and Heck 2009), there is a wealth of information 
still to discover. The identification of specific phospho-sites requires meticulous sample 
preparation and a number of steps to maximise potential identifications (IDs). The 
enrichment experiment performed as part of this project used 1mg of starting material. 
Tryptic digestion was followed by TiO2 enrichment, stage tipping and subsequent MS 
analysis. In contrast to previous studies, the number of IDs was quite low. A number of 
reasons may account for this including not least; low amounts of starting material and 
sample losses incurred during the workflow. As others have pointed out peptides can 
be lost during wash steps, elution steps and when samples are dried in a speed vac 
during sample preparation (Stewart, Thomson et al. 2001, Feist and Hummon 2015). 
Importantly, the percentage of sample loss seems to be largest when the amount of 
starting material is lowest. As such, future experiments utilizing this technique should 
incorporate more concentrated starting materials to maximise potential IDs. For 
example, using 100 mg of mouse brain tissue Wisniewski identified over 12000 
phospho-sites (Wisniewski, Nagaraj et al. 2010), highlighting the enormous potential of 
these techniques when starting material is high. Also of note, Finehout was able to 
show that tryptic digestion at 48oC, 11 degrees above the standard procedure, 
improved digestion efficiency and may be something to consider in future experiments 
(Finehout, Cantor et al. 2005).   
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6.2.2    Multiple correction testing 
False Discovery Rate (FDR) correction was initially applied to both the schwannoma 
phosphoprotein and total protein datasets. This is designed to control the expected 
proportion of rejected null hypotheses or ‘false positives’ i.e. cases where a statistically 
significant difference has been identified when there is not one. In doing so, the 
significantly changed phosphoproteins decreased by almost 50%. 91 were upregulated 
(log2 FC > 1) and 53 were downregulated (log2 FC < -1). Generally, the proteins with 
the largest fold changes in schwannoma were still able to pass the FDR threshold. One 
of the proteins involved in MAPK signalling, MAP2K1 (MEK1), known to be central to 
schwannoma proliferation (Ammoun and Provenzano 2014), was unable to pass the 
threshold. Its relatively small fold change in this experiment (log2 FC 2.8) may be the 
main reason for this. However, as it is widely known as a therapeutic target in 
schwannoma, its failure to appear significant after FDR shows it is likely a false 
negative in this case, which is consistent with the drawbacks of multiple correction 
testing.  
   MCT also limited the potential for functional annotation of proteomic data. DAVID 
analysis of the upregulated phosphoproteins in schwannoma after FDR was applied led 
to only one significantly enriched pathway identification, endocytosis. Both the MAPK 
and focal adhesion pathways were no longer identified regardless of their well-known 
contribution to schwannoma pathogenesis (Ammoun and Hanemann 2011). For the 
total protein dataset, application of MCT reduced the number of statistically significant 
upregulated proteins by half, to 8. The downregulated proteins reduced to 77, again 
making it more difficult to identify potential targets. 
   As the goal of this project was to perform a global analysis to identify common 
therapeutic targets, it was our aim to have as many proteins as possible on which to 
perform the final comparative analysis. Therefore, a standard raw p-value of 0.05 was 
the only statistical criteria applied. The compromise is that of several targets selected 
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for further analysis in the absence of any form of MCT, there is a higher chance that 
some of those would turn out to be false positives.  
6.3    Schwannoma proteomic data  
We quantified 2628 phosphoproteins in primary schwannoma cells compared to 
Schwann cells and the data obtained largely correlates with what is known in the field. 
Thus we were able to identify both NFκB and MEK as upregulated in schwannoma, 
echoing previous work (Ammoun, Provenzano et al. 2014). We also identified pYAP as 
upregulated in schwannoma cells, and further, were able to identify three sites of 
phosphorylation (S127, S128 and S131). Merlin has been shown previously to induce 
phosphorylation of YAP_S127, and its absence is associated with dephosphorylation, 
translocation to the nucleus and transcription of pro-proliferative, anti-apoptotic genes 
(Zhao, Li et al. 2010, Li, Cooper et al. 2014). As the three schwannoma samples 
analysed were all Merlin-negative, one possible explanation could be that other 
members of the ERM family can phosphorylate YAP in the absence of Merlin. It would 
therefore be necessary to confirm phospho-YAP_S127 expression in several Schwann 
and schwannoma samples by Western blot, to fully understand the phosphorylation 
status and overall expression profile of this protein.  
   TGFβ1 was also identified as upregulated in line with recent reports that found it was 
upregulated at the genome level and was present in 95% of vestibular schwannomas 
upon immunohistochemical examination (Lottrich, Mawrin et al. 2007, Torres-Martin, 
Lassaletta et al. 2013). We also found significant enrichment of the focal adhesion and 
MAPK pathways, both known to be implicated in schwannoma tumorigensis.  
   Boin et al. published the results of a study in 2014 that used a reverse phase protein 
array to quantify the expression of certain proteins in schwannoma tumour samples. 
The authors found that the most frequently activated RTKs were Her2, Axl and RON 
(Boin, Couvelard et al. 2014). We were unable to identify these receptors in our screen 
however we did identify PDGFRβ as 7-fold upregulated in schwannoma, in accordance 
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with the literature (Ammoun, Flaiz et al. 2008). Boin et al. also identified YAP as a 
transcriptional activator of several RTKs, including the PDGFRβ and Axl. They also 
concluded that overexpression of YAP, regardless of its phosphorylation status, is a 
positive regulator or proliferation. As such, our identification of overexpressed YAP in 
schwannoma provides further rationale for therapies targeting the Hippo pathway as 
valuable options for schwannoma treatment.  
   Boin’s study, whilst lacking global phosphoproteome analytical capability, did have 
the advantage of identifying activated receptors on the schwannoma membrane. Our 
approach is not specifically designed for membrane proteome coverage, and important 
receptors may be overlooked through the inability of the lysis buffer to efficiently disrupt 
the membrane. This is why FASP was developed, to allow comprehensive membrane 
coverage with the use of strong detergents (Wisniewski, Nagaraj et al. 2010). 
Unfortunately, such a technique can be associated with considerable sample loss, as 
was encountered when we attempted to use it in conjunction with phosphopeptide 
enrichment in chapter 4.  
   Nonetheless, we did identify some receptors that were significantly upregulated in 
schwannoma cells, including the transferrin receptor (TFRC). This has been proposed 
recently as a valuable target for treatment as it is upregulated in several cancers. It has 
been utilized with success pre-clinically in glioma treatment, allowing targeted therapy 
of cytotoxic drugs (Daniels, Bernabeu et al. 2012).  Validation of TFRC upregulation 
compared to Schwann cells followed by functional analysis may therefore represent a 
therapeutic strategy for schwannoma.    
   Seo et al. also performed a proteomic analysis comparing vestibular schwannoma 
against normal nerve tissue (Seo, Park et al. 2015). They found 29 proteins to be 
upregulated, including two of which we identified to be upregulated in this experiment; 
Annexin A5 (ANXA5) and tropomyosin 4 (TPM4). However, we also found conflicting 
data between our datasets i.e. calreticulin and aldehyde dehydrogenase were 
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downregulated in our study but identified as upregulated by Seo et al. This could be 
attributed to the use of different types of mass spectrometry, or variances between 
primary tumour specimens. This again highlights the fact that any proposed therapeutic 
targets would have to be validated across many tumour samples and verified with 
Western blotting. 
   The most upregulated phosphoprotein identified, TAGLN, may also represent a 
therapeutic target as it has already been proposed to have therapeutic value in 
Malignant Peripheral Nerve Sheath Tumours (Park, Lee et al. 2014). Knocking it down 
was able to attenuate MAPK signalling leading to a decrease in proliferation. Targeting 
proteins with regulatory influence over the MAPK pathway is of value in schwannoma 
treatment, therefore inhibiting TAGLN in schwannoma cells represents a potentially 
very valuable therapeutic strategy.  
6.3.1    Functional analysis of schwannoma proteomic data  
Our analysis of the phosphoproteome highlighted a functional cluster of proteins 
upregulated in schwannoma cells, found to contain either a PDZ or LIM domain, or 
both. This family of proteins perform a diverse array of functions in the cell and can 
have profound effects on cell signalling (Krcmery et al. 2010).  
   We were able to highlight a potential role for clathrin-mediated endocytosis in 
schwannoma pathology, as Gene Ontology (GO) analysis revealed significant 
enrichment of a number of terms related to this process. The purpose of endocytosis is 
in part to facilitate degradation of membrane components (Robinson 2015). However, 
we were also able to identify downregulation of lysosomal proteins in schwannoma 
cells, suggesting decreased protein degradation. In other cases, ligand bound 
receptors can be endocytosed through clathrin-coated pits in to endosomes, and 
subsequently recycled back to the membrane to maintain constitutive signalling. 
Further, endocytosis of some receptors can lead to activation of signal transduction e.g. 
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in the case of EGFR which is able to continue signalling from within the endosome 
(Burke, Schooler et al. 2001).  
Signalling through endosomes has also been linked to MAPK signalling. A protein, p14, 
was found to associate with the cytoplasmic face of endosomes and through its 
association with the MAPK scaffold protein MP1, was able to orchestrate intracellular 
ERK signalling in response to EGF stimulation (Teis, Wunderlich et al. 2002). As the 
MAPK pathway plays such a pivotal role in schwannoma, interruption of this process 
may be a valuable therapeutic strategy. Agnihotri and colleagues were also able to 
identify upregulation of endocytosis in their microarray analysis of 49 schwannomas 
(Agnihotri, Gugel et al. 2014), further highlighting it as a potential therapeutic target.  
   Glycolysis was also highlighted as a potential target pathway. Two upregulated 
proteins; ALDOA and ALDOC, are both aldolases involved in glycolysis and may 
represent therapeutic targets. An Increase in the rate of glycolysis is a hallmark of 
cancer and inhibition of this process holds potential as a cancer therapy (Hanahan and 
Weinberg 2011). ALDOA was knocked down in rat glioblastoma cells leading to an 
almost 90% reduction in cell proliferation (Ritterson Lew and Tolan 2012). Interestingly, 
the study also found that the reduction in proliferation was not due to the subsequent 
defects in glycolysis, indicating other roles for ALDOA in tumorigenesis. Further, 
ALDOC was identified as a positive regulator of Wnt signalling in colorectal cancer cells 
(Caspi, Perry et al. 2014). Our identification of both enzymes as upregulated in 
schwannoma therefore warrants further investigation.  
6.4    Meningioma proteomic data 
6.4.1    Meningioma cell culture  
Although meningioma samples were prepared and measured in the same way as 
schwannoma, the final dataset contained many missing values (LFQ = 0), leading to a 
reliance on the comparison between HMC and Ben-Men-1 for the final selection of 
common candidate targets. Whilst this was a relevant comparison, the aim of the study 
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was to base candidate target selection on primary tumour samples. The following 
section will discuss the potential reasons that may explain the lack of good quality 
primary meningioma data.  
   Firstly, as the system in use for primary schwannoma cell culture is well established 
and optimized, schwannoma cell growth and protein production can be assumed as 
optimal. The culture media used for the primary meningioma cells in this study 
contained insulin, as was used in the media described by James et al., who were able 
to maintain primary meningioma cells in culture for up to 10 passages (James, Lelke et 
al. 2008). We also attempted proteomics with meningioma samples that had been 
cultured in the same media as HMC cells that contains a number of growth factors, and 
ensured that no samples were analysed beyond passage 5. This did lead to a 
decrease in the number of missing values however could still be improved. Many 
studies looking at meningioma use a very basic medium without any added growth 
factors. Future proteomic studies involving primary meningioma might consider the 
addition of further growth factors to the media, to stimulate growth and protein 
production which must be maximal to ensure the best results.  
   James et al. noted that senescence is more rapidly induced in primary meningioma 
cells in culture than normal arachnoid cells. Senescence is characterised by reduced 
proliferative potential and, presumably, reduced global protein synthesis. Although the 
primary meningioma cells used in our study appeared to grow well, protein production 
may have been decreased overall due to some cells undergoing senescence.  
6.4.2    Primary meningioma and Ben-Men-1 proteomic data  
The most upregulated phosphoprotein identified in primary meningioma cells, TGM2 
(Transglutaminase 2), was also recently identified by Huang et al. as a potential 
therapeutic target in primary meningioma cell cultures (Huang, Wei et al. 2014). 
Although the number of missing values affected the quality of the data obtained, this 
observation helps to demonstrate the validity of the dataset overall. Furthermore TGM2 
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has also been shown to activate both NFκB and FAK (Siegel and Khosla 2007) which 
are relevant to schwannoma growth and proliferation, adding to the rationale of 
targeting TGM2 as a therapeutic strategy.  It would be interesting to validate TGM2 in 
more primary samples, to determine its significance in Merlin-deficient tumours and its 
suitability as an NF2 drug target. 
   We also validated SMAD2_T8 expression in three primary meningioma samples. T8 
phosphorylation has been attributed to both CDK2 (Baughn, Di Liberto et al. 2009) and 
ERK (Funaba, Zimmerman et al. 2002), the first inhibiting SMAD2 and the latter 
positively regulating it. We did not detect SMAD2_T8 expression in control HMC cells, 
suggesting that it may be expressed in meningioma as a way of combating growth 
inhibitory TGFβ signalling, and thus is a consequence of CDK2 phosphorylation in this 
instance. We also observed downregulation of TGFβ1 in meningioma, further 
suggesting dysregulation of this signalling pathway and highlighting it as a potential 
target. Contrastingly, Wang et al. identified TGFβ as upregulated in meningioma 
however this was at the genome level and this does not always correlate with protein 
abundance (Wang, Gong et al. 2012). 
   Fatty Acid Synthase (FAS) was also identified as upregulated in meningioma cells at 
both the total and phosphoprotein levels (Log2 FC = 2.89, 2.28, respectively). It has 
been previously identified as a marker of meningioma progression and as a potential 
therapeutic target (Haase, Schmidl et al. 2010, Makino, Nakamura et al. 2012). Sharma 
et al. also identified FAS signalling as a potential target in their proteomic analysis of 
meningioma (Sharma, Ray et al. 2014).  
   We were able to identify significant enrichment of several pathways/ processes 
across our analysis of Ben-Men-1 and primary meningioma cells. We found 
proteasome activation to be a recurring theme throughout, highlighting it as an 
important target in meningioma, in concordance with other reports. A 2014 study 
looking at the proteasome inhibitor bortezomib showed that it was effective in 
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sensitizing meningioma cells to TRAIL-induced apoptosis (Koschny, Boehm et al. 
2014). Further, the proteasome inhibitor MG132 was also found to increase levels of N-
cadherin in schwannoma cells, which in turn decreased proliferation (Zhou, Ercolano et 
al. 2011). Our data and previous reports highlight proteasome inhibition as a valuable 
NF2 therapy, either alone or in combination with drugs targeting other relevant 
pathways.  
   Our analysis of Ben-Men-1 cells identified a large number of integrins and collagens 
as upregulated compared to normal HMC cells. This is in line with a number of 
previous reports (Bello, Zhang et al. 2000, Wang, Gong et al. 2012, Sharma, Ray et al. 
2014) that identify upregulation of integrins in meningioma. Integrin signalling is related 
to a number of cellular processes including tumour proliferation and survival. Wilisch-
Neumann et al. showed that an integrin inhibitor, cilengitide, was able to supress 
meningioma cell motility and suggest that it may be useful in a combined therapy 
approach (Wilisch-Neumann, Kliese et al. 2013). Cilengitide is also in clinical trials for 
glioblastoma, further highlighting its potential (Desgrosellier and Cheresh 2010). 
Torres-Martin et al. also identified clear upregulation of integrin alpha-4 in their 
genomic analysis of schwannoma. We identified a log2 FC for this protein of 23.01 in 
Ben-Men-1 cells compared to HMC, indicating that it might be a potential common 
target for NF2 tumours.  
   We also identified significant upregulation of phosphorylated cathepsin D (CTSD) in 
both primary meningioma and Ben-Men-1 cells, indicating that it may act as a 
therapeutic target. In both cases, the total amount of the protein was actually 
downregulated, suggesting that its phosphorylation is relevant to meningioma 
pathogenesis. As very little is known regarding the effects of phosphorylation on 
Cathepsin D function, further investigation would be required before concluding that 
phospho-CTSD is in fact a potential meningioma target. Total CTSD secreted by 
ovarian cancer cells has however been linked to a myriad of processes including 
tumour cell migration and proliferation (Pranjol, Gutowski et al. 2015).  
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6.5    Phosphopeptide data  
We were able to identify 216 phosphopeptides in Ben-Men-1 cells corresponding to 
144 proteins, many of which are involved in focal adhesion and regulation of the 
cytoskeleton. The data obtained also fit the criteria set by Olsen et al. (Olsen, Blagoev 
et al. 2006) regarding the expected proportions of serine, threonine and tyrosine 
phosphorylated peptides.  
   We identified PAK2_S141, which was previously shown to be activated in response 
to EGF and that this contributes to cellular transformation and proliferation via c-Jun. 
(Li, Zhang et al. 2011). As PAK2 is able to phosphorylate Merlin at position S518 (Rong, 
Surace et al. 2004), whereby inactivating it, and the EGFR is known to be upregulated 
in schwannoma and meningioma (Ammoun, Cunliffe et al. 2010, Wernicke, Dicker et al. 
2010), this phosphorylated form of PAK2 might represent a novel therapeutic target for 
NF2. Similarly, we identified Cofilins 1 and 2 phosphorylated at S3 which is a known 
LIMK (LIM domain kinase) phosphorylation site. Petrilli and colleagues have already 
shown the potential of LIMK inhibitors for the treatment of NF2 tumours. They showed 
that LIMK inhibition decreased the viability of mouse Merlin-deficient Schwann cells 
(Petrilli, Copik et al. 2014). Our data provides further rationale for LIMK inhibition as a 
therapeutic strategy. Furthermore, Rak et al. demonstrated the effectiveness of a 
LIMK2 inhibitor, T56-LIMKi, in reducing proliferation of a schwannoma cell line 
mediated by inhibition of cofilin S3 phosphorylation (Rak, Haklai et al. 2014). As both 
studies are based in cell models of NF2, it would be interesting to conduct similar 
experiments using our primary cell culture system, to better understand the potential of 
T56-LIMKi and other inhibitors as therapeutic options for NF2 patients.  
   We were also able to validate EGFR_T693 in both primary meningioma cell cultures 
and primary tumour samples, irrespective of Merlin status, whilst seeing no expression 
in HMC or normal meningeal tissue. Maxquant identified T693, however in the cleaved, 
active form of the EGFR this changes to T669. It sits in the juxtamembrane region 
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spanning residues 664-682 which is crucial for activation of the receptor (Jura, Endres 
et al. 2009), and an earlier report showed that T669 is a MAPK phosphorylation site 
(Takishima, Griswold-Prenner et al. 1991). Li et al. found a mutant form of the EGFR 
that could not be phosphorylated at T669 was downregulated more slowly compared to 
the wild-type receptor upon EGF-induced stimulation (Li, Huang et al. 2008). This 
indicates that T669 phosphorylation is a negative regulator of the EGFR. Kluba et al. 
also show that T669 inhibits EGFR dimerization which is required for its activation 
(Kluba, Engelborghs et al. 2015). The fact that we detected this phosphorylation site in 
meningioma cells and not in normal controls would suggest that it might be beneficial to 
tumour growth. An experiment looking at the effects of EGFR_T693 inhibition in 
meningioma cells would be useful to better understand the specific function of the 
modified form of EGFR, given that the EGFR has already been identified as 
overexpressed and a potential target in both meningioma and schwannoma (Curto, 
Cole et al. 2007, Baxter, Orrego et al. 2014). 
6.6    FLNB as a target in NF2-related meningioma and schwannoma   
Western blot analysis showed the expression of total FLNB in primary meningioma 
cells was non-significantly increased compared to HMC cells. Overall, a significant 
increase in FLNB expression was observed in primary schwannoma compared to 
Schwann cells, although the intensity of the bands on the Western blot appear to be 
very similar across all samples (Figure 5.7A). The significant increase therefore is likely 
because one of the Schwann cell samples did not express FLNB at all.  
   The data obtained so far suggests that FLNB does not represent a good target, as it 
is expressed in normal as well as tumour cells. Interestingly though, a 2013 study 
looking at phosphorylation associated SNVs (Single Nucleotide Variants) identified 
pFLNB as a cancer driver gene frequently mutated at sites of phosphorylation leading 
to constitutive activation and enhanced oncogenic activity (Reimand and Bader 2013). 
We identified S2478 phosphorylation of FLNB in Ben-Men-1 cells via phosphopeptide 
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enrichment, but were unable to find a specific antibody to confirm this. There are also 
no reports in the literature regarding this specific phospho-site. Given FLNBs identified 
role as a driver of oncogenesis it would be interesting to investigate this 
phosphorylated form of FLNB in meningioma and schwannoma. The first stage would 
involve obtaining a specific antibody targeting S2478 to confirm its expression in 
primary tumour cells, before functional analysis experiments commence.  
   We also analysed pFLNA/ pFLNB expression in primary meningioma and 
schwannoma cells, as it was the only antibody available targeting any phosphorylated 
variant of FLNB. We found no significant difference between normal and cultured 
tumour cells but when we looked at its expression in meningioma tumours compared to 
meningeal tissue, we found it was not detected in the control but strongly in the 
tumours (Figure 5.6D). The reason for this could be that HMC are cultured in a system 
containing specific growth factors which are added to optimise and maximise growth in 
culture. The fact that we do not see activation in normal meningeal tissue implies that 
in vivo, external signals might instruct cells to ‘switch off’ pFLNA/ pFLNB. If this is the 
case, pFLNA/ pFLNB represents a valuable therapeutic target that may contribute to 
tumorigenesis, otherwise we would expect it to be expressed in normal tissue. What 
can be appreciated from this is that a cell culture system can provide a guide of in vivo 
signalling, but candidate therapeutic targets should also be properly validated in 
primary tissue samples. 
6.7    HSPA1A as a target in NF2-related meningioma and schwannoma  
When total HSPA1A was analysed in primary meningioma, we identified a significant 
increase compared to normal cells. It was however also expressed in HMC. In primary 
schwannoma cells, total HSPA1A expression was found to vary across tumours, and 
was also expressed in three primary Schwann cell samples. Overall these data indicate 
that total HSPA1A is not an ideal therapeutic target for meningioma or schwannoma. 
The expression of pHSPA1A_Y41 was similar to that of total HSPA1A. No significant 
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difference was observed overall in either primary meningioma or schwannoma 
compared to their respective controls.  
   IHC analysis of pHSPA1A_Y525 showed that it is expressed in both meningioma and 
schwannoma. It is generally cytoplasmic across all tumours with a small amount of 
nuclear staining observed, mostly in meningioma. It is generally expressed more 
strongly overall in schwannoma. The heat shock proteins in general promote cell 
survival and are cytoprotective in response to stress (Schmitt, Gehrmann et al. 2007). 
One group found that Y525 phosphorylation led to nuclear accumulation of HSPA1A in 
response to cell stress and that this enhanced its activity (Knowlton, Grenier et al. 
2000). As we do not really see nuclear staining in this case, it is unlikely to function in 
the same way. The linear pattern of staining observed in schwannoma is particularly 
interesting and provides an indication that pHSPA1A_Y525 is associated with the 
cytoskeleton, at least in a subset of schwannomas. This could influence cytoskeletal 
dynamics and affect intracellular transport. To confirm the association, dual staining for 
common cytoskeletal proteins could be performed to identify co-localization. Following 
that, mutagenesis studies followed by proliferation and survival assays would help to 
determine whether pHSPA1A_Y525 represents a worthwhile therapeutic target.  
   Wu et al. showed that HSPA1A released extracellularly was able to promote tumour 
cell growth via activation of NFκB (Wu, Yuan et al. 2012). In clear contrast, Tanaka and 
colleagues showed that HSPA1A was actually a chaperone required for PDLIM2 
mediated degradation of NFκB (Tanaka, Shibazaki et al. 2014). As we were able to 
identify HSPA1A in our PDLIM2 co-immunoprecipitation, this would suggest the latter. 
It would be beneficial to perform a co-ip with both HSPA1A and pHSPA1A_Y525 to see 
if PDLIM2 co-elutes, and also to identify other interactors that may provide more clues 
as to the specific function of this protein in meningioma cells. Leu and colleagues 
identified a HSPA1A inhibitor, termed PES (Leu, Pimkina et al. 2009), that has shown 
anti-tumour activity by promoting cell death and may represent a potential drug for 
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meningioma and schwannoma, should further experiments prove that pHSPA1A is a 
good target.  
6.8    STAT1 as a target in NF2-related meningioma and schwannoma  
We identified a significant increase in total STAT1 expression in primary meningioma 
cells compared to HMC. This is in concurrence with an earlier report, which also 
identified significant overexpression of STAT1 in 17 meningioma samples, compared to 
normal dura (Magrassi, De-Fraja et al. 1999). Overall, there was no significant 
difference observed between primary Schwann and schwannoma cells, and there have 
been no previous studies assessing STAT1 expression in schwannoma.  
   We were able to detect pSTAT1_Y701 and pSTAT1_S727 expression in several 
meningiomas and schwannomas, but not in respective controls. It has been reported 
that maximal transcriptional activity is only achieved when both sites are 
phosphorylated (Wen, Zhong et al. 1995), and transcriptionally active STAT1 must be 
located in the nucleus. However, we observed differences between the cellular 
localization of the two phosphorylated variants of STAT1; S727 was nuclear and Y701 
was located in the cytoplasm, indicating that the two may function independently of one 
another in these cells. The function of these phosphorylated forms of STAT1 is unclear 
as no prior work has functionally assessed either protein in meningioma or 
schwannoma.  
   Shuai et al. showed that upon Y701 phosphorylation, STAT1 translocates in to the 
nucleus within minutes (Shuai, Ziemiecki et al. 1993). A report in 2000 showed 
however that nuclear localization requires another signal beyond that of Y701 
phosphorylation, and that is inhibition of its nuclear export (Mowen and David 2000). 
The authors identified a NES (Nuclear Export Signal) region spanning amino acids 
197-205 of STAT1 that is regulated by Janus Kinase 1 (JAK1). In the absence of active 
JAK1, pSTAT1_Y701 is not retained in the nucleus. They also showed that tyrosine 
phosphorylation at 701 can be achieved by other kinases (TYK2 and JAK2), but that for 
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nuclear accumulation, JAK1 is completely indispensable. Other members of our group 
have shown that JAK1 is not activated in meningioma cells, suggesting this might be 
the reason for the cytoplasmic localization of STAT1. 
Phospho-STAT1_S727 has been identified as an MAPK regulated phosphorylation 
event (Zhang, Cho et al. 2004). Although most reports conclude that S727 
phosphorylation is a secondary, less significant event to Y701 phosphorylation, Putz et 
al. showed that activating S727 phosphorylation can be observed independently of 
Y701 in natural killer cells, suggesting that STAT1 phosphorylated at either site can be 
functionally active, and that the two phospho variants can play different roles, as is 
probably the case in meningioma and schwannoma as they were not identified in the 
same location.  
   As such, future experiments functionally assessing phospho-STAT1 in NF2 tumours 
would need to focus on each variant individually. What we have achieved so far is the 
knockdown of total STAT1 which has provided an indication of its suitability as a drug 
target. Although we did not achieve significant knockdown in all three primary 
meningioma cell populations, we did observe a good level of knockdown in one out of 
three. There was a decrease in proliferation of those cells compared to the control 
however this needs to be repeated.  
   We achieved significant knockdown across three Merlin-deficient primary 
schwannomas. This led to a marked reduction in proliferation and a considerable 
reduction in cell number, compared to cells treated with control shRNA. We analysed 
cleaved caspase-3 as a measure of apoptosis but were not able to detect it in control 
or KD cells. This suggests another method of cell death causing the decrease in cell 
number, or perhaps that STAT1 KD has an effect on cell adhesion causing cells to 
become detached from culture vessels. A report by Xie et al. however found that 
depletion of STAT1 actually led to an increase in cell-matrix adhesion (Xie, Zhao et al. 
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2001). To understand if adhesion if affected by STAT1 KD, we would need to perform 
an adhesion assay in cells with and without knockdown.  
   Our co-immunoprecipitation experiment looking at the interaction network of 
pSTAT1_Y701 identified a number of proteins. We were able to identify HSP90 that 
has been previously linked to STAT1 signalling (Bocchini, Kasembeli et al. 2014). We 
also identified JUP (Junction Plakoglobin) that was identified as downregulated in Ben-
Men-1 cells. JUP has a wide range of roles therefore it is difficult to infer the 
implications of its association with pSTAT1_Y701. As JUP is commonly found at the 
site of adherens junctions (Aktary and Pasdar 2012) it is plausible that JUP and 
pSTAT1_Y701 work together to regulate adhesion. This also supports what we found 
when STAT1 was knocked down in schwannoma cells i.e. a possible reduction in 
adhesion. Furthermore, another adhesion protein, DSG1 (Desmoglein) was also 
identified. This provides further evidence that STAT1 is involved in adhesion in NF2 
tumour cells, and that this association is potentially tumorigenic.  
   Overall, our results suggest that STAT1 is a pro-tumorigenic factor in schwannoma. 
This is supported by recent studies in both malignant mesothelioma and endometrial 
cancer that also found it contributed to tumour progression (Arzt, Kothmaier et al. 2014, 
Kharma, Baba et al. 2014). Future work would focus on validating the interactions 
between STAT1 and the adhesion proteins mentioned, followed by further 
characterization of the importance of STAT1 in adhesion. It would also be important to 
understand whether STAT1 KD causes cell death by means other than apoptosis, e.g. 
autophagy or necroptosis. This could be achieved via knocking down STAT1 and 
analysing the expression of markers specific to these processes.  
6.9    PDLIM2 as a target in NF2-related meningioma and schwannoma 
We were able to confirm PDLIM2 expression in meningioma and schwannoma 
samples and also show that it is not expressed in HMC or normal meningeal tissue. We 
identified a very faint band for PDLIM2 in one of three Schwann cell samples. It would 
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be useful to analyse more Schwann cell control samples in future experiments to 
confirm that it is largely expressed only in tumour cells.  
   PDLIM2 was first described in 2004 as an adaptor protein linking other proteins to the 
cytoskeleton (Torrado, Senatorov et al. 2004). Since, it has been found to have a 
number of different roles, and has been particularly well studied in breast cancer 
(Loughran, Healy et al. 2005, Deevi, Cox et al. 2014) where it has been identified as a 
driver of tumour progression and invasion. It has not been linked previously with either 
meningioma or schwannoma. 
   Cytoplasmic and nuclear extraction showed that PDLIM2 is localized to the nucleus 
in Ben-Men-1, and primary meningioma cells. This could potentially have important 
implications on its role within these cells. It was previously reported that PDLIM2 acts 
as an E3 ubiquitin ligase within the nucleus, targeting NFκB for degradation (Tanaka, 
Grusby et al. 2007). The findings of Healy and O’Connor further corroborate this, as 
they found that cytoplasmic sequestration of PDLIM2 led to accumulation of NFκB 
(Healy and O'Connor 2009). Furthermore, we identified S137 phosphorylation of 
PDLIM2 in Ben-Men-1 cells which was shown by Guo et al. to be necessary for 
ubiquitination and subsequent degradation of STAT1 (Guo, Mi et al. 2010), although 
we were unable to validate this in the absence of a specific antibody. The fact that we 
identified PDLIM2 in the nucleus shows that it is in the correct location in order to 
perform its ubiquitin ligase activity. This suggests either that PDLIM2_S137 may have 
an entirely different function in these tumours, or that STAT1 degradation is being 
inhibited by another mechanism. Future studies might focus on site-specific 
mutagenesis of PDLIM2 to better understand the role of pPDLIM2_S137 in 
meningioma and schwannoma.  
   After performing a co-immunoprecipitation, we were able to identify the other 
candidate proteins HSPA1A, STAT1 and FLNB as interactors of PDLIM2. Associations 
between PDLIM2 and STAT1 (Tanaka, Soriano et al. 2005) and PDLIM2/ HSPA1A 
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(Tanaka, Shibazaki et al. 2014) have been described previously however there are no 
reported links between PDLIM2 and FLNB.  
   We performed GO enrichment analysis of the co-ip data and found significant 
enrichment of ribosomal proteins and protein translation. This implies a link between 
PDLIM2 and protein synthesis however we found PDLIM2 to be localized to the 
nucleus, where this process does not take place. This might indicate that PDLIM2 is 
associated with the process of ribosome biogenesis, which does occur in the nucleus. 
It has been proposed that cancer cells are able to sustain higher rates of proliferation 
by increasing their translational capacity compared to their normal counterparts (van 
Sluis and McStay 2014). If so, PDLIM2 may be a central mediator of tumour cell 
proliferation and as such represents a valuable therapeutic target.  
   Integrin beta 1 (ITGB1) also eluted with PDLIM2 suggesting a link between the two 
proteins. Association between integrins and PDLIM2 has been reported before (Geiger 
and Zaidel-Bar 2012) and places both proteins within the ‘adhesome,’ a large network 
of proteins with diverse and substantial influence over cell signalling. As ITGB1 is a 
membrane component and in the cells analysed here PDLIM2 is nuclear, the 
association between them is unlikely to be direct. ITGB1 has been shown previously as 
an important effector of Merlin deficiency and schwannoma pathology (Utermark, 
Kaempchen et al. 2003), suggesting that PDLIM2 is also implicated in the pathological 
adhesion associated with NF2 tumour cells.  
   We significantly knocked down PDLIM2 in three primary meningioma and three 
primary schwannoma cell populations. This led to significant reductions in cell 
proliferation in both cell types, suggesting that PDLIM2 is potentially a valuable 
therapeutic target. These results are in line with a previous study that found PDLIM2 
suppression led to decreased proliferation in prostate cancer (Kang, Lee et al. 2016). 
Bowe et al. also showed that PDLIM2 was a significant contributor to malignant cancer 
cell invasion (Bowe, Cox et al. 2014). On the other hand, other studies have identified 
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PDLIM2 as an important tumour suppressor (Zhao L 2016, Sun F 2015). Our early 
studies indicate that PDLIM2 acts as a tumour promoting factor in both meningioma 
and schwannoma cells. 
6.10    Conclusion  
The aim of this project was to identify and validate novel therapeutic targets to enable 
simultaneous treatment of Merlin-deficient meningiomas and schwannomas that arise 
as part of the genetic condition Neurofibromatosis type 2 (NF2). Our global exploration 
of the phosphoproteome of primary meningioma and schwannoma cells led to the 
identification of many potential therapeutic targets and there is scope for validating a 
huge number of those in future studies. We have shown throughout this project that 
phosphoproteome profiling is an invaluable tool for elucidating new areas for 
therapeutic intervention. To name some; endocytosis may be an important target for 
schwannoma. Likewise, the proteome represents a promising area for further 
investigation in meningioma. STAT1, FLNB, PDLIM2 and HSPA1A were not previously 
linked to NF2 pathogenesis, and STAT1 and PDLIM2 in particular represent important 
targets for further characterization as much needed NF2 drug targets.  
   As surgery is at present the only available treatment option for NF2 patients, the work 
presented here provides a wealth of information upon which to build upon in future 
studies. Candidate targets identified as part of this project may eventually be translated 
in to the clinic, and thus may facilitate pioneering therapies for the combined treatment 
of all NF2 tumours; among the first therapies of their kind. 
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Supplementary Table S1: Phosphoproteins significantly up/ downregulated in primary schwannoma compared to Schwann cells 
Gene symbol  Protein name  Log2 FC 
HLA-DRA HLA class II histocompatibility antigen, DR alpha chain -26.15 
GUSB Beta-glucuronidase -25.49 
SCAF8 Protein SCAF8;Splicing factor, arginine/serine-rich 15 -25.04 
DKK3 Dickkopf-related protein 3 -25.02 
AFAP1L2 Actin filament-associated protein 1-like 2 -24.72 
HIST1H1C Histone H1.2 -24.63 
KIAA1598 Shootin-1 -24.57 
FAM192A Protein FAM192A -24.30 
NDE1 Nuclear distribution protein nudE homolog 1 -24.14 
THRAP3 Thyroid hormone receptor-associated protein 3 -24.11 
RUNX1 Runt-related transcription factor 1 -24.11 
EXOSC7 Exosome complex component RRP42 -23.98 
PDZRN3 E3 ubiquitin-protein ligase PDZRN3 -23.95 
PDCL Phosducin-like protein -23.87 
WHSC2 Negative elongation factor A -23.58 
HDAC2 Histone deacetylase 2;Histone deacetylase -23.57 
LMAN1 Protein ERGIC-53 -23.32 
WNK1 Serine/threonine-protein kinase WNK1 -23.31 
CD74 HLA class II histocompatibility antigen gamma chain -23.27 
PLCB3 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-3 -23.22 
XRCC1 DNA repair protein XRCC1 -23.05 
ODZ3 Teneurin-3 -22.90 
VAV2 Guanine nucleotide exchange factor VAV2 -22.83 
AHCY Adenosylhomocysteinase -22.62 
NUP214 Nuclear pore complex protein Nup214 -22.58 
MEF2A Myocyte-specific enhancer factor 2C -22.44 
PWP1 Periodic tryptophan protein 1 homolog -22.18 
TFRC Transferrin receptor protein 1 -22.13 
CLASP2 CLIP-associating protein 2 -22.11 
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RBM15 Putative RNA-binding protein 15 -22.09 
TCHH Trichohyalin -21.75 
PLEC Plectin -4.95 
CEP170 Centrosomal protein of 170 kDa -4.22 
XRCC6 X-ray repair cross-complementing protein 6 -3.99 
PRKDC DNA-dependent protein kinase catalytic subunit -3.96 
NUCB2 Nucleobindin-2 -3.23 
VIM Vimentin -3.15 
RANBP2 E3 SUMO-protein ligase RanBP2 -3.00 
CTSD Cathepsin D;Cathepsin D light chain -2.83 
ARSA Arylsulfatase A;Arylsulfatase A component B -2.78 
RPLP2 60S acidic ribosomal protein P2 -2.74 
MAP1B Microtubule-associated protein 1B;MAP1 light chain LC1 -2.68 
HMGB1 High mobility group protein B1 -2.67 
AGA N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase -2.64 
CRYAB Alpha-crystallin B chain -2.53 
KIF13B Kinesin-like protein KIF13B -2.52 
TUBB3 Tubulin beta-3 chain -2.28 
HDAC1 Histone deacetylase 1 -2.19 
RPN1 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 -2.18 
YTHDC2 Probable ATP-dependent RNA helicase YTHDC2 -2.14 
NPC2 Epididymal secretory protein E1 -2.11 
EZR Ezrin -2.08 
HMGA1 High mobility group protein HMG-I/HMG-Y -2.07 
MYO9B Unconventional myosin-IXb -2.06 
TMPO Lamina-associated polypeptide 2, isoforms beta/gamma -2.02 
RALY RNA-binding protein Raly -2.01 
SNRPN Small nuclear ribonucleoprotein-associated protein -2.00 
SPAG9 C-Jun-amino-terminal kinase-interacting protein 4 -1.99 
PSAP Proactivator polypeptide -1.99 
SAFB Scaffold attachment factor B1 -1.97 
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PCYT1A Choline-phosphate cytidylyltransferase A -1.92 
P4HA2 Prolyl 4-hydroxylase subunit alpha-2 -1.89 
HMGB2 High mobility group protein B2 -1.83 
CAP1 Adenylyl cyclase-associated protein 1 -1.80 
SAMHD1 SAM domain and HD domain-containing protein 1 -1.71 
HNRNPC Heterogeneous Nuclear Ribonucleoprotein C (C1/C2) -1.70 
LSM14A Protein LSM14 homolog A -1.70 
CLASP1 CLIP-associating protein 1 -1.69 
UBXN1 UBX domain-containing protein 1 -1.64 
SNRPD2 Small nuclear ribonucleoprotein Sm D2 -1.56 
RCC2 Protein RCC2 -1.55 
TNS3 Tensin-3 -1.53 
KLC1 Kinesin Light Chain 1 -1.47 
SMAP Small acidic protein -1.44 
UFL1 E3 UFM1-protein ligase 1 -1.43 
CBX5 Chromobox protein homolog 5 -1.42 
SGTA Small glutamine-rich tetratricopeptide repeat-containing protein alpha -1.41 
PDIA4 Protein disulfide-isomerase A4 -1.39 
U2AF2 Splicing factor U2AF 65 kDa subunit -1.38 
PSMB7 Proteasome subunit beta type-7 -1.33 
TMED10 Transmembrane emp24 domain-containing protein 10 -1.31 
ATG7 Ubiquitin-like modifier-activating enzyme ATG7 -1.30 
TALDO1 Transaldolase -1.26 
SET Protein SET -1.25 
GSK3B Glycogen synthase kinase-3 beta -1.24 
ESYT1 Extended synaptotagmin-1 -1.24 
KIAA1033 WASH complex subunit 7 -1.23 
SMPD1 Sphingomyelin phosphodiesterase -1.21 
PACSIN2 Protein kinase C and casein kinase substrate in neurons protein 2 -1.20 
RBM14 RNA-binding protein 14 -1.18 
TRIO Triple functional domain protein -1.17 
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MYH10 Myosin-10 -1.16 
PAPOLA Poly(A) polymerase alpha -1.15 
EXOSC6 Exosome complex component MTR3 -1.13 
HLA-B HLA class I histocompatibility antigen, B-44 alpha chain -1.11 
PSMA7 Proteasome subunit alpha type-7 -1.10 
DYNC1LI2 Cytoplasmic dynein 1 light intermediate chain 2 -1.09 
PPIL4 Peptidyl-prolyl cis-trans isomerase-like 4 -1.03 
ANP32B Acidic leucine-rich nuclear phosphoprotein 32 family member B -1.02 
NAP1L1 Nucleosome assembly protein 1-like 1 -1.01 
MAP1A Microtubule-associated protein 1A;MAP1 light chain LC2 -1.00 
ST13 Hsc70-interacting protein; Putative protein FAM10A5 -0.95 
ADD1 Alpha-adducin -0.95 
MTDH Protein LYRIC -0.92 
TEX264 Testis-expressed sequence 264 protein -0.90 
BABAM1 BRISC and BRCA1-A complex member 1 -0.90 
RPL10 60S ribosomal protein L10 -0.89 
CBX1 Chromobox protein homolog 1 -0.88 
PTMA Prothymosin alpha;Thymosin alpha-1 -0.87 
ATXN2L Ataxin-2-like protein -0.86 
NXF1 Nuclear RNA export factor 1 -0.86 
HNRNPAB Heterogeneous nuclear ribonucleoprotein A/B -0.81 
DYNC1I2 Cytoplasmic dynein 1 intermediate chain 2 -0.81 
CYFIP1 Cytoplasmic FMR1-interacting protein 1 -0.80 
HIST1H4A Histone H4 -0.80 
HNRNPK Heterogeneous nuclear ribonucleoprotein K -0.80 
USP8 Ubiquitin carboxyl-terminal hydrolase 8;Ubiquitin carboxyl-terminal hydrolase -0.73 
PSMA6 Proteasome subunit alpha type-6;Proteasome subunit alpha type -0.72 
HSP90AA1 Heat shock protein HSP 90-alpha -0.70 
RPL27A 60S ribosomal protein L27a -0.65 
NAP1L4 Nucleosome assembly protein 1-like 4 -0.65 
PLEKHF2 Pleckstrin homology domain-containing family F member 2 -0.64 
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PSMD1 26S proteasome non-ATPase regulatory subunit 1 -0.63 
TRIM28 Transcription intermediary factor 1-beta -0.58 
TMX1 Thioredoxin-related transmembrane protein 1 -0.54 
HNRNPH1 Heterogeneous nuclear ribonucleoprotein H -0.53 
ILF3 Interleukin enhancer-binding factor 3 -0.51 
CALR Calreticulin -0.51 
PSMA2 Proteasome subunit alpha type-2 -0.49 
SVIL Supervillin -0.40 
HNRNPUL1 Heterogeneous nuclear ribonucleoprotein U-like protein 1 -0.34 
C1QBP Complement component 1 Q subcomponent-binding protein, mitochondrial -0.23 
CTTN Src substrate cortactin 0.50 
CDC37 Hsp90 co-chaperone Cdc37 0.59 
CHMP3 Charged multivesicular body protein 3 0.60 
ARF3 ADP-ribosylation factor 3 0.61 
ZC3HAV1 Zinc finger CCCH-type antiviral protein 1 0.62 
SETD7 Histone-lysine N-methyltransferase SETD7 0.62 
GSPT1 Eukaryotic peptide chain release factor GTP-binding subunit ERF3A 0.67 
BRCC3 Lys-63-specific deubiquitinase BRCC36 0.67 
RPL11 60S ribosomal protein L11 0.69 
FLII Protein flightless-1 homolog 0.72 
PTGES3 Prostaglandin E synthase 3 0.75 
RIC8A Synembryn-A 0.75 
SNX6 Sorting nexin-6 0.77 
PGRMC2 Membrane-associated progesterone receptor component 2 0.80 
RAB3GAP2 Rab3 GTPase-activating protein non-catalytic subunit 0.81 
PSMB5 Proteasome subunit beta type-5 0.81 
Uncharacterised  Uncharacterized protein FLJ45252 0.81 
SKIV2L Helicase SKI2W 0.84 
CAND1 Cullin-associated NEDD8-dissociated protein 1 0.90 
PSMD9 26S proteasome non-ATPase regulatory subunit 9 0.92 
USO1 General vesicular transport factor p115 0.97 
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RAP1B Ras-related protein Rap-1b;Ras-related protein Rap-1b-like protein 0.98 
TCEB2 Transcription elongation factor B polypeptide 2 1.02 
ACLY ATP-citrate synthase 1.03 
LRRC59 Leucine-rich repeat-containing protein 59 1.13 
CORO1B Coronin-1B 1.14 
EIF2S1 Eukaryotic translation initiation factor 2 subunit 1 1.14 
SSR3 Translocon-associated protein subunit gamma 1.16 
NT5C2 Cytosolic purine 5-nucleotidase 1.25 
EIF4A1 Eukaryotic initiation factor 4A-I 1.28 
PSMB8 Proteasome subunit beta type-8 1.29 
PDE1C Calcium/calmodulin-dependent 3,5-cyclic nucleotide phosphodiesterase 1C 1.36 
UBAP2L Ubiquitin-associated protein 2-like 1.44 
CORO1C Coronin-1C 1.45 
USP7 Ubiquitin carboxyl-terminal hydrolase 7;Ubiquitin carboxyl-terminal hydrolase 1.51 
CUTA Protein CutA 1.51 
SCYL1 N-terminal kinase-like protein 1.54 
SMTN Smoothelin 1.56 
TUFM Elongation factor Tu, mitochondrial 1.56 
MAP2K2 Dual specificity mitogen-activated protein kinase 2 1.58 
UBE2H Ubiquitin-conjugating enzyme E2 H 1.58 
IPO5 Importin-5 1.61 
CAMK2D Calcium/calmodulin-dependent protein kinase type II subunit delta 1.68 
TPD52L2 Tumour protein D54 1.76 
ILK Integrin-linked protein kinase 1.78 
AP2B1 AP-2 complex subunit beta 1.80 
RCN2 Reticulocalbin-2 1.85 
AP2A1 AP-2 complex subunit alpha-1 1.85 
ANXA5 Annexin A5;Annexin 1.85 
FLNA Filamin-A 1.92 
TPI1 Triosephosphate isomerase 1.99 
RAB18 Ras-related protein Rab-18 2.14 
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ZYX Zyxin 2.20 
ANXA6 Annexin A6;Annexin 2.26 
EIF2S3 Eukaryotic translation initiation factor 2 subunit 3 2.38 
MICAL1 Protein-methionine sulfoxide oxidase MICAL1 2.61 
MVD Diphosphomevalonate decarboxylase 2.71 
RND3 Rho-related GTP-binding protein RhoE 2.73 
BAG3 BAG family molecular chaperone regulator 3 2.80 
MAP2K1 Dual specificity mitogen-activated protein kinase 1 2.81 
ENO1 Alpha-enolase 2.90 
HSPA1A Heat shock 70 kDa protein 1A/1B 3.24 
PPP1CA Serine/threonine-protein phosphatase PP1-alpha catalytic subunit 3.37 
EPS8 Epidermal growth factor receptor kinase substrate 8 3.42 
CTPS CTP synthase 1 3.71 
LASP1 LIM and SH3 domain protein 1 3.79 
CALD1 Caldesmon 3.80 
PALLD Palladin 5.48 
FLNC Filamin-C 5.74 
HN1 Hematological and neurological expressed 1 protein 22.17 
OAT Ornithine aminotransferase, mitochondrial 22.17 
VARS Valine--tRNA ligase 22.18 
VPS18 Vacuolar protein sorting-associated protein 18 homolog 22.24 
ACTR3 Actin-related protein 3 22.34 
MINK1 Misshapen-like kinase 1 22.38 
ATP6V1G1 V-type proton ATPase subunit G 1 22.43 
ROCK1 Rho-associated protein kinase 1 22.43 
AIMP2 Aminoacyl tRNA synthase complex-interacting multifunctional protein 2 22.53 
RSU1 Ras suppressor protein 1 22.64 
NFKB1 Nuclear factor NF-kappa-B p105 subunit 22.70 
BAG6 Large proline-rich protein BAG6 22.91 
GNB1 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 22.92 
INPP4A Type I inositol 3,4-bisphosphate 4-phosphatase 22.98 
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EIF2B3 Translation initiation factor eIF-2B subunit gamma 23.18 
MOB4 MOB-like protein phocein 23.27 
CYP51A1 Lanosterol 14-alpha demethylase 23.28 
MIF4GD MIF4G domain-containing protein 23.29 
NAA30 N-alpha-acetyltransferase 30 23.33 
AP2A2 AP-2 complex subunit alpha-2 23.34 
RAPH1 Ras-associated and pleckstrin homology domains-containing protein 1 23.35 
MAPKAPK2 MAP kinase-activated protein kinase 2 23.47 
RPS3A 40S ribosomal protein S3a 23.55 
TCEB1 Transcription elongation factor B polypeptide 1 23.58 
SYNPO Synaptopodin 23.61 
SAE1 SUMO-activating enzyme subunit 1 23.63 
ALKBH5 Probable alpha-ketoglutarate-dependent dioxygenase ABH5 23.71 
LDLRAP1 Low density lipoprotein receptor adapter protein 1 23.74 
SYNC Syncoilin 23.82 
NAPA Alpha-soluble NSF attachment protein 23.94 
VPS29 Vacuolar protein sorting-associated protein 29 23.99 
PAWR PRKC apoptosis WT1 regulator protein 24.00 
AP1M1 AP-1 complex subunit mu-1 24.02 
AP1B1 AP-1 complex subunit beta-1 24.07 
WDR61 WD repeat-containing protein 61 24.16 
PSMG1 Proteasome assembly chaperone 1 24.16 
LIN7C Protein lin-7 homolog C 24.17 
PDCD4 Programmed cell death protein 4 24.18 
NCK1 Cytoplasmic protein NCK1 24.19 
RAB23 Ras-related protein Rab-23 24.19 
ACSS2 Acetyl-coenzyme A synthetase 24.23 
EPS8L2 Epidermal growth factor receptor kinase substrate 8-like protein 2 24.27 
PACS1 Phosphofurin acidic cluster sorting protein 1 24.34 
FLNB Filamin-B 24.50 
DNAJB4 DnaJ homolog subfamily B member 4 24.52 
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PDLIM2 PDZ and LIM domain protein 2 24.53 
YAP1 Yorkie homolog 24.57 
ARFGAP1 ADP-ribosylation factor GTPase-activating protein 1 24.62 
HSPB8 Heat shock protein beta-8 24.69 
PACSIN3 Protein kinase C and casein kinase substrate in neurons protein 3 24.82 
DFFA DNA fragmentation factor subunit alpha 24.86 
EIF4E Eukaryotic translation initiation factor 4E 24.86 
PLEKHO2 Pleckstrin homology domain-containing family O member 2 24.89 
PFKL 6-phosphofructokinase, liver type 24.95 
GNL1 Guanine nucleotide-binding protein-like 1 24.96 
MYL9 Myosin regulatory light polypeptide 9 24.99 
C6orf108 Deoxyribonucleoside 5-monophosphate N-glycosidase 25.04 
CHMP2B Charged multivesicular body protein 2b 25.06 
RCAN1 Calcipressin-1 25.50 
ATG4B Cysteine protease ATG4B 25.51 
PDLIM7 PDZ and LIM domain protein 7 25.53 
NEXN Nexilin 25.57 
TGFB1I1 Transforming growth factor beta-1-induced transcript 1 protein 25.58 
DSP Desmoplakin 25.62 
NDRG3 Protein NDRG3 25.68 
LMOD1 Leiomodin-1 25.75 
KCTD10 Adapter for CUL3-mediated RhoA degradation protein 3 25.86 
TUBA4A Tubulin alpha-4A chain 25.92 
PPP1R14A Protein phosphatase 1 regulatory subunit 14A 26.18 
STAT1 Signal transducer and activator of transcription 1-alpha/beta 26.25 
VCL Vinculin 26.43 
SORBS2 Sorbin And SH3 Domain Containing 2 26.68 
PDLIM5 PDZ and LIM domain protein 5 26.96 
RRAS2 Ras-related protein R-Ras2 27.28 
TAGLN Transgelin 28.52 
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Supplementary Table S2: Total proteins significantly up/ downregulated in schwannoma compared to Schwann cells 
Gene symbol Protein names Log2 FC 
ALDOC Fructose-bisphosphate aldolase C 26.32 
PSMB5 Proteasome subunit beta type-5 23.42 
TAGLN Transgelin 22.47 
FLNC Filamin-C 5.71 
CALD1 Caldesmon 3.54 
LASP1 LIM and SH3 domain protein 1 3.13 
ALDOA Fructose-bisphosphate aldolase A 1.98 
CAPZB F-actin-capping protein subunit beta 1.69 
MYL6 Myosin light polypeptide 6 1.61 
MAP1A Microtubule-associated protein 1A;MAP1 light chain LC2 1.51 
PSMA1 Proteasome subunit alpha type-1;Proteasome subunit alpha type 1.49 
CLIC1 Chloride intracellular channel protein 1 1.25 
ANXA5 Annexin A5;Annexin 1.20 
PRDX1 Peroxiredoxin-1 1.13 
GSTP1 Glutathione S-transferase P 1.06 
ACTN4 Alpha-actinin-4 1.01 
GSTK1 Glutathione S-transferase kappa 1 -1.03 
CTNNA1 Catenin alpha-1 -1.12 
ATP2A2 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 -1.15 
HSP90B1 Endoplasmin -1.16 
ATP5B ATP synthase subunit beta, mitochondrial;ATP synthase subunit beta -1.29 
YWHAZ 14-3-3 protein zeta/delta -1.31 
EIF3A Eukaryotic translation initiation factor 3 subunit A -1.33 
ETFB Electron transfer flavoprotein subunit beta -1.40 
RPSA 40S ribosomal protein SA -1.44 
RPL26 60S ribosomal protein L26 -1.50 
CAP1 Adenylyl cyclase-associated protein 1 -1.57 
PDIA3 Protein disulfide-isomerase A3 -1.83 
RPL4 60S ribosomal protein L4 -1.91 
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ITGAV Integrin alpha-V;Integrin alpha-V heavy chain;Integrin alpha-V light chain -1.96 
LGALS3 Galectin-3 -2.04 
RPN1 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 -2.42 
SPAG9 C-Jun-amino-terminal kinase-interacting protein 4 -3.15 
EIF4G1 Eukaryotic translation initiation factor 4 gamma 1 -3.18 
HNRNPM Heterogeneous nuclear ribonucleoprotein M -3.89 
NES Nestin -5.87 
PACSIN2 Protein kinase C and casein kinase substrate in neurons protein 2 -21.40 
SEC24B Protein transport protein Sec24B -21.56 
BCLAF1 Bcl-2-associated transcription factor 1 -21.85 
SMARCC2 SWI/SNF complex subunit SMARCC2 -21.99 
HECTD1 E3 ubiquitin-protein ligase HECTD1 -22.22 
DIP2B Disco-interacting protein 2 homolog B -22.45 
SART3 Squamous cell carcinoma antigen recognized by T-cells 3 -22.65 
NUP214 Nuclear pore complex protein Nup214 -22.66 
RANBP2 E3 SUMO-protein ligase RanBP2;Putative peptidyl-prolyl cis-trans isomerase -22.87 
HNRNPA0 Heterogeneous nuclear ribonucleoprotein A0 -23.06 
DHX15 Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15 -23.08 
H1FX Histone H1x -23.11 
SLC27A4 Long-chain fatty acid transport protein 4 -23.15 
RPL10 60S ribosomal protein L10 -23.18 
FXR1 Fragile X mental retardation syndrome-related protein 1 -23.26 
SMC2 Structural maintenance of chromosomes protein 2 -23.37 
SH3PXD2A SH3 and PX domain-containing protein 2A -23.39 
S E P 1 0  Septin-10 -23.39 
HLA-C HLA class I histocompatibility antigen, Cw-12 alpha chain -23.39 
KLC1 Kinesin light chain 1 -23.44 
SVIL Supervillin -23.47 
KIF13B Kinesin-like protein KIF13B -23.48 
NUMA1 Nuclear mitotic apparatus protein 1 -23.61 
HSPH1 Heat shock protein 105 kDa -23.65 
182 
 
RHOB Rho-related GTP-binding protein RhoB -23.68 
OXCT1 Succinyl-CoA:3-ketoacid-coenzyme A transferase 1, mitochondrial -23.70 
IMPA1 Inositol monophosphatase 1 -23.87 
LMNB2 Lamin-B2 -23.88 
NDUFS3 NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial -23.91 
COL7A1 Collagen alpha-1(VII) chain -23.98 
IMPDH2 Inosine-5-monophosphate dehydrogenase 2 -24.01 
KHSRP Far upstream element-binding protein 2 -24.14 
NNT NAD(P) transhydrogenase, mitochondrial -24.18 
RPS15 40S ribosomal protein S15 -24.21 
GBE1 1,4-alpha-glucan-branching enzyme -24.23 
ODZ3 Teneurin-3 -24.30 
HIGD1A HIG1 domain family member 1A -24.36 
DDX3X ATP-dependent RNA helicase DDX3X;ATP-dependent RNA helicase DDX3Y -24.38 
NOMO2 Nodal modulator 2;Nodal modulator 1;Nodal modulator 3 -24.40 
ERH Enhancer of rudimentary homolog -24.42 
COX5A Cytochrome c oxidase subunit 5A, mitochondrial -24.48 
PLOD1 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 -24.58 
PSMD4 26S proteasome non-ATPase regulatory subunit 4 -24.63 
PAK2 Serine/threonine-protein kinase PAK 2;PAK-2p27;PAK-2p34 -24.65 
CD59 CD59 glycoprotein -24.69 
RPS9 40S ribosomal protein S9 -24.73 
PCDH1 Protocadherin-1 -24.75 
RBBP4 Histone-binding protein RBBP4 -24.76 
PYGB Glycogen phosphorylase, brain form -24.83 
SF3B2 Splicing factor 3B subunit 2 -24.90 
HIST1H2BB Histone H2B type 1-B -24.95 
NAMPT Nicotinamide phosphoribosyltransferase -25.05 
RPL36 60S ribosomal protein L36 -25.05 
GAS7 Growth arrest-specific protein 7 -25.06 
CDH19 Cadherin-19 -25.10 
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SRI Sorcin -25.18 
XRCC5 X-ray repair cross-complementing protein 5 -25.19 
MMP14 Matrix metalloproteinase-14 -25.45 
PPIF Peptidyl-prolyl cis-trans isomerase F, mitochondrial;Peptidyl-prolyl cis-trans isomerase -25.47 
EIF3K Eukaryotic translation initiation factor 3 subunit K -25.48 
HMGB3 High mobility group protein B3 -25.65 
FKBP2 Peptidyl-prolyl cis-trans isomerase FKBP2 -25.67 
CRLF1 Cytokine receptor-like factor 1 -25.76 
FUBP1 Far upstream element-binding protein 1 -25.77 
COX4I1 Cytochrome c oxidase subunit 4 isoform 1, mitochondrial -25.86 
RPL9 60S ribosomal protein L9 -25.95 
RPL13 60S ribosomal protein L13 -26.03 
HINT1 Histidine triad nucleotide-binding protein 1 -26.15 
RPS17 40S ribosomal protein S17;40S ribosomal protein S17-like -26.48 
XRCC6 X-ray repair cross-complementing protein 6 -26.61 
HLA-DRB1 HLA class II histocompatibility antigen, DRB1-4 beta chain -26.66 
ATP5I ATP synthase subunit e, mitochondrial -26.82 
PLXNB3 Plexin-B3 -26.99 
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Supplementary Table S3: Phosphoproteins significantly downregulated in primary meningioma compared to HMC 
Gene symbol Protein name  Log2 FC 
 
TALDO1  Transaldolase  -1.14 
 
PSMA5  Proteasome subunit alpha ty-5  -1.15 
 
HSP90AB1  Heat shock protein HSP 90-beta  -1.15 
 
HNRNPU  Heterogeneous nuclear ribonucleoprotein U  -1.18 
 
DDX3X Isoform 2 of ATP-dependent RNA helicase DDX3X  -1.18 
 
SNX1  Sorting nexin-1  -1.18 
 
RPS3  40S ribosomal protein S3  -1.18 
 
MAP2K2  Dual specificity mitogen-activated protein kinase kinase 2  -1.24 
 
PSMA3 Isoform 2 of Proteasome subunit alpha ty-3  -1.27 
 
PSMA1  Proteasome subunit alpha ty-1  -1.28 
 
DCTN1 Isoform 3 of Dynactin subunit 1  -1.33 
 
FAM129B  Niban-like protein 1  -1.34 
 
HIST2H2BE  Histone H2B ty 2-E  -1.40 
 
LRRC47  Leucine-rich repeat-containing protein 47  -1.42 
 
AP2B1  AP-2 complex subunit beta  -1.46 
 
PDLIM4  PDZ and LIM domain protein 4  -1.46 
 
RPS6  40S ribosomal protein S6  -1.49 
 
SORBS3  Vinexin  -1.51 
 
ILK  Integrin-linked protein kinase  -1.56 
 
CCDC25  Coiled-coil domain-containing protein 25  -1.59 
 
NOP58  Nucleolar protein 58  -1.59 
 
HSP90B1  Endoplasmin  -1.62 
 
CLINT1  Clathrin interactor 1  -1.65 
 
EHD2  EH domain-containing protein 2  -1.66 
 
PSMB7  Proteasome subunit beta ty-7  -1.72 
 
PSMB1  Proteasome subunit beta ty-1  -1.72 
 
CNN3  Calponin-3  -1.78 
 
FLNA Isoform 2 of Filamin-A  -1.79 
 
PSMB6  Proteasome subunit beta ty-6  -1.84 
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HNRNPC  Heterogeneous nuclear ribonucleoproteins C1/C2 (Fragment)  -1.97 
 
PDHA1  Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial  -2.02 
 
HNRNPUL1 Isoform 2 of Heterogeneous nuclear ribonucleoprotein U-like protein 1  -2.02 
 
MAP2K1  Dual specificity mitogen-activated protein kinase kinase 1  -2.03 
 
SPAG9  C-Jun-amino-terminal kinase-interacting protein 4  -2.05 
 
PGRMC2  Membrane-associated progesterone receptor component 2  -2.12 
 
USO1  General vesicular transport factor p115  -2.17 
 
PTRF  Polymerase I and transcript release factor  -2.17 
 
HDLBP  Vigilin  -2.35 
 
PSMA2  Proteasome subunit alpha ty-2  -2.37 
 
S E P 9 Isoform 5 of Septin-9  -2.52 
 
MAP4  Microtubule-associated protein  -2.57 
 
WDR44 Isoform 2 of WD repeat-containing protein 44  -2.63 
 
DBN1 Isoform 3 of Drebrin  -2.98 
 
AKAP12 Isoform 2 of A-kinase anchor protein 12  -2.99 
 
S E P 1 1  Septin 11, isoform CRA -3.46 
 
EPB41L3 Isoform B of Band 4.1-like protein 3  -4.59 
 
APBB1 Isoform 2 of Amyloid beta A4 precursor protein-binding family B member 1  -19.22 
 
FMNL3  Formin-like protein 3  -19.53 
 
NCSTN  Nicastrin (Fragment)  -19.69 
 
CARS Isoform 2 of Cysteine--tRNA ligase, cytoplasmic  -19.74 
 
LP1  Proline-, glutamic acid- and leucine-rich protein 1  -19.79 
 
XRCC1  DNA repair protein XRCC1  -19.89 
 
IBTK Isoform 2 of Inhibitor of Bruton tyrine kinase  -19.90 
 
NEK1 Isoform 4 of Serine/threonine-protein kinase Nek1  -19.97 
 
DIAPH1  Diaphanous homolog 1 (Drosophila), isoform CRA -20.02 
 
ECI2 Isoform 2 of Enoyl-CoA delta isomerase 2, mitochondrial  -20.02 
 
QARS  Glutamine--tRNA ligase  -20.04 
 
USP32  Ubiquitin carboxyl-terminal hydrolase 32  -20.07 
 
KIAA0196  WASH complex subunit strumllin  -20.08 
 
CUL4B Isoform 2 of Cullin-4B  -20.11 
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TP53BP2 Isoform 2 of Apoptosis-stimulating of p53 protein 2  -20.13 
 
NBAS Isoform 2 of Neuroblastoma-amplified sequence  -20.17 
 
YWHAH  14-3-3 protein eta  -20.19 
 
XPO6  Exporting 6, isoform CRA -20.19 
 
STRN Isoform 2 of Striating  -20.20 
 
TFRC  Transferrin receptor protein 1  -20.21 
 
BCAS3 Isoform 5 of Breast carcinoma-amplified sequence 3  -20.23 
 
BCAR1 Isoform 4 of Breast cancer anti-estrogenic resistance protein 1  -20.25 
 
MYO5A Isoform 2 of Unconventional myin-Va  -20.27 
 
ARAP3  Arf-GAP with Rho-GAP domain, ANK repeat and PH domain-containing protein 3  -20.28 
 
SPIRE1 Isoform 2 of Protein spire homolog 1  -20.34 
 
INPP4A  Ty I initol 3,4-bisphphate 4-phphatase  -20.35 
 
NOC2L  Nucleolar complex protein 2 homolog  -20.35 
 
IKBKAP  Elongator complex protein 1  -20.35 
 
PIK3R4  Phosphoinositide 3-kinase regulatory subunit 4  -20.36 
 
SMC1A  Structural maintenance of chromosomes protein 1A  -20.37 
 
STK10  Serine/threonine-protein kinase 10  -20.40 
 
ARFGEF1  Brefeldin A-inhibited guanine nucleotide-exchange protein 1  -20.45 
 
ZZEF1  Zinc finger ZZ-ty and EF-hand domain-containing protein 1  -20.47 
 
KPNB1  Importin subunit beta-1  -20.49 
 
IGFBP3  Insulin-like growth factor-binding protein 3  -20.50 
 
MPZL1 Isoform 4 of Myelin protein zero-like protein 1  -20.50 
 
FARP1  FERM, RhoGEF and pleckstrin domain-containing protein 1  -20.51 
 
CEP170 Isoform 3 of Centrosomal protein of 170 kDa  -20.55 
 
THOC2  THO complex subunit 2  -20.56 
 
UTP14A Isoform 3 of U3 small nucleolar RNA-associated protein 14 homolog A  -20.57 
 
RPP40 Isoform 2 of Ribonuclease P protein subunit p40  -20.58 
 
CAMSAP1  Calmodulin-regulated secretin-associated protein 1  -20.59 
 
CCDC9  Coiled-coil domain-containing protein 9  -20.59 
 
COL1A1  Collagen alpha-1(I) chain  -20.61 
 
TBC1D10B  TBC1 domain family member 10B  -20.63 
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NOC4L  Nucleolar complex protein 4 homolog  -20.66 
 
VPS26A  Vacuolar protein sorting-associated protein 26A  -20.67 
 
CCAR2 Isoform 2 of Cell cycle and apoptosis regulator protein 2  -20.68 
 
WAPAL  Wings apart-like protein homolog  -20.70 
 
ACTR2  Actin-related protein 2  -20.70 
 
SUGP2  SURP and G-patch domain-containing protein 2  -20.71 
 
DHX38  Pre-mRNA-splicing factor ATP-dependent RNA helicase PRP16  -20.71 
 
TCEB3  Transcription elongation factor B polypeptide 3  -20.72 
 
PAK1  Serine/threonine-protein kinase PAK 1  -20.74 
 
ARIH2  E3 ubiquitin-protein ligase ARIH2  -20.74 
 
SYNJ1  Synaptojanin-1  -20.74 
 
ATP6V1A  V-ty proton ATPase catalytic subunit A  -20.75 
 
ASMTL Isoform 2 of N-acetylserotonin O-methyltransferase-like protein  -20.76 
 
EXC10  Exome component 10  -20.77 
 
RICTOR  Rapamycin-insensitive companion of mTOR  -20.77 
 
PHLDB2 Isoform 2 of Pleckstrin homology-like domain family B member 2  -20.78 
 
PRMT3  Protein arginine N-methyltransferase 3  -20.79 
 
MYO6 Isoform 6 of Unconventional myosin-VI  -20.82 
 
MTMR6  Myotubularin-related protein 6  -20.86 
 
FKBP8  peptidyl-prolyl cis-trans isomerase FKBP8  -20.88 
 
PSMA3  Proteasome subunit alpha ty-3  -20.89 
 
SND1  Staphylococcal nuclease domain-containing protein 1  -20.89 
 
ATP2B1 Isoform K of Plasma membrane calcium-transporting ATPase 1  -20.91 
 
VPS41 Isoform Short of Vacuolar protein sorting-associated protein 41 homolog  -20.95 
 
STRIP1  Striatin-interacting protein 1  -20.95 
 
DBR1  Lariat debranching enzyme  -20.95 
 
TANC1  Protein TANC1  -20.96 
 
STK11IP  Serine/threonine-protein kinase 11-interacting protein  -20.98 
 
ANKRD17 Isoform 6 of Ankyrin repeat domain-containing protein 17  -21.00 
 
KIAA1468 Isoform 2 of Lis domain and HEAT repeat-containing protein KIAA1468  -21.00 
 
RBM28  RNA-binding protein 28  -21.02 
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TOP2B Isoform Beta-1 of DNA topoisomerase 2-beta  -21.04 
 
DICER1  Endoribonuclease Dicer  -21.06 
 
SGPL1  Sphingine-1-phphate lyase 1  -21.10 
 
GAK  Cyclin-G-associated kinase  -21.10 
 
FAM114A2  Protein FAM114A2  -21.10 
 
RABGAP1  Rab GTPase-activating protein 1  -21.11 
 
KIAA1217  Sickle tail protein homolog  -21.12 
 
RPS3A  40S ribomal protein S3a (Fragment)  -21.14 
 
WDR11  WD repeat-containing protein 11  -21.14 
 
NIFK  MKI67 FHA domain-interacting nucleolar phosphoprotein  -21.15 
 
IMP3  U3 small nucleolar ribonucleoprotein protein IMP3  -21.15 
 
FAM21A  WASH complex subunit FAM21A  -21.16 
 
INTS3 Isoform 3 of Integrator complex subunit 3  -21.16 
 
CBL  E3 ubiquitin-protein ligase CBL  -21.17 
 
ARHGEF12  Rho guanine nucleotide exchange factor 12  -21.17 
 
CDC42BPB  Serine/threonine-protein kinase MRCK beta  -21.18 
 
WDFY3 Isoform 2 of WD repeat and FYVE domain-containing protein 3  -21.19 
 
PLCB1  1-phphatidylinitol 4,5-bisphphate phosphodiesterase beta-1  -21.19 
 
TLN2  Talin-2  -21.20 
 
PRKD1  Serine/threonine-protein kinase D1  -21.20 
 
IPO4  Importin-4  -21.21 
 
SBF1  Myotubularin-related protein 5  -21.21 
 
FAF1  FAS-associated factor 1  -21.21 
 
ABL1  Tyrine-protein kinase ABL1  -21.21 
 
DOCK5  Dedicator of cytokinesis protein 5  -21.24 
 
UGGT1 Isoform 2 of UDP-glucose:glycoprotein glucyltransferase 1  -21.25 
 
TJP2 Isoform C1 of Tight junction protein ZO-2  -21.29 
 
BIRC6  Baculoviral IAP repeat-containing protein 6  -21.30 
 
FMNL2 Isoform 2 of Formin-like protein 2  -21.30 
 
ASCC3  Activating signal cointegrator 1 complex subunit 3  -21.30 
 
PPIL4  peptidyl-prolyl cis-trans isomerase-like 4  -21.31 
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MESDC2  LDLR chaperone MESD  -21.32 
 
RAPGEF2  Rap guanine nucleotide exchange factor 2  -21.33 
 
TXLNA  Alpha-taxin -21.34 
 
HMGCL  3-hydroxymethyl-3-methylglutaryl-Coenzyme A lyase (Hydroxymethylglutaricaciduria) -21.34 
 
SNX17 Isoform 2 of Sorting nexin-17  -21.35 
 
EEF2K  Eukaryotic elongation factor 2 kinase  -21.35 
 
ARMC9 Isoform 2 of LisH domain-containing protein ARMC9  -21.37 
 
BPL2 Isoform 2 of Oxysterol-binding protein-related protein 2  -21.38 
 
MLLT4 Isoform 1 of Afadin  -21.39 
 
POLR1A  DNA-directed RNA polymerase  -21.39 
 
DIP2B  Disco-interacting protein 2 homolog B  -21.41 
 
ITCH Isoform 2 of E3 ubiquitin-protein ligase Itchy homolog  -21.41 
 
SERPINB12  Serpin B12  -21.43 
 
REEP3  Receptor expression-enhancing protein 3  -21.44 
 
DMXL1  DmX-like protein 1  -21.45 
 
DHRS7 Isoform 2 of Dehydrogenase/reductase SDR family member 7  -21.45 
 
RUVBL1  RuvB-like 1  -21.46 
 
PIK3C2A  Phosphatidylinitol 4-phphate 3-kinase C2 domain-containing subunit alpha  -21.47 
 
KIF13B  Kinesin-like protein KIF13B  -21.47 
 
FAM91A1  Protein FAM91A1  -21.47 
 
CMSS1  Protein CMSS1 (Fragment)  -21.48 
 
STX4  Syntaxin-4  -21.49 
 
ATIC Isoform 2 of Bifunctional purine biosynthesis protein PURH  -21.50 
 
SF3A1  Splicing factor 3A subunit 1  -21.50 
 
S1  scadillo homolog  -21.50 
 
HSPA4  Heat shock 70 kDa protein 4  -21.51 
 
NEDD4 Isoform 4 of E3 ubiquitin-protein ligase NEDD4  -21.52 
 
UPF2  Regulator of nonsense transcripts 2  -21.52 
 
AZGP1  Zinc-alpha-2-glycoprotein  -21.52 
 
PFKL  6-phphofructokinase, liver ty  -21.53 
 
EMD  Emerin  -21.54 
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TNPO1 Isoform 2 of Transportin-1  -21.54 
 
NONO  Non-POU domain-containing octamer-binding protein  -21.54 
 
DOCK10  Dedicator of cytokinesis protein 10  -21.55 
 
DOCK6  Dedicator of cytokinesis protein 6  -21.56 
 
UBR4 Isoform 3 of E3 ubiquitin-protein ligase UBR4  -21.57 
 
GIGYF2 Isoform 3 of RQ amino acid-rich with GYF domain-containing protein 2  -21.57 
 
PRKRA  Interferon-inducible double-stranded RNA-dependent protein kinase activator A  -21.58 
 
MYO1B Isoform 2 of Unconventional myosin-Ib  -21.58 
 
MACF1  Microtubule-actin crs-linking factor 1, isoforms 1/2/3/5  -21.59 
 
IPO9  Importin-9  -21.60 
 
PTEN  Phosphatidylinitol 3,4,5-trisphphate 3-phphatase and dual-specificity protein phosphatase -21.61 
 
UBE4B Isoform 2 of Ubiquitin conjugation factor E4 B  -21.62 
 
USP4 Isoform 2 of Ubiquitin carboxyl-terminal hydrolase 4  -21.63 
 
GGH  Gamma-glutamyl hydrolase  -21.64 
 
RQCD1  Cell differentiation protein RCD1 homolog  -21.64 
 
BPL9  Oxysterol-binding protein  -21.64 
 
DHX16  Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX16  -21.66 
 
EXC4  Exome complex component RRP41  -21.67 
 
NIP7  60S ribosome subunit biogenesis protein NIP7 homolog  -21.68 
 
GPN3  GPN-loop GTPase 3  -21.69 
 
CDK5RAP3  CDK5 regulatory subunit-associated protein 3  -21.70 
 
PWP2  periodic tryptophan protein 2 homolog  -21.70 
 
PPP4R1 Isoform 2 of Serine/threonine-protein phosphatase 4 regulatory subunit 1  -21.71 
 
S E P 8  Isoform 2 of Septin-8  -21.72 
 
PFKM  6-phphofructokinase, muscle ty  -21.73 
 
RPL10  60S ribosomal protein L10  -21.73 
 
KIF2A Isoform 2 of Kinesin-like protein KIF2A  -21.73 
 
HDAC6  Histone deacetylase 6  -21.74 
 
GRK5  G protein-coupled receptor kinase 5  -21.74 
 
LDHB  L-lactate déshydrogénase B chain  -21.74 
 
MYO1E  Unconventional myosin-Ie  -21.74 
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EIF2AK4 Isoform 2 of Eukaryotic translation initiation factor 2-alpha kinase 4  -21.74 
 
HELZ  Probable helicase with zinc finger domain  -21.75 
 
SMEK1 Isoform 2 of Serine/threonine-protein phosphatase 4 regulatory subunit 3A  -21.75 
 
S1  Son of sevenless homolog 1  -21.75 
 
USP11  Ubiquitin carboxyl-terminal hydrolase  -21.76 
 
MDH1  Malate dehydrogenase, cytoplasmic  -21.77 
 
FAM160B1  Protein FAM160B1  -21.77 
 
GTPBP4  Nucleolar GTP-binding protein 1  -21.78 
 
PLEKHA5  Pleckstrin homology domain-containing family A member 5  -21.79 
 
SMARCA5  SWI/SNF-related matrix-associated actin-dependent regulator of chromatin  -21.79 
 
ASCC2  Activating signal cointegrator 1 complex subunit 2  -21.79 
 
CC2D1B  Coiled-coil and C2 domain-containing protein 1B (Fragment)  -21.80 
 
ARAP1 Isoform 7 of Arf-GAP with Rho-GAP domain -21.80 
 
MGEA5  Bifunctional protein NCOAT  -21.81 
 
LLGL1  Lethal(2) giant larvae protein homolog 1  -21.82 
 
ABI2 Isoform 2 of Abl interactor 2  -21.84 
 
TCEA1  Transcription elongation factor A protein 1  -21.84 
 
CPD  Carboxypeptidase D  -21.86 
 
FNDC3B  Fibronectin ty III domain-containing protein 3B  -21.86 
 
SIPA1  Signal-induced proliferation-associated protein 1  -21.86 
 
KIF1C  Kinesin-like protein KIF1C  -21.86 
 
RPS2  40S ribomal protein S2 (Fragment)  -21.86 
 
PUM1  Pumilio homolog 1 (Fragment)  -21.87 
 
DDX23  Probable ATP-dependent RNA helicase DDX23  -21.87 
 
ANK3 Isoform 3 of Ankyrin-3  -21.87 
 
PSMD14  26S proteasome non-ATPase regulatory subunit 14  -21.87 
 
EPS15  Epidermal growth factor receptor substrate 15  -21.88 
 
DLGAP4 Isoform 3 of Disks large-associated protein 4  -21.89 
 
PI4KB Isoform 2 of Phosphatidylinitol 4-kinase beta  -21.89 
 
PPM1F  Protein phosphatase 1F  -21.90 
 
AP1B1 Isoform C of AP-1 complex subunit beta-1  -21.90 
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LMAN2  Vesicular integral-membrane protein VIP36  -21.91 
 
ITGA4  Integrin alpha-4  -21.92 
 
ABR Isoform Short of Active breakpoint cluster region-related protein  -21.93 
 
WDR13  WD repeat-containing protein 13  -21.96 
 
AP1M1  AP-1 complex subunit mu-1  -21.97 
 
ARHGAP5 Isoform 2 of Rho GTPase-activating protein 5  -21.97 
 
ZNF622  Zinc finger protein 622  -21.97 
 
HS1BP3  HCLS1-binding protein 3  -21.98 
 
HTT  Huntingtin  -21.98 
 
C16orf62  Oesophageal cancer associated protein, isoform CRA -21.99 
 
MSH6  DNA mismatch repair protein Msh6  -21.99 
 
CRK  Adapter molecule crk  -21.99 
 
IK  Protein Red  -22.00 
 
DHX57  Putative ATP-dependent RNA helicase DHX57  -22.01 
 
CLASP1  CLIP-associating protein 1  -22.01 
 
DIS3L2  DIS3-like exonuclease 2  -22.01 
 
NUP205  Nuclear pore complex protein Nup205  -22.03 
 
FAM177A1  Protein FAM177A1  -22.03 
 
HEATR5A Isoform 2 of HEAT repeat-containing protein 5A  -22.04 
 
CCT5  T-complex protein 1 subunit epsilon  -22.05 
 
FN1  Ugl-Y3  -22.05 
 
TEX264  Testis-expressed sequence 264 protein  -22.06 
 
CENPV Isoform 3 of Centromere protein V  -22.07 
 
NUP107  Nuclear pore complex protein Nup107  -22.07 
 
PLS3  Plastin-3  -22.10 
 
CCNK  Cyclin-K  -22.10 
 
TUBGCP2  Gamma-tubulin complex component 2  -22.12 
 
TTC37  Tetratricoptide repeat protein 37  -22.12 
 
TMX3  Protein disulfide-isomerase TMX3  -22.13 
 
EDC3  Enhancer of mRNA-decapping protein 3  -22.15 
 
ROCK2  Rho-associated protein kinase 2  -22.16 
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KIF1B Isoform 2 of Kinesin-like protein KIF1B  -22.16 
 
ARCN1  Coatomer subunit delta  -22.17 
 
SART1  U4/U6.U5 tri-snRNP-associated protein 1  -22.20 
 
SRC  Proto-oncogene tyrine-protein kinase Src  -22.20 
 
HNRNPM Isoform 2 of Heterogeneous nuclear ribonucleoprotein M  -22.22 
 
PRKCDBP  Protein kinase C delta-binding protein  -22.22 
 
CD248  Endialin  -22.24 
 
LARP4  La-related protein 4  -22.24 
 
SPCS2  Signal peptidase complex subunit 2  -22.25 
 
USP8  Ubiquitin carboxyl-terminal hydrolase 8  -22.26 
 
PRKAG2 Isoform B of 5-AMP-activated protein kinase subunit gamma-2  -22.29 
 
HEXB  Beta-hexaminidase subunit beta  -22.29 
 
BAIAP2 Isoform 3 of Brain-specific angiogenesis inhibitor 1-associated protein 2  -22.30 
 
CD2AP  CD2-associated protein  -22.30 
 
RER1  Protein RER1 (Fragment)  -22.32 
 
ASAP1  Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1  -22.32 
 
FAM120A  Constitutive coactivator of PPAR-gamma-like protein 1  -22.32 
 
YTHDC2  Probable ATP-dependent RNA helicase YTHDC2  -22.33 
 
TRIM16  Tripartite motif-containing protein 16  -22.33 
 
MAPKAPK2  MAP kinase-activated protein kinase 2  -22.34 
 
UBXN7  UBX domain-containing protein 7  -22.35 
 
PIP  Prolactin-inducible protein  -22.35 
 
DSG1  Desmoglein-1  -22.35 
 
PKN2 Isoform 3 of Serine/threonine-protein kinase N2  -22.36 
 
VCL Isoform 1 of Vinculin  -22.37 
 
NF2 Isoform 3 of Merlin  -22.37 
 
PAPOLA  Poly(A) polymerase alpha  -22.38 
 
ERP44  Endoplasmic reticulum resident protein 44  -22.38 
 
PAK4  Serine/threonine-protein kinase PAK 4  -22.38 
 
CDK17  Cyclin-dependent kinase 17  -22.39 
 
CTBP1 Isoform 2 of C-terminal-binding protein 1  -22.39 
 
194 
 
PPP2R5D Isoform Delta-3 of Serine/threonine-protein phosphatase 2A  -22.39 
 
USP7  Ubiquitin carboxyl-terminal hydrolase  -22.39 
 
DPM1  Dolichol-phosphate mannyltransferase subunit 1  -22.41 
 
MICAL1  Protein-methionine sulfoxide oxidase MICAL1  -22.43 
 
SKIV2L  Helicase SKI2W  -22.44 
 
RILPL1  RILP-like protein 1  -22.44 
 
1 SV Uncharacterized protein FLJ45252  -22.45 
 
C6orf203  Uncharacterized protein C6orf203  -22.45 
 
AP2A2  AP-2 complex subunit alpha-2  -22.45 
 
COBLL1 Isoform 4 of Cordon-bleu protein-like 1  -22.46 
 
CTPS2  CTP synthase 2  -22.46 
 
EXOC2  Exocyst complex component 2  -22.47 
 
RAB12  Ras-related protein Rab-12  -22.47 
 
EIF3A  Eukaryotic translation initiation factor 3 subunit A  -22.47 
 
MON2  Protein MON2 homolog  -22.48 
 
ADARB1  Double-stranded RNA-specific editase 1  -22.48 
 
TPM1  Tropomyosin 1 (Alpha), isoform CRA -22.48 
 
PDS5B Isoform 2 of Sister chromatid cohesion protein PDS5 homolog B  -22.52 
 
PPIP5K2 Isoform 2 of Inositol hexakisphosphate and diphosphoinositol-ntakisphosphate kinase 2  -22.53 
 
NSUN2  tRNA (cytosine(34)-C(5))-methyltransferase  -22.53 
 
SAFB Isoform 2 of Scaffold attachment factor B1  -22.53 
 
ATP2A2 Isoform 5 of Sarcoplasmic/endoplasmic reticulum calcium ATPase 2  -22.53 
 
SF3A3  Splicing factor 3A subunit 3  -22.53 
 
PRPF31  U4/U6 small nuclear ribonucleoprotein Prp31  -22.55 
 
ATXN2 Isoform 2 of Ataxin-2  -22.56 
 
EFTUD2 Isoform 2 of 116 kDa U5 small nuclear ribonucleoprotein component  -22.57 
 
SF1 Isoform 4 of Splicing factor 1  -22.57 
 
FAM65A Isoform 2 of Protein FAM65A  -22.58 
 
RRP12  RRP12-like protein  -22.58 
 
PPFIBP1 Isoform 4 of Liprin-beta-1  -22.58 
 
NAGK  N-acetyl-D-glucamine kinase  -22.58 
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DDX27  Probable ATP-dependent RNA helicase DDX27  -22.60 
 
GPX8  Probable glutathione peroxidase 8  -22.60 
 
DDX54  ATP-dependent RNA helicase DDX54  -22.62 
 
ARFGAP2  ADP-ribosylation factor GTPase-activating protein 2  -22.62 
 
RAB2A  Ras-related protein Rab-2A  -22.63 
 
ARAF  Serine/threonine-protein kinase A-Raf  -22.63 
 
SF3B3  Splicing factor 3B subunit 3  -22.66 
 
PRPF3  U4/U6 small nuclear ribonucleoprotein Prp3  -22.67 
 
AP2M1 Isoform 2 of AP-2 complex subunit mu  -22.67 
 
COMT Isoform Soluble of Catechol O-methyltransferase  -22.67 
 
EPB41L2  Band 4.1-like protein 2  -22.67 
 
PRMT5  Protein arginine N-methyltransferase 5  -22.68 
 
DUSP1  Dual specificity protein phosphatase 1  -22.69 
 
GEP  Probable tRNA N6-adenine threonylcarbamoyltransferase  -22.70 
 
FOCAD  Focadhesin  -22.71 
 
MYO9B Isoform Short of Unconventional myin-IXb  -22.72 
 
ARFGAP3  ADP-ribosylation factor GTPase-activating protein 3  -22.72 
 
DHX15  Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15  -22.73 
 
GLRX3  Glutaredoxin-3  -22.74 
 
EXOC1 Isoform 2 of Exocyst complex component 1  -22.74 
 
ARHGEF40 Isoform 4 of Rho guanine nucleotide exchange factor 40  -22.75 
 
CSNK1D Isoform 2 of Casein kinase I isoform delta  -22.76 
 
NAA15  N-alpha-acetyltransferase 15, NatA auxiliary subunit  -22.76 
 
CNOT1 Isoform 2 of CCR4-NOT transcription complex subunit 1  -22.77 
 
DKC1  H/ACA ribonucleoprotein complex subunit 4  -22.79 
 
USP14  Ubiquitin carboxyl-terminal hydrolase  -22.79 
 
MLEC  Malectin  -22.79 
 
GIPC1  PDZ domain-containing protein GIPC1  -22.79 
 
SEC11A  Signal peptidase complex catalytic subunit SEC11A  -22.80 
 
PDGFRB  Platelet-derived growth factor receptor beta  -22.81 
 
UBE2O  Ubiquitin-conjugating enzyme E2 O  -22.83 
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AKT3 Isoform 2 of RAC-gamma serine/threonine-protein kinase  -22.83 
 
HDAC2  Histone deacetylase  -22.84 
 
ANK2  Ankyrin-2  -22.85 
 
PRPSAP1 Isoform 2 of Phosphoribyl pyrophosphate synthase-associated protein 1  -22.86 
 
CNTNAP1  Contactin-associated protein 1  -22.88 
 
IARS  Isoleucine--tRNA ligase, cytoplasmic  -22.91 
 
PDLIM7  PDZ and LIM domain protein 7  -22.92 
 
RPP30  Ribonuclease P protein subunit p30  -22.94 
 
PLCG1  1-phphatidylinitol 4,5-bisphphate phosphodiesterase gamma-1  -22.94 
 
PI4KA  Phosphatidylinitol 4-kinase alpha  -22.95 
 
mTOR  Serine/threonine-protein kinase mTOR  -22.96 
 
DNM2 Isoform 2 of Dynamin-2  -22.96 
 
PIP4K2A  Phosphatidylinitol 5-phphate 4-kinase ty-2 alpha  -22.96 
 
XRN2  5-3 exoribonuclease 2  -22.97 
 
RRAS2  Ras-related protein R-Ras2  -22.98 
 
NASP  Nuclear autoantigenic srm protein  -23.02 
 
PPP2R5E  Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit epsilon isoform  -23.06 
 
DCLK1 Isoform 1 of Serine/threonine-protein kinase DCLK1  -23.08 
 
WDR77  Methylene protein 50  -23.09 
 
TMED9  Transmembrane emp24 domain-containing protein 9  -23.11 
 
EHBP1  EH domain-binding protein 1  -23.13 
 
BAIAP2L1  Brain-specific angiogenesis inhibitor 1-associated protein 2-like protein 1  -23.14 
 
NEXN  Nexilin  -23.14 
 
STT3A  Dolichyl-diphosphooligaccharide--protein glycyltransferase subunit STT3A  -23.14 
 
RPL5  60S ribosomal protein L5  -23.17 
 
S E P 5 Septin-5  -23.17 
 
SEC61A1  Protein transport protein Sec61 subunit alpha isoform 1  -23.18 
 
RPL11  60S ribosomal protein L11  -23.20 
 
PGK1  Phosphoglycerate kinase 1  -23.21 
 
CDC42EP1 Isoform 2 of Cdc42 effector protein 1  -23.22 
 
RASA3  Ras GTPase-activating protein 3  -23.25 
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SYNJ2  Synaptojanin-2  -23.28 
 
INPPL1  Phosphatidylinitol 3,4,5-trisphphate 5-phphatase 2  -23.30 
 
GEMIN5  Gem-associated protein 5  -23.31 
 
GPN1  GPN-loop GTPase 1  -23.31 
 
C20orf27  UPF0687 protein C20orf27  -23.37 
 
PUS1  tRNA pseudouridine synthase (Fragment)  -23.38 
 
TMEM43  Transmembrane protein 43  -23.41 
 
CKAP5 Isoform 2 of Cytoskeleton-associated protein 5  -23.43 
 
IFI16 Isoform 3 of Gamma-interferon-inducible protein 16  -23.49 
 
RPS24 Isoform 2 of 40S ribosomal protein S24  -23.51 
 
TRIO  Triple functional domain protein  -23.53 
 
PKN1  Serine/threonine-protein kinase N1  -23.54 
 
CDK16  Cyclin-dependent kinase 16  -23.56 
 
PBDC1  Protein PBDC1  -23.58 
 
SH3BP1  SH3 domain-binding protein 1  -23.62 
 
SEC22B  Vesicle-trafficking protein SEC22b  -23.64 
 
CLNS1A  Methylome subunit pICln  -23.65 
 
PACS1  Phosphofurin acidic cluster sorting protein 1  -23.67 
 
GNL3 Isoform 2 of Guanine nucleotide-binding protein-like 3  -23.70 
 
SURF4 Isoform 2 of Surfeit locus protein 4  -23.70 
 
ARFGAP1  ADP-ribosylation factor GTPase-activating protein 1  -23.70 
 
CTNNA1  Catenin alpha-1  -23.78 
 
RPL18  60S ribosomal protein L18 (Fragment)  -23.79 
 
RRBP1  Ribose-binding protein 1  -23.85 
 
AMPD2  AMP deaminase 2 (Fragment)  -23.88 
 
TGFB1I1  Transforming growth factor beta-1-induced transcript 1 protein  -24.06 
 
PPP1R18  Phosphotensin  -24.09 
 
SNRPD1  Small nuclear ribonucleoprotein Sm D1  -24.11 
 
RPS9  40S ribosomal protein S9  -24.13 
 
NAV1 Isoform 2 of Neuron navigator 1  -24.15 
 
CAD  CAD protein  -24.17 
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MRTO4  mRNA turnover protein 4 homolog  -24.18 
 
MAP1S  MAP1S light chain  -24.19 
 
IGF2BP3  Insulin-like growth factor 2 mRNA-binding protein 3  -24.30 
 
SEC61B  Protein transport protein Sec61 subunit beta  -24.40 
 
HP1BP3  Heterochromatin protein 1-binding protein 3  -24.45 
 
USP47  Ubiquitin carboxyl-terminal hydrolase  -24.56 
 
RAP1B Isoform 3 of Ras-related protein Rap-1b  -24.69 
 
PPIB  peptidyl-prolyl cis-trans isomerase B  -24.71 
 
SSR1  Translocon-associated protein subunit alpha  -25.38 
 
PITPNB  Phphatidylinitol transfer protein beta isoform  -25.40 
 
KCTD12  BTB/POZ domain-containing protein KCTD12  -25.71 
 
199 
 
Supplementary Table S4: Total proteins significantly up/ downregulated in primary meningioma compared to HMC 
Gene symbol Protein name  
Log2 
FC 
 
RBGP1 Rab GTPase-activating protein 1  26.52 
 
KIF14 Kinesin-like protein KIF14  26.28 
 
MAP1A Microtubule-associated protein 1A  25.24 
 
HSPB6 Heat shock protein beta-6  24.58 
 
COBA1 Isoform C of Collagen alpha-1(XI) chain  24.50 
 
FRIH Ferritin heavy chain  24.19 
 
ADIRF Adipogenesis regulatory factor  23.73 
 
IBP7 Isoform 2 of Insulin-like growth factor-binding protein 7  23.50 
 
ALDR Aldose reductase  23.46 
 
RS30 40S ribosomal protein S30  23.20 
 
ACBP Acyl-CoA-binding protein 23.09 
 
FRIL Ferritin light chain  23.08 
 
GDIR2 Rho GDP-dissociation inhibitor 2  22.82 
 
TYB4 Thymosin beta-4  22.81 
 
MGST1 Microsomal glutathione S-transferase 1  22.76 
 
ICAM1 Intercellular adhesion molecule 1  22.42 
 
TENX Isoform 3 of Tenascin-X 22.34 
 
F5GY99 Polypeptide N-acetylgalactosaminyltransferase 1 soluble form  22.33 
 
CBPA4 Isoform 2 of Carboxypeptidase A4  22.23 
 
GPX1 Glutathione peroxidase 1  22.21 
 
PTN12 Tyrosine-protein phosphatase non-receptor type 12  22.07 
 
AP2S1 AP-2 complex subunit sigma  22.01 
 
GPX4 Isoform Cytoplasmic of Phospholipid hydroperoxide glutathione peroxidase 21.98 
 
S10AD Protein S100-A13  21.93 
 
CPPED Calcineurin-like phosphoesterase domain-containing protein 1  21.91 
 
B4DUX5 Methionine aminopeptidase 2  21.90 
 
ACACA Isoform 4 of Acetyl-CoA carboxylase 1  21.86 
 
THIC Acetyl-CoA acetyltransferase, cytosolic 21.82 
 
B4DZ70 Malic enzyme  21.79 
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SUMO2 Isoform 2 of Small ubiquitin-related modifier 2 21.78 
 
ATOX1 Copper transport protein ATOX1  21.74 
 
C9JWU9 Mesoderm-specific transcript homolog protein (Fragment)  21.74 
 
GT251 Procollagen galactosyltransferase 1  21.57 
 
TP53B Tumor suppressor p53-binding protein 1  21.51 
 
AMRP Alpha-2-macroglobulin receptor-associated protein  21.50 
 
FBN1 Fibrillin-1  21.49 
 
HMCS1 Hydroxymethylglutaryl-CoA synthase, cytoplasmic  21.47 
 
J3QRG6 Cyclin-dependent kinase inhibitor 2A, isoforms 1/2/3  21.45 
 
ACSL4 Isoform Short of Long-chain-fatty-acid--CoA ligase 4  21.45 
 
S4R371 Fatty acid-binding protein, heart (Fragment)  21.40 
 
BDH2 3-hydroxybutyrate dehydrogenase type 2  21.38 
 
WDR44 Isoform 4 of WD repeat-containing protein 44  21.37 
 
SKIV2 Helicase SKI2W  21.25 
 
YKT6 Synaptobrevin homolog YKT6  21.14 
 
FADS2 Fatty acid desaturase 2  21.12 
 
E41L1 Isoform 2 of Band 4.1-like protein 1  21.10 
 
UBL5 Ubiquitin-like protein 5  21.06 
 
EIF3H Eukaryotic translation initiation factor 3 subunit H  21.04 
 
MAOM NAD-dependent malic enzyme, mitochondrial  21.03 
 
CLCB Isoform Non-brain of Clathrin light chain B  21.00 
 
PRC2C Isoform 6 of Protein PRRC2C  20.98 
 
TRI25 E3 ubiquitin/ISG15 ligase TRIM25  20.98 
 
PGM2 Phosphoglucomutase-2  20.97 
 
RN213 E3 ubiquitin-protein ligase RNF213  20.88 
 
J3KNL6 Protein transport protein Sec16A  20.81 
 
UBQL2 Ubiquilin-2  20.80 
 
PDCD5 Programmed cell death protein 5  20.79 
 
MTND 1,2-dihydroxy-3-keto-5-methylthiopentene dioxygenase  20.77 
 
DPM3 Dolichol-phosphate mannosyltransferase subunit 3  20.77 
 
PRP19 Pre-mRNA-processing factor 19  20.70 
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NMT1 Glycylpeptide N-tetradecanoyltransferase 1  20.68 
 
E41L3 Isoform B of Band 4.1-like protein 3  20.59 
 
H0YBL1 Inositol monophosphatase 1 (Fragment)  20.34 
 
LAMA5 Laminin subunit alpha-5  20.24 
 
HMGA1 Isoform HMG-Y of High mobility group protein HMG-I/HMG-Y  20.23 
 
CPIN1 Isoform 3 of Anamorsin  20.23 
 
MVD1 Diphosphomevalonate decarboxylase  20.11 
 
DBLOH Isoform 2 of Diablo homolog, mitochondrial  20.11 
 
CMBL Carboxymethylenebutenolidase homolog  20.06 
 
LACTB Serine beta-lactamase-like protein LACTB, mitochondrial  19.95 
 
MGP Matrix Gla protein  19.92 
 
B3KQ95 Squalene synthase  19.91 
 
PLEC Isoform 3 of Plectin  19.89 
 
TLN2 Talin-2  19.86 
 
SYUG Gamma-synuclein  19.81 
 
NEUA N-acylneuraminate cytidylyltransferase  19.79 
 
Q5H9A7 Metalloproteinase inhibitor 1  19.73 
 
MCCB Isoform 2 of Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial  19.65 
 
CHIP E3 ubiquitin-protein ligase CHIP  19.61 
 
HDGR2 Isoform 2 of Hepatoma-derived growth factor-related protein 2  19.60 
 
A8MUB1 Tubulin alpha-4A chain  19.55 
 
R4GN55 YTH domain-containing family protein 3  19.46 
 
LYPA1 Isoform 2 of Acyl-protein thioesterase 1  19.43 
 
E9PF19 Transducin beta-like protein 2  19.43 
 
E9PEM5 Lipopolysaccharide-responsive and beige-like anchor protein  19.38 
 
DHCR7 7-dehydrocholesterol reductase  19.37 
 
CCDC6 Coiled-coil domain-containing protein 6  19.29 
 
AAPK1 5-AMP-activated protein kinase catalytic subunit alpha-1  19.21 
 
BIG1 Brefeldin A-inhibited guanine nucleotide-exchange protein 1  19.21 
 
H0YDU8 Serine/threonine-protein phosphatase (Fragment)  19.19 
 
ERG7 Isoform 2 of Lanosterol synthase  19.13 
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TCOF Isoform 8 of Treacle protein  19.09 
 
ELP1 Elongator complex protein 1  19.06 
 
COMD9 Isoform 2 of COMM domain-containing protein 9  19.02 
 
ACAD9 Acyl-CoA dehydrogenase family member 9, mitochondrial  19.00 
 
SC24B Isoform 2 of Protein transport protein Sec24B  19.00 
 
K7EIJ0 WW domain-binding protein 2 (Fragment)  18.85 
 
NXN Nucleoredoxin  18.79 
 
AKAP9 Isoform 3 of A-kinase anchor protein 9  18.74 
 
NHLC2 NHL repeat-containing protein 2  18.74 
 
HYPK Huntingtin-interacting protein K  18.59 
 
BID BH3-interacting domain death agonist  18.58 
 
J3KP84 Ethylmalonyl-CoA decarboxylase  18.58 
 
PLCG1 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1  18.55 
 
EBP 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase  18.52 
 
LACB2 Beta-lactamase-like protein 2  18.43 
 
DRG1 Developmentally-regulated GTP-binding protein 1  18.43 
 
B4DME2 Protein phosphatase 1 regulatory subunit 12C  18.32 
 
SVIL Isoform 2 of Supervillin  18.19 
 
WIBG Isoform 2 of Partner of Y14 and mago  17.96 
 
SGPL1 Sphingosine-1-phosphate lyase 1  17.90 
 
IMA5 Importin subunit alpha-5  17.74 
 
RPB1 DNA-directed RNA polymerase II subunit RPB1  17.64 
 
TES Isoform 2 of Testin  17.59 
 
MP2K3 Isoform 1 of Dual specificity mitogen-activated protein kinase kinase 3  17.45 
 
DNJC7 Isoform 2 of DnaJ homolog subfamily C member 7  17.31 
 
YLPM1 Isoform 3 of YLP motif-containing protein 1  17.13 
 
GCC2 GRIP and coiled-coil domain-containing protein 2  17.01 
 
E9PC52 Histone-binding protein RBBP7  17.00 
 
J3QSY4 H/ACA ribonucleoprotein complex subunit 2  16.96 
 
UBXN4 UBX domain-containing protein 4 16.82 
 
ZN428 Zinc finger protein 428  16.74 
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B3KR64 Calcium-binding mitochondrial carrier protein Aralar1  16.65 
 
MYO5A Isoform 2 of Unconventional myosin-Va  16.64 
 
TGON2 Isoform 4 of Trans-Golgi network integral membrane protein 2  16.49 
 
TB10B TBC1 domain family member 10B  16.37 
 
PUR8 Adenylosuccinate lyase  16.00 
 
ZCCHL Zinc finger CCCH-type antiviral protein 1-like  15.35 
 
HTRA1 Serine protease HTRA1  15.07 
 
FHL1 Isoform 1 of Four and a half LIM domains protein 1  5.11 
 
E9PIR7 Thioredoxin reductase 1, cytoplasmic  4.37 
 
ENAH Isoform 3 of Protein enabled homolog  4.11 
 
E5RHG8 Transcription elongation factor B polypeptide 1 (Fragment)  3.63 
 
SRBS2 Isoform 9 of Sorbin and SH3 domain-containing protein 2  3.55 
 
TGM2 Protein-glutamine gamma-glutamyltransferase 2  3.04 
 
ACLY ATP-citrate synthase  3.00 
 
SH3L1 SH3 domain-binding glutamic acid-rich-like protein  2.98 
 
C9J0K6 Sorcin  2.97 
 
SIAS Sialic acid synthase  2.92 
 
FAS Fatty acid synthase  2.89 
 
NTF2 Nuclear transport factor 2  2.74 
 
SAHH Adenosylhomocysteinase  2.73 
 
LASP1 LIM and SH3 domain protein 1  2.63 
 
SYVC Valine--tRNA ligase  2.56 
 
PDLI5 PDZ and LIM domain protein 5  2.51 
 
SUMF1 Isoform 2 of Sulfatase-modifying factor 1  2.49 
 
FKB1A Peptidyl-prolyl cis-trans isomerase FKBP1A  2.44 
 
AKA12 A-kinase anchor protein 12  2.30 
 
FKB10 Peptidyl-prolyl cis-trans isomerase FKBP10  2.27 
 
COTL1 Coactosin-like protein  2.20 
 
COPD Coatomer subunit delta  2.15 
 
UGPA UTP--glucose-1-phosphate uridylyltransferase  2.10 
 
TPD54 Tumor protein D54  2.10 
 
204 
 
OSBP1 Oxysterol-binding protein 1  2.09 
 
THIO Thioredoxin  2.08 
 
VAT1 Synaptic vesicle membrane protein VAT-1 homolog  2.01 
 
TCTP Translationally-controlled tumor protein  2.00 
 
IDI1 Isopentenyl-diphosphate Delta-isomerase 1  1.99 
 
PEA15 Astrocytic phosphoprotein PEA-15  1.98 
 
S10AG Protein S100-A16  1.97 
 
SODC Superoxide dismutase [Cu-Zn]  1.91 
 
TXNL1 Thioredoxin-like protein 1  1.88 
 
FINC Isoform 3 of Fibronectin  1.77 
 
S10A6 Protein S100-A6  1.72 
 
TKT Transketolase  1.72 
 
PCYOX Prenylcysteine oxidase 1  1.67 
 
RS3 40S ribosomal protein S3  1.65 
 
ETHE1 Persulfide dioxygenase ETHE1, mitochondrial 1.64 
 
KCC2D Isoform Delta 6 of Calcium/calmodulin-dependent protein kinase type II subunit 1.63 
 
H3BPE1 Microtubule-actin cross-linking factor 1, isoforms 1/2/3/5  1.61 
 
G6PD Glucose-6-phosphate 1-dehydrogenase  1.59 
 
EF1B Elongation factor 1-beta  1.56 
 
TFG Isoform 2 of Protein TFG  1.54 
 
F8W031 Uncharacterized protein (Fragment)  1.48 
 
STIP1 Stress-induced-phosphoprotein 1  1.44 
 
HEBP1 Heme-binding protein 1  1.42 
 
IPYR Inorganic pyrophosphatase  1.37 
 
ECHB Trifunctional enzyme subunit beta, mitochondrial  1.36 
 
EFTU Elongation factor Tu, mitochondrial  1.36 
 
ANXA3 Annexin A3  1.35 
 
PRDX6 Peroxiredoxin-6  1.33 
 
FLNC Filamin-C  1.32 
 
PYGB Glycogen phosphorylase, brain form  1.31 
 
6PGD 6-phosphogluconate dehydrogenase, decarboxylating  1.29 
 
205 
 
SYNC Asparagine--tRNA ligase, cytoplasmic  1.28 
 
B4DVE7 Annexin  1.26 
 
AP3B1 AP-3 complex subunit beta-1  1.25 
 
PPME1 Protein phosphatase methylesterase 1  1.24 
 
TX1B3 Tax1-binding protein 3  1.22 
 
MAP1B Microtubule-associated protein 1B  1.21 
 
UBP14 Isoform 2 of Ubiquitin carboxyl-terminal hydrolase 14  1.20 
 
E9PKL9 GDP-L-fucose synthase (Fragment)  1.16 
 
DREB Drebrin  1.13 
 
MANF Mesencephalic astrocyte-derived neurotrophic factor  1.11 
 
DHE3 Glutamate dehydrogenase 1, mitochondrial  1.10 
 
ERP29 Endoplasmic reticulum resident protein 29  1.08 
 
ECHA Trifunctional enzyme subunit alpha, mitochondrial  1.03 
 
PDIA1 Protein disulfide-isomerase  1.00 
 
NEK7 Serine/threonine-protein kinase Nek7  -1.01 
 
PTPA Isoform 1 of Serine/threonine-protein phosphatase 2A activator  -1.06 
 
RS13 40S ribosomal protein S13  -1.06 
 
RAB5C Ras-related protein Rab-5C  -1.09 
 
NAA15 N-alpha-acetyltransferase 15, NatA auxiliary subunit  -1.09 
 
I3L0H8 ATP-dependent RNA helicase DDX19A  -1.10 
 
BIEA Biliverdin reductase A  -1.12 
 
AIMP2 Aminoacyl tRNA synthase complex-interacting multifunctional protein 2  -1.12 
 
PP2AA Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform  -1.14 
 
RS26 40S ribosomal protein S26  -1.15 
 
G6PI Glucose-6-phosphate isomerase  -1.17 
 
SCRN1 Secernin-1  -1.17 
 
RS17L 40S ribosomal protein S17-like  -1.19 
 
CPNS1 Calpain small subunit 1  -1.21 
 
DDX6 Probable ATP-dependent RNA helicase DDX6  -1.22 
 
PSA3 Isoform 2 of Proteasome subunit alpha type-3  -1.22 
 
EXOC4 Exocyst complex component 4  -1.22 
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RS16 40S ribosomal protein S16  -1.22 
 
PP1A Serine/threonine-protein phosphatase PP1-alpha catalytic subunit  -1.22 
 
DDX3X Isoform 2 of ATP-dependent RNA helicase DDX3X  -1.22 
 
TPPC3 Isoform 2 of Trafficking protein particle complex subunit 3  -1.23 
 
ODO2 Dihydrolipoyllysine-residue succinyltransferase  -1.24 
 
B4DJA5 Ras-related protein Rab-5A  -1.24 
 
ENOA Alpha-enolase  -1.24 
 
UGDH UDP-glucose 6-dehydrogenase  -1.25 
 
RS18 40S ribosomal protein S18  -1.28 
 
RS4X 40S ribosomal protein S4, X isoform  -1.35 
 
TPIS Isoform 2 of Triosephosphate isomerase -1.35 
 
SF3B1 Splicing factor 3B subunit 1  -1.39 
 
HMOX2 Heme oxygenase 2  -1.39 
 
ROA1 Isoform 2 of Heterogeneous nuclear ribonucleoprotein A1  -1.41 
 
PURA Transcriptional activator protein Pur-alpha  -1.41 
 
JIP4 Isoform 4 of C-Jun-amino-terminal kinase-interacting protein 4  -1.42 
 
ODO1 2-oxoglutarate dehydrogenase, mitochondrial  -1.43 
 
SRP19 Signal recognition particle 19 kDa protein  -1.44 
 
SURF4 Isoform 2 of Surfeit locus protein 4  -1.45 
 
SRP14 Signal recognition particle 14 kDa protein  -1.47 
 
UBA1 Ubiquitin-like modifier-activating enzyme 1  -1.48 
 
RS19 40S ribosomal protein S19  -1.49 
 
DPP9 Dipeptidyl peptidase 9  -1.50 
 
TNPO1 Isoform 2 of Transportin-1 -1.50 
 
DDX1 ATP-dependent RNA helicase DDX1  -1.50 
 
VAPA Vesicle-associated membrane protein-associated protein A  -1.51 
 
LIPB1 Isoform 2 of Liprin-beta-1  -1.52 
 
HS90A Heat shock protein HSP 90-alpha  -1.55 
 
ACOT9 Isoform 3 of Acyl-coenzyme A thioesterase 9, mitochondrial  -1.55 
 
XPO2 Exportin-2  -1.56 
 
TM109 Transmembrane protein 109  -1.60 
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SAR1A GTP-binding protein SAR1a  -1.60 
 
EDF1 Isoform 2 of Endothelial differentiation-related factor 1  -1.60 
 
HS105 Isoform Beta of Heat shock protein 105 kDa  -1.61 
 
EIF3E Eukaryotic translation initiation factor 3 subunit E  -1.61 
 
IMDH2 Inosine-5-monophosphate dehydrogenase 2  -1.61 
 
PGAM1 Phosphoglycerate mutase 1  -1.61 
 
RAB7A Ras-related protein Rab-7a  -1.62 
 
CYBP Calcyclin-binding protein  -1.63 
 
ETUD1 Isoform 2 of Elongation factor Tu GTP-binding domain-containing protein 1 -1.65 
 
UTRO Utrophin  -1.71 
 
PTBP1 Polypyrimidine tract-binding protein 1  -1.72 
 
TWF1 Twinfilin-1  -1.77 
 
IPO5 Importin-5  -1.83 
 
RS20 40S ribosomal protein S20  -1.88 
 
GBB1 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1  -1.88 
 
RHOG Rho-related GTP-binding protein RhoG  -1.89 
 
HNRH1 Heterogeneous nuclear ribonucleoprotein H  -1.90 
 
K6PL 6-phosphofructokinase, liver type  -1.93 
 
LDHA L-lactate dehydrogenase A chain  -1.93 
 
RS25 40S ribosomal protein S25  -1.96 
 
CATB Cathepsin B  -1.97 
 
HPRT Hypoxanthine-guanine phosphoribosyltransferase  -2.00 
 
AN32B Isoform 2 of Acidic leucine-rich nuclear phosphoprotein 32 family member B  -2.00 
 
SP16H FACT complex subunit SPT16  -2.08 
 
PRS6B 26S protease regulatory subunit 6B  -2.10 
 
XPO1 Exportin-1  -2.15 
 
RADI Radixin  -2.20 
 
STAT1 Signal transducer and activator of transcription 1-alpha/beta  -2.21 
 
M0R0F0 40S ribosomal protein S5 (Fragment)  -2.22 
 
RAGP1 Ran GTPase-activating protein 1  -2.23 
 
A8MXP9 Matrin-3  -2.25 
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UN45A Isoform 2 of Protein unc-45 homolog A  -2.26 
 
THOP1 Thimet oligopeptidase  -2.31 
 
AFAP1 Actin filament-associated protein 1  -2.32 
 
IPO7 Importin-7  -2.35 
 
VAMP3 Vesicle-associated membrane protein 3  -2.44 
 
ROA0 Heterogeneous nuclear ribonucleoprotein A0  -2.47 
 
SF3A1 Splicing factor 3A subunit 1  -2.48 
 
EIF3F Eukaryotic translation initiation factor 3 subunit F  -2.49 
 
LARP1 La-related protein 1  -2.51 
 
UBE4A Ubiquitin conjugation factor E4 A  -2.52 
 
MBB1A Myb-binding protein 1A  -2.59 
 
H2B1L Histone H2B type 1-L  -2.60 
 
DNM1L Isoform 4 of Dynamin-1-like protein  -2.73 
 
CTND1 Isoform 1A of Catenin delta-1  -2.73 
 
CPSF5 Cleavage and polyadenylation specificity factor subunit 5  -2.74 
 
EMD Emerin  -2.77 
 
CCAR2 Cell cycle and apoptosis regulator protein 2  -2.87 
 
E2AK2 Interferon-induced, double-stranded RNA-activated protein kinase  -3.00 
 
EZRI Ezrin  -3.49 
 
CTNA1 Catenin alpha-1  -3.50 
 
TIF1B Transcription intermediary factor 1-beta  -3.79 
 
PALLD Isoform 3 of Palladin  -3.93 
 
CKAP5 Cytoskeleton-associated protein 5  -4.09 
 
MGN Protein mago nashi homolog  -4.46 
 
EGFR Epidermal growth factor receptor  -4.81 
 
VDAC2 Voltage-dependent anion-selective channel protein 2  -4.92 
 
K1C18 Keratin, type I cytoskeletal 18  -6.34 
 
VIME Vimentin  -6.96 
 
VDAC1 Voltage-dependent anion-selective channel protein 1  -7.06 
 
E5RGV5 Nucleolysin TIA-1 isoform p40  -16.48 
 
ARFP2 Isoform 3 of Arfaptin-2  -16.61 
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D6RF48 Syntaxin-18  -17.00 
 
EDC3 Enhancer of mRNA-decapping protein 3  -17.10 
 
RU2A U2 small nuclear ribonucleoprotein A  -17.21 
 
MGLL Monoglyceride lipase  -17.29 
 
B4DPW1 Nuclear pore complex protein Nup85  -17.31 
 
TIAR Nucleolysin TIAR  -17.33 
 
ENDD1 Endonuclease domain-containing 1 protein  -17.40 
 
ASPP2 Isoform 2 of Apoptosis-stimulating of p53 protein 2 -17.43 
 
H3BVG8 UPF0505 protein C16orf62 (Fragment)  -17.49 
 
B4DNI9 Vacuolar protein sorting-associated protein 52 homolog  -17.55 
 
OSGEP Probable tRNA N6-adenosine threonylcarbamoyltransferase -17.57 
 
SYCM Probable cysteine--tRNA ligase, mitochondrial  -17.59 
 
J3KS22 L-xylulose reductase (Fragment)  -17.63 
 
PEX5 Isoform 2 of Peroxisomal targeting signal 1 receptor  -17.64 
 
E9PGE5 TBC1 domain family member 23  -17.65 
 
DPOA2 DNA polymerase alpha subunit B  -17.68 
 
G8JLC6 Melanoma inhibitory activity protein 3  -17.83 
 
SSRG Translocon-associated protein subunit gamma  -17.98 
 
AHR Aryl hydrocarbon receptor  -17.98 
 
B7WP74 Pre-mRNA-splicing factor CWC22 homolog (Fragment)  -18.07 
 
ENOG Gamma-enolase  -18.15 
 
D6RDI2 Luc7-like protein 3 (Fragment)  -18.15 
 
B7ZLW7 MTR protein  -18.16 
 
Q5VW33 BRO1 domain-containing protein BROX (Fragment)  -18.16 
 
HXK2 Hexokinase-2  -18.18 
 
NU160 Nuclear pore complex protein Nup160  -18.21 
 
FA65A Isoform 2 of Protein FAM65A  -18.29 
 
CIP2A Isoform 2 of Protein CIP2A  -18.31 
 
V9GYH7 Proteasome assembly chaperone 2  -18.31 
 
PTN14 Tyrosine-protein phosphatase non-receptor type 14  -18.31 
 
CDK13 Isoform 2 of Cyclin-dependent kinase 13  -18.37 
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RNBP6 Ran-binding protein 6 -18.38 
 
E9PJ81 UBX domain-containing protein 1 (Fragment)  -18.44 
 
GLRX5 Glutaredoxin-related protein 5, mitochondrial  -18.45 
 
ASCC3 Activating signal cointegrator 1 complex subunit 3  -18.49 
 
TMED5 Transmembrane emp24 domain-containing protein 5  -18.50 
 
SPTC2 Serine palmitoyltransferase 2  -18.52 
 
PSME4 Proteasome activator complex subunit 4  -18.54 
 
TGFI1 Transforming growth factor beta-1-induced transcript 1 protein -18.56 
 
B4E2J1 ATPase family AAA domain-containing protein 1  -18.57 
 
F8W9D1 5-AMP-activated protein kinase subunit gamma-1  -18.57 
 
PGP Phosphoglycolate phosphatase  -18.65 
 
INO1 Isoform 3 of Inositol-3-phosphate synthase 1  -18.67 
 
RT28 28S ribosomal protein S28, mitochondrial  -18.70 
 
ARHL2 Poly(ADP-ribose) glycohydrolase ARH3  -18.70 
 
B7WPF4 Ubiquitin carboxyl-terminal hydrolase  -18.71 
 
U3KQJ1 Polymerase delta-interacting protein 2  -18.71 
 
F5H1E5 Conserved oligomeric Golgi complex subunit 2  -18.78 
 
MTX2 Metaxin-2  -18.79 
 
UBE3C Ubiquitin-protein ligase E3C  -18.80 
 
KIF3A Kinesin-like protein KIF3A  -18.83 
 
FADD FAS-associated death domain protein  -18.84 
 
NUP98 Isoform 6 of Nuclear pore complex protein Nup98-Nup96  -18.85 
 
RT09 28S ribosomal protein S9, mitochondrial  -18.86 
 
H7BYD0 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5 (Fragment)  -18.89 
 
IF4A3 Eukaryotic initiation factor 4A-III  -18.89 
 
ARG28 Isoform 4 of Rho guanine nucleotide exchange factor 28  -18.90 
 
KANK2 Isoform 3 of KN motif and ankyrin repeat domain-containing protein 2  -18.92 
 
CBS Cystathionine beta-synthase  -18.93 
 
ZN622 Zinc finger protein 622  -18.97 
 
K0020 Pumilio domain-containing protein KIAA0020  -18.99 
 
ARBK2 Beta-adrenergic receptor kinase 2  -19.00 
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VPS53 Isoform 4 of Vacuolar protein sorting-associated protein 53 homolog  -19.01 
 
RAB9A Ras-related protein Rab-9A  -19.04 
 
E9PQX9 Dr1-associated corepressor  -19.05 
 
SHLB1 Endophilin-B1  -19.10 
 
C9JA93 TBC1 domain family member 15 (Fragment)  -19.12 
 
B4DKA8 Ubiquitin carboxyl-terminal hydrolase  -19.13 
 
LANC1 LanC-like protein 1  -19.14 
 
RETST Isoform 2 of All-trans-retinol 13,14-reductase  -19.15 
 
SMAD3 Isoform 3 of Mothers against decapentaplegic homolog 3  -19.16 
 
E9PHM2 Probable leucine--tRNA ligase, mitochondrial  -19.16 
 
LSM3 U6 snRNA-associated Sm-like protein LSm3  -19.16 
 
H0YJL5 Vesicle transport through interaction with t-SNAREs homolog 1B (Fragment)  -19.19 
 
M0QZ24 Uncharacterized protein (Fragment)  -19.21 
 
NR2CA Nuclear receptor 2C2-associated protein  -19.21 
 
F8VSC5 SCY1-like protein 2 (Fragment)  -19.21 
 
NADAP Kanadaptin  -19.22 
 
GIT2 Isoform 11 of ARF GTPase-activating protein GIT2  -19.24 
 
DNJC2 Isoform 2 of DnaJ homolog subfamily C member 2  -19.24 
 
SRR Serine racemase  -19.26 
 
MK67I MKI67 FHA domain-interacting nucleolar phosphoprotein  -19.27 
 
BYST Bystin  -19.27 
 
NDUS7 NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrial  -19.27 
 
OGFD1 2-oxoglutarate and iron-dependent oxygenase domain-containing protein 1  -19.27 
 
GSDMD Gasdermin-D  -19.29 
 
C9JIK8 Cysteine protease ATG4B (Fragment)  -19.33 
 
PCH2 Pachytene checkpoint protein 2 homolog  -19.34 
 
RIFK Riboflavin kinase  -19.35 
 
H3BMM5 Uncharacterized protein  -19.37 
 
UK114 Ribonuclease UK114  -19.38 
 
VTI1A Isoform 1 of Vesicle transport through interaction with t-SNAREs homolog 1A  -19.38 
 
F8W1Z6 Protein MON2 homolog  -19.38 
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OGT1 UDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase -19.38 
 
TCEA1 Isoform 2 of Transcription elongation factor A protein 1  -19.41 
 
SMUF2 E3 ubiquitin-protein ligase SMURF2  -19.41 
 
ASPG N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase  -19.42 
 
SFR15 Isoform 3 of Splicing factor, arginine/serine-rich 15  -19.44 
 
HIBCH 3-hydroxyisobutyryl-CoA hydrolase, mitochondrial  -19.44 
 
EI2BB Translation initiation factor eIF-2B subunit beta  -19.45 
 
RBM28 Isoform 2 of RNA-binding protein 28  -19.45 
 
HAP28 28 kDa heat- and acid-stable phosphoprotein  -19.45 
 
ARP10 Actin-related protein 10  -19.46 
 
PPID Peptidyl-prolyl cis-trans isomerase D  -19.46 
 
SAP18 Histone deacetylase complex subunit SAP18 (Fragment)  -19.47 
 
VAC14 Protein VAC14 homolog  -19.47 
 
ELOV1 Isoform 2 of Elongation of very long chain fatty acids protein 1  -19.48 
 
RT29 Isoform 2 of 28S ribosomal protein S29, mitochondrial  -19.49 
 
RFA2 Replication protein A 32 kDa subunit  -19.50 
 
B4DFQ4 COMM domain-containing protein 1  -19.53 
 
E7EQI7 WASH complex subunit strumpellin  -19.54 
 
M0QXN5 Nuclear pore glycoprotein p62  -19.54 
 
DCTP1 dCTP pyrophosphatase 1  -19.56 
 
ILVBL Acetolactate synthase-like protein  -19.57 
 
G3V2T4 Legumain (Fragment)  -19.58 
 
CLAP1 Isoform 2 of CLIP-associating protein 1  -19.58 
 
F5H5C2 Nuclear pore complex protein Nup133  -19.58 
 
G5E9W7 28S ribosomal protein S22, mitochondrial  -19.59 
 
B4DTE8 Phospholipid scramblase 1  -19.60 
 
F5H2H5 Ankyrin repeat and LEM domain-containing protein 2  -19.60 
 
FKBP8 Peptidyl-prolyl cis-trans isomerase FKBP8  -19.61 
 
E7ES96 Presenilin-1  -19.61 
 
FNTA Isoform 2 of Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha  -19.61 
 
SREK1 Isoform 2 of Splicing regulatory glutamine/lysine-rich protein 1  -19.61 
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COMD4 COMM domain-containing protein 4  -19.62 
 
H3BMU1 IST1 homolog (Fragment)  -19.62 
 
HMOX1 Heme oxygenase 1  -19.64 
 
E7EQZ7 Protein Red (Fragment)  -19.64 
 
ABD12 Monoacylglycerol lipase ABHD12  -19.65 
 
ASCC2 Activating signal cointegrator 1 complex subunit 2  -19.65 
 
TAOK1 Isoform 3 of Serine/threonine-protein kinase TAO1  -19.67 
 
DAG1 Dystroglycan  -19.68 
 
ARMX3 Armadillo repeat-containing X-linked protein 3  -19.71 
 
EVA1B Protein eva-1 homolog B  -19.71 
 
GOGA7 Isoform 2 of Golgin subfamily A member 7  -19.72 
 
CSN7B COP9 signalosome complex subunit 7b  -19.72 
 
Q5TDF0 Cancer-related nucleoside-triphosphatase  -19.72 
 
NUDC3 NudC domain-containing protein 3  -19.75 
 
NU214 Isoform 2 of Nuclear pore complex protein Nup214  -19.75 
 
F5H8F7 Set1/Ash2 histone methyltransferase complex subunit ASH2  -19.77 
 
TEX10 Isoform 2 of Testis-expressed sequence 10 protein  -19.77 
 
C9JKF1 Sterile alpha motif domain-containing protein 9 (Fragment)  -19.79 
 
NCBP2 Nuclear cap-binding protein subunit 2  -19.79 
 
EXOC5 Exocyst complex component 5  -19.80 
 
INT1 Integrator complex subunit 1  -19.80 
 
CPT2 Carnitine O-palmitoyltransferase 2, mitochondrial  -19.80 
 
ADPPT L-aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase -19.81 
 
TBG2 Tubulin gamma-2 chain  -19.81 
 
B4DDV1 Interferon-induced protein with tetratricopeptide repeats 5  -19.81 
 
DYL2 Dynein light chain 2, cytoplasmic  -19.82 
 
LAS1L Isoform 2 of Ribosomal biogenesis protein LAS1L  -19.82 
 
NOP58 Nucleolar protein 58  -19.82 
 
RABL6 Rab-like protein 6  -19.83 
 
MACD1 O-acetyl-ADP-ribose deacetylase MACROD1  -19.84 
 
NUD16 U8 snoRNA-decapping enzyme  -19.84 
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IN35 Interferon-induced 35 kDa protein  -19.85 
 
F5H019 GPI transamidase component PIG-S  -19.85 
 
UBE4B Isoform 2 of Ubiquitin conjugation factor E4 B  -19.86 
 
NDUS2 Isoform 2 of NADH dehydrogenase [ubiquinone] iron-sulfur protein 2 -19.86 
 
RM01 39S ribosomal protein L1, mitochondrial  -19.87 
 
RIOK2 Isoform 2 of Serine/threonine-protein kinase RIO2  -19.89 
 
UB2L6 Ubiquitin/ISG15-conjugating enzyme E2 L6  -19.90 
 
TOP2A DNA topoisomerase 2-alpha  -19.90 
 
IKKB Inhibitor of nuclear factor kappa-B kinase subunit beta  -19.92 
 
A6NJ11 Ubiquitin fusion degradation protein 1 homolog  -19.94 
 
B4DWW1 ADP-ribosylation factor-like protein 1  -19.94 
 
QSOX2 Sulfhydryl oxidase 2  -19.94 
 
SH24A Isoform 2 of SH2 domain-containing protein 4A  -19.95 
 
NU205 Nuclear pore complex protein Nup205  -19.95 
 
CK5P3 CDK5 regulatory subunit-associated protein 3  -19.97 
 
F6T1Q0 2,5-phosphodiesterase 12  -19.97 
 
EXOC8 Exocyst complex component 8  -19.98 
 
CTCF Transcriptional repressor CTCF  -19.98 
 
WAPL Wings apart-like protein homolog  -20.00 
 
G5E9Z2 Cisplatin resistance related protein CRR9p, isoform CRA -20.02 
 
NT5C Isoform 2 of 5(3)-deoxyribonucleotidase, cytosolic type  -20.02 
 
PNPT1 Polyribonucleotide nucleotidyltransferase 1, mitochondrial  -20.03 
 
NEDD4 Isoform 4 of E3 ubiquitin-protein ligase NEDD4  -20.03 
 
OSTF1 Osteoclast-stimulating factor 1  -20.07 
 
CTL2 Isoform 3 of Choline transporter-like protein 2  -20.08 
 
F5GZY7 Gamma-aminobutyric acid receptor-associated protein-like 1 (Fragment)  -20.10 
 
B3KQZ9 Tumor necrosis factor receptor type 1-associated DEATH domain protein  -20.10 
 
RAB31 Ras-related protein Rab-31  -20.11 
 
VAMP4 Isoform 2 of Vesicle-associated membrane protein 4  -20.12 
 
B7ZKK9 PPP2R5E protein  -20.13 
 
TOR1B Torsin-1B  -20.14 
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BPNT1 3(2),5-bisphosphate nucleotidase 1  -20.16 
 
EXOC7 Isoform 2 of Exocyst complex component 7  -20.16 
 
ADT3 ADP/ATP translocase 3  -20.16 
 
F5H669 Cleavage and polyadenylation-specificity factor subunit 7 (Fragment)  -20.16 
 
GAK Cyclin-G-associated kinase -20.17 
 
SPAG5 Sperm-associated antigen 5  -20.17 
 
B4DKR0 Syntaxin 5A, isoform CRA -20.18 
 
HBS1L Isoform 3 of HBS1-like protein  -20.18 
 
F5H604 CLIP-associating protein 2  -20.20 
 
H0YMB3 GMP reductase 2  -20.20 
 
SPAT5 Isoform 2 of Spermatogenesis-associated protein 5  -20.22 
 
KPRA Phosphoribosyl pyrophosphate synthase-associated protein 1 -20.23 
 
B3KWW1 Probable ATP-dependent RNA helicase DDX58  -20.23 
 
IPO11 Importin-11  -20.24 
 
F8WAK8 Cohesin subunit SA-2  -20.25 
 
TOR1A Torsin-1A  -20.26 
 
RAP2B Ras-related protein Rap-2b  -20.30 
 
CDK5 Cyclin-dependent kinase 5  -20.30 
 
CN37 Isoform CNPI of 2,3-cyclic-nucleotide 3-phosphodiesterase  -20.31 
 
RM14 39S ribosomal protein L14, mitochondrial  -20.31 
 
PUS7 Pseudouridylate synthase 7 homolog  -20.33 
 
PMVK Phosphomevalonate kinase -20.34 
 
HEAT2 HEAT repeat-containing protein 2  -20.34 
 
RAB23 Ras-related protein Rab-23  -20.37 
 
PPIH Peptidyl-prolyl cis-trans isomerase H  -20.37 
 
E9PS97 Alpha-parvin (Fragment)  -20.39 
 
BICD2 Protein bicaudal D homolog 2  -20.39 
 
E7EUT8 Splicing factor 3A subunit 3  -20.40 
 
CATC Dipeptidyl peptidase 1  -20.40 
 
ARF5 ADP-ribosylation factor 5  -20.40 
 
NFKB2 Isoform 4 of Nuclear factor NF-kappa-B p100 subunit  -20.40 
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IGHG1 Ig gamma-1 chain C region  -20.41 
 
DNJC5 DnaJ homolog subfamily C member 5  -20.41 
 
B4DDS3 Cleft lip and palate associated transmembrane protein 1, isoform CRA -20.42 
 
BAZ1B Tyrosine-protein kinase BAZ1B  -20.42 
 
SAP Prosaposin  -20.42 
 
B4E329 Phosphoribosyl pyrophosphate synthase-associated protein 2  -20.44 
 
IPO8 Importin-8  -20.45 
 
B4E2V5 Erythrocyte band 7 integral membrane protein  -20.47 
 
PLCD3 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-3  -20.49 
 
DDX50 ATP-dependent RNA helicase DDX50  -20.49 
 
GNL1 Guanine nucleotide-binding protein-like 1  -20.50 
 
KIF11 Kinesin-like protein KIF11  -20.52 
 
DP13B DCC-interacting protein 13-beta  -20.54 
 
EXOC2 Exocyst complex component 2  -20.55 
 
S4R3N1 Protein HSPE1-MOB4  -20.55 
 
COX5A Cytochrome c oxidase subunit 5A, mitochondrial  -20.55 
 
C9JBB3 Tissue factor pathway inhibitor (Fragment)  -20.55 
 
NC2B Protein Dr1  -20.56 
 
FAF2 FAS-associated factor 2  -20.56 
 
J3QR44 Cyclin-dependent kinase 11B  -20.57 
 
RB11A Ras-related protein Rab-11A  -20.58 
 
PRPS2 Ribose-phosphate pyrophosphokinase 2  -20.58 
 
TIM14 Mitochondrial import inner membrane translocase subunit TIM14  -20.58 
 
J3KSI4 Mannose-P-dolichol utilization defect 1 protein  -20.60 
 
CX7A2 Cytochrome c oxidase subunit 7A2, mitochondrial  -20.62 
 
CAB39 Calcium-binding protein 39  -20.63 
 
A16A1 Aldehyde dehydrogenase family 16 member A1  -20.64 
 
EXC6B Exocyst complex component 6B  -20.65 
 
TIM50 Mitochondrial import inner membrane translocase subunit TIM50  -20.66 
 
TFIP8 Isoform 3 of Tumor necrosis factor alpha-induced protein 8  -20.66 
 
RT34 28S ribosomal protein S34, mitochondrial  -20.67 
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NU107 Nuclear pore complex protein Nup107  -20.67 
 
GNAS1 Isoform XLas-2 of Guanine nucleotide-binding protein G(s) subunit alpha  -20.69 
 
PPGB Lysosomal protective protein  -20.71 
 
Q71TU5 Casein kinase 1, alpha 1, isoform CRA -20.71 
 
RU2B U2 small nuclear ribonucleoprotein B  -20.72 
 
E9PFH4 Transportin-3  -20.73 
 
DOCK7 Isoform 4 of Dedicator of cytokinesis protein 7  -20.73 
 
RM41 39S ribosomal protein L41, mitochondrial  -20.73 
 
PCP Lysosomal Pro-X carboxypeptidase  -20.74 
 
TXTP Tricarboxylate transport protein, mitochondrial  -20.75 
 
RIR1 Ribonucleoside-diphosphate reductase large subunit  -20.75 
 
IMA4 Importin subunit alpha-4  -20.76 
 
NDUA4 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4  -20.77 
 
S4A7 Isoform 11 of Sodium bicarbonate cotransporter 3  -20.78 
 
HIG2A HIG1 domain family member 2A, mitochondrial  -20.78 
 
TBC9B Isoform 2 of TBC1 domain family member 9B  -20.81 
 
NDUA9 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9 -20.82 
 
VLDLR Isoform Short of Very low-density lipoprotein receptor  -20.82 
 
LYPL1 Isoform 2 of Lysophospholipase-like protein 1  -20.85 
 
RRP12 Isoform 2 of RRP12-like protein  -20.85 
 
SMRC1 SWI/SNF complex subunit SMARCC1  -20.86 
 
UCRI Cytochrome b-c1 complex subunit Rieske, mitochondrial  -20.86 
 
J3KQG4 Glucosylceramidase  -20.86 
 
LAP2B Lamina-associated polypeptide 2, isoforms beta/gamma  -20.86 
 
NQO2 Ribosyldihydronicotinamide dehydrogenase [quinone]  -20.86 
 
J3KQE0 SUN domain-containing protein 2  -20.88 
 
TOM22 Mitochondrial import receptor subunit TOM22 homolog  -20.89 
 
GYS1 Isoform 2 of Glycogen [starch] synthase, muscle  -20.89 
 
CUL5 Cullin-5  -20.89 
 
PSIP1 PC4 and SFRS1-interacting protein -20.89 
 
PAPS1 Bifunctional 3-phosphoadenosine 5-phosphosulfate synthase 1  -20.89 
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F134A Protein FAM134A  -20.90 
 
PLXB2 Plexin-B2  -20.91 
 
IR3IP Immediate early response 3-interacting protein 1  -20.91 
 
CTBP1 Isoform 2 of C-terminal-binding protein 1  -20.93 
 
EXOC1 Isoform 2 of Exocyst complex component 1  -20.94 
 
OCAD2 OCIA domain-containing protein 2  -20.94 
 
PP1R7 Protein phosphatase 1 regulatory subunit 7  -20.97 
 
SRPR Isoform 2 of Signal recognition particle receptor subunit alpha  -20.98 
 
M0QX35 Paf1, RNA polymerase II associated factor, homolog (S. cerevisiae) -20.99 
 
ATP5H Isoform 2 of ATP synthase subunit d, mitochondrial  -20.99 
 
B1AJQ6 Syntaxin-12 (Fragment)  -20.99 
 
NDUA8 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 8  -21.00 
 
LMNB2 Lamin-B2  -21.00 
 
Q6IQ42 FUSIP1 protein  -21.03 
 
ODP2 Dihydrolipoyllysine-residue acetyltransferase  -21.04 
 
RBP56 Isoform Short of TATA-binding protein-associated factor 2N  -21.04 
 
KCRS Creatine kinase S-type, mitochondrial  -21.05 
 
DNJA2 DnaJ homolog subfamily A member 2  -21.07 
 
G8JLI6 Prolyl 3-hydroxylase 3  -21.09 
 
PA1B3 Platelet-activating factor acetylhydrolase IB subunit gamma  -21.11 
 
PABP2 Isoform 2 of Polyadenylate-binding protein 2  -21.12 
 
ATD3A Isoform 2 of ATPase family AAA domain-containing protein 3A  -21.13 
 
KPCA Protein kinase C alpha type  -21.15 
 
ARHG7 Isoform 1 of Rho guanine nucleotide exchange factor 7  -21.15 
 
RAB5B Ras-related protein Rab-5B  -21.15 
 
TOM34 Mitochondrial import receptor subunit TOM34  -21.18 
 
1B42 HLA class I histocompatibility antigen, B-42 alpha chain  -21.18 
 
PSB10 Proteasome subunit beta type-10  -21.20 
 
DCUP Uroporphyrinogen decarboxylase  -21.22 
 
STK10 Serine/threonine-protein kinase 10 -21.23 
 
TSR1 Pre-rRNA-processing protein TSR1 homolog  -21.24 
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SMC1A Structural maintenance of chromosomes protein 1A  -21.25 
 
TAP1 Antigen peptide transporter 1  -21.26 
 
F2Z2V0 Copine-1 (Fragment)  -21.26 
 
NDUB4 Isoform 2 of NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4 -21.26 
 
XRN2 Isoform 2 of 5-3 exoribonuclease 2  -21.27 
 
NDUAD NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13  -21.27 
 
DHRS7 Isoform 2 of Dehydrogenase/reductase SDR family member 7  -21.27 
 
SCPDL Saccharopine dehydrogenase-like oxidoreductase  -21.28 
 
E9PIE4 Mitochondrial carrier homolog 2 (Fragment)  -21.33 
 
F8WJN3 Cleavage and polyadenylation-specificity factor subunit 6  -21.35 
 
TM14C Transmembrane protein 14C  -21.35 
 
SNX24 Isoform 2 of Sorting nexin-24  -21.35 
 
UBP15 Isoform 2 of Ubiquitin carboxyl-terminal hydrolase 15  -21.38 
 
FGF1 Fibroblast growth factor 1  -21.40 
 
GTR1 Solute carrier family 2, facilitated glucose transporter member 1  -21.41 
 
SPB4 Serpin B4  -21.41 
 
EXOC3 Isoform 2 of Exocyst complex component 3 -21.41 
 
RHG18 Isoform 2 of Rho GTPase-activating protein 18  -21.42 
 
GGH Gamma-glutamyl hydrolase  -21.43 
 
A2MG Alpha-2-macroglobulin  -21.46 
 
STML2 Stomatin-like protein 2, mitochondrial  -21.48 
 
CIP4 Cdc42-interacting protein 4  -21.48 
 
J3QQY2 Transmembrane and coiled-coil domain-containing protein 1  -21.48 
 
PRP8 Pre-mRNA-processing-splicing factor 8  -21.49 
 
CAV2 Isoform Beta of Caveolin-2  -21.50 
 
SEC63 Translocation protein SEC63 homolog  -21.51 
 
SYPL1 Isoform 2 of Synaptophysin-like protein 1  -21.52 
 
RAVR1 Isoform 2 of Ribonucleoprotein PTB-binding 1  -21.53 
 
CATZ Cathepsin Z  -21.53 
 
COX20 Cytochrome c oxidase protein 20 homolog  -21.54 
 
NDUBA NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 10  -21.55 
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SPB12 Serpin B12 -21.55 
 
SDCB1 Syntenin-1  -21.55 
 
B1ANR0 Poly(A) binding protein, cytoplasmic 4 (Inducible form), isoform CRA -21.57 
 
HDHD1 Pseudouridine-5-monophosphatase  -21.63 
 
SNP23 Synaptosomal-associated protein 23  -21.67 
 
M0R0W6 Tyrosine-protein kinase receptor UFO  -21.68 
 
A8MXQ1 Pituitary tumor-transforming gene 1 protein-interacting protein  -21.69 
 
MSH2 DNA mismatch repair protein Msh2  -21.69 
 
COPG2 Coatomer subunit gamma-2  -21.74 
 
RAB3B Ras-related protein Rab-3B  -21.75 
 
Q5T760 Serine/arginine-rich-splicing factor 11 (Fragment) -21.76 
 
SAR1B GTP-binding protein SAR1b  -21.76 
 
VDAC3 Voltage-dependent anion-selective channel protein 3  -21.79 
 
QCR2 Cytochrome b-c1 complex subunit 2, mitochondrial  -21.80 
 
EPN1 Isoform 3 of Epsin-1  -21.85 
 
2A5D Isoform Delta-3 of Serine/threonine-protein phosphatase 2A  -21.86 
 
GPDM Isoform 2 of Glycerol-3-phosphate dehydrogenase, mitochondrial  -21.91 
 
C9JAW5 HIG1 domain family member 1A, mitochondrial  -21.91 
 
DYLT1 Dynein light chain Tctex-type 1  -21.91 
 
D3DR31 Interferon-induced protein with tetratricopeptide repeats 1  -21.91 
 
H7C1U8 Apolipoprotein O (Fragment)  -21.93 
 
SCMC1 Calcium-binding mitochondrial carrier protein SCaMC-1  -21.94 
 
NASP Nuclear autoantigenic sperm protein  -21.94 
 
M2OM Mitochondrial 2-oxoglutarate/malate carrier protein  -21.94 
 
MOT4 Monocarboxylate transporter 4  -21.98 
 
U3KQ30 Secretory carrier-associated membrane protein 1  -21.99 
 
STING Stimulator of interferon genes protein  -22.02 
 
PP4R1 Isoform 2 of Serine/threonine-protein phosphatase 4 regulatory subunit 1  -22.05 
 
SYJ2B Synaptojanin-2-binding protein  -22.08 
 
I3L4X2 Multidrug resistance-associated protein 1 (Fragment)  -22.14 
 
GNA11 Guanine nucleotide-binding protein subunit alpha-11  -22.21 
 
221 
 
SATT Neutral amino acid transporter A  -22.22 
 
UFL1 Isoform 2 of E3 UFM1-protein ligase 1  -22.28 
 
HCDH Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial OS -22.37 
 
NCBP1 Nuclear cap-binding protein subunit 1 -22.37 
 
LTOR1 Ragulator complex protein LAMTOR1  -22.39 
 
SCRIB Protein scribble homolog  -22.43 
 
CTNB1 Catenin beta-1  -22.45 
 
MCM7 DNA replication licensing factor MCM7  -22.47 
 
SFXN1 Sideroflexin-1  -22.49 
 
CND3 Condensin complex subunit 3  -22.49 
 
MCM4 DNA replication licensing factor MCM4  -22.53 
 
ISG15 Ubiquitin-like protein ISG15  -22.55 
 
TOM70 Mitochondrial import receptor subunit TOM70  -22.56 
 
WASF2 Wiskott-Aldrich syndrome protein family member 2  -22.57 
 
MGST3 Microsomal glutathione S-transferase 3  -22.58 
 
CTNA2 Isoform 3 of Catenin alpha-2  -22.61 
 
J3QRU4 Vesicle-associated membrane protein 2  -22.62 
 
ASNS Isoform 2 of Asparagine synthetase [glutamine-hydrolyzing]  -22.62 
 
MCM3 DNA replication licensing factor MCM3  -22.66 
 
ATP5I ATP synthase subunit e, mitochondrial  -22.71 
 
TRIPC Isoform 2 of E3 ubiquitin-protein ligase TRIP12  -22.71 
 
ANK1 Isoform Er9 of Ankyrin-1 -22.71 
 
PLAK Junction plakoglobin  -22.72 
 
K1468 Isoform 2 of LisH domain and HEAT repeat-containing protein KIAA1468 -22.73 
 
NDUS3 NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial  -22.82 
 
SLN11 Schlafen family member 11  -22.87 
 
SPSY Spermine synthase  -22.95 
 
CND1 Condensin complex subunit 1  -22.96 
 
Q5URX0 Beta-hexosaminidase subunit beta  -23.06 
 
CY1 Cytochrome c1, heme protein, mitochondrial  -23.07 
 
C1TM Monofunctional C1-tetrahydrofolate synthase, mitochondrial  -23.09 
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C9JYQ9 60S ribosomal protein L22-like 1  -23.18 
 
ATPK Isoform 3 of ATP synthase subunit f, mitochondrial  -23.21 
 
LAP2 Isoform 7 of Protein LAP2  -23.31 
 
SMC2 Structural maintenance of chromosomes protein 2  -23.38 
 
MCM2 DNA replication licensing factor MCM2  -23.45 
 
LMNB1 Lamin-B1  -23.48 
 
A8MWK3 Cadherin-2  -23.48 
 
PELP1 Proline-, glutamic acid- and leucine-rich protein 1  -23.52 
 
SCRB2 Lysosome membrane protein 2  -23.70 
 
ITA6 Isoform Alpha-6X2A of Integrin alpha-6  -23.73 
 
AL1A3 Aldehyde dehydrogenase family 1 member A3  -23.75 
 
LETM1 LETM1 and EF-hand domain-containing protein 1, mitochondrial  -23.76 
 
E9PN17 ATP synthase subunit g, mitochondrial  -23.77 
 
IMMT Isoform 2 of Mitochondrial inner membrane protein  -23.84 
 
COX41 Cytochrome c oxidase subunit 4 isoform 1, mitochondrial  -24.00 
 
COX2 Cytochrome c oxidase subunit 2  -24.06 
 
MX1 Interferon-induced GTP-binding protein Mx1  -24.11 
 
F8W7Q4 Protein FAM162A  -24.18 
 
AAAT Neutral amino acid transporter B(0)  -24.20 
 
CSPG4 Chondroitin sulfate proteoglycan 4  -24.21 
 
ADT2 ADP/ATP translocase 2 -24.68 
 
ATPO ATP synthase subunit O, mitochondrial  -24.71 
 
HBA Hemoglobin subunit alpha  -24.71 
 
J3KPX7 Prohibitin-2  -24.95 
 
ECE1 Isoform D of Endothelin-converting enzyme 1  -25.19 
 
ANXA8 Annexin A8  -25.27 
 
PHB Prohibitin  -26.02 
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Supplementary Table S5: Phosphoproteins significantly up/ downregulated in Ben-Men-1 cells compared to HMC 
Gene symbol Protein name  Log2 FC 
ANXA8 Annexin A8;Annexin A8-like protein 1;Annexin A8-like protein 2;Annexin 22.50 
FAM192A Protein FAM192A 22.46 
DDA1 DET1- and DDB1-associated protein 1 22.38 
C10orf47 Uncharacterized protein C10orf47 21.89 
HNRNPR Heterogeneous nuclear ribonucleoprotein R 21.85 
NPM3 Nucleoplasmin-3 21.81 
SCP2 Non-specific lipid-transfer protein 21.61 
TERT Telomerase reverse transcriptase 21.46 
C12orf43 Uncharacterized protein C12orf43 21.33 
MAT2A S-adenosylmethionine synthase isoform type-2;S-adenosylmethionine synthase 21.25 
CNPY2 Protein canopy homolog 2 21.24 
RAB11FIP1 Rab11 family-interacting protein 1 21.17 
STAU2 Double-stranded RNA-binding protein Staufen homolog 2 21.10 
GBE1 1,4-alpha-glucan-branching enzyme 21.08 
ZFP36L1 Zinc finger protein 36, C3H1 type-like 1 21.08 
RPS21 40S ribosomal protein S21 21.05 
DEPTOR DEP domain-containing mTOR-interacting protein 21.02 
UHRF2 E3 ubiquitin-protein ligase UHRF2 20.93 
CBR3 Carbonyl reductase [NADPH] 3 20.88 
IWS1 Protein IWS1 homolog 20.85 
CDCA5 Sororin 20.82 
AMPH Amphiphysin 20.79 
KIAA1598 Shootin-1 20.76 
CACYBP Calcyclin-binding protein 20.70 
ALPK2 Alpha-protein kinase 2 20.68 
ARFGEF3 Brefeldin A-inhibited guanine nucleotide-exchange protein 3 20.62 
ITPA Inosine triphosphate pyrophosphatase 20.61 
IVNS1ABP Influenza virus NS1A-binding protein 20.53 
JMY Junction-mediating and -regulatory protein 20.39 
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TAGLN2 Transgelin-2 20.29 
NSUN5 Putative methyltransferase NSUN5 20.27 
TRAPPC1 Trafficking protein particle complex subunit 1 20.16 
DTX3L E3 ubiquitin-protein ligase DTX3L 20.08 
SCAF11 Protein SCAF11 20.05 
RPL32 60S ribosomal protein L32 19.99 
S100A10 Protein S100-A10 19.88 
APOBEC3C Probable DNA dC->dU-editing enzyme APOBEC-3C 19.86 
KLHDC4 Kelch domain-containing protein 4 19.85 
MRPS14 28S ribosomal protein S14, mitochondrial 19.84 
C16orf88 Protein C16orf88 19.84 
MRPL1 39S ribosomal protein L1, mitochondrial 19.82 
MBD2 Methyl-CpG-binding domain protein 2 19.79 
NOM1 Nucleolar MIF4G domain-containing protein 1 19.79 
CRNKL1 Crooked neck-like protein 1 19.64 
SYNRG Synergin gamma 19.57 
CLPTM1L Cleft lip and palate transmembrane protein 1-like protein 19.55 
NPHP3 Nephrocystin-3 19.44 
RGS10 Regulator of G-protein signaling 10 19.40 
NCOR2 Nuclear receptor corepressor 2 19.34 
RBM34 RNA-binding protein 34 19.29 
ARID1A AT-rich interactive domain-containing protein 1A 19.25 
CWC27 Peptidyl-prolyl cis-trans isomerase CWC27 homolog 19.14 
HIST1H1C Histone H1.2 6.72 
KRT18 Keratin, type I cytoskeletal 18 5.30 
ANK1 Ankyrin-1 4.84 
DDB2 DNA damage-binding protein 2 4.75 
STAT1 Signal transducer and activator of transcription 1-alpha/beta 4.58 
EZR Ezrin 4.52 
LIMCH1 LIM and calponin homology domains-containing protein 1 4.46 
PSMB9 Proteasome subunit beta type-9;Proteasome subunit beta type 4.28 
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CRYAB Alpha-crystallin B chain 4.23 
PDLIM2 PDZ and LIM domain protein 2 3.95 
CDK1 Cyclin-dependent kinase 1 3.87 
SLC9A3R1 Na(+)/H(+) exchange regulatory cofactor NHE-RF1 3.76 
ZNF185 Zinc finger protein 185 3.72 
DNAJC6 Putative tyrosine-protein phosphatase auxilin 3.70 
TCEAL5 Transcription elongation factor A protein-like 5;Transcription elongation factor A protein-like 3 3.56 
SYAP1 Synapse-associated protein 1 3.52 
FOXC2 Forkhead box protein C2 3.47 
EPS8L2 Epidermal growth factor receptor kinase substrate 8-like protein 2 3.37 
DPYSL3 Dihydropyrimidinase-related protein 3 3.22 
PDE1C Calcium/calmodulin-dependent 3,5-cyclic nucleotide phosphodiesterase 1C 3.16 
MLTK Mitogen-activated protein kinase kinase kinase MLT 3.14 
LYSMD2 LysM and putative peptidoglycan-binding domain-containing protein 2 3.11 
SAMHD1 SAM domain and HD domain-containing protein 1 3.04 
ANXA3 Annexin A3;Annexin 3.03 
ARSB Arylsulfatase B 3.01 
LMNA Prelamin-A/C;Lamin-A/C 2.99 
CDK2 Cyclin-dependent kinase 2 2.95 
MOSPD2 Motile sperm domain-containing protein 2 2.92 
DCK Deoxycytidine kinase 2.90 
DDX24 ATP-dependent RNA helicase DDX24 2.87 
NCEH1 Neutral cholesterol ester hydrolase 1 2.80 
TNS3 Tensin-3 2.80 
TOP2A DNA topoisomerase 2-alpha 2.75 
DYNLL1 Dynein light chain 1, cytoplasmic 2.75 
CSDE1 Cold shock domain-containing protein E1 2.74 
MRE11A Double-strand break repair protein MRE11A 2.71 
FAM169A Protein FAM169A 2.70 
RPS27 40S ribosomal protein S27 2.65 
CAP2 Adenylyl cyclase-associated protein 2;Adenylyl cyclase-associated protein 2.63 
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SUPT16H FACT complex subunit SPT16 2.61 
CORO1C Coronin-1C 2.60 
PPM1H Protein phosphatase 1H 2.58 
EHBP1L1 EH domain-binding protein 1-like protein 1 2.57 
API5 Apoptosis inhibitor 5 2.49 
IQGAP3 Ras GTPase-activating-like protein IQGAP3 2.46 
HMGB2 High mobility group protein B2 2.45 
FTSJD2 Cap-specific mRNA (nucleoside-2-O-)-methyltransferase 1 2.41 
RECQL ATP-dependent DNA helicase Q1 2.41 
RPL24 60S ribosomal protein L24 2.33 
PTPN14 Tyrosine-protein phosphatase non-receptor type 14 2.30 
DOPEY2 Protein dopey-2 2.30 
C3orf26 Uncharacterized protein C3orf26 2.27 
HCA90 Targeting protein for Xklp2 2.23 
FNBP1 Formin-binding protein 1 2.20 
PSIP1 PC4 and SFRS1-interacting protein 2.17 
PSME2 Proteasome activator complex subunit 2 2.16 
CTSC Dipeptidyl peptidase 1;Dipeptidyl peptidase 1 exclusion domain chain 2.15 
DEK Protein DEK 2.14 
DHX29 ATP-dependent RNA helicase DHX29 2.13 
SPIN1 Spindlin-1 2.12 
RPL31 60S ribosomal protein L31 2.12 
HIST1H2BJ Histone H2B type 1-J;Histone H2B type 2-E 2.09 
CPQ Carboxypeptidase Q 2.08 
DDX5 Probable ATP-dependent RNA helicase DDX5 2.05 
MICAL2 Protein-methionine sulfoxide oxidase MICAL2 2.04 
UCK2 Uridine-cytidine kinase 2 2.03 
FMR1 Fragile X mental retardation protein 1 2.03 
DRAP1 Dr1-associated corepressor 2.01 
MYOF Myoferlin 2.01 
RPS14 40S ribosomal protein S14 2.00 
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CALM2 Calmodulin 1.98 
EIF1AX Eukaryotic translation initiation factor 1A, X-chromosomal 1.97 
PSMB10 Proteasome subunit beta type-10 1.94 
PUS7 Pseudouridylate synthase 7 homolog 1.90 
DHX9 ATP-dependent RNA helicase A 1.90 
FRMD6 FERM domain-containing protein 6 1.87 
CTSD Cathepsin D;Cathepsin D light chain;Cathepsin D heavy chain 1.85 
HIST1H2BK Histone H2B type 1-K 1.84 
PSME3 Proteasome activator complex subunit 3 1.83 
EPHA2 Ephrin type-A receptor 2 1.80 
NONO Non-POU domain-containing octamer-binding protein 1.79 
DDX50 ATP-dependent RNA helicase DDX50 1.78 
FNIP1 Rap guanine nucleotide exchange factor 6 1.77 
DDB1 DNA damage-binding protein 1 1.76 
AHNAK2 Protein AHNAK2 1.76 
FKBP4 Peptidyl-prolyl cis-trans isomerase FKBP4;Peptidyl-prolyl cis-trans isomerase FKBP4 1.76 
SSRP1 FACT complex subunit SSRP1 1.75 
EGFR Epidermal growth factor receptor 1.75 
SMAD3 Mothers against decapentaplegic homolog 3 1.74 
SRSF2 Serine/arginine-rich splicing factor 2 1.73 
CSE1L Exportin-2 1.71 
P4HA2 Prolyl 4-hydroxylase subunit alpha-2 1.69 
DNAJC17 DnaJ homolog subfamily C member 17 1.68 
RNPEP Aminopeptidase B 1.68 
NOB1 RNA-binding protein NOB1 1.68 
C17orf49 Chromatin complexes subunit BAP18 1.68 
HNRNPM Heterogeneous nuclear ribonucleoprotein M 1.67 
SNRPD3 Small nuclear ribonucleoprotein Sm D3 1.66 
ANAPC7 Anaphase-promoting complex subunit 7 1.65 
UNC45A Protein unc-45 homolog A 1.63 
ERCC6 DNA excision repair protein ERCC-6 1.62 
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RFC5 Replication factor C subunit 5 1.61 
AFAP1 Actin filament-associated protein 1 1.60 
MECP2 Methyl-CpG-binding protein 2 1.60 
PPA2 Inorganic pyrophosphatase 2, mitochondrial 1.60 
CTSA Lysosomal protective protein 1.59 
CALU Isoform 4 of Calumenin 1.58 
PSME1 Proteasome activator complex subunit 1 1.57 
SRSF7 Serine/arginine-rich splicing factor 7 1.56 
BAZ1B Tyrosine-protein kinase BAZ1B 1.56 
RPL19 60S ribosomal protein L19 1.55 
PFDN2 Prefoldin subunit 2 1.54 
DIAPH1 Protein diaphanous homolog 1 1.54 
TALDO1 Transaldolase 1.53 
PRKDC DNA-dependent protein kinase catalytic subunit 1.53 
RPL28 60S ribosomal protein L28 1.52 
TJP2 Tight junction protein ZO-2 1.50 
PLCD1 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-1 1.50 
HSPB1 Heat shock protein beta-1 1.50 
HIST1H2AG Histone H2A type 1 1.49 
SPTLC2 Serine palmitoyltransferase 2 1.48 
NSFL1C NSFL1 cofactor p47 1.48 
CBX3 Chromobox protein homolog 3 1.48 
DDX46 Probable ATP-dependent RNA helicase DDX46 1.47 
DHX15 Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15 1.47 
SLC9A3R2 Na(+)/H(+) exchange regulatory cofactor NHE-RF2 1.45 
PCBP1 Poly(rC)-binding protein 1 1.44 
CUTA Protein CutA 1.44 
NMNAT1 Nicotinamide mononucleotide adenylyltransferase 1 1.44 
MYH3 myosin, heavy chain 3 1.41 
PSMB8 Proteasome subunit beta type-8 1.40 
RAD50 DNA repair protein RAD50 1.40 
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TMPO Lamina-associated polypeptide 2, isoforms beta/gamma;Thymopoietin;Thymopentin 1.40 
HSPA8 Heat shock cognate 71 kDa protein 1.40 
DOCK5 Dedicator of cytokinesis protein 5 1.39 
MAGOHB Protein mago nashi homolog 2 1.39 
C7orf50 Uncharacterized protein C7orf50 1.39 
HIST1H4A Histone H4 1.38 
RFC4 Replication factor C subunit 4 1.38 
RNH1 Ribonuclease inhibitor 1.35 
ANKHD1 Ankyrin repeat and KH domain-containing protein 1 1.35 
WDR70 WD repeat-containing protein 70 1.34 
RPRD1B Regulation of nuclear pre-mRNA domain-containing protein 1B 1.34 
LNPEP Leucyl-cystinyl aminopeptidase;Leucyl-cystinyl aminopeptidase, pregnancy serum form 1.32 
PPP1R13L RelA-associated inhibitor 1.31 
LDHA L-lactate dehydrogenase A chain 1.30 
MSH6 DNA mismatch repair protein Msh6 1.30 
MYL6 myosin, light chain 6 1.28 
RBM39 RNA-binding protein 39 1.26 
EIF2AK2 Interferon-induced, double-stranded RNA-activated protein kinase 1.26 
HSPA4 Heat shock 70 kDa protein 4 1.25 
C7orf55 Isoform 2 of UPF0562 1.23 
HP1BP3 Heterochromatin protein 1-binding protein 3 1.23 
SMC4 Structural maintenance of chromosomes protein 4;Structural maintenance of chromosomes protein 1.23 
CTPS CTP synthase 1 1.23 
FLNB Filamin-B 1.23 
HSPA1A Heat shock 70 kDa protein 1A/1B 1.21 
ACTN4 Alpha-actinin-4 1.21 
SKP1 S-phase kinase-associated protein 1 1.21 
TBC1D9B TBC1 domain family member 9B 1.20 
LRRFIP2 Leucine-rich repeat flightless-interacting protein 2 1.20 
DHX16 Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX16 1.19 
MYO1C Unconventional myosin-Ic 1.18 
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MYLK Myosin light chain kinase, smooth muscle;Myosin light chain kinase, smooth muscle, deglutamylated form 1.18 
DNAJA1 DnaJ homolog subfamily A member 1 1.18 
SUPT6H Transcription elongation factor SPT6 1.17 
BAIAP2 Brain-specific angiogenesis inhibitor 1-associated protein 2 1.17 
THBS1 Thrombospondin-1 1.17 
HEXA Beta-hexosaminidase subunit alpha 1.14 
NOL9 Polynucleotide 5-hydroxyl-kinase NOL9 1.14 
PPM1G Protein phosphatase 1G 1.10 
SRP68 Signal recognition particle 68 kDa protein 1.10 
RPS6KA4 Ribosomal protein S6 kinase alpha-4;Ribosomal protein S6 kinase 1.08 
TMEM189 Ubiquitin-conjugating enzyme E2 variant 1;Ubiquitin-conjugating enzyme E2 variant 2 1.08 
WAPAL Wings apart-like protein homolog 1.08 
STIP1 Stress-induced-phosphoprotein 1 1.07 
PABPN1 Polyadenylate-binding protein 2 1.07 
GEMIN5 Gem-associated protein 5 1.07 
PABPC1 Polyadenylate-binding protein 1;Polyadenylate-binding protein 4;Polyadenylate-binding protein 3 1.07 
DDX10 Probable ATP-dependent RNA helicase DDX10 1.07 
TNPO1 Transportin-1 1.06 
DNAJA2 DnaJ homolog subfamily A member 2 1.06 
PUF60 Poly(U)-binding-splicing factor PUF60 1.02 
TCEB2 Transcription elongation factor B polypeptide 2 1.02 
ZNF326 DBIRD complex subunit ZNF326 1.01 
ARHGAP35 Rho GTPase-activating protein 35 1.01 
YWHAE 14-3-3 protein epsilon 1.01 
DHX38 Pre-mRNA-splicing factor ATP-dependent RNA helicase PRP16 1.01 
CBX1 Chromobox protein homolog 1 1.01 
SNX2 Sorting nexin-2 1.01 
SRP72 Signal recognition particle 72 kDa protein 1.00 
TMOD3 Tropomodulin-3 1.00 
CKAP5 Cytoskeleton-associated protein 5 0.99 
ENO1 Alpha-enolase 0.98 
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ANP32A Acidic leucine-rich nuclear phosphoprotein 32 family member A 0.98 
DSP Desmoplakin 0.97 
CAPN2 Calpain-2 catalytic subunit 0.97 
FAM160B1 Protein FAM160B1 0.96 
NRD1 Nardilysin 0.94 
DDX3X ATP-dependent RNA helicase DDX3X 0.94 
PPP2R1A Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform 0.93 
ARHGAP18 Rho GTPase-activating protein 18 0.93 
RP11-114F7.3 Dynamin-binding protein 0.92 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 0.92 
RPS18 40S ribosomal protein S18 0.91 
RBBP4 Histone-binding protein RBBP4 0.91 
KDM5C Lysine-specific demethylase 5C;Lysine-specific demethylase 5D 0.91 
XRN1 5-3 exoribonuclease 1 0.91 
RPS3A 40S ribosomal protein S3a 0.90 
PTPN11 Tyrosine-protein phosphatase non-receptor type 11 0.89 
ARAP1 Arf-GAP with Rho-GAP domain, ANK repeat and PH domain-containing protein 1 0.89 
HSP90AA1 Heat shock protein HSP 90-alpha 0.88 
IMPDH2 Inosine-5-monophosphate dehydrogenase 2 0.87 
GTF2E1 General transcription factor IIE subunit 1 0.86 
EXOSC10 Exosome component 10 0.86 
GSPT1 Eukaryotic peptide chain release factor GTP-binding subunit ERF3A 0.86 
YTHDC2 Probable ATP-dependent RNA helicase YTHDC2 0.85 
USP9X Probable ubiquitin carboxyl-terminal hydrolase FAF-X 0.85 
FAM50A Protein FAM50A 0.84 
C9orf142 Uncharacterized protein C9orf142 0.84 
ZC3H11A Zinc finger CCCH domain-containing protein 11A 0.83 
SPIRE1 Protein spire homolog 1 0.83 
PFKP 6-phosphofructokinase type C 0.81 
HECTD1 E3 ubiquitin-protein ligase HECTD1 0.81 
TNPO3 Transportin-3 0.79 
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WHSC2 Negative elongation factor A 0.78 
STRAP Serine-threonine kinase receptor-associated protein 0.78 
SRSF1 Serine/arginine-rich splicing factor 1 0.77 
OXCT1 Succinyl-CoA:3-ketoacid-coenzyme A transferase 1, mitochondrial 0.77 
FAM120A Constitutive coactivator of PPAR-gamma-like protein 1 0.76 
TXLNA Alpha-taxilin 0.76 
DDX41 Probable ATP-dependent RNA helicase DDX41 0.76 
CROCC Rootletin 0.72 
HNRNPA1 Heterogeneous nuclear ribonucleoprotein A1;Heterogeneous nuclear ribonucleoprotein A1-like 2 0.72 
CDK7 Cyclin-dependent kinase 7 0.70 
ARFGAP2 ADP-ribosylation factor GTPase-activating protein 2 0.70 
PSMD2 26S proteasome non-ATPase regulatory subunit 2 0.70 
MLLT4 Afadin 0.69 
TTLL5 Tubulin polyglutamylase TTLL5 0.67 
RIC8A Synembryn-A 0.67 
CLINT1 Clathrin interactor 1 0.66 
CAST Calpastatin 0.66 
LARP1 La-related protein 1 0.65 
RNF213 E3 ubiquitin-protein ligase RNF213 0.64 
IMP3 U3 small nucleolar ribonucleoprotein protein IMP3 0.64 
YWHAZ 14-3-3 protein zeta/delta 0.61 
UBL4A Ubiquitin-like protein 4A 0.60 
ALKBH5 Probable alpha-ketoglutarate-dependent dioxygenase ABH5 0.60 
BAG6 Large proline-rich protein BAG6 0.57 
SNRNP70 U1 small nuclear ribonucleoprotein 70 kDa 0.57 
DDX23 Probable ATP-dependent RNA helicase DDX23 0.57 
EIF4G2 Eukaryotic translation initiation factor 4 gamma 2 0.54 
SPTLC1 Serine palmitoyltransferase 1 0.53 
TBCD Tubulin-specific chaperone D 0.53 
SNTB2 Beta-2-syntrophin 0.51 
HNRNPUL2 Heterogeneous nuclear ribonucleoprotein U-like protein 2 0.51 
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PKM2 Pyruvate kinase isozymes M1/M2;Pyruvate kinase 0.49 
CTIF CBP80/20-dependent translation initiation factor 0.44 
CPSF7 Cleavage and polyadenylation specificity factor subunit 7 0.44 
HUWE1 E3 ubiquitin-protein ligase HUWE1 0.43 
PPIL4 Peptidyl-prolyl cis-trans isomerase-like 4 0.42 
TECR Trans-2,3-enoyl-CoA reductase 0.41 
SP100 Nuclear autoantigen Sp-100 0.41 
NAA15 N-alpha-acetyltransferase 15, NatA auxiliary subunit 0.34 
UTP18 U3 small nucleolar RNA-associated protein 18 homolog -0.22 
FAM40A Protein FAM40A -0.39 
KHNYN Protein KHNYN -0.42 
VCL Vinculin -0.45 
EXOC4 Exocyst complex component 4 -0.50 
ACACA Acetyl-CoA carboxylase 1;Biotin carboxylase -0.51 
TUBGCP2 Gamma-tubulin complex component 2 -0.52 
PDIA4 Protein disulfide-isomerase A4 -0.52 
PPP4R1 Serine/threonine-protein phosphatase 4 regulatory subunit 1 -0.58 
HSP90B1 Endoplasmin -0.58 
PARVA Alpha-parvin -0.58 
PUS1 tRNA pseudouridine synthase A, mitochondrial;Pseudouridine synthase -0.61 
CDC42EP1 Cdc42 effector protein 1 -0.64 
SUGP2 SURP and G-patch domain-containing protein 2 -0.65 
AP2A2 AP-2 complex subunit alpha-2 -0.66 
PRRC1 Protein PRRC1 -0.66 
DIP2B Disco-interacting protein 2 homolog B -0.67 
PSMB1 Proteasome subunit beta type-1 -0.67 
NOP56 Nucleolar protein 56 -0.68 
VIM Vimentin -0.69 
AP3S1 AP-3 complex subunit sigma-1 -0.69 
SETD7 Histone-lysine N-methyltransferase SETD7 -0.72 
PPFIBP1 Liprin-beta-1 -0.72 
234 
 
PPP1R12A Protein phosphatase 1 regulatory subunit 12A -0.75 
STRN3 Striatin-3 -0.76 
USP11 Ubiquitin carboxyl-terminal hydrolase 11;Ubiquitin carboxyl-terminal hydrolase -0.79 
SRPK2 SRSF protein kinase 2;SRSF protein kinase 2 N-terminal;SRSF protein kinase 2 C-terminal -0.80 
UBE2Z Ubiquitin-conjugating enzyme E2 Z -0.81 
MAP4 Microtubule-associated protein -0.83 
DNAJC1 DnaJ homolog subfamily C member 1 -0.83 
DDRGK1 DDRGK domain-containing protein 1 -0.85 
SCYL1 N-terminal kinase-like protein -0.86 
PCYT1A Choline-phosphate cytidylyltransferase A -0.88 
UBE3C Ubiquitin-protein ligase E3C -0.88 
PKN1 Serine/threonine-protein kinase N1 -0.89 
C16orf62 UPF0505 protein C16orf62 -0.90 
ATG7 Ubiquitin-like modifier-activating enzyme ATG7 -0.92 
NCK2 Cytoplasmic protein NCK2 -0.92 
LIMS1 LIM and senescent cell antigen-like-containing domain protein 1 -0.94 
PSMB5 Proteasome subunit beta type-5 -0.94 
PIK3R4 Phosphoinositide 3-kinase regulatory subunit 4 -0.95 
PI4KB Phosphatidylinositol 4-kinase beta -0.95 
FAM129B Niban-like protein 1 -0.95 
ARHGAP10 Rho GTPase-activating protein 10 -0.95 
OTUD7B OTU domain-containing protein 7B -0.95 
ANXA11 Annexin A11;Annexin -0.97 
NUMBL Numb-like protein -0.97 
Uncharacterised Uncharacterized protein FLJ45252 -0.98 
ITGB1 Integrin beta-1 -0.98 
PSMA2 Proteasome subunit alpha type-2 -0.99 
DCAF7 DDB1- and CUL4-associated factor 7 -1.00 
RLTPR Leucine-rich repeat-containing protein 16C -1.01 
USO1 General vesicular transport factor p115 -1.01 
MAGED2 Melanoma-associated antigen D2 -1.02 
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NEDD4 E3 ubiquitin-protein ligase NEDD4;E3 ubiquitin-protein ligase -1.02 
MRPS9 28S ribosomal protein S9, mitochondrial -1.03 
ARHGEF40 Rho guanine nucleotide exchange factor 40 -1.03 
PIP Prolactin-inducible protein -1.04 
NAV1 Neuron navigator 1 -1.05 
PRKACB cAMP-dependent protein kinase catalytic subunit beta -1.05 
CSNK1D Casein kinase I isoform delta -1.05 
PSMB2 Proteasome subunit beta type-2 -1.05 
DRG1 Developmentally-regulated GTP-binding protein 1 -1.06 
POLR1C DNA-directed RNA polymerases I and III subunit RPAC1 -1.06 
ARHGAP12 Rho GTPase-activating protein 12 -1.06 
TOR1AIP1 Torsin-1A-interacting protein 1 -1.07 
KIAA1432 Protein RIC1 homolog -1.08 
LUZP1 Leucine zipper protein 1 -1.10 
UBE4B Ubiquitin conjugation factor E4 B -1.10 
GPN1 GPN-loop GTPase 1 -1.11 
PXN Paxillin -1.11 
HELZ Probable helicase with zinc finger domain -1.12 
CDK17 Cyclin-dependent kinase 17 -1.13 
UFL1 E3 UFM1-protein ligase 1 -1.14 
LIN7C Protein lin-7 homolog C -1.14 
SRPRB Signal recognition particle receptor subunit beta -1.15 
BZW2 Basic leucine zipper and W2 domain-containing protein 2 -1.16 
TAB1 TGF-beta-activated kinase 1 and MAP3K7-binding protein 1 -1.16 
SNX18 Sorting nexin-18 -1.16 
PACS1 Phosphofurin acidic cluster sorting protein 1 -1.16 
RRBP1 Ribosome-binding protein 1 -1.16 
ASCC2 Activating signal cointegrator 1 complex subunit 2 -1.16 
PSMB7 Proteasome subunit beta type-7 -1.18 
DRG2 Developmentally-regulated GTP-binding protein 2 -1.18 
RPN1 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 -1.19 
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IKBIP Inhibitor of nuclear factor kappa-B kinase-interacting protein -1.19 
ACTR10 Actin-related protein 10 -1.19 
COL1A1 Collagen alpha-1(I) chain -1.20 
CENPV Isoform 3 of Centromere protein V -1.20 
BSG Basigin -1.21 
ABL1 Tyrosine-protein kinase ABL1 -1.21 
TTC37 Tetratricopeptide repeat protein 37 -1.23 
PDLIM5 PDZ and LIM domain protein 5 -1.24 
LEPREL4 Synaptonemal complex protein SC65 -1.24 
HS1BP3 HCLS1-binding protein 3 -1.25 
HMGCL Hydroxymethylglutaryl-CoA lyase, mitochondrial -1.25 
ASAP1 Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1 -1.26 
PTPN12 Tyrosine-protein phosphatase non-receptor type 12 -1.26 
SRPR Signal recognition particle receptor subunit alpha -1.27 
OPTN Optineurin -1.27 
COPS4 COP9 signalosome complex subunit 4 -1.27 
CTNND1 Catenin delta-1 -1.27 
RTN1 Reticulon-1 -1.28 
ST13 Hsc70-interacting protein;Putative protein FAM10A5;Putative protein FAM10A4 -1.30 
RTN4 Reticulon-4 -1.31 
PPP2R5B Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit beta isoform -1.32 
COMT Catechol O-methyltransferase -1.33 
NXN Nucleoredoxin -1.34 
PLCB1 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1 -1.34 
ATG4B Cysteine protease ATG4B -1.35 
SYNJ2 Synaptojanin-2 -1.35 
NCOA7 Nuclear receptor coactivator 7 -1.37 
S E P 9 Septin-9 -1.38 
LEPRE1 Prolyl 3-hydroxylase 1 -1.39 
SKIV2L Helicase SKI2W -1.40 
DMD Dystrophin -1.42 
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RND3 Rho-related GTP-binding protein RhoE -1.42 
ASCC3 Activating signal cointegrator 1 complex subunit 3 -1.43 
MYO5A Unconventional myosin-Va -1.44 
RCAN1 Calcipressin-1 -1.46 
NEXN Nexilin -1.47 
STK39 STE20/SPS1-related proline-alanine-rich protein kinase -1.47 
SIRT2 NAD-dependent protein deacetylase sirtuin-2 -1.48 
TRIM3 Tripartite motif-containing protein 3 -1.48 
USP35 Ubiquitin carboxyl-terminal hydrolase 35 -1.50 
GTPBP1 GTP-binding protein 1 -1.51 
BCKDK [3-methyl-2-oxobutanoate dehydrogenase [lipoamide]] kinase, mitochondrial -1.52 
EHBP1 EH domain-binding protein 1 -1.52 
GIPC1 PDZ domain-containing protein GIPC1 -1.52 
LEPREL2 Prolyl 3-hydroxylase 3 -1.52 
VPS41 Vacuolar protein sorting-associated protein 41 homolog -1.53 
S E P 2 Septin-2 -1.56 
ZZEF1 Zinc finger ZZ-type and EF-hand domain-containing protein 1 -1.57 
CRELD1 Cysteine-rich with EGF-like domain protein 1 -1.59 
PDLIM1 PDZ and LIM domain protein 1 -1.60 
TANC1 Protein TANC1 -1.60 
AAK1 AP2-associated protein kinase 1 -1.60 
RPP40 Ribonuclease P protein subunit p40 -1.60 
TGFB1I1 Transforming growth factor beta-1-induced transcript 1 protein -1.61 
PRDX6 Peroxiredoxin-6 -1.62 
EPS15 Epidermal growth factor receptor substrate 15 -1.62 
ASPH Aspartyl/asparaginyl beta-hydroxylase -1.62 
MPZL1 Myelin protein zero-like protein 1 -1.64 
AP1G1 AP-1 complex subunit gamma-1 -1.65 
EPS8 Epidermal growth factor receptor kinase substrate 8 -1.66 
RABGAP1L Rab GTPase-activating protein 1-like -1.67 
AKAP2 A kinase (PRKA) anchor protein 2) -1.67 
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BAIAP2L1 Brain-specific angiogenesis inhibitor 1-associated protein 2-like protein 1 -1.68 
PLEKHA5 Pleckstrin homology domain-containing family A member 5 -1.68 
RPN2 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 2 -1.69 
WDR13 WD repeat-containing protein 13 -1.71 
LRPAP1 Alpha-2-macroglobulin receptor-associated protein -1.72 
CYB5R3 NADH-cytochrome b5 reductase 3 -1.75 
DDOST Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 kDa subunit -1.77 
LCMT1 Leucine carboxyl methyltransferase 1 -1.79 
PKP2 Plakophilin-2 -1.80 
FHOD1 FH1/FH2 domain-containing protein 1 -1.82 
MPST 3-mercaptopyruvate sulfurtransferase;Sulfurtransferase -1.83 
RAI14 Ankycorbin -1.85 
S E P 5 Septin-5 -1.85 
WARS Tryptophan--tRNA ligase, cytoplasmic;T1-TrpRS;T2-TrpRS -1.87 
HNRNPH2 Heterogeneous nuclear ribonucleoprotein H2 -1.88 
VASP Vasodilator-stimulated phosphoprotein -1.90 
CTNNB1 Catenin beta-1 -1.92 
PGRMC1 Membrane-associated progesterone receptor component 1 -1.95 
ARFGAP1 ADP-ribosylation factor GTPase-activating protein 1 -1.97 
ITSN1 Intersectin-1 -2.01 
VPS16 Vacuolar protein sorting-associated protein 16 homolog -2.02 
TOM1 Target of Myb protein 1 -2.02 
AMPD2 AMP deaminase 2 -2.04 
STK11IP Serine/threonine-protein kinase 11-interacting protein -2.08 
FRMD8 FERM domain-containing protein 8 -2.08 
ANK3 Ankyrin-3 -2.10 
PACSIN2 Protein kinase C and casein kinase substrate in neurons protein 2 -2.12 
TBC1D2B TBC1 domain family member 2B -2.15 
DBN1 Isoform 3 of Drebrin -2.19 
FNDC3B Fibronectin type III domain-containing protein 3B -2.20 
SKT Sickle tail protein homolog -2.21 
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PYGB Glycogen phosphorylase, brain form -2.22 
ACTC1 Actin, alpha cardiac muscle 1 -2.24 
PITPNB Phosphatidylinositol transfer protein beta isoform -2.24 
OXSR1 Serine/threonine-protein kinase OSR1 -2.25 
FMNL2 Formin-like protein 2 -2.30 
MICAL1 Protein-methionine sulfoxide oxidase MICAL1 -2.32 
SNTB1 Beta-1-syntrophin -2.34 
RAPGEF2 Rap guanine nucleotide exchange factor 2 -2.36 
SERPINB12 Serpin B12 -2.39 
CASK Peripheral plasma membrane protein CASK -2.43 
SH3BP1 SH3 domain-binding protein 1 -2.44 
PFKM 6-phosphofructokinase, muscle type -2.49 
RAP1B Ras-related protein Rap-1b;Ras-related protein Rap-1b-like protein;Ras-related protein Rap-1A -2.49 
ACLY ATP-citrate synthase -2.50 
PRKD1 Serine/threonine-protein kinase D1 -2.59 
GRK5 G protein-coupled receptor kinase 5 -2.63 
BCL2L13 Bcl-2-like protein 13 -2.70 
TLN2 Talin-2 -2.72 
TPI1 Triosephosphate isomerase -2.75 
KCTD12 BTB/POZ domain-containing protein KCTD12 -2.78 
PITPNM1 Membrane-associated phosphatidylinositol transfer protein 1 -2.97 
DCLK1 Serine/threonine-protein kinase DCLK1 -3.08 
SUFU Suppressor of fused homolog -3.19 
NF2 Merlin -3.22 
DOCK6 Dedicator of cytokinesis protein 6 -3.22 
COBLL1 Cordon-bleu protein-like 1 -3.30 
FN1 Fibronectin;Anastellin;Ugl-Y1;Ugl-Y2;Ugl-Y3 -3.32 
SIPA1 Signal-induced proliferation-associated protein 1 -3.47 
PLA2G4A Cytosolic phospholipase A2;Phospholipase A2;Lysophospholipase -3.63 
AKAP12 A-kinase anchor protein 12 -3.63 
ENDOD1 Endonuclease domain-containing 1 protein -3.82 
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MVD Diphosphomevalonate decarboxylase -3.94 
ARMC9 LisH domain-containing protein ARMC9 -4.25 
TRIM16 Tripartite motif-containing protein 16 -4.56 
IGF2BP3 Insulin-like growth factor 2 mRNA-binding protein 3 -4.70 
EPB41L3 Isoform B of Band 4.1-like protein 3 -6.33 
GFPT2 Glucosamine--fructose-6-phosphate aminotransferase [isomerizing] 2 -6.63 
PPP1R12C Protein phosphatase 1 regulatory subunit 12C -19.38 
PRKAR2B cAMP-dependent protein kinase type II-beta regulatory subunit -19.42 
PPP1R9B Neurabin-2 -19.60 
MAP1A Microtubule-associated protein 1A;MAP1 light chain LC2 -19.90 
ATP5F1 ATP synthase subunit b, mitochondrial -20.32 
AMPD3 AMP deaminase 3 -20.36 
SNX25 Sorting nexin-25 -20.39 
PEX11B Peroxisomal membrane protein 11B -20.48 
DNM1 Dynamin-1 -20.57 
CEBPD CCAAT/enhancer-binding protein delta -20.60 
JUP Junction plakoglobin -20.66 
USP40 Ubiquitin carboxyl-terminal hydrolase 40 -20.68 
NHSL1 NHS-like protein 1 -20.81 
DENND2A DENN domain-containing protein 2A -21.08 
RFTN1 Raftlin -21.13 
TES Testin -21.20 
C12orf29 Uncharacterized protein C12orf29 -21.28 
LRCH3 Leucine-rich repeat and calponin homology domain-containing protein 3 -21.30 
BSDC1 BSD domain-containing protein 1 -21.52 
FKBP5 Peptidyl-prolyl cis-trans isomerase FKBP5 -21.64 
ROBO1 Roundabout homolog 1 -21.71 
LMNA Lamin A/C -21.73 
CPNE7 Copine-7 -21.75 
PPP1R14A Protein phosphatase 1 regulatory subunit 14A -21.77 
MGST1 Microsomal glutathione S-transferase 1 -22.19 
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PTGES Prostaglandin E synthase -22.62 
RSU1 Ras suppressor protein 1 -22.73 
PTK7 Inactive tyrosine-protein kinase 7 -23.01 
CD248 Endosialin -23.31 
SCD Acyl-CoA desaturase -23.78 
IGF2BP1 Insulin-like growth factor 2 mRNA-binding protein 1 -24.14 
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Supplementary Table S6: Total proteins significantly up/ downregulated in Ben-Men-1 cells compared to HMC 
Gene symbol Protein name  Log2 FC 
ATP13A1 Probable cation-transporting ATPase 13A1 25.65 
TNFRSF10D Tumor necrosis factor receptor superfamily member 10D 25.05 
TMEM109 Transmembrane protein 109 24.79 
ITGB3 Integrin beta-3;Integrin beta 24.36 
RBP1 Retinol-binding protein 1 24.16 
LXN Latexin 24.15 
CTHRC1 Collagen triple helix repeat-containing protein 1 24.08 
COL11A1 Collagen alpha-1(XI) chain 24.00 
CD248 Endosialin 23.96 
RPL21 60S ribosomal protein L21 23.94 
PTGES Prostaglandin E synthase 23.79 
SLC7A5 Large neutral amino acids transporter small subunit 1 23.38 
PTTG1IP Pituitary tumor-transforming gene 1 protein-interacting protein 23.36 
IGF2BP1 Insulin-like growth factor 2 mRNA-binding protein 1 23.31 
IGFBP7 Insulin-like growth factor-binding protein 7 23.25 
MTHFD2 Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial 23.21 
ITGA8 Integrin alpha-8;Integrin alpha-8 heavy chain;Integrin alpha-8 light chain 23.20 
VCAN Versican core protein 23.16 
ITGA4 Integrin alpha-4 23.02 
DSG2 Desmoglein-2 22.82 
SCARB1 Scavenger receptor class B member 1 22.81 
PLAT Tissue-type plasminogen activator;Tissue-type plasminogen activator chain A 22.79 
TES Testin 22.76 
LDLR Low-density lipoprotein receptor 22.75 
POLR2C DNA-directed RNA polymerase II subunit RPB3 22.71 
DHRS3 Short-chain dehydrogenase/reductase 3 22.65 
FTL Ferritin light chain 22.48 
ARHGDIB Rho GDP-dissociation inhibitor 2 22.40 
NUDT4 Diphosphoinositol polyphosphate phosphohydrolase 2 22.38 
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GPX1 Glutathione peroxidase 1 22.37 
ISLR Immunoglobulin superfamily containing leucine-rich repeat protein 22.36 
PVRL2 Poliovirus receptor-related protein 2 22.35 
TTLL12 Tubulin--tyrosine ligase-like protein 12 22.33 
MGST1 Microsomal glutathione S-transferase 1 22.29 
TNFRSF10B Tumor necrosis factor receptor superfamily member 10B 22.27 
SPG20 Spartin 22.12 
NID2 Nidogen-2 22.07 
CCDC88A Girdin 22.07 
HLA-A HLA class I histocompatibility antigen, A-69 alpha chain 22.03 
EMILIN2 EMILIN-2 22.00 
MRPL15 39S ribosomal protein L15, mitochondrial 21.98 
GLIPR2 Golgi-associated plant pathogenesis-related protein 1 21.97 
RAB13 Ras-related protein Rab-13 21.89 
CDC42EP4 Cdc42 effector protein 4 21.89 
CIAPIN1 Anamorsin 21.88 
PDCD4 Programmed cell death protein 4 21.84 
DFFA DNA fragmentation factor subunit alpha 21.82 
SUCLG1 Succinyl-CoA ligase [ADP/GDP-forming] subunit alpha, mitochondrial 21.80 
HSPA2 Heat shock-related 70 kDa protein 2 21.72 
NUMB Protein numb homolog 21.65 
TGOLN2 Trans-Golgi network integral membrane protein 2 21.63 
EXOSC4 Exosome complex component RRP41 21.59 
CDK6 Cyclin-dependent kinase 6 21.53 
SLC16A1 Monocarboxylate transporter 1 21.51 
PRPF31 U4/U6 small nuclear ribonucleoprotein Prp31 21.45 
PRPF4 U4/U6 small nuclear ribonucleoprotein Prp4 21.43 
EHBP1 EH domain-binding protein 1 21.38 
SEC16A Protein transport protein Sec16A 21.35 
LRRC17 Leucine-rich repeat-containing protein 17 21.35 
NCOR2 Nuclear receptor corepressor 2 21.31 
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MORF4L2 Mortality factor 4-like protein 2 21.30 
PCOLCE Procollagen C-endopeptidase enhancer 1 21.27 
MAPRE2 Microtubule-associated protein RP/EB family member 2 21.21 
ITGA1 Integrin alpha-1 21.19 
OXR1 Oxidation resistance protein 1 21.15 
COBRA1 Negative elongation factor B 21.13 
EXOSC2 Exosome complex component RRP4 21.12 
PSMG2 Proteasome assembly chaperone 2 21.10 
TGFB2 Transforming growth factor beta-2 21.08 
SPAG7 Sperm-associated antigen 7 21.03 
USE1 Vesicle transport protein USE1 21.01 
PPAT Amidophosphoribosyltransferase 20.98 
MAP7D3 MAP7 domain-containing protein 3 20.95 
ATP6AP2 Renin receptor 20.93 
TRMT5 tRNA (guanine(37)-N1)-methyltransferase 20.89 
LPCAT1 Lysophosphatidylcholine acyltransferase 1 20.87 
ESF1 ESF1 homolog 20.87 
TEX264 Testis-expressed sequence 264 protein 20.81 
DCTN4 Dynactin subunit 4 20.66 
CDH6 Cadherin-6 20.65 
MARCKSL1 MARCKS-related protein 20.59 
ASMTL N-acetylserotonin O-methyltransferase-like protein 20.53 
PCYT2 Ethanolamine-phosphate cytidylyltransferase 20.52 
SPATS2 Spermatogenesis-associated serine-rich protein 2 20.51 
FAM175B BRISC complex subunit Abro1 20.49 
PNKP Bifunctional polynucleotide phosphatase/kinase 20.48 
ARID1A AT-rich interactive domain-containing protein 1A 20.34 
TFPI2 Tissue factor pathway inhibitor 2 20.27 
YY1 Transcriptional repressor protein YY1 20.20 
ZC3H11A Zinc finger CCCH domain-containing protein 11A 20.18 
TTYH3 Protein tweety homolog 3 20.05 
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EXD2 Exonuclease 3-5 domain-containing protein 2 19.99 
ZC3H14 Zinc finger CCCH domain-containing protein 14 19.87 
ANAPC7 Anaphase-promoting complex subunit 7 19.64 
C2orf29 UPF0760 protein C2orf29 19.14 
CLDN11 Claudin-11 18.79 
HERPUD1 Homocysteine-responsive endoplasmic reticulum-resident ubiquitin-like domain member 1 protein 16.63 
NES Nestin 4.84 
PDLIM1 PDZ and LIM domain protein 1 4.81 
COL1A1 Collagen alpha-1(I) chain 4.77 
SPARC SPARC 3.96 
TGM2 Protein-glutamine gamma-glutamyltransferase 2 3.94 
ANPEP Aminopeptidase N 3.86 
UCHL1 Ubiquitin carboxyl-terminal hydrolase isozyme L1 3.73 
HNRNPM Heterogeneous nuclear ribonucleoprotein M 3.71 
LMNB2 Lamin-B2 3.67 
GGT5 Gamma-glutamyltransferase 5 3.60 
HNRNPC Heterogeneous Nuclear Ribonucleoprotein C 3.58 
COL1A2 Collagen alpha-2(I) chain 3.49 
AKAP12 A-kinase anchor protein 12 3.36 
TGFBI Transforming growth factor-beta-induced protein ig-h3 3.34 
NASP Nuclear autoantigenic sperm protein 3.30 
IGF2BP3 Insulin-like growth factor 2 mRNA-binding protein 3 3.18 
COL18A1 Collagen alpha-1(XVIII) chain;Endostatin 3.15 
DBN1 Drebrin 3.13 
PRMT1 Protein arginine N-methyltransferase 1 3.05 
RRBP1 Ribosome-binding protein 1 3.00 
COL5A2 Collagen alpha-2(V) chain 2.97 
SRSF9 Serine/arginine-rich splicing factor 9 2.92 
STIP1 Stress-induced-phosphoprotein 1 2.88 
CNN3 Calponin-3 2.77 
HIST1H1B Histone H1.5 2.74 
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FUBP1 Far upstream element-binding protein 1 2.66 
SF3B2 Splicing factor 3B subunit 2 2.61 
S E P 9 Septin-9 2.54 
FN1 Fibronectin 1  2.53 
LMNB1 Lamin-B1 2.53 
COL5A1 Collagen alpha-1(V) chain 2.45 
ITGA2 Integrin alpha-2 2.43 
KHSRP Far upstream element-binding protein 2 2.43 
TOM1 Target of Myb protein 1 2.39 
TIAL1 Nucleolysin TIAR 2.38 
CNN2 Calponin-2 2.32 
SERPINE1 Plasminogen activator inhibitor 1 2.29 
ACO2 Aconitate hydratase, mitochondrial 2.27 
ITGA5 Integrin alpha-5;Integrin alpha-5 heavy chain;Integrin alpha-5 light chain 2.23 
NRP1 Neuropilin-1 2.22 
FDPS Farnesyl pyrophosphate synthase 2.15 
SHMT2 Serine hydroxymethyltransferase, mitochondrial;Serine hydroxymethyltransferase 2.15 
TPM3 Tropomyosin 3 2.14 
NACA Nascent polypeptide-associated complex subunit alpha 2.13 
SLC25A6 ADP/ATP translocase 3 2.10 
ST13;ST13P5 Hsc70-interacting protein;Putative protein FAM10A5 2.05 
ATP1A1 Sodium/potassium-transporting ATPase subunit alpha-1 2.04 
SMARCC1 SWI/SNF complex subunit SMARCC1 1.98 
CKAP4 Cytoskeleton-associated protein 4 1.95 
COL4A1 Collagen alpha-1(IV) chain;Arresten 1.95 
COL6A2 Collagen alpha-2(VI) chain 1.93 
RPL12 60S ribosomal protein L12 1.90 
EPS8 Epidermal growth factor receptor kinase substrate 8 1.80 
TFRC Transferrin receptor protein 1;Transferrin receptor protein 1, serum form 1.70 
HDLBP Vigilin 1.68 
FSCN1 Fascin 1.67 
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PDGFRB Platelet-derived growth factor receptor beta 1.63 
CTSD Cathepsin D 1.61 
YARS Tyrosine--tRNA ligase, cytoplasmic 1.45 
MYH9 Myosin-9 1.42 
CCT8 T-complex protein 1 subunit theta 1.40 
SND1 Staphylococcal nuclease domain-containing protein 1 1.32 
KARS Lysine--tRNA ligase 1.31 
PRKAR2A cAMP-dependent protein kinase type II-alpha regulatory subunit 1.30 
UQCRFS1 Cytochrome b-c1 complex subunit Rieske, mitochondrial 1.30 
PDIA4 Protein disulfide-isomerase A4 1.27 
ANXA11 Annexin A11;Annexin 1.26 
FKBP1A Peptidyl-prolyl cis-trans isomerase FKBP1A 1.24 
HNRNPH3 Heterogeneous nuclear ribonucleoprotein H3 1.22 
PGM3 Phosphoacetylglucosamine mutase 1.22 
FKBP4 Peptidyl-prolyl cis-trans isomerase FKBP4 1.19 
SRSF1 Serine/arginine-rich splicing factor 1 1.13 
HNRNPA3 Heterogeneous nuclear ribonucleoprotein A3 1.12 
PLOD3 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3 1.10 
UGP2 UTP--glucose-1-phosphate uridylyltransferase 1.08 
RAC1;RAC3 Ras-related C3 botulinum toxin substrate 1;Ras-related C3 botulinum toxin substrate 3 1.06 
FBL rRNA 2-O-methyltransferase fibrillarin 1.06 
M6PR Cation-dependent mannose-6-phosphate receptor 1.05 
ETFA Electron transfer flavoprotein subunit alpha, mitochondrial 1.04 
IDE Insulin-degrading enzyme -1.00 
AK1 Adenylate kinase isoenzyme 1 -1.03 
ANXA6 Annexin A6;Annexin -1.03 
DAB2 Disabled homolog 2 -1.05 
XPOT Exportin-T -1.06 
PSMA6 Proteasome subunit alpha type-6;Proteasome subunit alpha type -1.12 
EHD2 EH domain-containing protein 2 -1.14 
RAB6A RAB6A, Member RAS Oncogene Family -1.17 
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AP3D1 AP-3 complex subunit delta-1 -1.17 
RHOG Rho-related GTP-binding protein RhoG -1.17 
OLA1 Obg-like ATPase 1 -1.18 
AK4 Adenylate kinase isoenzyme 4, mitochondrial -1.19 
TOM1L2 TOM1-like protein 2 -1.19 
GLS Glutaminase kidney isoform, mitochondrial -1.20 
GDI1 Rab GDP dissociation inhibitor alpha -1.20 
RARS Arginine--tRNA ligase, cytoplasmic -1.23 
TMED10 Transmembrane emp24 domain-containing protein 10 -1.24 
STK24 Serine/threonine-protein kinase 24 -1.24 
DNPEP Aspartyl aminopeptidase -1.25 
PKM2 Pyruvate kinase isozymes M1/M2;Pyruvate kinase -1.25 
UBA1 Ubiquitin-like modifier-activating enzyme 1 -1.28 
STOM Erythrocyte band 7 integral membrane protein -1.28 
DDB1 DNA damage-binding protein 1 -1.28 
RPS26 40S ribosomal protein S26;Putative 40S ribosomal protein S26-like 1 -1.34 
LARS Leucine--tRNA ligase, cytoplasmic -1.39 
NCAPG Condensin complex subunit 3 -1.39 
LTA4H Leukotriene A-4 hydrolase -1.42 
SARS Serine--tRNA ligase, cytoplasmic -1.46 
CNP 2,3-cyclic-nucleotide 3-phosphodiesterase -1.46 
RPL10 60S ribosomal protein L10 -1.46 
ANXA4 Annexin A4;Annexin -1.49 
BLVRA Biliverdin reductase A -1.50 
ESYT1 Extended synaptotagmin-1 -1.51 
KPNA6 Importin subunit alpha-7;Importin subunit alpha -1.53 
MYO1E Unconventional myosin-Ie -1.54 
OAT Ornithine aminotransferase, mitochondrial -1.54 
C19orf10 UPF0556 protein C19orf10 -1.55 
TMPO Lamina-associated polypeptide 2, isoforms beta/gamma;Thymopoietin;Thymopentin -1.56 
H2AFZ Histone H2A.Z;Histone H2A.V;Histone H2A -1.57 
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UBE4A Ubiquitin conjugation factor E4 A -1.57 
EZR Ezrin -1.57 
CSNK1A1 Casein kinase I isoform alpha;Casein kinase I isoform alpha-like -1.57 
CYCS Cytochrome c -1.58 
NPLOC4 Nuclear protein localization protein 4 homolog -1.61 
CTSD Cathepsin D;Cathepsin D light chain;Cathepsin D heavy chain -1.62 
NT5C 5(3)-deoxyribonucleotidase, cytosolic type -1.62 
DPYSL3 Dihydropyrimidinase-related protein 3 -1.64 
PRKCDBP Protein kinase C delta-binding protein -1.67 
NME3 Nucleoside diphosphate kinase 3 -1.67 
PLEC Plectin -1.69 
LDHA L-lactate dehydrogenase A chain -1.69 
NFKB2 Nuclear factor NF-kappa-B p100 subunit;Nuclear factor NF-kappa-B p52 subunit -1.70 
HK2 Hexokinase-2 -1.70 
PIP4K2C Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma -1.70 
PAIP1 Polyadenylate-binding protein-interacting protein 1 -1.71 
CTSC Dipeptidyl peptidase 1 -1.71 
PSMA7 Proteasome subunit alpha type-7 -1.72 
GNPNAT1 Glucosamine 6-phosphate N-acetyltransferase -1.73 
ADK Adenosine kinase -1.74 
GPD2 Glycerol-3-phosphate dehydrogenase, mitochondrial -1.74 
DSTN Destrin -1.75 
LEPREL1 Prolyl 3-hydroxylase 2 -1.76 
MYOF Myoferlin -1.80 
ANXA3 Annexin A3;Annexin -1.82 
LOX Protein-lysine 6-oxidase -1.82 
GRPEL1 GrpE protein homolog 1, mitochondrial -1.85 
UBLCP1 Ubiquitin-like domain-containing CTD phosphatase 1 -1.85 
RNH1 Ribonuclease inhibitor -1.87 
ARHGAP18 Rho GTPase-activating protein 18 -1.88 
PRPS1 Ribose-phosphate pyrophosphokinase 1;Ribose-phosphate pyrophosphokinase -1.94 
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HLA-A HLA class I histocompatibility antigen, A-3 alpha chain -1.95 
PGM1 Phosphoglucomutase-1 -1.97 
SCCPDH Saccharopine dehydrogenase-like oxidoreductase -1.97 
SF3B14 Pre-mRNA branch site protein p14 -1.98 
PC Pyruvate carboxylase, mitochondrial -1.99 
MTHFD1L Monofunctional C1-tetrahydrofolate synthase, mitochondrial -2.00 
G6PD Glucose-6-phosphate 1-dehydrogenase -2.01 
STK10 Serine/threonine-protein kinase 10 -2.01 
PGAM1 Phosphoglycerate mutase 1 -2.02 
GSTM2 Glutathione S-transferase Mu 2 -2.05 
SPAG9 C-Jun-amino-terminal kinase-interacting protein 4 -2.09 
CYR61 Protein CYR61 -2.11 
GNA11 Guanine nucleotide-binding protein subunit alpha-11 -2.12 
PSME1 Proteasome activator complex subunit 1 -2.12 
CAPN2 Calpain-2 catalytic subunit -2.13 
MYO1B Unconventional myosin-Ib -2.15 
PSMB3 Proteasome subunit beta type-3 -2.16 
UAP1 UDP-N-acetylhexosamine pyrophosphorylase -2.18 
TNPO1 Transportin-1 -2.19 
NEK7 Serine/threonine-protein kinase Nek7 -2.20 
CAST Calpastatin -2.26 
MARS Methionine--tRNA ligase, cytoplasmic -2.26 
FGD4 FYVE, RhoGEF and PH domain-containing protein 4 -2.28 
EIF2AK2 Interferon-induced, double-stranded RNA-activated protein kinase -2.34 
ATP6V0C V-type proton ATPase 16 kDa proteolipid subunit -2.34 
IPO5 Importin-5 -2.35 
EPHA2 Ephrin type-A receptor 2 -2.38 
PGLS 6-phosphogluconolactonase -2.39 
PRDX5 Peroxiredoxin-5, mitochondrial -2.41 
ECE1 Endothelin-converting enzyme 1 -2.43 
HSPB1 Heat shock protein beta-1 -2.54 
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PPIC Peptidyl-prolyl cis-trans isomerase C -2.54 
MYO1C Unconventional myosin-Ic -2.55 
STAT1 Signal transducer and activator of transcription 1-alpha/beta -2.57 
LGALS3 Galectin-3 -2.57 
EGFR Epidermal growth factor receptor -2.61 
ATL3 Atlastin GTPase 3 -2.65 
HDHD1 Pseudouridine-5-monophosphatase -2.67 
PDLIM2 PDZ and LIM domain protein 2 -2.68 
PNP Purine nucleoside phosphorylase -2.70 
PDXK Pyridoxal kinase -2.70 
UGDH UDP-glucose 6-dehydrogenase -2.73 
RNPEP Aminopeptidase B -2.73 
EIF4A2 Eukaryotic initiation factor 4A-II -2.79 
EHD1 EH domain-containing protein 1 -2.79 
CCDC80 Coiled-coil domain-containing protein 80 -2.82 
GALNT2 Polypeptide N-acetylgalactosaminyltransferase 2 -2.84 
AXL Tyrosine-protein kinase receptor UFO -3.04 
GBE1 1,4-alpha-glucan-branching enzyme -3.17 
AHNAK2 Protein AHNAK2 -3.17 
PYGL Glycogen phosphorylase, liver form;Phosphorylase -3.23 
ABHD14B Abhydrolase domain-containing protein 14B -3.24 
ALDH1A3 Aldehyde dehydrogenase family 1 member A3 -3.29 
DST Dystonin -3.32 
ALCAM CD166 antigen -3.37 
AFAP1 Actin filament-associated protein 1 -3.51 
ACOT9 Acyl-coenzyme A thioesterase 9, mitochondrial -3.55 
MGLL Monoglyceride lipase -4.29 
KRT18 Keratin, type I cytoskeletal 18 -4.48 
EPS8L2 Epidermal growth factor receptor kinase substrate 8-like protein 2 -4.49 
SPR Sepiapterin reductase -4.61 
NQO1 NAD(P)H dehydrogenase [quinone] 1 -5.94 
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AAAS Aladin -19.79 
MRI1 Methylthioribose-1-phosphate isomerase -19.88 
NOP10 H/ACA ribonucleoprotein complex subunit 3 -20.09 
POLR1A DNA-directed RNA polymerase I subunit RPA1;DNA-directed RNA polymerase -20.11 
IQGAP2 Ras GTPase-activating-like protein IQGAP2 -20.19 
IQGAP3 Ras GTPase-activating-like protein IQGAP3 -20.30 
DGKA Diacylglycerol kinase alpha -20.30 
GCC1 GRIP and coiled-coil domain-containing protein 1 -20.45 
CCDC132 Coiled-coil domain-containing protein 132 -20.53 
ADRBK1 Beta-adrenergic receptor kinase 1;Beta-adrenergic receptor kinase 2 -20.54 
WHSC2 Negative elongation factor A -20.58 
KIF13A Kinesin-like protein KIF13A -20.63 
ZNF622 Zinc finger protein 622 -20.65 
CCPG1 Cell cycle progression protein 1 -20.68 
USP4 Ubiquitin carboxyl-terminal hydrolase 4;Ubiquitin carboxyl-terminal hydrolase -20.71 
ARHGEF40 Rho guanine nucleotide exchange factor 40 -20.80 
TIMMDC1 Translocase of inner mitochondrial membrane domain-containing protein 1 -20.84 
ZNF185 Zinc finger protein 185 -20.88 
ARHGAP21 Rho GTPase-activating protein 21;Rho GTPase-activating protein 23 -20.95 
HRSP12 Ribonuclease UK114 -20.99 
MRPL12 39S ribosomal protein L12, mitochondrial -20.99 
C16orf13 UPF0585 protein C16orf13 -21.06 
CUL1 Cullin-1 -21.14 
MRPL38 39S ribosomal protein L38, mitochondrial -21.14 
MGAT1 Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase -21.19 
KIF3A Kinesin-like protein KIF3A -21.30 
COASY Bifunctional coenzyme A synthase -21.35 
SNAPIN SNARE-associated protein Snapin -21.38 
SEC24B Protein transport protein Sec24B -21.41 
HTRA1 Serine protease HTRA1 -21.46 
SCAF4 Splicing factor, arginine/serine-rich 15 -21.48 
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VAMP4 Vesicle-associated membrane protein 4 -21.50 
MAN2B1 Lysosomal alpha-mannosidase -21.51 
BUD31 Protein BUD31 homolog -21.51 
PTP4A2 Protein tyrosine phosphatase type IVA 2 -21.55 
PLXNA1 Plexin-A1 -21.55 
PPIP5K2 Inositol hexakisphosphate and diphosphoinositol-pentakisphosphate kinase 2 -21.57 
XPC DNA repair protein complementing XP-C cells -21.61 
MAP4K4 Mitogen-activated protein kinase kinase kinase kinase 4 -21.61 
HPCAL1 Hippocalcin-like protein 1 -21.67 
PPP4C Serine/threonine-protein phosphatase 4 catalytic subunit;Serine/threonine-protein phosphatase -21.76 
MMGT1 Membrane magnesium transporter 1 -21.79 
JAG1 Protein jagged-1 -21.80 
HINT2 Histidine triad nucleotide-binding protein 2, mitochondrial -21.81 
CLPTM1 Cleft lip and palate transmembrane protein 1 -21.87 
AKR1C1 Aldo-keto reductase family 1 member C1;Aldo-keto reductase family 1 member C2 -21.88 
POLD1 DNA polymerase delta catalytic subunit -21.96 
DOCK5 Dedicator of cytokinesis protein 5 -21.98 
TRADD Tumor necrosis factor receptor type 1-associated DEATH domain protein -21.99 
GNL2 Nucleolar GTP-binding protein 2 -22.05 
MYH14 Myosin-14 -22.08 
RBM12B RNA-binding protein 12B -22.08 
GFM1 Elongation factor G, mitochondrial -22.10 
SCAMP1 Secretory carrier-associated membrane protein 1 -22.14 
LYRM7 LYR motif-containing protein 7 -22.14 
FYCO1 FYVE and coiled-coil domain-containing protein 1 -22.15 
USP8 Ubiquitin carboxyl-terminal hydrolase 8;Ubiquitin carboxyl-terminal hydrolase -22.17 
COX7A2 Cytochrome c oxidase subunit 7A2, mitochondrial -22.18 
PARP14 Poly [ADP-ribose] polymerase 14 -22.21 
TP53RK TP53-regulating kinase -22.21 
SACM1L Phosphatidylinositide phosphatase SAC1 -22.22 
TFPI Tissue factor pathway inhibitor -22.24 
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DFNA5 Non-syndromic hearing impairment protein 5 -22.31 
MRPS14 28S ribosomal protein S14, mitochondrial -22.39 
DNAJC5 DnaJ homolog subfamily C member 5 -22.41 
MTPN Myotrophin -22.41 
PPT1 Palmitoyl-protein thioesterase 1 -22.41 
ELN Elastin -22.48 
ALAD Delta-aminolevulinic acid dehydratase -22.50 
VPS29 Vacuolar protein sorting-associated protein 29 -22.51 
FGF1 Fibroblast growth factor 1 -22.51 
LRRC32 Leucine-rich repeat-containing protein 32 -22.53 
H2AFY Core histone macro-H2A.1;Histone H2A;Core histone macro-H2A.2 -22.53 
OPLAH 5-oxoprolinase -22.54 
COG7 Conserved oligomeric Golgi complex subunit 7 -22.56 
PRSS23 Serine protease 23 -22.59 
TAP1 Antigen peptide transporter 1 -22.61 
TRIM25 E3 ubiquitin/ISG15 ligase TRIM25 -22.68 
SLIT3 Slit homolog 3 protein -22.69 
COX5B Cytochrome c oxidase subunit 5B, mitochondrial -22.81 
PROSC Proline synthase co-transcribed bacterial homolog protein -22.84 
IER3IP1 Immediate early response 3-interacting protein 1 -22.94 
SAMD9 Sterile alpha motif domain-containing protein 9 -22.96 
BPGM Bisphosphoglycerate mutase -22.96 
HIGD2A HIG1 domain family member 2A -23.00 
SULT1A1 Sulfotransferase 1A1 -23.00 
CTSZ Cathepsin Z -23.04 
AKR1B1 Aldose reductase -23.04 
DCTD Deoxycytidylate deaminase -23.12 
SLC44A2 Choline transporter-like protein 2 -23.13 
KIAA1524 Protein CIP2A -23.17 
SYNE1 Nesprin-1 -23.21 
GNG12 Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-12 -23.26 
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PARP10 Poly [ADP-ribose] polymerase 10 -23.49 
SH2D4A SH2 domain-containing protein 4A -23.50 
UQCRQ Cytochrome b-c1 complex subunit 8 -23.55 
ABI3BP Target of Nesh-SH3 -23.77 
HSPA4L Heat shock 70 kDa protein 4L -24.23 
PHPT1 14 kDa phosphohistidine phosphatase -24.50 
C6orf108 Deoxyribonucleoside 5-monophosphate N-glycosidase -24.76 
THY1 Thy-1 membrane glycoprotein -24.89 
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Supplementary Table S7: Phosphopeptides identified by TiO2 phosphopeptide emrichment in Ben-Men-1 cells 
Gene names Protein names Localization score Peptide score Modified sequence 
ABCB10 ATP-binding cassette sub-family B member 10, mitochondrial 0.997604 94.688 _IRTS(ph)IFS(ph)SIIR_ 
ADGB Androglobin 0.993943 90.827 _(ac)N(de)IEQY(ph)AVSIIR_ 
AGK Acylglycerol kinase, mitochondrial 1 84.365 _(ac)MT(ph)VFFKT(ph)IR_ 
AGK Acylglycerol kinase, mitochondrial 1 84.365 _(ac)MT(ph)VFFKT(ph)IR_ 
AHNAK Neuroblast differentiation-associated protein AHNAK 1 98.766 _AS(ph)IGS(ph)IEGEAEAEASSPK_ 
AHNAK Neuroblast differentiation-associated protein AHNAK 1 183.56 _AS(ph)IGS(ph)IEGEAEAEASSPK_ 
AHNAK Neuroblast differentiation-associated protein AHNAK 0.997751 221.85 _ASIGSIEGEAEAEASS(ph)PK_ 
AHNAK Neuroblast differentiation-associated protein AHNAK 1 124.2 _FKAEAPIPS(ph)PK_ 
AHNAK Neuroblast differentiation-associated protein AHNAK 0.999755 198.1 _GKGGVTGS(ph)PEASISGSK_ 
AHNAK Neuroblast differentiation-associated protein AHNAK 0.997794 178.56 _IPS(ph)GSGAASPTGSAVDIR_ 
AHNAK Neuroblast differentiation-associated protein AHNAK 0.89232 238.89 _IPSGS(ph)GAAS(ph)PTGSAVDIR_ 
AHNAK Neuroblast differentiation-associated protein AHNAK 0.997895 260.24 _IPSGSGAAS(ph)PTGSAVDIR_ 
AHNAK Neuroblast differentiation-associated protein AHNAK 1 138.97 _IS(ph)APNVDFNIEGPK_ 
ARHGAP21 Rho GTPase-activating protein 21 1 96.745 _DIN(de)VIS(ph)S(ph)IIKS(ph)FFR_ 
ARHGAP21 Rho GTPase-activating protein 21 1 96.745 _DIN(de)VIS(ph)S(ph)IIKS(ph)FFR_ 
ARHGAP21 Rho GTPase-activating protein 21 1 96.745 _DIN(de)VIS(ph)S(ph)IIKS(ph)FFR_ 
ARNT2 Aryl hydrocarbon receptor nuclear translocator 2 0.949639 72.399 _EQICT(ph)SEN(de)SM(ox)T(ph)GRIIDIK_ 
BAIAP2 Brain-specific angiogenesis inhibitor 1-associated protein 2 1 62.203 _(ac)MEQFNPS(ph)IRN(de)FIAMGK_ 
BCLAF1 Bcl-2-associated transcription factor 1 1 257.37 _AEGEWEDQEAIDYFS(ph)DK_ 
BCLAF1 Bcl-2-associated transcription factor 1 1 145.81 _DIFDYS(ph)PPIHK_ 
BTBD7 BTB/POZ domain-containing protein 7 0.999985 88.239 _IADREPN(de)IIS(ph)GTAHS(ph)VN(de)KR_ 
C14orf135 Pecanex-like protein C14orf135 0.99998 58.274 _(ac)M(ox)S(ph)PDVPIINDYK_ 
C17orf85 Uncharacterized protein C17orf85 0.998917 136.14 _AEAPAGPAIGIPS(ph)PEAESGVDR_ 
C2orf73 Uncharacterized protein C2orf73 1 78.244 _EIKPGS(ph)RPT(ph)VPK_ 
C2orf73 Uncharacterized protein C2orf73 1 78.244 _EIKPGS(ph)RPT(ph)VPK_ 
CANX Calnexin 1 122.33 _AEEDEIIN(de)RS(ph)PR_ 
CCDC102A Coiled-coil domain-containing protein 102A 1 114.97 _AAQMEKT(ph)MRR_ 
CCDC120 Coiled-coil domain-containing protein 120 0.997046 52.391 _RSN(de)S(ph)S(ph)EAIIVDR_ 
CCDC120 Coiled-coil domain-containing protein 120 0.990636 52.391 _RSN(de)S(ph)S(ph)EAIIVDR_ 
CCDC86 Coiled-coil domain-containing protein 86 0.999758 155.86 _IGGIRPES(ph)PESITSVSR_ 
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CCIN Calicin 0.999901 54.281 _M(ox)S(ph)IPMDGT(ph)AVITK_ 
CCIN Calicin 0.984891 54.281 _M(ox)S(ph)IPMDGT(ph)AVITK_ 
CEP170 Centrosomal protein of 170 kDa 0.999207 151.42 _ARIGEAS(ph)DSEIADADK_ 
CFL1 Cofilin-1 1 154.72 _(ac)AS(ph)GVAVSDGVIK_ 
CFL2 Cofilin-2 0.999232 130.21 _AS(ph)GVTVNDEVIK_ 
CHL1 Neural cell adhesion molecule L1-like protein 0.929466 52.576 _VMTPAVY(ph)APY(ph)DVK_ 
CHL1 Neural cell adhesion molecule L1-like protein 0.999938 52.576 _VMTPAVY(ph)APY(ph)DVK_ 
CHMP2B Charged multivesicular body protein 2b 0.999361 98.337 _ATIS(ph)DEEIER_ 
CHMP6 Charged multivesicular body protein 6 1 76.679 _RY(ph)QEQIIDR_ 
COG8 Conserved oligomeric Golgi complex subunit 8 0.925939 50.149 _RM(ox)N(de)S(ph)ITIN(de)R_ 
CTH Cystathionine gamma-lyase 0.999867 89.911 _AVAAIDGAKYCT(ph)N(de)R_ 
CTNNA1 Catenin alpha-1 0.999984 197.68 _TPEEIDDS(ph)DFETEDFDVR_ 
DDX4 Probable ATP-dependent RNA helicase DDX4 0.842258 68.845 _RDNT(ph)S(ph)TM(ox)GGFGVGK_ 
DDX4 Probable ATP-dependent RNA helicase DDX4 0.805702 68.845 _RDNT(ph)S(ph)TM(ox)GGFGVGK_ 
DPF1 DPF1 protein 1 55.452 _(ac)M(ox)AT(ph)AIQNPIK_ 
DST Dystonin 0.91406 120.57 _S(ph)FSEDVISHK_ 
DYNC1LI1 Cytoplasmic dynein 1 light intermediate chain 1 0.9896 162.43 _KPVTVS(ph)PTTPTSPTEGEAS_ 
EEF1D Elongation factor 1-delta 1 163.4 _KPATPAEDDEDDDIDIFGS(ph)DNEEEDK_ 
EGFR Epidermal growth factor receptor 0.965891 137.64 _EIVEPIT(ph)PSGEAPNQAIIR_ 
EIF4EBP1 Eukaryotic translation initiation factor 4E-binding protein 1 0.762844 75.718 _VVIGDGVQIPPGDYSTT(ph)PGGTIFSTT(ph)PGGTR_ 
ELL RNA polymerase II elongation factor ELL 0.999159 99.283 _QDSVS(ph)IRPS(ph)IR_ 
ELL RNA polymerase II elongation factor ELL 0.999994 99.283 _QDSVS(ph)IRPS(ph)IR_ 
EXOSC9 Exosome complex component RRP45 0.951017 179.5 _APIDTS(ph)DVEEK_ 
EXPH5 Exophilin-5 0.999999 60.489 _S(ph)NGFGFN(de)AS(ph)T(ph)IIS(ph)S(ph)KKSPR_ 
EXPH5 Exophilin-5 0.999999 60.489 _S(ph)NGFGFN(de)AS(ph)T(ph)IIS(ph)S(ph)KKSPR_ 
EXPH5 Exophilin-5 0.892262 60.489 _S(ph)NGFGFN(de)AS(ph)T(ph)IIS(ph)S(ph)KKSPR_ 
EXPH5 Exophilin-5 0.999999 60.489 _S(ph)NGFGFN(de)AS(ph)T(ph)IIS(ph)S(ph)KKSPR_ 
FAM129B Niban-like protein 1 0.999976 109.68 _AAPEAS(ph)SPPAS(ph)PIQHIIPGK_ 
FAM129B Niban-like protein 1 1 88.708 _GIIAQGIRPES(ph)PPPAGPIIN(de)GAPAGESPQPK_ 
FAM3C Protein FAM3C 1 78.428 _GINVAIANGKT(ph)GEVIDT(ph)K_ 
FAM3C Protein FAM3C 1 78.428 _GINVAIANGKT(ph)GEVIDT(ph)K_ 
FAM83H Protein FAM83H 0.999992 128.76 _KGS(ph)PTPGFSTR_ 
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FHDC1 FH2 domain-containing protein 1 0.999192 78.505 _KDS(ph)SRTT(ph)IGR_ 
FHDC1 FH2 domain-containing protein 1 0.887568 78.505 _KDS(ph)SRTT(ph)IGR_ 
FKBP15 FK506-binding protein 15 0.969712 131.72 _SSIS(ph)GDEEDEIFK_ 
FLNB Filamin-B 0.999993 150.26 _IVS(ph)PGSANETSSIIVESVTR_ 
FNDC3B Fibronectin type III domain-containing protein 3B 0.999992 115.12 _INS(ph)PPSSIYK_ 
FOXK2 Forkhead box protein K2 1 169.67 _EGS(ph)PAPIEPEPGAAQPK_ 
FRYL Protein Furry Homolog-Like 1 58.487 _N(de)IIMS(ph)N(de)IT(ph)IDPDVK_ 
FRYL Protein Furry Homolog-Like 1 58.487 _N(de)IIMS(ph)N(de)IT(ph)IDPDVK_ 
G3BP1 Ras GTPase-activating protein-binding protein 1 0.842968 172.83 _S(ph)SSPAPADIAQTVQEDIR_ 
GBE1 1,4-alpha-glucan-branching enzyme 1 98.392 _(ac)MN(de)IAKVRY(ph)K_ 
GGH Gamma-glutamyl hydrolase 1 72.315 _KFFN(de)VIT(ph)T(ph)N(de)T(ph)DGK_ 
GGH Gamma-glutamyl hydrolase 1 72.315 _KFFN(de)VIT(ph)T(ph)N(de)T(ph)DGK_ 
GGH Gamma-glutamyl hydrolase 1 72.315 _KFFN(de)VIT(ph)T(ph)N(de)T(ph)DGK_ 
GRHL1 Grainyhead-like protein 1 homolog 0.777196 55.885 _GIPIN(de)IQVDTYS(ph)Y(ph)N(de)NR_ 
GRHL1 Grainyhead-like protein 1 homolog 0.928346 55.885 _GIPIN(de)IQVDTYS(ph)Y(ph)N(de)NR_ 
HIST1H1B Histone H1.5 0.983235 264.38 _S(ph)ETAPAETATPAPVEK_ 
HIST1H1B Histone H1.5 0.843748 107.03 _(ac)SET(ph)APAETATPAPVEK_ 
HIST1H1D Histone H1.3 0.896168 176.81 _(ac)SETAPIAPTIPAPAEKT(ph)PVK_ 
HLTF Helicase-like transcription factor 1 86.539 _T(ph)IQRPVT(ph)MGDEGGIRR_ 
HLTF Helicase-like transcription factor 1 86.539 _T(ph)IQRPVT(ph)MGDEGGIRR_ 
HN1 Hematological and neurological expressed 1 protein 0.996105 177.12 _RNS(ph)SEASSGDFIDIK_ 
HSD17B6 17-beta-hydroxysteroid dehydrogenase type 6 0.999792 56.424 _ET(ph)Y(ph)GQQYFDAIYNIM(ox)K_ 
HSD17B6 17-beta-hydroxysteroid dehydrogenase type 6 0.821576 56.424 _ET(ph)Y(ph)GQQYFDAIYNIM(ox)K_ 
IGF2BP2 Insulin-like growth factor 2 mRNA-binding protein 2 0.812876 137.69 _ISYIPDEEVS(ph)SPSPPQR_ 
IGF2R Cation-independent mannose-6-phosphate receptor 1 134.25 _IVSFHDDS(ph)DEDIIHI_ 
IL17RA Interleukin-17 receptor A 0.991167 71.527 _QEM(ox)VES(ph)NSKIIVICS(ph)R_ 
IL17RA Interleukin-17 receptor A 0.999497 71.527 _QEM(ox)VES(ph)NSKIIVICS(ph)R_ 
INPP4B Type II inositol 3,4-bisphosphate 4-phosphatase 1 72.531 _Y(ph)AFN(de)M(ox)IQIMAFPK_ 
KIAA1432 Protein RIC1 homolog 0.999674 54.103 _SDGPNTTAGIQVIQEVS(ph)M(ox)S(ph)R_ 
KIAA1432 Protein RIC1 homolog 0.999916 54.103 _SDGPNTTAGIQVIQEVS(ph)M(ox)S(ph)R_ 
KIRREL Kin of IRRE-like protein 1 0.996509 53.453 _(ac)M(ox)IS(ph)IIVWIITISDTFS(ph)QGTQT(ph)R_ 
KIRREL Kin of IRRE-like protein 1 0.9037 53.453 _(ac)M(ox)IS(ph)IIVWIITISDTFS(ph)QGTQT(ph)R_ 
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KIRREL Kin of IRRE-like protein 1 0.944559 53.453 _(ac)M(ox)IS(ph)IIVWIITISDTFS(ph)QGTQT(ph)R_ 
KLC1 Kinesin light chain 1 0.999414 132.31 _ASS(ph)INVINVGGK_ 
KLC4 Kinesin light chain 4 1 149.07 _AAS(ph)INYIN(de)QPSAAPIQVSR_ 
KPNA3 Importin subunit alpha-3 0.942758 107.88 _NVPQEESIEDS(ph)DVDADFK_ 
KRT18 Keratin, type I cytoskeletal 18 0.888985 192.1 _PVSSAASVYAGAGGS(ph)GSR_ 
LAMA5 Laminin subunit alpha-5 1 65.423 _GVHNAS(ph)IAIS(ph)AS(ph)IGR_ 
LAMA5 Laminin subunit alpha-5 1 65.423 _GVHNAS(ph)IAIS(ph)AS(ph)IGR_ 
LAMA5 Laminin subunit alpha-5 1 65.423 _GVHNAS(ph)IAIS(ph)AS(ph)IGR_ 
LMO7 LIM domain only protein 7 0.999053 184.83 _IPS(ph)PTSPFSSISQDQAATSK_ 
LMO7 LIM domain only protein 7 1 101.53 _RGES(ph)IDNIDSPR_ 
LMO7 LIM domain only protein 7 1 101.53 _RGES(ph)IDNIDS(ph)PR_ 
LMO7 LIM domain only protein 7 0.997294 177.87 _GGREGFES(ph)DTDSEFTFK_ 
LPIN2 Phosphatidate phosphatase LPIN2 0.953262 163.79 _IPAYIAT(ph)SPIPTEDQFFK_ 
LRCH4 Leucine-rich repeat and calponin homology domain-containing protein 4 0.999638 113.73 _(ac)AAAVAAPIAAGGEEAAATTSVPGS(ph)PGIPGRR_ 
LRRFIP1 Leucine-rich repeat flightless-interacting protein 1 0.936353 183.25 _RGS(ph)GDTSISIDTEASIR_ 
LRRFIP2 Leucine-rich repeat flightless-interacting protein 2 0.871779 191.2 _RGSGDTS(ph)SIIDPDTSISEIR_ 
LTN1 E3 ubiquitin-protein ligase listerin 0.894774 76.015 _IIYHIFRIM(ox)PENPT(ph)Y(ph)AET(ph)AVEVPN(de)K_ 
LTN1 E3 ubiquitin-protein ligase listerin 0.976466 76.015 _IIYHIFRIM(ox)PENPT(ph)Y(ph)AET(ph)AVEVPN(de)K_ 
LTN1 E3 ubiquitin-protein ligase listerin 0.974281 76.015 _IIY(ph)HIFRIM(ox)PEN(de)PT(ph)YAET(ph)AVEVPN(de)K_ 
LTN1 E3 ubiquitin-protein ligase listerin 0.879649 73.405 _IIYHIFRIM(ox)PENPT(ph)Y(ph)AET(ph)AVEVPN(de)K_ 
LUZP1 Leucine zipper protein 1 1 124.84 _EKPDS(ph)DDDIDIASIVTAK_ 
MAEL Protein maelstrom homolog 1 130.01 _HM(ox)AKAS(ph)EIR_ 
MAN2C1 Alpha-mannosidase 2C1 1 82.55 _RIS(ph)N(de)T(ph)DGIPR_ 
MAN2C1 Alpha-mannosidase 2C1 1 82.55 _RIS(ph)N(de)T(ph)DGIPR_ 
MAP1B Microtubule-associated protein 1B;MAP1 light chain LC1 0.996306 149.44 _ESS(ph)PIYS(ph)PTFSDSTSAVK_ 
MAP1B Microtubule-associated protein 1B;MAP1 light chain LC1 1 226.75 _S(ph)PPIIGSESAYESFISADDK_ 
MAP1B Microtubule-associated protein 1B;MAP1 light chain LC1 1 133.78 _VQS(ph)IEGEKIS(ph)PK_ 
MAP1B Microtubule-associated protein 1B;MAP1 light chain LC1 1 133.78 _VQSIEGEKIS(ph)PK_ 
MAP1B Microtubule-associated protein 1B;MAP1 light chain LC1 0.997993 101.6 _VSAEAEVAPVSPEVT(ph)QEVVEEHCAS(ph)PEDK_ 
MAP3K7 Mitogen-activated protein kinase kinase kinase 7 0.999917 156.36 _S(ph)IQDITVTGTEPGQVSSR_ 
MAP4 Microtubule-associated protein;Microtubule-associated protein 4 1 191.96 _DVT(ph)PPPETEVVIIK_ 
MCM2 DNA replication licensing factor MCM2 1 157.47 _GIIYDS(ph)DEEDEERPAR_ 
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MEI1 Meiosis inhibitor protein 1 1 74.392 _(ac)M(ox)CINIIS(ph)APEK_ 
MPHOSPH8 M-phase phosphoprotein 8 1 128.98 _GAEAFGDS(ph)EEDGEDVFEVEK_ 
MTA3 Metastasis-associated protein MTA3 0.993189 78.964 _IKQVY(ph)IPT(ph)YK_ 
MTA3 Metastasis-associated protein MTA3 0.99512 78.964 _IKQVY(ph)IPT(ph)YK_ 
NDRG1 Protein NDRG1 0.970147 115.87 _TAS(ph)GSSVTSIDGTR_ 
NDUFV3 NADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial 0.997076 114.4 _VAS(ph)PSPSGSVIFTDEGVPK_ 
NIPBL Nipped-B-like protein 0.996521 87.083 _AMGIMDKISTDKT(ph)VK_ 
NUCKS1 Nipped-B-like protein 0.85053 84.762 _VVDYSQFQES(ph)DDADEDYGRDSGPPTK_ 
OR2G3 Olfactory receptor 2G3 0.847765 57.432 _(ac)M(ox)GIGN(de)ES(ph)SIMDFIIIGFSDHPR_ 
PA2G4 Proliferation-associated protein 2G4 1 220.66 _S(ph)GEDEQQEQTIAEDIVVTK_ 
PAK2 Serine/threonine-protein kinase PAK 2;PAK-2p27;PAK-2p34 0.996758 122.69 _YIS(ph)FTPPEK_ 
PAK6 Serine/threonine-protein kinase PAK 6 1 76.943 _(ac)MPGPGT(ph)MFR_ 
PARP12 Poly [ADP-ribose] polymerase 12 0.999673 106.67 _RIS(ph)T(ph)ASSVTK_ 
PATL1 Protein PAT1 homolog 1 0.873804 92.993 _RSTS(ph)PIIGS(ph)PPVR_ 
PATL1 Protein PAT1 homolog 1 0.999875 92.993 _RSTS(ph)PIIGS(ph)PPVR_ 
PDLIM2 PDZ and LIM domain protein 2 1 141.6 _AGDSAVIVIPPS(ph)PGPR_ 
PDLIM2 PDZ and LIM domain protein 2 1 225.2 _AGS(ph)PFS(ph)PPPSSSSITGEAAISR_ 
PDLIM2 PDZ and LIM domain protein 2 0.99988 208.97 _AGS(ph)PFS(ph)PPPSSSSITGEAAISR_ 
PDLIM2 PDZ and LIM domain protein 2 0.988311 202.97 _GGTPAFIPSSIS(ph)PQSSIPASR_ 
PDPK1 3-phosphoinositide-dependent protein kinase 1 0.999999 147.87 _ANS(ph)FVGTAQYVSPEIITEK_ 
PGK1 Phosphoglycerate kinase 1;Phosphoglycerate kinase 1 119.32 _AIES(ph)PERPFIAIIGGAK_ 
PGRMC2 Membrane-associated progesterone receptor component 2 0.981148 119.38 _IIKPGEEPSEYT(ph)DEEDTK_ 
PKM2 Pyruvate kinase isozymes M1/M2;Pyruvate kinase;Pyruvate kinase 0.999992 151.07 _IDIDS(ph)PPITAR_ 
PLEC Plectin 0.998864 137.89 _EIEEVS(ph)PETPVVPATTQR_ 
PLXND1 Plexin-D1 0.975323 78.326 _IN(de)IN(de)ES(ph)M(ox)QVVSRR_ 
PPP1CA Serine/threonine-protein phosphatase PP1-alpha catalytic subunit 0.906835 87.388 _(ac)MSDS(ph)EKIN(de)IDS(ph)IIGR_ 
PPP1CA Serine/threonine-protein phosphatase PP1-alpha catalytic subunit 0.999832 87.388 _(ac)MSDS(ph)EKIN(de)IDS(ph)IIGR_ 
PPP1R12A Protein phosphatase 1 regulatory subunit 12A 0.764795 111.01 _TGS(ph)YGAIAEITASK_ 
PRDM6 Putative histone-lysine N-methyltransferase PRDM6 1 105.03 _AEPPPDS(ph)IRPR_ 
PTCD1 Pentatricopeptide repeat-containing protein 1 0.984478 60.307 _SQVT(ph)PNT(ph)HIY(ph)SAIINAAIR_ 
PTCD1 Pentatricopeptide repeat-containing protein 1 0.808628 60.307 _SQVT(ph)PNT(ph)HIY(ph)SAIINAAIR_ 
RAB12 Ras-related protein Rab-12 0.999908 131.04 _AGGGGGIGAGS(ph)PAISGGQGR_ 
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RAVER1 Ribonucleoprotein PTB-binding 1 1 153.36 _(ac)AADVSVTHRPPIS(ph)PK_ 
RBM5 RNA-binding protein 5 0.999864 187.72 _GIVAAYSGDS(ph)DNEEEIVER_ 
RIMBP3C RIMS-binding protein 3C;RIMS-binding protein 3B 1 55.469 _VFVAIS(ph)DY(ph)NPIVM(ox)S(ph)AN(de)IK_ 
RIMBP3C RIMS-binding protein 3C;RIMS-binding protein 3B 1 55.469 _VFVAIS(ph)DY(ph)NPIVM(ox)S(ph)AN(de)IK_ 
RIMBP3C RIMS-binding protein 3C;RIMS-binding protein 3B 1 55.469 _VFVAIS(ph)DY(ph)NPIVM(ox)S(ph)AN(de)IK_ 
RIMS2 Regulating synaptic membrane exocytosis protein 2 0.999689 86.539 _S(ph)M(ox)PSIM(ox)TGRSAPPSPAISR_ 
RPS20 40S ribosomal protein S20 0.999988 78.964 _(ac)M(ox)PT(ph)KTIRITTR_ 
RYR2 Ryanodine receptor 2 0.903271 51.888 _Y(ph)N(de)EVM(ox)QAINM(ox)S(ph)AAITARK_ 
RYR2 Ryanodine receptor 2 0.998608 51.888 _Y(ph)N(de)EVM(ox)QAINM(ox)S(ph)AAITARK_ 
S E P 2 Septin-2 1 146.78 _IYHIPDAES(ph)DEDEDFK_ 
SIPA1L1 Signal-induced proliferation-associated 1-like protein 1 0.990593 146.2 _IIDIES(ph)PTPESQK_ 
SKIV2L Helicase SKI2W 0.996422 123.95 _ASS(ph)IEDIVIK_ 
SLC12A4 Solute carrier family 12 member 4 0.999188 141.1 _IESIYS(ph)DEEDESAVGADK_ 
SLC25A32 Mitochondrial folate transporter/carrier 0.995834 55.975 _(ac)TICIT(ph)NPIWVT(ph)K_ 
SLC25A32 Mitochondrial folate transporter/carrier 0.999995 55.975 _(ac)TICIT(ph)NPIWVT(ph)K_ 
SLIT3 Slit homolog 3 protein 0.991623 125.03 _DS(ph)Y(ph)VEIASAKVR_ 
SLIT3 Slit homolog 3 protein 0.975311 125.03 _DS(ph)Y(ph)VEIASAKVR_ 
SMC4 Structural maintenance of chromosomes protein 4 0.807338 245.61 _TES(ph)PATAAETASEEIDN(de)R_ 
SNTB2 Beta-2-syntrophin 1 144.73 _GPAGEAGAS(ph)PPVR_ 
SP100 Nuclear autoantigen Sp-100 1 235.25 _SEPVINN(de)DNPIES(ph)NDEK_ 
SRRM1 Serine/arginine repetitive matrix protein 1 0.999926 139.66 _RIS(ph)PSAS(ph)PPR_ 
SRRM1 Serine/arginine repetitive matrix protein 1 0.944856 139.66 _RIS(ph)PSAS(ph)PPR_ 
SULT1B1 Sulfotransferase family cytosolic 1B member 1 1 104.82 _(ac)MIS(ph)PKDIIR_ 
SUMO1 Small ubiquitin-related modifier 1 0.999985 97.095 _(ac)S(ph)DQEAKPSTEDIGDKK_ 
SYNE2 Nesprin-2 0.999949 60.246 _T(ph)IS(ph)HHAS(ph)TVQM(ox)AIEDS(ph)EQK_ 
SYNE2 Nesprin-2 0.829057 60.246 _T(ph)IS(ph)HHAS(ph)TVQM(ox)AIEDS(ph)EQK_ 
SYNE2 Nesprin-2 0.998905 60.246 _T(ph)IS(ph)HHAS(ph)TVQM(ox)AIEDS(ph)EQK_ 
SYNE2 Nesprin-2 0.999996 60.246 _T(ph)IS(ph)HHAS(ph)TVQM(ox)AIEDS(ph)EQK_ 
SYNPO Synaptopodin 0.99999 85.932 _AAS(ph)PAKPSSIDIVPNIPK_ 
TCOF1 Treacle protein 1 227.08 _KIGAGEGGEASVS(ph)PEK_ 
TCTN1 Tectonic-1 0.999993 64.069 _FPSSITS(ph)SICTDNNPAAFIVN(de)QAVKCT(ph)R_ 
TJP2 Tight junction protein ZO-2 0.89833 71.927 _AAS(ph)S(ph)DQIRDNSPPPAFKPEPPK_ 
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TJP2 Tight junction protein ZO-2 1 127.61 _DNS(ph)PPPAFKPEPPK_ 
TK2 Thymidine kinase 2, mitochondrial 0.993357 51.771 _WGIT(ph)IQT(ph)YVQIT(ph)M(ox)IDR_ 
TK2 Thymidine kinase 2, mitochondrial 0.994665 51.771 _WGIT(ph)IQT(ph)YVQIT(ph)M(ox)IDR_ 
TMPO Lamina-associated polypeptide 2, isoform alpha 0.832309 142.88 _S(ph)STPIPTISSSAENTR_ 
TNKS1BP1 182 kDa tankyrase-1-binding protein 0.999944 116.2 _YESQEPIAGQES(ph)PIPIATR_ 
TOP2B DNA topoisomerase 2-beta 1 185.34 _FDS(ph)NEEDSASVFSPSFGIK_ 
TP53BP1 Tumor suppressor p53-binding protein 1 1 217.73 _S(ph)PEPEVISTQEDIFDQSN(de)K_ 
TRAFD1 TRAF-type zinc finger domain-containing protein 1 0.797962 125.52 _IDSQPQETS(ph)PEIPR_ 
TRIM28 Transcription intermediary factor 1-beta 0.983773 140.31 _(ac)AASAAAASAAAASAASGS(ph)PGPGEGSAGGEK_ 
TRIO Triple functional domain protein 0.999308 95.834 _AGAAS(ph)PINS(ph)PISSAVPSIGK_ 
TRIO Triple functional domain protein 0.833841 95.834 _AGAAS(ph)PINS(ph)PISSAVPSIGK_ 
TSPAN16 Tetraspanin-16 1 109 _(ac)RDVS(ph)PN(de)VIHQK_ 
UBE2NL Putative ubiquitin-conjugating enzyme E2 N-like 1 114.31 _TNEAQAIET(ph)AR_ 
UBE2W Ubiquitin-conjugating enzyme E2 W 0.999369 76.073 _RS(ph)WGDGSIM(ox)ASM(ox)QK_ 
UBR1 E3 ubiquitin-protein ligase UBR1 1 54.974 _T(ph)GPFCVN(de)HEPGRAGT(ph)IKEN(de)S(ph)R_ 
UBR1 E3 ubiquitin-protein ligase UBR1 1 54.974 _T(ph)GPFCVN(de)HEPGRAGT(ph)IKEN(de)S(ph)R_ 
UBR1 E3 ubiquitin-protein ligase UBR1 1 54.974 _T(ph)GPFCVN(de)HEPGRAGT(ph)IKEN(de)S(ph)R_ 
Uncharacterised Uncharacterised 0.999999 82.645 _(ac)M(ox)T(ph)KEIDESR_ 
URGCP Upregulator of cell proliferation 0.999969 103.88 _(ac)AS(ph)PGHSDIGEVAPEIK_ 
USP24 Ubiquitin carboxyl-terminal hydrolase 24 1 127.79 _VSDQNS(ph)PVIPK_ 
USP31 Ubiquitin carboxyl-terminal hydrolase 31 0.994276 77.744 _SVGS(ph)FM(ox)S(ph)RVIK_ 
USP31 Ubiquitin carboxyl-terminal hydrolase 31 0.998569 77.744 _SVGS(ph)FM(ox)S(ph)RVIK_ 
USP53 Inactive ubiquitin carboxyl-terminal hydrolase 53 0.942239 96.391 _QRENQKFPTDN(de)ISS(ph)S(ph)N(de)R_ 
USP53 Inactive ubiquitin carboxyl-terminal hydrolase 53 0.999999 96.391 _QRENQKFPTDN(de)ISS(ph)S(ph)N(de)R_ 
WDR44 WD repeat-containing protein 44 1 125.73 _VGN(de)ES(ph)PVQEIK_ 
ZNF687 Zinc finger protein 687 0.997795 163.68 _ATDIPASAS(ph)PPPVAGVPFFK_ 
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Supplementary Table S8: Phosphoproteins significantly up/ downregulated in both primary meningioma and Ben-Men-1 cells compared to HMC 
Gene symbol Protein name  
Log2 FC 
Meningioma Log2 FC Ben-Men-1 
MAP4 Microtubule-associated protein -2.57 -0.83 
IGF2BP3 Insulin-like growth factor 2 mRNA-binding protein 3 -24.30 -4.70 
DDX3X ATP-dependent RNA helicase DDX3X -1.18 0.94 
GIPC1 PDZ domain-containing protein GIPC1 -22.79 -1.52 
SYNJ2 Synaptojanin-2 -23.28 -1.35 
DCLK1 Serine/threonine-protein kinase DCLK1 -23.08 -3.08 
DHX15 Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15 -22.73 1.47 
ZZEF1 Zinc finger ZZ-type and EF-hand domain-containing protein 1 -20.47 -1.57 
TGFB1I1 Transforming growth factor beta-1-induced transcript 1 protein -24.06 -1.61 
CALU Isoform 4 of Calumenin 1.75 1.58 
DHX16 Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX16 -21.66 1.19 
USO1 General vesicular transport factor p115 -2.17 -1.01 
RPP40 Ribonuclease P protein subunit p40 -20.58 -1.60 
AP2A2 AP-2 complex subunit alpha-2 -22.45 -0.66 
UBE4B Ubiquitin conjugation factor E4 B -21.62 -1.10 
MPZL1 Myelin protein zero-like protein 1 -20.50 -1.64 
TRIM16 Tripartite motif-containing protein 16 -22.33 -4.56 
ABL1 Tyrosine-protein kinase ABL1 -21.21 -1.21 
COL1A1 Collagen alpha-1(I) chain -20.61 -1.20 
CTSD Cathepsin D;Cathepsin D light chain;Cathepsin D heavy chain 24.61 1.85 
PFKM 6-phosphofructokinase, muscle type -21.73 -2.49 
PIP Prolactin-inducible protein -22.35 -1.04 
HSP90B1 Endoplasmin -1.62 -0.58 
VCL Vinculin -22.37 -0.45 
PSMB1 Proteasome subunit beta type-1 -1.72 -0.67 
COMT Catechol O-methyltransferase -22.67 -1.33 
PSMA2 Proteasome subunit alpha type-2 -2.37 -0.99 
DNAJA1 DnaJ homolog subfamily A member 1 21.16 1.18 
HSPA4 Heat shock 70 kDa protein 4 -21.51 1.25 
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NF2 Merlin -22.37 -3.22 
TALDO1 Transaldolase -1.14 1.53 
TXLNA Alpha-taxilin -21.34 0.76 
EPS15 Epidermal growth factor receptor substrate 15 -21.88 -1.62 
NEDD4 E3 ubiquitin-protein ligase NEDD4;E3 ubiquitin-protein ligase -21.52 -1.02 
CSNK1D Casein kinase I isoform delta -22.76 -1.05 
PSMB2 Proteasome subunit beta type-2 2.06 -1.05 
VPS41 Vacuolar protein sorting-associated protein 41 homolog -20.95 -1.53 
ST13 Hsc70-interacting protein;Putative protein FAM10A5;Putative protein FAM10A4 -0.95 -1.30 
HNRNPM Heterogeneous nuclear ribonucleoprotein M -22.22 1.67 
MSH6 DNA mismatch repair protein Msh6 -21.99 1.30 
MLLT4 Afadin -21.39 0.69 
RAP1B Ras-related protein Rap-1b -24.69 -2.49 
CDC42EP1 Cdc42 effector protein 1 -23.22 -0.64 
EXOSC10 Exosome component 10 -20.77 0.86 
AKAP12 A-kinase anchor protein 12 -2.99 -3.63 
PSME1 Proteasome activator complex subunit 1 1.63 1.57 
SPIRE1 Protein spire homolog 1 -20.34 0.83 
NEXN Nexilin -23.14 -1.47 
ANK3 Ankyrin-3 -21.87 -2.10 
CKAP5 Cytoskeleton-associated protein 5 -23.43 0.99 
CLINT1 Clathrin interactor 1 -1.65 0.66 
NONO Non-POU domain-containing octamer-binding protein -21.54 1.79 
SKIV2L Helicase SKI2W -22.44 -1.40 
PKN1 Serine/threonine-protein kinase N1 -23.54 -0.89 
DBN1 Isoform 3 of Drebrin -2.98 -2.19 
FNDC3B Fibronectin type III domain-containing protein 3B -21.86 -2.20 
HS1BP3 HCLS1-binding protein 3 -21.98 -1.25 
HP1BP3 Heterochromatin protein 1-binding protein 3 -24.45 1.23 
SKT Sickle tail protein homolog -21.12 -2.21 
FAM40A Protein FAM40A -20.95 -0.39 
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FAM160B1 Protein FAM160B1 -21.77 0.96 
TTC37 Tetratricopeptide repeat protein 37 -22.12 -1.23 
PACS1 Phosphofurin acidic cluster sorting protein 1 -23.67 -1.16 
Uncharacterised Uncharacterized protein FLJ45252 -22.45 -0.98 
ARMC9 LisH domain-containing protein ARMC9 -21.37 -4.25 
WAPAL Wings apart-like protein homolog -20.70 1.08 
CENPV Isoform 3 of Centromere protein V -22.07 -1.20 
PPFIBP1 Liprin-beta-1 -22.58 -0.72 
ASCC3 Activating signal cointegrator 1 complex subunit 3 -21.30 -1.43 
ARFGAP1 ADP-ribosylation factor GTPase-activating protein 1 -23.70 -1.97 
EHBP1 EH domain-binding protein 1 -23.13 -1.52 
NAV1 Neuron navigator 1 -24.15 -1.05 
MICAL1 Protein-methionine sulfoxide oxidase MICAL1 -22.43 -2.32 
GEMIN5 Gem-associated protein 5 -23.31 1.07 
ARHGEF40 Rho guanine nucleotide exchange factor 40 -22.75 -1.03 
PPP4R1 Serine/threonine-protein phosphatase 4 regulatory subunit 1 -21.71 -0.58 
PPIL4 Peptidyl-prolyl cis-trans isomerase-like 4 -21.31 0.42 
DHX38 Pre-mRNA-splicing factor ATP-dependent RNA helicase PRP16 -20.71 1.01 
TNPO1 Transportin-1 -21.54 1.06 
USP9X Probable ubiquitin carboxyl-terminal hydrolase FAF-X 0.70 0.85 
MAGOHB Protein mago nashi homolog 2 1.71 1.39 
KCTD12 BTB/POZ domain-containing protein KCTD12 -25.71 -2.78 
SIPA1 Signal-induced proliferation-associated protein 1 -21.86 -3.47 
DOCK6 Dedicator of cytokinesis protein 6 -21.56 -3.22 
ARAP1 Arf-GAP with Rho-GAP domain, ANK repeat and PH domain-containing protein 1 -21.80 0.89 
FMNL2 Formin-like protein 2 -21.30 -2.30 
FAM129B Niban-like protein 1 -1.34 -0.95 
PSMB7 Proteasome subunit beta type-7 -1.72 -1.18 
PIK3R4 Phosphoinositide 3-kinase regulatory subunit 4 -20.36 -0.95 
TUBGCP2 Gamma-tubulin complex component 2 -22.12 -0.52 
DDX23 Probable ATP-dependent RNA helicase DDX23 -21.87 0.57 
266 
 
NAA15 N-alpha-acetyltransferase 15, NatA auxiliary subunit -22.76 0.34 
TANC1 Protein TANC1 -20.96 -1.60 
ASCC2 Activating signal cointegrator 1 complex subunit 2 -21.79 -1.16 
WDR13 WD repeat-containing protein 13 -21.96 -1.71 
YTHDC2 Probable ATP-dependent RNA helicase YTHDC2 -22.33 0.85 
DOCK5 Dedicator of cytokinesis protein 5 -21.24 1.39 
UBE2Z Ubiquitin-conjugating enzyme E2 Z -0.66 -0.81 
PLEKHA5 Pleckstrin homology domain-containing family A member 5 -21.79 -1.68 
CD248 Endosialin -22.24 -23.31 
PLCB1 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1 -21.19 -1.34 
IMP3 U3 small nucleolar ribonucleoprotein protein IMP3 -21.15 0.64 
FAM120A Constitutive coactivator of PPAR-gamma-like protein 1 -22.32 0.76 
DIP2B Disco-interacting protein 2 homolog B -21.41 -0.67 
RRBP1 Ribosome-binding protein 1 -23.85 -1.16 
PI4KB Phosphatidylinositol 4-kinase beta -21.89 -0.95 
TJP2 Tight junction protein ZO-2 -21.29 1.50 
S E P 9 Septin-9 -2.52 -1.38 
BAIAP2L1 Brain-specific angiogenesis inhibitor 1-associated protein 2-like protein 1 -23.14 -1.68 
ASAP1 Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1 -22.32 -1.26 
EPB41L3 Isoform B of Band 4.1-like protein 3 -4.59 -6.33 
SH3BP1 SH3 domain-binding protein 1 -23.62 -2.44 
TLN2 Talin-2 -21.20 -2.72 
RAPGEF2 Rap guanine nucleotide exchange factor 2 -21.33 -2.36 
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Supplementary Table S9: Proteins identified in a PDLIM2 co-immuinoprecipitation experiment  
Gene symbol  Protein name  
RPSAP58 40S ribosomal protein SA 
ALDOC Fructose-bisphosphate aldolase C;Fructose-bisphosphate aldolase 
CAPZB F-actin-capping protein subunit beta 
CANX Calnexin 
ATP5C1 ATP synthase subunit gamma, mitochondrial;ATP synthase gamma chain 
SCML2 Sex comb on midleg-like protein 2 
MAP4 Microtubule-associated protein;Microtubule-associated protein 4 
EEF1G Elongation factor 1-gamma 
XRN2 5-3 exoribonuclease 2 
TKT Transketolase 
HADHB Trifunctional enzyme subunit beta, mitochondrial;3-ketoacyl-CoA thiolase 
PDIA6 Protein disulfide-isomerase A6 
RAN GTP-binding nuclear protein Ran 
RPL31 60S ribosomal protein L31 
MYL6 Myosin light polypeptide 6 
PGK1 Phosphoglycerate kinase 1;Phosphoglycerate kinase 
PCMT1 Protein-L-isoaspartate O-methyltransferase;Protein-L-isoaspartate(D-aspartate) O-methyltransferase 
RPL37A 60S ribosomal protein L37a 
CALD1 Caldesmon 
LASP1 LIM and SH3 domain protein 1 
MBNL1 Muscleblind-like protein 1;Muscleblind-like protein 3 
RPL9 60S ribosomal protein L9 
RPS3A 40S ribosomal protein S3a 
S E P 1 1  Septin-11 
FLNB Filamin-B 
TCP1 T-complex protein 1 subunit alpha 
DDOST Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 kDa subunit 
RAVER1 Ribonucleoprotein, PTB-Binding 1 
MDH2 Malate dehydrogenase, mitochondrial;Malate dehydrogenase 
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CACNA1C Voltage-dependent L-type calcium channel subunit alpha-1C 
PUF60 Poly(U)-binding-splicing factor PUF60 
CRYAB Alpha-crystallin B chain 
ALCAM CD166 antigen 
PHB2 Prohibitin-2 
MTHFD1 C-1-tetrahydrofolate synthase, cytoplasmic 
TUBA1C Tubulin alpha-1C chain 
MYO1C Unconventional myosin-Ic 
P4HB Protein disulfide-isomerase 
RBMS2 RNA-binding motif, single-stranded-interacting protein 2 
FN1 Fibronectin;Anastellin;Ugl-Y1;Ugl-Y2;Ugl-Y3 
RTN4 Reticulon-4 
PDIA3 Protein disulfide-isomerase A3 
ZYX Zyxin 
ATP5B ATP synthase subunit beta, mitochondrial;ATP synthase subunit beta 
RPS17 40S ribosomal protein S17;40S ribosomal protein S17-like 
SRP14 Signal recognition particle 14 kDa protein 
NCL Nucleolin 
NONO Non-POU domain-containing octamer-binding protein 
MAP3K3 Mitogen-activated protein kinase kinase kinase 3 
EIF4A1 Eukaryotic initiation factor 4A-I;Eukaryotic initiation factor 4A-II 
RPL13 60S ribosomal protein L13 
GPI Glucose-6-phosphate isomerase 
RPS5 40S ribosomal protein S5;40S ribosomal protein S5, N-terminally processed 
GIPC1 PDZ domain-containing protein GIPC1 
P4HA2 Prolyl 4-hydroxylase subunit alpha-2 
ACSL4 Long-chain-fatty-acid--CoA ligase 4 
UGDH UDP-glucose 6-dehydrogenase 
CRTAP Cartilage-associated protein 
LMNA Prelamin-A/C;Lamin-A/C 
SLC25A5 ADP/ATP translocase 2 
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RPLP0 60S acidic ribosomal protein P0;60S acidic ribosomal protein P0-like 
ITGB1 Integrin beta-1;Integrin beta 
NPM1 Nucleophosmin 
CTSD Cathepsin D;Cathepsin D light chain;Cathepsin D heavy chain 
HSPA1A Heat shock 70 kDa protein 1A/1B;Heat shock 70 kDa protein 6;Heat shock 70 kDa protein 1-like 
HSP90AB1 Heat shock protein HSP 90-beta 
CNP 2,3-cyclic-nucleotide 3-phosphodiesterase 
HSPD1 60 kDa heat shock protein, mitochondrial 
PABPC1 Polyadenylate-binding protein 1 
SLC25A6 ADP/ATP translocase 3;ADP/ATP translocase 1 
RNH1 Ribonuclease inhibitor 
EEF2 Elongation factor 2 
P4HA1 Prolyl 4-hydroxylase subunit alpha-1 
HSP90B1 Endoplasmin 
VCL Vinculin 
PGAM1 Phosphoglycerate mutase 1;Phosphoglycerate mutase 2 
MX1 Interferon-induced GTP-binding protein Mx1 
PAICS Multifunctional protein ADE2 
SPRR2G Small proline-rich protein 2G 
UQCRC2 Cytochrome b-c1 complex subunit 2, mitochondrial 
PPIB Peptidyl-prolyl cis-trans isomerase B 
RPS3 40S ribosomal protein S3 
ATP5A1 ATP synthase subunit alpha, mitochondrial 
DDX6 Probable ATP-dependent RNA helicase DDX6 
LOX Protein-lysine 6-oxidase 
MARCKS Myristoylated alanine-rich C-kinase substrate 
RPL12 60S ribosomal protein L12 
HSPA4 Heat shock 70 kDa protein 4 
STAT1 Signal transducer and activator of transcription 1-alpha/beta 
RPS27 40S ribosomal protein S27;40S ribosomal protein S27-like 
RPL5 60S ribosomal protein L5 
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RPS10 40S ribosomal protein S10;Putative 40S ribosomal protein S10-like 
IQGAP1 Ras GTPase-activating-like protein IQGAP1 
ATP5O ATP synthase subunit O, mitochondrial 
TUFM Elongation factor Tu, mitochondrial 
SERPINH1 Serpin H1 
HNRNPM Heterogeneous nuclear ribonucleoprotein M 
CAPZA1 F-actin-capping protein subunit alpha-1 
VCP Transitional endoplasmic reticulum ATPase 
RPS20 40S ribosomal protein S20 
YWHAG 14-3-3 protein gamma;14-3-3 protein gamma, N-terminally processed 
PPP1CA Serine/threonine-protein phosphatase PP1-alpha catalytic subunit 
RPS16 40S ribosomal protein S16 
YWHAE 14-3-3 protein epsilon 
RPS18 40S ribosomal protein S18 
RPS11 40S ribosomal protein S11 
PSMC6 26S protease regulatory subunit 10B 
RPS4X 40S ribosomal protein S4, X isoform 
RPL23 60S ribosomal protein L23 
RPS25 40S ribosomal protein S25 
RPL10A 60S ribosomal protein L10a 
PPIA Peptidyl-prolyl cis-trans isomerase A;Peptidyl-prolyl cis-trans isomerase 
AP2B1 AP-2 complex subunit beta 
YBX1 Nuclease-sensitive element-binding protein 1;DNA-binding protein A 
ACTC1 Actin, alpha cardiac muscle 1 
TUBB4B Tubulin beta-4B chain 
HNRNPU Heterogeneous nuclear ribonucleoprotein U 
PFKP 6-phosphofructokinase type C 
LGALS3BP Galectin-3-binding protein 
LOXL1 Lysyl oxidase homolog 1 
AHNAK Neuroblast differentiation-associated protein AHNAK 
TUBB3 Tubulin beta-3 chain 
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TUBB2A Tubulin beta-2A chain;Tubulin beta-2B chain 
MVP Major vault protein 
PLEC Plectin 
PCBP1 Poly(rC)-binding protein 1 
PTPN14 Tyrosine-protein phosphatase non-receptor type 14 
DPYSL2 Dihydropyrimidinase-related protein 2 
HLA-C HLA class I histocompatibility antigen, Cw-6 alpha chainchain 
LEPRE1 Prolyl 3-hydroxylase 1 
DECR2 Peroxisomal 2,4-dienoyl-CoA reductase 
TLN1 Talin-1 
C1orf57 Cancer-related nucleoside-triphosphatase 
PTRF Polymerase I and transcript release factor 
MRPL14 39S ribosomal protein L14, mitochondrial 
GPR155 Integral membrane protein GPR155 
LEPREL1 Prolyl 3-hydroxylase 2 
KIAA1967 DBIRD complex subunit KIAA1967 
SCCPDH Saccharopine dehydrogenase-like oxidoreductase 
PPP1R13L RelA-associated inhibitor 
PALLD Palladin 
LARP4B La-related protein 4B 
LRRC59 Leucine-rich repeat-containing protein 59 
ZC3HAV1L Zinc finger CCCH-type antiviral protein 1-like 
PDLIM2 PDZ and LIM domain protein 2 
RBM14 RNA-binding protein 14 
VAT1 Synaptic vesicle membrane protein VAT-1 homolog 
TUBB6 Tubulin beta-6 chain 
EHD1 EH domain-containing protein 1 
SLC25A22 Mitochondrial glutamate carrier 1 
QPCTL Glutaminyl-peptide cyclotransferase-like protein 
FAM120A Constitutive coactivator of PPAR-gamma-like protein 1 
DNAJB11 DnaJ homolog subfamily B member 11 
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ACOT9 Acyl-coenzyme A thioesterase 9, mitochondrial 
SAMHD1 SAM domain and HD domain-containing protein 1 
SQRDL Sulfide:quinone oxidoreductase, mitochondrial 
SAMHD1 SAM domain and HD domain-containing protein 1  
SQRDL Sulfide Quinone Reductase-Like 
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Supplementary Table S10: Proteins identified in a pSTAT1_Y701 co-immunoprecipitation experiment 
Gene symbol Protein name 
 
RS29 40S ribosomal protein S29  
 
RPSA 40S ribosomal protein SA (Fragment)  
 
RPL23A 60S ribosomal protein L23a  
 
SLC25A6 ADP/ATP translocase 3 (Fragment)  
 
ACTN4 Alpha-actinin-4  
 
AMY1B Alpha-amylase 1 (Fragment)  
 
ATPA ATP synthase subunit alpha, mitochondrial  
 
ATPO ATP synthase subunit O, mitochondrial  
 
BASP1 Brain acid soluble protein 1  
 
CLIP1 CAP-Gly domain-containing linker protein 1  
 
CRTAP Cartilage-associated protein  
 
CSTA Cystatin-A  
 
CKAP4 Cytoskeleton-associated protein 4  
 
DSG1 Desmoglein-1  
 
DST Dystonin  
 
TRIM21 E3 ubiquitin-protein ligase TRIM21  
 
ENPL Endoplasmin  
 
IF2B Eukaryotic translation initiation factor 2 subunit 2  
 
IF2G Eukaryotic translation initiation factor 2 subunit 3  
 
CAZA1 F-actin-capping protein subunit alpha-1  
 
HS90A Heat shock protein HSP 90-alpha  
 
HBB Hemoglobin subunit beta  
 
IGLL5 Immunoglobulin lambda-like polypeptide 5  
 
FINC Isoform 10 of Fibronectin  
 
GOLM1 Isoform 2 of Golgi membrane protein 1  
 
P3H2 Isoform 2 of Prolyl 3-hydroxylase 2  
 
STOX2 Isoform 2 of Storkhead-box protein 2  
 
DUS3L Isoform 2 of tRNA-dihydrouridine(47) synthase [NAD(P)(+)]-like  
 
CUX1 Isoform 3 of Homeobox protein cut-like 1  
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MRCKA Isoform 3 of Serine/threonine-protein kinase MRCK alpha  
 
AKAP9 Isoform 5 of A-kinase anchor protein 9  
 
CALD1 Isoform 5 of Caldesmon  
 
MK14 Isoform CSBP1 of Mitogen-activated protein kinase 14  
 
PLAK Junction plakoglobin  
 
KRT19 Keratin, type I cytoskeletal 19 (Fragment)  
 
PUR6 Multifunctional protein ADE2  
 
HSD17B4 Peroxisomal multifunctional enzyme type 2  
 
PDIA3 Protein disulfide isomerase family A, member 3, isoform CRA 
 
S10A9 Protein S100-A9  
 
RABGAP1 Rab GTPase-activating protein 1  
 
RALGAPA2  Ral GTPase-activating protein subunit alpha-2  
 
LATS1 Serine/threonine-protein kinase LATS1  
 
SERPH Serpin H1 OS 
 
STAT1 Signal transducer and activator of transcription 1-alpha/beta  
 
SBSN Suprabasin  
 
TAGL Transgelin  
 
TUBB Tubulin beta chain  
 
Uncharacterised Uncharacterized protein  
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